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1.1 Transition-Metal-Catalyzed C−H Functionalizations  
A long-standing challenge in synthetic organic chemistry is the development of methods for 
the direct conversion of unactivated carbon−hydrogen bonds into carbon−carbon, 
carbon−nitrogen, carbon−halogen, or carbon−oxygen bonds among others. Mild and selective 
transformations of this type will undoubtedly obtain a wide range of potential applications in 
varies applied fields. During the last few decades of the previous century, a new family of 
C−C bond forming reactions based on transition-metal catalysts has emerged as a powerful 
tool and experienced a remarkable progress which played a vital role in the synthesis of 
pharmaceuticals, natural products, agrochemicals, polymers and feedstock commodity 
chemicals.1 Among them, transition-metal-catalyzed cross-coupling reactions are arguably 
the most prominent approach to the construction of C−C bonds (Scheme 1.1).1a,2  
 
Scheme 1.1. Transition-metal-catalyzed cross-coupling reactions. 
However, the formation of such bonds relies on prefunctionalized starting materials, such as 
organoboron, organozinc or organotin compounds, which add costly chemical steps to the 
overall synthesis. Circumventing the disadvantages of the traditional approaches will not only 
improve atom economy,3  but also increase the overall efficiency of multistep synthetic 
sequences. In recent decades, transition-metal-catalyzed C−H bond functionalizations became 
                                                                 
1 a) Transition Metals for Organic Synthesis (Eds .: M. Beller and C. Bolm), 2nd ed., Wiley-VCH, Weinheim, 2004; b) 
Metal-Catalyzed Cross-Coupling Reactions and More; (Eds.: A. de Mei jere, S. Bräse, M. Oestreich), Wiley-VCH, 
Weinheim, 2014. 
2 a) Metal-Catalyzed Cross-Coupling Reactions, (Eds : A. de Mei jere and F. Diederich), 2nd ed. Wiley-VCH, 
Weinheim, 2004. For selected reviews  on C–C bond formation via traditional cross-coupling reactions, see: b) C. C. 
C. J. Seechurn, M. O. Ki tching, T. J. Colacot, V. Snieckus , Angew. Chem. Int. Ed. 2012, 51, 5062–5085; c) H. Li , C. C. 
C. J. Seechurn, T. J. Colacot, ACS Catal. 2012, 2, 1147–1164; d) B. M. Rosen, K. W. Quasdorf, D. A. Wilson, N. Zhang, 
A. M. Resmerita , N. K. Garg, V. Percec, Chem. Rev. 2011, 111, 1346–1416; e) G. Cahiez, A. Moyeux, Chem. Rev. 
2010, 110, 1435–1462; f) A. Roglans , A. Pla -Quintana, M. Moreno-Mañas , Chem. Rev. 2006, 106, 4622–4643; g) J. 
P. Corbet, G. Mignani, Chem. Rev. 2006, 106, 2651–2710, and references ci ted therein. 
3 B. M. Trost, Acc. Chem. Res. 2002, 35, 695–705. 
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an attractive strategy to streamline chemical synthesis. 4  Due to its high atom- and 
step-economy, intensive research efforts have led to the remarkable progress for challenging 
C−H bond functionalization.5  
 
Scheme 1.2. Regioselective intermolecular cleavage of C−H bonds through the use of a directing 
group (DG). 
Direct C−H bond functionalizations are limited by mainly two challenging issues: (i) The 
requirement to control site-selectivity of the C−H functionalization in a molecule that 
contains various potentially reactive C−H bond; and (ii) the requirement to achieve selective 
functionalization of a single C−H bond within a complex molecule. The most common 
strategy involves the use of substrates that contain a directing group (DG). These directing 
groups coordinate to the metal center and selectively bring the metal to the proximity of a 
C−H bond (Scheme 1.2)6 and subsequently allow its activation and cleavage. Many transition 
metals, including, ruthenium, rhodium, palladium and cobalt, undergo stoichiometric 
cyclometalations.5,6b,7 By far, a large remarkable progress in organometallic chemistry has set 
the stage for the development of increasingly viable metal catalysts for C−H bond 
                                                                 
4 a) Handbook of C―H Transformations (Ed: G. Dyker), Wiley-VCH, Weinheim, 2005; b) F.Kakiuchi , N. Chatani, Adv. 
Synth. Catal. 2003, 345, 1077–1101; c) M. Miura, M. Nomura, Top. Curr. Chem. 2002, 219, 212–237; d) V. Ri tleng, 
C. Si rlin, M. Pfeffer, Chem. Rev. 2002, 102, 1731-1770; e) L. Ackermann, Synlett 2007, 4, 507–526.  
5 a) Modern Arylation Methods, (Ed: L. Ackermann), Wiley-VCH, Weinheim, 2009; For recent representative 
general reviews on C―H bond functionalizations , see: b) J. Mo, L. Wang, Y. Liu, X. Cui , Synthesis 2015, 47, 
439–459; c) G. Qiu, J. Wu, Org. Chem. Front. 2015, 2, 169–178; d) J. Yang, Org. Biomol. Chem. 2015, 13, 
1930-1941; e) L. Ackermann, Org. Process Res. Dev. 2015, 18, 260-269; f) F. Zhang, D. R. Spring, Chem. Soc. Rev. 
2014, 43, 6906–6919; g) A. F. M. Noisier, M. A. Brimble, Chem. Rev. 2014, 114, 8775–8806; h) V. S. 
Thirunavukkarasu, S. I . Kozhushkov, L. Ackermann, Chem. Commun. 2014, 50, 29–39; i ) L. Ackermann, Acc. Chem. 
Res. 2014, 47, 281–295; j) K. Gao, N. Yoshikai, Acc. Chem. Res. 2014, 47, 1208–1219; k) L. Ackermann, J.Org. Chem. 
2014, 79, 8948-8954; l) J. J. Mousseau, A. B. Charrette, Acc. Chem. Res. 2013, 46, 412-424; m) K. M. Engle, T. S. 
Mei , M. Wasa, J. Q. Yu, Acc. Chem. Res. 2012, 45, 788–802; n) S. R. Neufeldt, M. S. Sanford, Acc. Chem. Res. 2012, 
45, 936-946; o) J. Wencel-Delord, T. Droege, F. Glorius, Chem. Soc. Rev. 2011, 40, 4740–4761; p) C. S. Yeung, V. M. 
Dong, Chem. Rev. 2011, 111, 1215-1292; q) L. Ackermann, Chem. Rev. 2011, 111, 1315–1345; r) M. C. Willis, 
Chem. Rev. 2010, 110, 725-748; s ) D. A. Colby, R. G. Bergman, J. A. Ellman, Chem. Rev. 2010, 110, 624-655; t) D. 
Alberico, M. E. Scott, M. Lautens, Chem. Rev. 2007, 107, 174–238; u) P. Sehnal, R. J. K. Taylor, I . J. S. Fai rlamb, 
Chem. Rev. 2010, 110, 824–889, and the references  therein. 
6 a) L. Ackermann, R. Vicente, A. R. Kapdi , Angew. Chem. Int. Ed. 2009, 48, 9792–9826; b) L. Ackermann, Top. 
Organoment. Chem. 2007, 24, 35–60; c) I . Omae, Coord. Chem. Rev. 2004, 248, 995–1023. 
7 a) N. Kuhl , N. Schroeder, F. Glorius, Adv. Synth. Catal. 2014, 356, 1443–1460; b) S. D. Sarkar, W. Liu, S. I . 
Kozhushkov, L. Ackermann, Adv. Synth. Catal. 2014, 356, 1461–1479; c) S. I . Kozhushkov, L. Ackermann, Chem. Sci. 
2013, 4, 886–896; d) T. S. Mei , L. Kou, S. Ma, K. M. Engle, J. Q. Yu, Synthesis 2012, 44, 1778–1791, and references 




1.2 Carboxylate-Assisted Ruthenium-Catalyzed C−H Functionalizations 
Looking at the development in the area of utilizing unreactive C−H bonds in chemical 
synthesis via transition metal catalysis, one can easily realize that the majority of 
achievements in C−H functionalization reactions rely on noble metal catalysts, typically 
based on palladium, rhodium or ruthenium.5b−5i,5l−5u,8 The pivotal metalation step of C−H 
bond activation reactions, was proposed to proceeded by oxidative addition, electrophilic 
substitution, σ-bond metathesis or 1,2-addition.5i,5q A few early reports indicated another 
potential possibility, which suggests that the reactions proceed via base-assisted 
metalation.5i,5q An early stoichiometric cyclometalation reactions of ruthenium was disclosed 
by Davies and coworkers, and revealed the beneficial effect of NaOAc.9 However, the first 
ruthenium(II)-catalyzed C−H bond functionalization with carboxylate assistance was reported 
by Ackermann in 2008 (Scheme 1.3).10 Since then, the use of various carboxylates as 
cocatalytic additives for ruthenium catalysis became popular and widespread. 
 
Scheme 1.3. Proposed rationalization for base-assisted C−H ruthenation. 
1.2.1 Carboxylate-Assisted Ruthenium-Catalyzed Oxidative Alkyne 
Annulations and Oxidative Alkenylations via C−H Functionalization 
Since Ackermann and coworkers suggested that ruthenium-catalyzed direct arylation involves 
reversible C−H bond activations via carboxylate-assisted and subsequent deprotonative 
ruthenations, carboxylates were also explored as cocatalytic additives for ruthenium-catalyzed 
oxidative C−H bond functionalizations 11 . The Ackermann group developed ruthenium 
                                                                 
8 Recent examples for C−H functionalizations. Pd: a) K. S. L. Chan, H.-Y. Fu, J.-Q. Yu, J. Am. Chem. Soc. 2015, 137, 
2042-2046. Rh: b) S. Yu, S. Liu, Y. Lan, B. Wan, X. Li , J. Am. Chem. Soc. 2015, 137, 1623–1631; c) G. Zhang, H. Yu, G. 
Qin, H. Huang, Chem. Commun. 2014, 50, 4331–4334. Ru: d) S. Warratz, C. Kornhaass, A. Ca jaraville, B. Niepoetter, 
D. Stalke, L. Ackermann, Angew. Chem. Int. Ed. 2015, 54, 5513–5517; e) F. Yang, K. Rauch, K. Kettelhoit, L. 
Ackermann, Angew. Chem. Int. Ed. 2014, 53, 11285–11288. 
9
 D. L. Davies, O. Al-Duaij, J. Fawcett, M. Giardiello, S. T. Hilton, D. R. Russell, Dalton Trans. 2003, 4132–4138. 
10 L. Ackermann, R. Vicente, A. Al thammer, Org. Lett. 2008, 10, 2299–2302. 
11 a) H. Weissman, X. Song, D. Milstein, J. Am. Chem. Soc. 2001, 123, 337–338; b) T. Ueyama, S. Mochida, T. 
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catalytic systems for oxidative alkyne annulations, with the assistance of various directing 
groups. As a consequence, the first ruthenium-catalyzed oxidative annulations of alkynes 
through C−H and N−H bond cleavages for the synthesis of bioactive isoquinolones were 
reported in 2011.12 
Scheme 1.4. The synthesis of heterocycles through alkyne annulations via ruthenium-catalyzed 
C−H bond cleavage.  
Further mechanistic studies proposed the ruthenium-catalyzed oxidative annulations to 
proceed by an initial carboruthenation via acetate-assisted C−H bond cleavage, followed by 
migratory insertion, reductive elimination and reoxidation of the ruthenium(0) species.5i,12 
Thereafter, additional evidence was provided, through synthesis and isolation of key 
intermediates.8f,13 Notably, during the last few years, the scope of alkyne annulations by 
                                                                                                                                                                                          
Fukutani , K. Hirano, T. Satoh, M. Miura, Org. Lett. 2011, 13, 706–708. 
12 L. Ackermann, A. V. Lygin, N. Hofmann, Angew. Chem. Int. Ed. 2011, 50, 6379–6382. 
13 a) B. Li , H. Feng, N. Wang, J. Ma, H. Song, S. Xu, B. Wang, Chem. Eur. J. 2012, 18, 12873–12879; b) B. Li , T. 
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C−H/Het−H bond functionalization have witnessed significant progress in the following 
aspects: oxidative alkyne annulations through (i) C−H/N−H bonds cleavages;12, 14  (ii) 
C−H/O−H bonds cleavages; 15  (iii) C−H/N−O bonds cleavages. 16  Therefore, 
ruthenium(II)-catalyzed annulations of alkynes are among the most important approaches for 
the preparation of heterocyclic molecules (Scheme 1.4). 
In the meantime, carboxylate-assisted ruthenium-catalyzed direct oxidative alkenylations 
were also developed in recent years, although the first ruthenium-catalyzed oxidative 
alkenylation can be traced back to 2001, as reported by Milstein and coworkers. They 
employed molecular oxygen as the terminal oxidant, and obtained a rather narrow and limited 
scope under these harsh reaction conditions.11a A carboxylate-assisted procedure for the 
successful ruthenium-catalyzed direct alkenylation of heteroaromatic11b and aromatic17 acids 
was reported in 2011 by Miura and coworkers as well as by Ackermann and coworkers. 
Further mechanistic studies showed the importance of acetates to be dominated for efficient 
C−H bond metalations.17 Thereafter, the groups of Miura and Ackermann independently 
revealed the powerful ruthenium-catalyzed direct oxidative alkenylation of N,N-di-18 and 
N-monoalkylated benzamides 2.19 
The direct alkenylation of acrylamides 4 with alkenes was reported by Zhang and Loh.20 
Similarly, Wang and coworkers described an alkenylation reaction of N-methoxybenzamides 
2 bearing an internal oxidizing directing group.21 
                                                                                                                                                                                          
Roisnel, C. Darcel , P. H. Dixneuf, Dalton Trans. 2012, 41, 10934–10937. 
14 a) L. Ackermann, A. V. Lygin, N. Hofmann, Org. Lett. 2011, 13, 3278–3281; b) L. Ackermann, A. V. Lygin, Org. 
Lett. 2012, 14, 764–767; c) L. Ackermann, L. Wang, A. V. Lygin, Chem. Sci. 2012, 3, 177–180; d) W. Ma, K. Graczyk, 
L. Ackermann, Org. Lett. 2012, 14, 6318–6321; e) L. Wang, L. Ackermann, Org. Lett. 2013, 15, 176–179. 
15 a) M. Deponti , S. I . Kozhushkov, D. S. Yufi t, L. Ackermann, Org. Biomol. Chem. 2013, 11, 142–148, and 
references cited therein; b) L. Ackermann, J. Pospech, K. Graczyk, K. Rauch, Org. Lett. 2012, 14, 930–933; c) R. K. 
Chinnagolla, M. Jeganmohan, Chem. Commun. 2012, 48, 2030–2032; d) V. S. Thirunavuarasu, M. Donati , L. 
Ackermann, Org. Lett. 2012, 14, 4210–4213. 
16
 a) L. Ackermann, S. Fenner, Org. Lett. 2011, 13, 6548–6551; b) B. Li, H. Feng, S. Xu, B. Wang, Chem. Eur. J. 2011, 
17, 12573–12577; c) K. Parthasarathy, N. Senthilkumar, J. Jayakumar, C.-H. Cheng, Org. Lett. 2012, 14, 3478–3481; 
d) C. Kornhaass, J. Li , L. Ackermann, J. Org. Chem. 2012, 77, 9190–9198; e) R.K. Chinnagolla, S. Pimparkar, M. 
Jeganmohan, Org. Lett. 2012, 14, 3032–3035; f) F. Yang, L. Ackermann, J. Org. Chem. 2014, 79, 12070–12082. 
17 L. Ackermann, J. Pospech, Org. Lett. 2011, 13, 4153–4155. 
18 Y. Hashimoto, T. Ortloff, K. Hirano, T. Satoh, C. Bolm, M. Miura, Chem. Lett. 2012, 41, 151–153. 
19
 L. Ackermann, L. Wang, R. Wolfram, A. V. Lygin, Org. Lett. 2012, 14, 728–731. 
20 J. Zhang, T.-P. Loh, Chem. Commun. 2012, 48, 11232–11234. 




Scheme 1.5. Carboxylate-assisted ruthenium-catalyzed oxidative C−H bond alkenylations. 
Based on these contributions, the following research for the mentioned ruthenium(II) catalytic 
system came to extend the scope of directing groups, to include ester (35),22−23 ketone (30),24 
aldehyde,25 carbamate (22),26−27 2-pyridyloxy (24),28 sulfonic acid (26),29  oxazole (28),30 
                                                                 
22
 K. Graczyk, W. Ma, L. Ackermann, Org. Lett. 2012, 14, 4110–4113. 
23 K. Padala, S. Pimparkar, P. Madasamy, M. Jeganmohan, Chem. Commun. 2012, 48, 7140–7142. 
24 K. Padala. M. Jeganmhan, Org. Lett. 2011, 13, 6144–6147. 
25 K. Padala. M. Jeganmhan, Org. Lett. 2012, 14, 1134–1137. 
26 J. Li , C. Kornhaass, L. Ackermann, Chem. Commun. 2012, 48, 11343–11345. 
27 M. C. Reddy, M. Jeganmohan, Eur. J. Org. Chem. 2013, 1150–1157. 
28
 W. Ma, L. Ackermann, Chem. Eur. J. 2013, 19, 1150–1157. 
29 W. Ma, R. Mei, G. Tenti , L. Ackermann, Chem. Eur. J. 2014, 20, 15248–15251. 
30 B. Li , K. Devara j, C. Darcel, P. Dixneuf, Green Chem. 2012, 14, 2706–2709. 
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triazole,31 among others. (Scheme 1.5).32 
1.2.2 Carboxylate-Assisted Ruthenium-Catalyzed Hydroarylations via C−H 
Bond Functionalization 
As discussed above, the carboxylate-assisted ruthenium-catalyzed oxidative C−H bond 
functionalizations can be used as one of the reliable methods for C−C bond formation. 
Meanwhile, the developments of ruthenium-catalyzed hydroarylation reactions in an atom- 
and step-economical way, under mild reaction conditions were also achieved. Pioneering 
finding by Lewis, indicated the first ortho-hydroarylation of alkenes with phenol.33 A further 
breakthrough was made in 1993 by Murai and coworkers, when they reported on the 
ruthenium(0)-catalyzed direct hydroarylation of alkenes 20 via chelation-assisted C−H bond 
activation in aromatic ketones 30 (Scheme 1.6).34  The reaction can be considered to 
constitute an ideal pathway, not only in terms of atom- and step-economy, but also because of 
its high site-selectivity. A series of hydroarylation reactions were reported by Murai and 
coworkers in the following years, 35 − 36  including a direct alkylation with decorated 
vinylsilanes 20, as reported by Trost.37  
 
Scheme 1.6. Ruthenium(0)-catalyzed direct hydroarylation by Murai. 
Subsequently, progress was made by Genet, Darses and coworkers utilizing a more flexible 
and practical [RuCl2(p-cymene)]2 precursor, in association with sodium formiate and a 
                                                                 
31
 C. Ti rler, L. Ackermann, Tetrahedron 2015, DOI:10.1016/j.tet.2015.02.033. 
32 a) Y. Hashimoto, T. Ueyama, T. Fukutani , K. Hirano, T. Satoh, M. Miura, Chem. Lett. 2011, 40, 1165–1166; b) P. B. 
Arockiam, C. Fischmeister, C. Bruneau, P. H. Dixneuf, Green Chem. 2011, 13, 3075-3078; c) L.-Q. Zhang, S. Yang, X. 
Huang, J. You, F. Sodirectng, Chem. Commun. 2013, 49, 8830–8832; d) B. Li , J. Ma, W. Xie, H. Song, S. Xu, B. Wang, 
J. Org. Chem. 2013, 78, 9345–9353. 
33
 L. N. Lewis, J. F. Smith, J. Am. Chem. Soc. 1986, 108, 2728–2735. 
34 S. Murai, F. Kakiuchi , S. Sekine, Y. Tanaka, A. Kamatani, M. Sonoda, N. Chatani , Nature 1993, 366, 529–531. 
35 a) M. Sonoda, F. Kakiuchi , A. Kamatani , N. Chatani, S. Murai, Chem. Lett. 1996, 109–110; b) F. Kakiuchi , M. 
Yamauchi, N. Chatani , S. Murai , Chem. Lett. 1996, 111–112; c) T. Sato, F. Kakiuchi , N. Chatani , S. Murai, Chem. 
Lett. 1998, 893–894; d) F. Kakiuchi, T. Sato, M. Yanauchi , N. Chatani , S. Murai , Chem. Lett. 1999, 19–20. 
36 a) F. Kakiuchi , T. Sato, K. Igi , N. Chatani, S. Murai, Chem. Lett, 2001, 386–387. Selected reviews: b) J. R. 
Andreatta , B. A. McKeown, T. B. Gunnoe, J. Organomet. Chem. 2011, 696, 305–315; c) F. Kakiuchi, Top. 
Organomet. Chem. 2007, 24, 1–33. 
37 B. M. Trost, K. Imi, I . W. Davies, J. Am. Chem. Soc. 1995, 117, 5371–5372. 
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phosphine ligand (Scheme 1.7).38  
 
Scheme 1.7. In-situ ruthenium(0) catalyst for hydroarylation by Genet and Darses. 
Meanwhile, the Ackermann group disclosed a ruthenium-based catalytic system, consisting of 
[RuCl2(cod)]n and XPhos, that promoted the addition of arenes to various 
methylenecyclopropanes 38.39 
Nevertheless, among the many strategies available, carboxylate-assisted 
ruthenium(II)-catalyzed C−H bond functionalizations were successfully utilized in the 
hydroarylations by Ackermann and coworkers in 2013. 40−41 The reaction unveiled a highly 
efficient and broadly applicable ruthenium(II)biscarboxylate catalyst for additions of C−H 
bonds to methylenecyclopanes and even unactivated alkenes (Scheme 1.8). Very recently, a 
highly efficient ruthenium-catalyzed α-alkylation of a C(sp3)−H bonds in pyrrolidines was 
also reported by Ackermann and coworkers.42 
 
Scheme 1.8. Carboxylate-assisted ruthenium(II)-catalyzed direct hydroarylation.  
Despite these notable advances, the hydroarylation with olefins bearing functional groups 
remained challenging, especially those of more important families of acceptors, such as 
α,β-unsaturated acceptors. Moreover, sporadic early reports were limited to the use of rather 
                                                                 
38 a) R. Martinez, R. Chevalier, S. Darses, J. P. Genet, Angew. Chem. Int. Ed. 2006, 45, 8232–8235; b) R. Martinez, J. 
P. Genet, S. Darses , Chem. Commun. 2008, 3855–3857; c) R. Martinez, M. O. Simon, R. Chevalier, C. Pautigny, J. P. 
Genet, S. Darses, J. Am. Chem. Soc. 2009, 131, 7887–7895; d) M.-O. Simon, R. Martinez, J.-P. Genet, S. Darses, Adv. 
Synth. Catal. 2009, 351, 153–157; e) M. O. Simon, R. Martinez, J. P. Genet, S. Darses , J. Org. Chem. 2010, 75, 
208–210; f) M.-O. Simon, S. Darses, J. Org. Chem. 2013, 78, 9981–9985. 
39 a) S. I . Kozhushkov, D. S. Yufi t, L. Ackermann, Org. Lett. 2008, 10, 3409–3412; b) L. Ackermann, S. I . Kozhushkov, 
D. S. Yufi t, Chem. Eur. J. 2012, 18, 12068–12077. 
40
 M. Schinkel , I . Marek, L. Ackermann, Angew. Chem. Int. Ed. 2013, 52, 3977–3980. 
41 M. Schinkel , J. Wallbaum, S. I . Kozhushkov, I . Marek, L. Ackermann, Org. Lett. 2013, 15, 4482–4484. 
42 M. Schinkel , L. Wang, K. Bielefeld, L. Ackermann, Org. Lett. 2014, 16, 1876–1879. 
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expensive 43 rhodium44 or rhenium45 catalysts. Until the introduction of bidentate-chelation 
assistance, Chatani and coworkers described a new ruthenium-catalyzed C−H hydroarylation 
of aromatic amides (40) with a wide range of α,β-unsaturated ketones (41) via 
bidentate-chelation assistance (Scheme 1.9).46 
 
Scheme 1.9. Ruthenium(II)-catalyzed direct hydroarylation of aromatic amides 40 with 
α,β-unsaturated ketones 41. 
In spite of the significant progress achieved in the last two decades in the area of 
ruthenium-catalyzed direct hydroarylation, a great deal of work, such as improving the 
tolerance of a range of functional groups, still has to be done in this field of catalysis. 
1.3 Cobalt-Catalyzed C−H Bond Functionalizations  
Over the last few decades, most of the remarkable advances in transition metal-catalyzed 
C−H bond functionalization were achieved employing the expensive43 second-row transition 
metals. The development of catalysts based on the naturally more abundant first-row 
transition metals and complexes, which would enable C−H bond functionalization to be 
accomplished under mild reaction conditions, would present a more activation strategy. 
Consequently, the use of 3d transition metal catalysts has witnessed considerable recent 
attention.47  
Among the first-row transition metals, the notable power of cobalt salts as effective catalysts 
                                                                 
43 The price of transi tion metals: see a) http://www.platinum.matthey.com/; b) http://www.chemicool.com/ 
(20.05.2015). 
44 a) S. G. Lim, J. A. Ahn, C. H. Jun, Org. Lett. 2004, 6, 4687–4690; b) L. Yang, C. Correia, C. Li , Org. Biomol. Chem. 
2011, 9, 7176–7179; c) L. Yang, B. Qian, H. Huang, Chem. Eur. J. 2012, 18, 9511–9515. 
45 Y. Kuninobu, Y. Nishina, K. Okaguchi , M. Shouho, K. Takai , Bull. Chem. Soc. Jpn. 2008, 81, 1393–1401. 
46 G. Rouquet, N. Chatani , Chem. Sci. 2013, 4, 2201–2208. 
47 a) B. Su, Z.-C. Cao, Z.-J. Shi , Acc. Chem. Res. 2015, 48, 886–896; b) E. Nakamura, T. Hatakeyama, S. Ito, K. 
Ishizuka, L. Ilies , M. Nakamura, Org. React. 2014, 83, 1–209; c) J. Yamaguchi, K. Muto, K. Itami, Eur. J. Org. Chem. 
2013, 19–30; d) N. Yoshikai, Synlett 2011, 1047–1051; e) Y. Nakao, Chem. Rec. 2011, 11, 242–251; f) E. Nakamura, 
N. Yoshikai, J. Org. Chem. 2010, 75, 6061–6067; f) A. Kulkarni , O. Daugulis, Synthesis 2009, 4087–4109. 
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for homocouplings of Grignard reagents was pioneered by Kharasch and Fields in 1941.48 
The first example of cobalt used in chelation-assisted C−H functionalization was developed in 
1955 by Murahashi who revealed an ortho-carbonylation reaction of aldimine 43 using 
dicobalt octacarbonyl as the catalyst, giving phthalimidine 44 again under rather harsh 
reaction conditions, however under high temperature and pressure (Scheme 1.10a).49 Later, 
Murahashi and Horiie showed that azobenzene 45 could undergo a similar direct metalation 
furnishing the indazolone 46 (Scheme 1.10b).50 In the next few decades, the application of 
cobalt in chelation-assisted C−H bond functionalization was stagnant until 1994, when a 
Co(H)(N2)(PPh3)3-catalyzed ortho-alkenylation of azobenzene derivative 47 with tolane (1) 
was reported (Scheme 1.10c).51 Meanwhile, Klein and coworkers described the first example 
of a well-defined stoichiometric cyclometalation, employing azobenzene and 
Co(Me)(PMe3)4.52  
 
Scheme 1.10. Cobalt-mediated chelation-assisted C−H bond functionalizations  
reported before 1995. 
Further research provided a series of aromatic and olefinic substrates bearing various 
                                                                 
48 M. S. Kharasch, E. K. Fields , J. Am. Chem. Soc. 1941, 63, 2316–2320. 
49 S. Murahashi, J. Am. Chem. Soc. 1955, 77, 6403–6404. 
50
 S. Murahashi, S. Horiie, J. Am. Chem. Soc. 1956, 78, 4816–4817. 
51 G. Halbritter, F. Knoch, A. Wolski , H. Kisch, Angew. Chem. Int. Ed. 1994, 33, 1603–1605. 
52 H.-F. Klein, M. Helwig, U. Koch, U. Flörke, H.-J. Haupt, Z. Naturforsch. B: Chem. Sci. 1993, 48, 778–784. 
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directing groups containing nitrogen,52−53 oxygen,54 sulfur55 and phosphorus56−57,58  atoms, 
which could assist the stoichimetric oxidative addition of the ortho C−H bond to the cobalt 
complex, with concomitant reductive elimination of methane. In particular, both the five- and 
six-membered cobaltocycles can be formed with phosphorus chelating ligands via C−H bond 
activation, including a C(sp3)−H bond (Scheme 1.11).54 All of this knowledge implied that 
complexes of cobalt could potentially allow for mild C−H bond functionalization although 
still facing many challenges. 
 
Scheme 1.11. Stoichiometric cyclometalation with cobalt complex 60. 
                                                                 
53 H.-F. Klein, S. Camadanli , R. Beck, D. Leukel, U. Flörke, Angew. Chem. Int. Ed. 2005, 44, 975–977. 
54 S. Camadanli , R. Beck, U. Flörke, H.-F. Klein, Dalton Trans. 2008, 5701–5704. 
55 R. Beck, H. Sun, X. Li , S. Camadanli, H.-F. Klein, Eur. J. Inorg. Chem. 2008, 3253–3257. 
56
 H.-F. Klein, S. Schneider, M. He, U. Flörke, H.-J. Haupt, Eur. J. Inorg. Chem. 2000, 2295–2301. 
57 H.-F. Klein, R. Beck, U. Flörke, H.-J. Haupt, Eur. J. Inorg. Chem. 2003, 1380–1387. 
58 R. Beck, H. Sun, X. Li , H.-F. Klein, Z. Anorg. Allg. Chem. 2009, 635, 99–105. 
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1.3.1 Cobalt-Catalyzed C−H Bond Functionalizations in Aldehydes 
Based on early contributions, functionalization of the aldehyde C−H bond was first reported 
by Brookhart and coworkers in 1997. The Cp*Co(CH2＝CHSiMe3)2 (61) catalyst succeeded 
in the hydroacylation of olefins (Scheme 1.12).59−60 Further research described clear evidence 
for the oxidative addition of C(sp2)−H bonds to the Cp*Co(I) moiety. 61  
 
Scheme 1.12. Cobalt-catalyzed formyl C−H functionalization in aldehydes 62 reported before 
2014. 
Recent progress in the formyl−H bond functionalization of aldehydes was made in 2014 by 
Dong and Yoshikai. Dong and coworkers described a cobalt-catalyzed hydroacylation of 
1,3-dienes 65 with aldehydes 62, and proposed an oxidative cyclization mechanism that 
involved a cobaltacycle intermediate, which predetermined the regio- and stereoselectivity of 
the transformation (Scheme 1.13a).62 Taking in consideration this recent work on cobalt and 
the previously reported contributions on enantioselective Rh-catalyzed transformations,63 
                                                                 
59 C. P. Lenges , M. Brookhart, J. Am. Chem. Soc. 1997, 119, 3165–3166. 
60 C. P. Lenges , P. S. White, M. Brookhart, J. Am. Chem. Soc. 1998, 120, 6965–6979. 
61 C. P. Lenges , M. Brookhart, B. E. Grant, J. Organomet. Chem. 1997, 528, 199–203. 
62
 Q.-A. Chen, D. K. Kim, V. M. Dong, J. Am. Chem. Soc. 2014, 136, 3772–3775. 
63 a) D. H. Phan, K. G. M. Kou, V. M. Dong, J. Am. Chem. Soc. 2010, 132, 16354–16355; b) M. M. Coulter, K. G. M. 
Kou, B. Galligan, V. M. Dong, J. Am. Chem. Soc. 2010, 132, 16330–16333; c) D. H. T. Phan, B. Kim, V. M. Dong, J. 
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Yoshikai and coworkers reported the first chiral cobalt-diphosphine catalytic system, which 
allowed for intramolecular hydroacylation of 2-acylbenzaldehydes 67 and 
2-alkenylbenzaldehydes 69, to generate phthalides 68 or indanones 70 derivatives, 
respectively (Scheme 1.13b).64 
 
Scheme 1.13. a) Cobalt-catalyzed hydroacylation by oxidative cyclization. b) Cobalt-catalyzed 
enantioselective intramolecular hydroacylation. 
1.3.2 Low-Valent Cobalt-Catalyzed Chelation-Assisted C−H Bond 
Functionalizations 
The chelation-assisted direct conversion of C−H bonds into C−C bonds using low-valent 
cobalt catalysts was studied independently by the research groups of Yoshikai,65 Nakamura,66 
                                                                                                                                                                                          
Am. Chem. Soc. 2009, 131, 15608–15609; d) K. Kundu, J. V. McCullagh, A. T. Jr. Morehead, J. Am. Chem. Soc. 2005, 
127, 16042–16043. 
64
 J. Yang, N. Yoshikai, J. Am. Chem. Soc. 2014, 136, 16748–16751. 
65 Selected representative examples : a) W. Xu, N. Yoshikai, Angew. Chem. Int. Ed. 2014, 53, 14166–14170; b) Z. 
Ding, N. Yoshikai , Angew. Chem. Int. Ed. 2013, 52, 8574–8578; c) K. Gao, N. Yoshikai , J. Am. Chem. Soc. 2013, 135, 
9279–9282; d) Z. Ding, N. Yoshikai, Angew. Chem. Int. Ed. 2012, 51, 4698–4701; e) P.-S. Lee, T. Fuji ta, N. Yoshikai, J. 
Am. Chem. Soc. 2011, 133, 17283–17295; f) K. Gao, P.-S. Lee, T. Fujita , N. Yoshikai , J. Am. Chem. Soc. 2010, 132, 
12249–12251. 
66
 a) Q. Chen, L. Ilies, N. Yoshikai, E. Nakamura, Org. Lett. 2011, 13, 3232–3234; b) L. Ilies, Q. Chen, X. Zeng, E. 





1.3.2.1    Low-Valent Cobalt-Catalyzed C−H Bond Functionalizations 
According to the two different types of developed cobalt-catalyzed C−H bond 
functionalization, the subsequent discussion in this section will be divided in two topics: 
(a) Cobalt-catalyzed hydroarylation of alkynes and olefins 
Based on Kisch’s report on the first cobalt(I)-catalyzed ortho-dialkenylation reactions,51 
Yoshikai and coworkers devised a ternary catalytic system consisted of CoBr2, phosphine 
ligand (PMePh2) and a reductant (MeMgCl), which catalyzed the hydroarylation reaction 
between 2-arylpyridines 28 and oct-4-yne 1 to yield the desired hydroarylated product 71 
(Scheme 1.14a).65f The scope of cobalt-catalysis was further expanded to use pyrimidin-2-yl 
as a removable directing group. 69  Remarkably, the C2-selective alkenylation of 
N-pyrimidylindoles 7 with internal alkynes 1 was catalyzed by low-valent cobalt at ambient 
temperature (Scheme 1.14b).65d  
 
Scheme 1.14. Cobalt-catalyzed hydroarylation via C−H bond activation in 2-arylpyridines 28 and 
N-(pyrimidin-2-yl)indoles 7. 
                                                                 
67 a) B. Punji, W. Song, G. Shevchenko, L. Ackermann, Chem. E. J. 2013, 19, 10605–10610; b) W. Song, L. 
Ackermann, Angew. Chem. Int. Ed. 2012, 51, 8251–8254. 
68
 See also: a) L. Grigorjeva, O. Daugulis, Org. Lett. 2014, 16, 4688-4690; b) L. Griorjeva, O. Daugulis, Org. Lett. 
2014, 16, 4684–4687; c) L. Grigorjeva, O. Daugulis, Angew. Chem. Int. Ed. 2014, 53, 10209–10212. 
69 L. Ackermann, A. V. Lygin, Org. Lett. 2012, 14, 764-767. 
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Schiff bases (73 and 43) as directing groups behaved in a similar fashion to phenylpyridine 
(28). The additions of aryl ketimines 73 and aldimines 43 to internal alkynes were achieved 
by a catalytic system of CoBr2, phosphine ligand, Grignard reagent and pyridine.67e Under 
acidic reaction conditions, the diarylacetylenes 1 afforded the corresponding ketones 74 
(Scheme 1.15a) and aldehydes 75 (Scheme 1.15b), while the products of dialkyl- and 
alkylarylacetylenes underwent cyclization to give benzofulvene derivatives.65e,70  
 
Scheme 1.15. Cobalt-catalyzed hydroarylations with aryl ketimines 73 and aldimines 43 via C−H 
activation.  
The proposed catalytic cycle of these novel cobalt-catalyzed direct hydroarylations began 
with the reduced form of the active cobalt catalyst, which was generated from the cobalt(II) 
precatalyst and an excess of tBuCH2MgBr. Precoordination of the alkyne 1 to the active 
cobalt species was followed by oxidative addition of the ortho C−H bond in 73 to the cobalt 
complex A. Intramolecular hydrocobaltation in complex B and subsequent reductive 
elimination in the intermediate C furnished the desired product and regenerated the cobalt 
catalyst (Scheme 1.16).5j,65e In the case of unsymmertrical alkynes 1, the product via C–C 
bond formation at the less hindered acetylenic carbon was formed predominantly. Such a 
regioselectivity was rationalized in terms of significant steric interactions on the cobalt center 
upon the transformation BC. 
                                                                 




Scheme 1.16. Plausible catalytic cycle for the cobalt-catalyzed hydroarylation with internal 
alkynes 1. 
Notably, the hydroarylation proceeded not only on aryl imines but also on olefins via alkenyl 
C−H activation. Thus, dihydropyridine derivatives 76 were generated by annulations of 
α,β-unsaturated imines (Scheme 1.17).71 
 
Scheme 1.17. Annulation of alkynes 1 with α,β-unsaturated imines 73. 
Utilizing the differences in bond acidities of diversely positioned C−H bonds is another viable 
approach to perform site-selective C−H bond functionalizations in heteroaromatic compounds. 
Thus, Yoshikai and coworkers developed a cobalt-based catalytic system for the syn-additions 
of (benzo)azoles 77 or 79 to internal alkynes via C−H bond functionalization with high 
chemo-, regio- and stereoselectivities under mild conditions (Scheme 1.18).72 
                                                                 
71 T. Yamakawa, N. Yoshikai , Org. Lett. 2013, 15, 196–199. 




Scheme 1.18. Alkenylations of azoles 77 and 79 with alkynes 1. 
Considering the remarkabe high efficacy of alkyne hydroarylation, Yoshikai and coworkers 
next became intrigued by the development of analogous novel reactions for styrenes. So far, 
the low-valent cobalt have already successfully catalyzed pyridinyl- (28),73 benzamide- (2)66b 
and imine-assisted (73)65a−65b,74 C−H bond hydroarylation with good regioselectivity (Scheme 
1.19).  
 
Scheme 1.19. Various directing groups assisted hydroarylations of olefins. 
The first example of intramolecular cobalt catalysis, namely the cobalt/NHC-catalyzed 
intramolecular hydroarylation of alkene moieties after C–H bond activation on C2 position of 
indole fragments, was investigated by Yoshikai’s group (Scheme 1.20).65b The reaction 
allowed for the direct transformation of indole derivatives 43 into dihydropyrroloindoles 81 
or tetrahydropyridoindoles 82 under mild conditions. Interestingly, the size of the formed 
cycle was not only dependent on the length of the olefin tether, but also controlled by the 
steric properties of the NHC ligand. Thus, the cobalt-IPr catalyst promoted the regioselective 
intramolecular cyclizations of olefins to tetrahydropyridoindole 82, whereas the cobalt-SIMes 
analogue switched regioselectivity toward the formation of dihydropyrroloindole 81. 
                                                                 
73
 K. Gao, N. Yoshikai, J. Am. Chem. Soc. 2011, 133, 400–402. 
74 a) K. Gao, N. Yoshikai, Angew. Chem. Int. Ed. 2011, 50, 6888-6892; b) P.-S. Lee, N. Yoshikai , Angew. Chem. Int. 
Ed. 2013, 52, 1240–1244; c) T. Yamakawa, N. Yoshikai, Chem. Asian. J. 2014, 9, 1242–1246. 
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Scheme 1.20. Cobalt/NHC-catalyzed intramolecular hydroarylation leading to 
dihydropyrroloindoles 81 or tetrahydropyridoindoles 82. 
(b) Cobalt-catalyzed coupling reactions with organic electrophiles 
In recent years, some examples of cobalt-catalyzed C−H coupling reactions with organic 
electrophiles have been reported. Cobalt-catalyzed ortho-alkylation of benzamides 2 with 
primary alkyl chlorides 81 was reported by Nakamura and coworkers (Scheme 1.21a),66c  
 
Scheme 1.21. Cobalt-catalyzed C−H alkylation with diverse directing groups. 
The reaction could also be performed with ketimine- (73),65c pyridyl- and 
pyrimidyl-assistance (28),67a thus achieving direct alkylation with a broad range of primary 
and secondary alkyl chlorides and bromides through C−H bond activation (Schemes 
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1.21b–1.21c). In addition, oxidative ortho-alkylation of benzamides 2 and 2-arylpyridines 28 
with alkyl Grignard reagents was also reported by Nakamura and coworkers.66a 
The cobalt-catalyzed functionalization of C−H bonds could be applied to challenging direct 
arylation. Ackermann and coworkers initially developed a cobalt-IMes catalytic system for 
direct C−H arylations of arenes with the electronically deactivated aryl sulfamates 85 and aryl 
carbamates 86.67b These direct functionalizations chemoselectively delivered the 
monoarylated products 87 (Scheme 1.22a). The versatile cobalt catalyst was not limited to 
2-arylpyridines 28 but also set the stage for the synthesis of potentially bioactive 
N-substituted indoles 7.  
 
Scheme 1.22. Cobalt/NHC-catalyzed C−H bond arylations with diverse directing groups. 
Aryl chlorides 88 are the ideal electrophilic aryl halides for direct arylation reactions, since 
they are cost-effective, whilst being widely available. Ackermann and Yoshikai explored a 
cobalt-based catalytic system that allowed the direct arylation of aryl pyridines 28 and 
ketimines 73 with decorated chlorobenzene at ambient or elevated temperatures in the 
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presence of NHC or phosphine ligands, respectively. After hydrolysis, biarylketones 89 were 
obtained (Scheme 1.22b).67a,75 In contrast, oxidative arylation of 2-arylpyridines with aryl 
Grignard reagents was reported by Shi and coworkers.76 
Meanwhile, the cobalt-IMes catalyst was not restricted to the synthesis of biaryl compounds, 
but also enabled effective C−H bond benzylation reactions on indole 7a with benzyl 
phosphates 90 as electrophiles at ambient temperature (Scheme 1.23).67b 
 
Scheme 1.23. Cobalt-catalyzed C−H benzylation of indole 7. 
The general consensus is that the cobalt-catalyzed C−H alkylation involves a radical 
intermediate. Thus, a proposed catalytic cycle is shown below (Scheme 1.24).5j−5k  
 
Scheme 1.24. Proposed catalytic cycle for the cobalt-catalyzed C−H bond functionalization. 
The cycle is initiated by a C−H cyclocobaltation and subsequent single electron transfer (SET) 
                                                                 
75 K. Gao, P.-S. Lee,C. Long, N. Yoshikai, Org. Lett. 2011, 14, 4234–4237. 
76 B. Li , Z.-H. Wu, Y.-F. Gu, C.-L. Sun, B.-Q. Wang, Z.-J. Shi , Angew. Chem. Int. Ed. 2011, 50, 1109–1113. 
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from the cobalt center to the alkyl halide 83. The desired product resulted from radical C−C 
coupling followed by reductive elimination, and the alkyl cobalt species was regenerated after 
the transmetalation of cobalt halide with the Grignard reagent. 
1.3.2.2    Cobalt-Catalyzed Oxidative C−H Bond Functionalizations 
Since Daugulis initially devised the 2-aminoquinoline and picolinamide directing groups for 
the palladium-catalyzed arylation of C(sp3)−H bonds in 2005,77 the bidentate-type directing 
groups have quickly emerged as a new tool in exploring C−H activation reactions. 78 
Interestingly, another remarkable progress was made by Daugulis and coworkers, by reporting 
an approach for cobalt-catalyzed direct oxidative alkyne annulation via aminoquinoline 40 
and picolinamide 92 as bidentate-chelation assistance. The reaction was successful with both 
terminal and internal alkynes. This approach provided expedient access to diversely decorated 
isoquinolin-1-ones 93 with ample scope of substrates, such as heteroarenes and vinyl amide 
40 (Scheme 1.25a). Furthermore, it allowed the subsequent removal of the directing groups 
under simple reaction conditions (Scheme 1.25b).68c 
                                                                 
77 V. G. Zai tsev, D. Shabashov, O. Daugulis , J. Am. Chem. Soc. 2005, 127, 13154–13155. 
78 Recent reviews  on C—H activation with bidentate di recting groups : a) O. Daugulis, J. Roane, L. D. Tran, Acc. 
Chem. Res. 2015, 48, 1053–1064; b) L. C. M. Castro, N. Chatani , Chem. Lett. 2015, 44, 410–421; c) M. Corbet, F. De 
Campo, Angew. Chem. Int. Ed. 2013, 52, 9896–9898; d) G. Rouquet, N. Chatani , Angew. Chem. Int. Ed. 2013, 52, 
11942–11959. Selected recent examples demonstrating the power of bidentate directing groups : e) Q. Gu, H. H. 
Al  Mamari , K. Graczyk, E. Diers , L. Ackermann, Angew. Chem. Int. Ed. 2014, 53, 3868–3871; f) W. Song, S. Lackner, 





Scheme 1.25. (a) Substrate scope for cobalt-catalyzed C−H annulations. (b) Directing group 
removal. 
After the successful development of cobalt-catalyzed oxidative cyclizations with alkyne 1, 
further studies indicated that the cobalt catalytic system was not restricted to alkynes, but also 
exhibited notable power in C(sp2)−H bond coupling with alkenes. Upon further investigations 
of the reaction of N-(quinolin-8-yl)benzamide (40) and styrene (20), employing Co(acac)2 as 
a catalyst, Mn(OAc)3∙2H2O as a co-catalyst, and oxygen from air as a terminal oxidant, a 
remarkable scope of aminoquinoline-protected amides of benzoic, heteroaromatic and acrylic 




Scheme 1.26. Substrate scope for cobalt-catalyzed alkene annulations through C−H bond 
activation. [a] Co(acac)2 (50 mol %), 80 °C. 
Based on the high catalytic efficacy of the cobalt catalyst in oxidative annulations of alkynes 
1 and alkenes 20, Daugulis and coworkers thereafter developed a cobalt-catalyzed direct 
carbonylation of benzoic- and acrylic acid-derivatives amides 40 with carbon monoxide 
through bidentate-chelation assistance. The entire scope was completed at ambient 
temperature and afforded the desired phthal- and succinimides 97 in good yields (Scheme 
1.27a).68a  
 
Scheme 1.27. Carbonylation of aminoquinoline-derived amides 40. 
A wide range of functional groups, such as halogen, nitrile, ester and cyano substituents, can 
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be tolerated under the optimizaed reaction conditions. Intramolecular competition 
experiments with meta-substituted arenes exhibited high levels of site-selectivity (Scheme 
1.27).68a The directing group can be easily removed by treatment with methanolic ammonia, 
and the desired phthalimide 97 were obtained in high yield.  
Meanwhile, very recently Song and coworkers developed the cobalt-catalyzed C−H bond 
alkoxylation with alcohols in benzamides 98 derived from 2-aminopyridine-1-oxide through a 
N,O-bidentate-type directing groups.79 The reaction proceeded under mild conditions using 
Co(OAc)2∙4H2O as the catalyst and with a wide range of substituted alcohols as well as of 
benzamides, heteroarenes and substituted vinyl amides 98 decorated with a variety of 
functional groups (Scheme 1.28a).79 
 
Scheme 1.28. (a) Substrate scope for cobalt-catalyzed C−H alkoxylation. (b) Directing group 
removal. 
In addition, the reaction showed a high site-selectivity when meta-substituted substrates were 
employed. The mechanistic studies revealed that a radical pathway was involved. Further, 
                                                                 
79 L.-B. Zhang, X.-Q. Hao, S.-K. Zhang, Z.-J. Liu, X.-X. Zheng, J.-F. Gong, J.-L. Niu, M.-P. Song, Angew. Chem. Int. Ed. 
2015, 54, 272–275. 
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kinetic isotope effect (KIE) studies suggested the C−H bond activation not to be the 
rate-limiting step. The 2-aminopyridine-1-oxide directing group can easily be removed 
affording benzoic acid 101 (Scheme 1.28b).  
1.3.3 High-Valent Cobalt-Catalyzed C−H Bond Functionalizations 
In recent years, Cp*Rh(III) complexes have been involved in the rapidly progregressing 
step-economical 80  C−H bonds functionalizations.5b,7a However, a number of analogous 
Cp*Co(III) complexes have been prepared and characterized up to now (Scheme 1.29).81  
 
Scheme 1.29. Selected synthesized cationic high-valent cobalt(III) complexes. 
Kanai and coworkers chose cobalt, which is isoelectronic to rhodium, but less expensive and 
more abundant, and tried to emulate the reactivity of Cp*Rh(III). In 2013, they reported on 
the application of a variety of Cp*Co(III) complexes (Scheme 1.29) for synthetic organic 
transformations, and the [Cp*Co(benzene)](PF6)2 complex (102a) appeared to be successful 
in promoting the addition of 2-arylpyridines 28 onto multiple bonds in imines 103 (Scheme 
1.30a) as well as in α,β-unsaturated enones 104, and 1-pyrrolylenones 105 (Scheme 1.30b).82  
                                                                 
80 P. A. Wender, V. A. Verma, T. J. Paxton, T. H. Pillow, Acc. Chem. Res. 2008, 41, 40–49. 
81 a) E. O. Fischer, R. D. Fisher, Naturforsch. B 1961, 16, 556–557; b) G. Fai rhurst, C. White, J. Chem. Soc., Dalton 
Trans. 1979, 1531–1538; c) U. Koelle, B. Fuss, M. V. Ra jasekharan, B. L. Ramakrishna, J. H. Ammeter, M. C. Boehm, 
J. Am. Chem. Soc, 1984, 106, 4252–4160. 




Scheme 1.30. Cobalt(III)-catalyzed addition of 2-aryl pyridines to imines 103, α,β-unsaturated 
enones 104 and 105. 
Taking into consideration the important biological activity of indole and its derivatives, their 
modification and functionalization have extensively been studied inter alia by Kanai group 
applying the high-valent [Cp*Co(benzene)(PF6)2] complex (102a). The catalyst efficiently 
promoted the C2-selective hydroindolation of imines 103 with broad scope (Scheme 1.31).83 
The pyrimid-2-yl directing group can be easily removed upon treatment with NaOEt, yielding 
the NH-free indole derivative in a high yield.69 
 
Scheme 1.31. Cobalt(III)-catalyzed addition of N-(pyrimidin-2-yl)indoles 7 to imines 102. 
                                                                 




Scheme 1.32. Cobalt(III)-catalyzed annulations and alkenlations of indoles 109 via C−H bond 
alkenylation.  
Further studies with Cp*Co(III) complexes were extended to catalyze the annulations and 
alkenylations of N-carbamoylindoles 109 via direct C−H activation in reactions with internal 
alkynes 1 to afford pyrroloindolones 110. The results demonstrated that the Cp*Co(III) 
complexes possess the characteristic reactivity similar to those of the Cp*Rh(III) system 
(Scheme 1.32).84 Furthermore, intensive mechanistic studies revealed the difference in the 
mode of catalytic activity between the Cp*Co(III) and Cp*Rh(III) complexes, thus 
highlighted the unique nucleophilic activity of the latter.84 
Besides their contributions on developing catalytically efficient Cp*Co(III) complexes, 
recently the Kanai group successfully applied the air-stable [Cp*CoI2(CO)] complex 112, 
prepared by Li and Jin as early as 2004,85 for the C2-selective C−H bond amidation in 
                                                                 
84 H. Ikemoto, T. Yoshino, K. Sakata, S. Matsunaga, M. Kanai , J. Am. Chem. Soc. 2014, 136, 5424–5431. 
85 W. Li , L. Weng, G. Jin, Inorg. Chem. Commun. 2004, 7, 1174–1177. 
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indoles 7 (Scheme 1.33).86  
 
Scheme 1.33. Cobalt(III)-catalyzed C−H bond amidation of indoles 7. 
 
Scheme 1.34. Cp*CoI2(CO) catalyzed C−H bond functionalizations. 
The use of the [Cp*CoI2(CO)] complex (112) attracts an increasing attention in the past 
several months (Scheme 1.34). Thus, more examples of C−H bond amidation were reported 
using acetoxycarbamates as convenient nitrogen sources, as reported by the Chang group.87 
Likewise the direct C−H phosphoramidation was developed by the Kanai group.88 Moreover, 
the cobalt(III)-catalyzed direct C−H cyanations, halogenations, allylations were developed by 
the Ackermann,89 Glorius,90  and Chang groups.91  Very recently, Glorius and coworkers 
provided a reactive modular route towards a new class of conjugated polycyclic hydrocarbons 
using diazo compounds carbine precursors. 92  The Kanai group also reported on 
Cp*Co(III)-catalyzed oxidative alkenylation of bezamides 2 and acetanilides with ethyl 
acrylate.93
                                                                 
86
 B. Sun, T. Yoshino, S. Matsunaga, M. Kanai, Adv. Synth. Catal. 2014, 356, 1491–1495. 
87 P. Patel , S. Chang, ACS Catal. 2015, 5, 853–858. 
88 B. Sun, T. Yoshino, S. Matsunaga, M. Kanai, Chem. Commun. 2015, 51, 4659–4661. 
89 J. Li , L. Ackermann, Angew. Chem. Int. Ed. 2015, 54, 3635–3638.  
90  D.-G. Yu, T. Gensch, F. de Azambuja, S. Vásquez-Céspedes, F. Glorius , J. Am. Chem. Soc. 2014, 136, 
17722–17725. 
91
 A. B. Pawar, S. Chang, Org. Lett. 2015, 17, 660–663. 
92 D. Zhao, J. H. Kim, L. Stegemann, C. A. Strassert, F. Glorius , Angew. Chem. Int. Ed. 2015, 54, 4508–4511. 




Over the last decade, remarkable advances in transition-metal-catalyzed C–H bond 
functionalization have been achieved, which provided a more straightforward pathway for the 
development of chemo- and site-selective syntheses of valuable organic molecules. As a 
consequence, the center of gravity in researches of Prof. Dr. Lutz Ackermann and coworkers 
mainly focused on the development of synthetically useful transition-metal catalyzed C–H 
bond functionalizations. Within this context, major efforts were made to develop further 
applications of ruthenium and cobalt complexes in catalyzed C–H activation. 
Isoquinolines are key structural motifs of various heterocyclic compounds with diverse 
bioactivities. The new efficient methods for the selective preparation of these heterocycles are 
in strong demand. As a consequence, the method to synthesize decorated isoquinolines 
through annulations of alkynes with ortho-halosubstituted aromatic imines under transition 
netal catalysis has been reported.94 However, a more step- and atom-economical approach by 
the transition-metal-catalyzed oxidative C–H functionalization has been recognized as an 
increasingly viable tool for the preparation of substituted heterocycles. Therefore, a new 
protocol for ruthenium-catalyzed oxidative alkyne annulations by C–H bond activation of 
ketimines 73 was the prime focus of the first project (Scheme 2.1). 
 
Scheme 2.1. Oxidative C–H bond functionalizations with decorated ketimines 73 and alkynes 1. 
As was mentioned above, we were going to manage the extension of isoquinolines to 
decorated 1-aminoisoquinolines 118 and isoindolines 119. One of the reasons for the 
significance of these heterocycles is that they constitute important structural motifs of various 
compounds with activities of relevance to biology or medicinal chemistry. For example, the 
aminoisoquinoline moiety was found in nonbenzamidine factor VIIa inhibitors against 
nonthromboembolic cardiovascular disease (Scheme 2.2 and Scheme 2.3). 
                                                                 




Scheme 2.2. Oxidative annulations of alkynes 1 with decorated amidines 117 through C–H 
activation.  
 
Scheme 2.3. Oxidative alkenylation of decorated amidines 117 with acrylated 20 through C–H 
bond activation. 
The synthetic utility of the transition-metal-catalyzed hydroarylation via C–H bond activation 
was illustrated by Murai.34 Despite the remarkable progress achieved during the last decade, 
α,β-unsaturated acceptors still could not be utilized for such alkylations until 
8-aminoquinoline was introduced as a removable bidentate directing group by Chatani.46 We 
planned to establish ruthenium-catalyzed direct hydroarylation of α,β-unsaturated ketones 41 
with aromatic amides 2 via monodentate coordination in an environmentally friendly medium 
(Scheme 2.4).  
 
Scheme 2.4. Hydroarylation of α,β-unsaturated ketones 41 with mono-dentate amides 2. 
Meanwhile, oxidative annulations of α ,β-unsaturated ketones 41 with acetanilides 121 to 




Scheme 2.5. Oxidative annulations of α,β-unsaturated ketones 41 with acetanilides 121. 
Biaryls constitute the key structural motifs of biologically active and naturally occurring 
compounds, for example, in angiotensin-II-receptor blockers (ARBs).5e The synthesis of these 
structural moiety mostly relied on palladium(0)-catalyzed cross-coupling reactions. Recently, 
the development of catalysts based on the naturally more abundant and less expensive 
first-row transition metals and their complexes has witnessed considerable growth.47 Among 
them, inexpensive cobalt catalysts have been recognized as increasingly viable tools for C–H 
bond activations during the last years. Consequently, the use of cobalt complexes were 
another focus in this context to develop a new step- and atom-economic strategy for the 
synthesis of ARBs 124 and derivatives, as shown in Scheme 2.6.  
 
Scheme 2.6. Strategy for the synthesis of ARBs and derivatives. 
Generally, many cobalt catalytic systems required Grignard reagents as the base and the 
reductant to generate the reactive low-valent cobalt catalysts. Hence, most of the functional 
groups could not be tolerated under these reaction conditions. In order to avoid these 
disadvantages, the research groups of Kanai, Ackermann, Daugulis and Song developed 
milder reaction conditions with cobalt catalysts, including high-valent Cp*Co(III) derivatives. 
Based on this progress, we set out to develop an unprecedented cobalt(III)-catalyzed C–H 




Scheme 2.7. Cobalt(III)-catalyzed C–H cyanation.  
In the last few years, transition-metal-catalyzed direct insertion of isocyanates into C–H 
bonds is in great demand, because this approach efficiently provides synthetically valuable 
amides. However, acyl azides were only found to work as amino sources in the iridium- and 
ruthenium-catalyzed amidation reactions. Moreover, further application of acyl azides was 
strongly limited by the difficulty in controlling the dual reactivity of acyl azides, as the 
reaction results in C–C and C–N bond formations and often affords a mixture of products. For 
this reason, it was our goal to develop the first cobalt(III)-catalyzed C–H aminocarbonylation 
with isocyanates 129 and acyl azides 131 (Scheme 2.8). 
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3 Ruthenium(II)-Catalyzed Oxidative Alkyne Annulation by C–H Bond 
Activation on Ketimines 
Isoquinolines are key structural moieties of various practically useful compounds. One of the 
most efficient methods for their preparation has been so far the transition-metal-catalyzed 
oxidative annulation of alkynes with ortho-halo-substituted aromatic imines with alkynes to 
furnish these heterocycles.95 Herein, we established a more straightforward approach to 
decorated isoquinolines 115 through ruthenium(II)-catalyzed oxidative alkyne annulations 
with easily accessible ketimines 73 as the starting materials. The reaction provided an 
expedient access to exo-methylene-1,2-dihydroisoquinolines 116.96  
3.1 Optimization studies 
At the outset of our studies, we explored various reaction conditions for the envisioned 
ruthenium(II)-catalyzed annulations of tolane (1a) with ketimine 73a, along with 
Cu(OAc)2∙H2O as the oxidant (Table 3.1). Preliminary experiments indicated DCE to be the 
solvent of choice, while significantly lower yields were obtained with t-AmOH, MeOH, H2O, 
DMF or toluene. Furthermore, KPF6 and MesCO2K proved to be suitable as cocatalytic 
additives. Yet, the most effective catalysis was achieved with AgSbF6 (Table 3.1, entries 1–4), 
which is likely due to the in situ formation of a cationic ruthenium catalyst. It is worth noting 
that the C–H bond functionalization proceeded efficiently under an ambient atmosphere of air, 
which highlights the user-friendly system (entry 5). While CuBr2 as the oxidant shut down the 
oxidative alkyne annulation completely (entry 6), interestingly, the catalytic activity was 
restored through the addition of metal acetates, indicating carboxylate assistance to be of 
major importance for the C–H bond functionalization (entries 7–9).5q,97 Additionally, we 
found that the ruthenium(II) catalyst outcompeted typical rhodium or palladium complexes 
(Table 3.1, entries 5, 10, and 11). 
Table 3.1. Optimization of the oxidative annulations with ketimine 73a.[a] 
                                                                 
95
 R. C. Larock, Top. Organomet. Chem. 2005, 14, 147–182. 
96 J. Li , L. Ackermann, Tetrahedron 2014, 70, 3342–3348. 
97 L. Ackermann, Chem. Commun. 2010, 46, 4866–4877. 
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Entry  Catalyst  Additive Oxidant Yield [%][b]  
1  -- -- Cu(OAc)2∙H2O 0 
2  [RuCl2(p-cymene)]2 KPF6 Cu(OAc)2∙H2O 51[c] 
3  [RuCl2(p-cymene)]2 MesO2K Cu(OAc)2∙H2O 61[c] 
4  [RuCl2(p-cymene)]2 AgSbF6 Cu(OAc)2∙H2O 67[c] 
5  [RuCl2(p-cymene)]2 AgSbF6 Cu(OAc)2∙H2O 71 
6  [RuCl2(p-cymene)]2 AgSbF6 CuBr2 0 
7  [RuCl2(p-cymene)]2 AgSbF6 CuBr2/NaOAc  54[d] 
8  [RuCl2(p-cymene)]2 AgSbF6 CuBr2/KOAc  53[d] 
9  [RuCl2(p-cymene)]2 AgSbF6 CuBr2/CsOAc  37[d] 
10  [RhCpCl2]2 AgSbF6 Cu(OAc)2∙H2O 46 
11 PdCl2(PPh3)2 AgSbF6 Cu(OAc)2∙H2O 0 
[a] General reaction conditions: 73a (0.50 mmol), 1a (1.00 mmol), catalyst (5.0 mol %), additive 
(20–30 mol %), oxidant (0.50 mmol), DCE (2.0 mL), under ambient air, 100 °C , 20 h. [b] Isolated 
yields. [c] Under an atmosphere of N2. [d] MOAc (1.0 mmol). 
3.2 Scope and Limitations 
3.2.1 Scope of Aromatic Alkyne Annulation 
With the optimized reaction conditions in hand, we explored its scope and limitations in the 
oxidative C–H functionalization with differently substituted ketimines 73 and alkynes 1 
(Scheme 3.1). The oxidative annulation efficiently occurred with acetophenonimines 73 
bearing substituents on the N-aryl moiety. Notably, transformations of 
electron-rich-methylsubstituted ketimines 73a and 73d proceeded very smoothly (115aa, 
115da), whereas substrate 73c with the electron-deficient fluoro group provided only a 
negligible conversion under the optimized conditions. Furthermore, a more sterically hindered 
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substrate 73e bearing an ortho-methyl substituent was also converted, albeit with a relative ly 
low isolated yield of product 115ea. Intramolecular competition experiments with substrate 
73f bearing a meta-methyl group was controlled by steric interaction to deliver the product 
115fa, which can be rationalized in terms of significant steric interactions. Compound 115ba' 
was obtained in low yield when (E)-N-[1-(2-bromophenyl)ethylidene]-4-methoxyaniline (73g) 
was employed. Meanwhile, substituted tolane derivatives 1b–1d were found to be viable 
substrates as well, thereby delivering the desired products 115ab–115ad, respectively. Yields 
of the desired products can be affected by different electronic factors in the substituted 
alkynes. Thus, compounds 1b and 1c with electron-rich methyl and methoxyl groups 
delivered the target products in relatively better yields.  
 
 
Scheme 3.1. Oxidative C–H functionalization of aromatic ketimines 73. [a] 
(E)-N-[1-(2-bromophenyl)ethylidene]-4-methoxyaniline (73g, 0.5 mmol) was used. 
3.2.2 Scope of the Annulation with Alkyl Alkynes 
Fortunately, the optimized catalytic system was not restricted to the use of diarylalkynes 1 as 
Ruthenium(II)-Catalyzed Oxidative Alkyne Annulation by C-H Activation on Ketimines 
36 
starting materials (Scheme 3.1). We initially tested dialkylsubstituted substrate 1e , which 
delivered the desired product 115ae  in acceptable yield (Scheme 3.2). Here, we particularly 
focused our efforts on the use of unsymmetrical substrates 1 to probe the challenging 
regiocontrol in the oxidative annulation. We were delighted to observe that the C–H bond 
functionalizations proceeded with perfect regioselectivities, placing the aromatic substituent 
proximal to the nitrogen atom, which can be ascribed to the steric hindrance of the alkyl 
groups. Furthermore, the ruthenium catalyst displayed high chemoselectivity in which 
oxidative annulations of alkynes 1j and 1k bearing an ester or a ketone group solely took 
place through chelation assistance by the ketimine moiety to furnish products 115aj and 
115ak in moderate yields (Scheme 3.2).  
 
 
Scheme 3.2. Oxidative C–H functionalization with alkylalkynes 1. 
3.2.3 Multicatalytic Synthesis of Dihydroisoquinolines 
Considering that the 2-substituted isoquinoline moiety plays an important role in various 
heterocyclic compounds with different bioactivities as key structural motifs , we subsequently 
devised a two-step reaction sequence consisting of the initial ruthenium(II)-catalyzed C–H 
bond functionalization followed by the palladium-catalyzed hydrogenation in a one-pot 
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fashion (Scheme 3.3). The multicatalytic approach set the stage for the efficient preparation of 
the decorated products 116, again occurring with excellent regio- and chemo-selectivities 
(116af, 116fa). It is noteworthy that a more sterically congested ketimine 73h gave the 
ethyl-substituted dihydroisoquinoline 116ha in a comparable yield.  
 
 
Scheme 3.3. Multicatalytic synthesis of 1,2-dihydroisoquinolines 116. 
3.3 Mechanistic Studies 
3.3.1 Intermolecular Competition Experiment  
Given the unique selectivity and outstanding efficacy of our ruthenium(II)-catalyzed C–H 
bond functionalization approach, we became interested in exploring its mode of action. Hence, 
keeping this purpose in mind, a competition experiment between arylalkyne 1a and 
alkylalkyne 1l was performed and revealed the former to be solely converted (Scheme 3.4). 
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Scheme 3.4. Competition experiment between alkynes 1a and 1l. 
3.3.2 Reaction in the Presence of Isotopically Labeled Solvent 
Furthermore, significant H/D exchange was observed in the presence of the deuterated 
cosolvent [D4]-MeOH, which can be rationalized in terms of a reversible carboxylate-assisted 
C–H bond metalation step by the ruthenium(II) complex (Scheme 3.5). 
 
Scheme 3.5. C–H bond functionalization in the presence of deuterated cosolvent [D4]-MeOH. 
3.4 Proposed Catalytic Cycle 
Based on these mechanistic studies, we propose the following catalytic cycle for the 
ruthenium(II)-catalyzed oxidative annulation, which commences with a reversible 
chelation-assisted C(sp2)–H bond ruthenation (Scheme 3.6) with a loss of one molecular 
acetic acid thereby affording intermediate B. Subsequently, a two-step sequence started from 
coordination of alkyne 1 and followed by regioselective migratory insertion5i along with 
tautomerization98 occurred. Thus, a seven-membered key intermediate C is generated. Finally, 
the desired product 115 was furnished via reductive elimination, while the catalytically active 
species 134 was regenerated through oxidation by Cu(OAc)2. 
                                                                 
98 Y. Boutadla , O. Al-Duaij, D. L. Davies , G. A. Griffi th, K. Singh, Organometallics 2009, 28, 433–440. 
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Scheme 3.6. Proposed catalytic cycle. 
3.5 Conclusion 
In summary, we have reported on a novel ruthenium(II)-catalyzed oxidative alkyne 
annulation to furnish exo-methylene-1,2-dihydroisoquinolines by C–H activation on 
ketimines. Particularly, carboxylate-assisted ruthenium(II) catalysis proved to be decisive for 
the success of the synthesis of diversely decorated products in high yields. Compounds 115 
can easily be transformed into heterocycles 116 via palladium-catalyzed hydrogenation in a 
one-pot fashion. The ruthenium(II)-catalyzed C–H bond functionalizations proceeded with 
excellent chemo-, site-, and regio-selectivities under an ambient atmosphere of air. 
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4 Amidines for Versatile Ruthenium(II)-Catalyzed Oxidative C–H Bond 
Activation with Internal Alkynes and Acrylates 
Aminoisoquinolines and isoindolines are among the most abundant heterocycles and 
represent indispensable structural motifs in bioactive compounds (see Chapter 1.2).99 With 
the successful utilization of ruthenium(II) catalysts for oxidative C–H bond activations, we 
were interested to establish the first ruthenium-catalyzed oxidative C–H bond 
functionalizations with benzamidines 117.100  
 
Scheme 4.1. Ruthenium(II)-catalyzed C–H bond activation on amidines 117. 
4.1 Oxidative Alkyne Annulation 
4.1.1 Optimization Studies 
We initiated our studies by testing different reaction conditions for the desired oxidative 
annulation of tolane (1a) with benzamidine 117a. Preliminary experiments proved 
[RuCl2(p-cymene)]2 as the ideal metal complex and KPF6 as the cocatalytic additive of choice, 
while significantly lower yields were obtained with AgSbF6 or AgOAc. Among a set of 
representative solvents, DME provided optimal results (Table 4.1, entries 1–5 and 8). 
However, it is worth noting that inexpensive, non-toxic H2O101,5o was found to be a viable 
reaction medium as well (entries 6 and 7). 
                                                                 
99 a) R. Ala jarin, C. Burgoes, in Modern Heterocyclic Chemistry (Eds .: J. Alvarez-Builla, J. J. Vaquero, J. Barluenga), 
Wiley-VCH, Weinheim, 2011, 1527–1629; b) N. L. Subasinghe, J. Lanter, T. Markotan, E. Opas , S. McKenne y, C. 
Crysler, C. Hou, J. O’Neill , D. Johnson, Z. Sui , Bioorg. Med. Chem. Lett. 2013, 23, 1063–1069. 
100 J. Li , M. John, L. Ackermann, Chem. Eur. J. 2014, 20, 5403–5408. 
101 B. Li , P. H. Dixneuf, Chem. Soc. Rev. 2013, 42, 5744–6337. 
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Table 4.1. Optimization of oxidat ive annulation with benzamidine 117a.[a] 
 
Entry  T [oC]  Solvent  Yield [%][b]  
1  100  DMF  7  
2  100  PhMe  21  
3  100  m-xylene  25  
4  100  1,4-dioxane  20  
5  100  DME  58  
6  100  H2O  46[c]  
7  120  H2O  76[c]  
8  120  DME  86[c]  
[a] Reaction conditions: 117a (0.5 mmol), 1a (0.6 mmol), Cu(OAc)2·H2O (1.0 mmol), 
[RuCl2(p-cymene)]2 (5.0 mol %), KPF6 (30 mol%), solvent (2.0 mL). [b] Yields of isolated 
products. [c] 2.0 equiv of alkyne 1a. 
4.1.2 Scope and Limitations 
4.1.2.1    Scope of Annulations with Alkynes 
Thereafter, with the optimized catalytic system in hand, we probed its scope and limitations in 
the oxidative annulation of differently decorated alkynes 1 (Scheme 4.2). We were delighted 
to find that arylalkynes 1b–1d and 1m bearing different functional groups were well tolerated 
by the ruthenium catalyst, though slightly lower yields were obtained when the electron-rich 
(1b) or electron-deficient diarylalkynes 1d and 1m as well as alkyne with sulfur-containing 
heteroaromatic moieties in substrate 1n were employed. The catalytic system was not limited 
to the use of diarylalkynes, but also allowed for the efficient conversion of the more 
challenging dialkylalkynes 1e  and 1l. Unsymmetrically substituted alkynes 1h and 1f were 
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converted with high regioselectivity, furnishing solely the products 118ah and 118af, 
respectively, with the aromatic substitutents in the neighbouring position to the nitrogen atom. 
 
 
Scheme 4.2. Ruthenium(II)-catalyzed oxidative annulation with alkynes 1. 
4.1.2.2    Scope of Annulations with Substituted Amidines 
Next, the tolerance of various electrophilic functional groups was investigated under this 
catalytic system. Substituted benzamidines 117b–117h bearing fluoro, chloro, bromo, iodio, 
or nitro substituents were well tolerated by the robust ruthenium(II) catalyst (Scheme 4.3).  
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Scheme 4.3. Scope of annulation with substituted amidines 117. 
Intramolecular competition experiments with substrates 117i and 117j bearing meta-methyl or 
meta-trifluoromethyl substituents were controlled by steric interactions to deliver the sole 
products 118ia and 118ja, respectively. In contrast, the functionalization occurred 
predominantly at the more sterically congested C–H bond when there is a secondary 
directing-group installed on the amidine 117k. Substrate 117l bearing a sterically hindering 
ortho-substituent gave the desired product 117la in a slightly reduced yield, as was also 
observed when using substrates 117n with a less bulky N-substitution pattern. It is worth 
noting that cyclic amidine 117o also proved to be viable starting materials and underwent the 
efficient conversion into product 118oa. Moreover, indole and thiophene derivatives 117p 
and 117q gave the desired products of the C–H/N–H bonds functionalization as well, thus 
delivering γ-carboline 118pe and annulated azabenzothiophene 118qe. 
Interestingly, a cascade twofold C–H/N–H bonds functionalization occurred when utilizing 
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the para-methoxybenzyl (PMB)-substituted benzamidine 117r and dialkylalkyne 1e  as the 
starting materials, thereby highlighting the ability of the 1-aminoisoquinolines 118 themselves 
to serve as useful substrates for directed C–H bond transformations. In contrast, the 
arylalkyne 1a uniquely furnished the product 118ra through a single C–H/N–H bonds 
functionalization (Scheme 4.4).  
 
Scheme 4.4. Cascade twofold vs single C–H/N–H bonds functionalizations. 
4.1.3 Mechanistic Studies 
4.1.3.1    Intermolecular Competition Experiments 
Given the remarkable activity of the alkyne-annulation catalyst, we performed mechanistic 
studies to delineate its mode of action. To this end, intermolecular competition experiments 
revealed electron-rich benzamidine 117c to be preferentially converted (Scheme 4.5).  
 
Scheme 4.5. Intermolecular competition experiment with benzamidines 117c and 117e. 
This observation is in good agreement with the in situ generated cationic ruthenium(II) 
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complex operating by an electrophilic-type activation mode. 
Additionally, a competition experiment between diarylalkyne 1d and dialkylalkyne 1e 
highlighted that aromatic alkynes outperformed the corresponding alkyl-substituted substrate 
(Scheme 4.6). 
 
Scheme 4.6. Intermolecular competition experiment between alkynes 1. 
4.1.3.2    Reactions in the Presence of Isotopically Labeled Solvent 
Subsequently, we explored the catalytic C–H bond functionalization on benzamidine 117b in 
the presence of isotopically labeled water (D2O) as the cosolvent. These studies demonstrated 
a significant H/D exchange in the ortho-positions of both the reisolated starting material 117b 
(Scheme 4.7a) and the product 118, albeit with a considerably reduced deuterium 
incorporation when performing the reaction in the presence of alkyne 1e (Scheme 4.7b). 
 
Scheme 4.7. H/D exchange reactions: (a) In the absence of 1. (b) In the presence of 1e. 
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4.1.4 Proposed Catalytic Cycle 
Given our mechanistic studies and the literature precedents,5i we proposed a plausible 
catalytic cycle which involves an initial reversible C–H bond activation in substrate 117, 
along with subsequent migratory insertion of alkyne 1 into intermediate A (Scheme 4.8). 
Thereafter, reductive elimination in ruthenacycle B delivered the desired product 118, while 
reoxidation regenerated the catalytically active ruthenium(II) complex.  
 
Scheme 4.8. Plausible mode of the catalyst action. 
4.2 Oxidative Alkenylation 
4.2.1 Optimization Studies 
Taking into consideration the high catalytic efficacy of the ruthenium(II)-catalyzed oxidative 
annulation of alkynes 1, we became intrigued by developing novel oxidative twofold C–H 
bond functionalizations with alkenes 20. Therefore, we initially studied the effect exerted by 
representative additives and solvents on the cross-dehydrogenative coupling of alkene 20a 
with amidine 117b (Table 4.2). Apparently, employing the catalytic system previously 
optimized for the oxidative alkyne annulation catalytic system delivered 
3-alkylydene-1-iminoisoindoline 119ba in unsatisfactorily low yield (entry 1). This was 
caused by the formation of an undesired by-product stemming from N-deprotection, which 
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could be isolated in 43% yield.  
Table 4.2. Optimization of oxidative annulation with alkene 20a.[a] 
 
Entry  Additive ([equiv])  T [°C ]  Solvent  Yield [%][b]  
1  KPF6 (0.3)  120  DME  18[c]  
2  AgSbF6 (0.2)  120  DME  41  
3  KPF6 (0.3)  120  DCE  63  
4  AgSbF6 (0.2)  120  DCE  66  
5  AgPF6 (0.2) 120  DCE  13  
6  CF3CO2Ag (0.2)  120  DCE  59  
7  AgOAc (0.3)  120  DCE  70  
8  AgOAc (0.5)  120  DCE  75  
9  AgOAc (0.5)  100  DCE  73[d]  
10  AgOAc (0.5)  80  DCE  69[d]  
11  AgOAc (0.5)  60  DCE  64[d]  
[a] Reaction conditions: 117b (0.5 mmol), 20a (1.5 equiv), Cu(OAc)2·H2O (2.0 equiv), 
[RuCl2(p-cymene)]2 (5.0 mol%), cat. additive, solvent (2.0 mL), 18–22 h. [b] Yields of isolated 
products. [c] Along with 43% of the corresponding N-deprotected product. [d] 
[RuCl2(p-cymene)]2 (2.5 mol %). 
However, we were pleased to observe that the efficacy of the oxidative alkenylation process 
was remarkably improved when using AgSbF6 as the additive in DCE as the solvent (entries 2 
and 3). Among a series of silver(I) salts (entries 4–8), 50 mol % of AgOAc gave the product 
in optimal yields (entries 8 and 9). This allowed for efficient catalysis to occur at a reduced 
catalyst loading and at reaction temperatures as low as 60 °C .5o Various oxidants other than 
Cu(OAc)2·H2O, such as CuBr2, K2S2O8, or PhI(OAc)2, did not furnish the desired product 
119ba. 
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4.2.2 Scope and Limitations 
4.2.2.1    Scope of N-Substituents on Amidines 
In order to test the range of our optimized catalytic system for the oxidative alkenylation, we 
initially evaluated the influence exerted by the different steric bulk of the N-substituent in 
benzamidines 117 (Scheme 4.9). Among the less sterically hindered iso- or 
n-butyl-substituted substrates, amidines 117m and 117n (Scheme 4.9) delivered inferior 
results as compared to the tert-butyl analogue 117b (Table 4.2). It is worth noting that 
detailed spectroscopic studies on the product’s connectivity revealed that the reduced steric 
bulk of the N-substituent strongly influenced the chemo- and diastereoselectivity of the 
isoindoline formation in that the substituted nitrogen atom of the amidine underwent the C–N 
bond formation. Furthermore, the PMB-substituted benzamidine 117r gave the desired 
products 119'ra–119'uc in high yields as well. 
 
 
Scheme 4.9. Reactivity of benzamidines 117 with less bulky N-substituents. 
4.2.2.2    Scope of the Oxidative Alkenylation with Aromatic Amidines and Acrylates 
Thereafter, we examined the scope of the ruthenium(II)-catalyzed cross-dehydrogenative 
alkenylation with different substituted benzamidines 117 and alkenes 20 (Scheme 4.10a). 
Remarkably, the ruthenium(II) catalyst turned out to be widely applicable and tolerated 
various electrophilic functional groups, such as fluoro, chloro, bromo, and nitro substituents, 
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albeit with a low yield of the desired product 119ha in the latter case. The C–H bond 
functionalizations occurred efficiently with para- and more sterically hindered 
ortho-substituted amidines 117b, 117c and 117l.  
 
Scheme 4.10. Scope of oxidative synthesis of 1-iminoisoindolines 119. 
Intramolecular competition experiments with meta-substituted amidines 117i and 117j were 
also tested and disclosed the formation of products 119ia and 119ja to be controlled 
predominantly by steric interactions. Yet, when using substrates having heteroatom 
substituents with a secondary directing group chelation effect102 (substrate 117s) or the fluoro 
substituent possessing the ortho-orienting effect (substrate 117k),103 sterically more hindered 
                                                                 
102 D. Balcells, E. Clot, O. Eisenstein, Chem. Rev. 2010, 110, 749–823. 
103 E. Clot, O. Eisenstein, N. Jasim, S. A. Macgregor, J. E. McGrady, N. Perutz, Acc. Chem. Res. 2011, 44, 333–348. 
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compounds 119sa and 119ka were obtained as the major or the sole product, respectively 
(Scheme 4.10). The results of 119sa revealed a considerable secondary directing group effect 
exerted by fluoro and methylenedioxy present in benzamidines 117s  and 117k, respectively 
(Scheme 4.10). 
4.2.3 Mechanistic Studies 
4.2.3.1    Intermolecular Competition Experiments 
To understand the working mode of our novel 1-imino-isoindoline (119) synthes, we 
performed intermolecular competition experiments between differently substituted 
benzamidines 117. These studies revealed that the electron-rich substrate 117b is inherently 
more reactive (Scheme 4.11), which coincides with the observation made within the 
ruthenium-catalyzed oxidative alkyne annulation (see above). 
 
Scheme 4.11. Intermolecular competition experiment. 
4.2.3.2    Experiment in the Presence of Isotopically Labeled Solvent 
In addition, we performed reactions with the isotopically labeled cosolvent [D4]-MeOH. 
These experiments revealed the high efficiency of the optimized catalytic system with 
cationic ruthenium(II) catalyst by giving a remarkable conversion of the substrate 117c within 
only 15 min. Obvious evidence of H/D scrambling on both of the recycled starting material 
[Dn]-117c and desired product [Dn]-119ca was gathered (Scheme 4.12), which unraveled that 
the ruthenium(II)-catalyzed alkenylation is undergoing a reversible C–H bond metalation step.  
Notably, an important intermediate 135ca was also isolated from the reaction mixture, thus 
indicating the reaction sequence to comprise an initial oxidative alkenylation followed by 
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subsequent intramolecular aza-Michael reaction. Both products 119ca and 135ca showed 
deuterium incorporation in the α-position to the carbonyl group, which is likely owing to the 
rapid H/D exchange on the N–H-acidic amidine group prior to the intramolecular conjugate 
addition. 
 
Scheme 4.12. C–H bond activation in the presence of [D4]-MeOH. 
The intermediate 135ca was obtained as a sole product by performing the cyclization without 
copper(II) acetate. Moreover, we established that the dehydrogenative formation of product 
119ca from 135ca was indeed viable in the absence of the ruthenium catalyst, thus solely 
being mediated by the copper(II) oxidant (Scheme 4.13). 
 
Scheme 4.13. Synthesis of intermediate 135ca and copper(II)-mediated oxidative alkene 
formation. 
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4.2.4 Proposed Catalytic Cycle 
Based on our mechanistic studies, we propose the initial C–H bond activation to involve a 
reversible acetate-assisted cycloruthenation of amidine 117 with the cationic species to form 
complex 136 (Scheme 4.14), which then undergoes a migratory insertion of alkene 20 to give 
the intermediate 137. Subsequently, acetate-assisted β-hydride elimination gives rise to the 
product of oxidative alkenylation 138, while reductive elimination and reoxidation by 
Cu(OAc)2·H2O regenerates the catalytically active ruthenium(II) complex. The desired 
product 119 is yielded through an intramolecular aza-Michael addition of compound 138, 
followed by dehydrogenation of the obtained intermediate 135. 
 
Scheme 4.14. Proposed catalytic cycle. 
4.2.5 Conclusion 
In summary, we have reported on the unprecedented ruthenium(II)-catalyzed oxidative C–H 
bond functionalization on easily accessible aryl amidines 117 with alkynes 1 and alkenes 20. 
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Thus, in situ formed cationic ruthenium(II) complexes allowed for alkyne annulations by 
C–H/N–H bonds functionalizations to give diversely substituted 1-aminoisoquinolines 118, 
which served as viable substrates for catalyzed C–H bond activation reactions themselves. 
Furthermore, novel oxidative alkenylations of benzamidines proved to be viable with versatile 
cationic ruthenium(II) complexes and, thereby, provided access to structurally diverse 
iminoisoindolines 119. Detailed mechanistic studies indicated the reversibility of the key C–H 
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5 Ruthenium(II)-Catalyzed C–H Bond Hydroarylation and Oxidative 
Annulation with α,β-Unsaturated Ketones via Monodentate Directing 
Group 
Early development of ruthenium-catalyzed C–H bond hydroarylation was started by Lewis 
and Smith,33 as well as Murai and coworkers who published a report on the 
“ruthenium-catalyzed ortho-C–H bond hydroarylation of aromatic ketones with olefins via a 
chelation assisted strategy” in 1993.46 Advances were subsequently made with the more 
flexible and practical ruthenium complex [RuCl2(p-cymene)]2. However, despite of a few 
examples in the literature which were rather rare and limited to the use expensive rhodium44 
or rhenium45 catalysts, several important families of acceptors, such as α,β-unsaturated 
ketones, could thus far not be utilized. In recent years, bidentate directing groups have 
emerged as a new powerful tool in C–H functionalization. A major progress was achieved by 
Daugulis,68c,77,104  Chatani,105  and Ackermann78e,f, 106  et al. Thus, Chatani and coworkers 
developed the ruthenium-catalyzed C–H hydroarylation of aromatic substrates with 
α,β-unsaturated ketones via a removable 8-aminoquinoline bidentate directing group.46 Herein, 
we developed ruthenium-catalyzed C–H bond hydroarylation and oxidative annulation with 
α,β-unsaturated ketones via more atom-economical monodentate directing group. 
5.1 Optimization Studies 
We initiated our studies by testing the feasibility of the ruthenium(II)-catalyzed C–H bond 
hydroarylation of methyl vinyl ketone (41a) with benzamide 2a (Table 5.1). Thus far, the 
reported ruthenium-catalyzed direct hydroarylation with MVK by Chatani was accomplished 
with RuCl2(PPh3)3 as the catalyst.46 However, catalyst delivered no desired product with the 
assistance of monodentate amide (entries 1–2). Similar observations were made when 
employing combinations of [RuCl2(p-cymene)]2 and additives (entries 3–5). A significant 
breakthrough was made using MesCO2K and MesCO2H as the cocatalysts (entry 6). 
                                                                 
104 a) D. Shabashov, O. Daugulis, J. Am. Chem. Soc. 2010, 132, 3965–3972; b) E. T. Nadres , O. Daugulis, J. Am. 
Chem. Soc. 2012, 134, 7–10; c) L. D. Tran, I . Popov, O. Daugulis, J. Am. Chem. Soc. 2012, 134, 18237–18240. 
105 a) Y. Aihara, N. Chatani , J. Am. Chem. Soc. 2013, 135, 5308–5311; b) Y. Aihara, N. Chatani , Chem. Sci. 2013, 4, 
664-670; c) Y. Ano, M. Tobisu, N. Chatani, Org. Lett. 2012, 14, 354–357; d) Y. Ano, M. Tobisu, N. Chatani, J. Am. 
Chem. Soc. 2011, 133, 12984–12986. 
106 H. H. Al  Mamari , E. Diers, L. Ackermann, Chem. Eur. J. 2014, 20, 9739–9743. 
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Stoichiometric MesCO2H loading provided the optimal result (entry 7). Notably, omission of 
either of the two additives, or employing [Ru(MesCO2)2(p-cymene)] as the catalyst, or 
reducing the catalyst loading resulted in significantly reduced yield of the desired product 
120aa (entries 8–11). Furthermore, it is worth noting that the combination of KOAc and 
HOAc was found to be suitable as well, albeit with lower efficacy (entry 12). 
Table 5.1. Optimization of ruthenium(II)-catalyzed C–H bond hydroarylation in benzamide 2a.[a] 
 
Entry  Additive A [equiv]  Additive B [equiv]  Solvent  Yield [%][b]  
1  NaOAc (0.3) -- PhMe  0[c]  
2  NaOAc (0.3) -- H2O   0[c] 
3  KPF6 (0.2) -- H2O  0  
4  KPF6 (0.2) NaOAc (2.0)  H2O  0  
5  PPh3 (0.15) NaO2CH (0.3)  PhMe 0  
6 MesCO2K (0.3) MesCO2H (0.3)  H2O  69  
7  MesCO2K (0.3) MesCO2H (1.0)  H2O  80  
8  MesCO2K (0.3) -- H2O  51  
9  -- MesCO2H (1.0) H2O  29  
10  -- --  H2O   58[d]  
11  MesCO2K (0.3) MesCO2H (1.0)  H2O   46[e]  
12  KOAc (1.0) HOAc (1.0)  H2O  64  
[a]General reaction conditions: 2a (0.5 mmol), 41a (1.0 mmol), [RuCl2(p-cymene)]2 (5.0 mol %), 
MesCO2K (0.3 equiv), MesCO2H (1.0 equiv), H2O (2.0 mL), under N2, 120 °C , 20 h. [b] Isolated 
yields. [c] RuCl2(PPh3)3 (10 mol %). [d] [Ru(MesCO2)2(p-cymene)] (10 mol %). [e] 
[RuCl2(p-cymene)]2 (2.5 mol %). 
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5.2 Scope of the Alkylation with α,β-unsaturated Ketones 
With the optimized ruthenium(II) catalyst in hand, we tested its versatility in the C–H bond 
hydroarylation with weakly-coordinating7b benzamides 2 (Scheme 5.1). Notably, in these 
chelation-assisted direct hydroarylations, both electron-rich and electron-poor 
para-substituted benzamides 2a–2f were identified as viable substrates. Furthermore, a 
variation of the substitution pattern on the nitrogen atom was also investigated, such as benzyl 
(2g–2i), cyclohexyl (2j) and methoxyethyl (2k), which proved to be suitable and did not 
significantly alter the catalytic efficacy. More sterically hindered ortho-substituted benzamide 
2l was successfully employed as well, albeit furnishing the desired product in a slightly 
reduced yield. Intramolecular competition experiments with meta-substituted benzamides 2m 
and 2n featured a considerable secondary directing group effect102 or ortho-orienting effect,103 
respectively, thus leading to a site-selective formation of sterically more hindered compounds 
120ma and 120na as the sole product. In contrast, the conversion of the meta-methyl and 
meta-trifluoromethyl substituted arenes 2o–2q was largely governed by steric interactions to 
deliver the products 120oa–120qa at the less sterically hindered position. The widely 
applicable ruthenium(II) catalyst was not limited to aromatic benzamides. Indeed, the reaction 
of the heteroaromatic indole derivative 2r also led to the site-selective hydroarylation in 
modest yield. Interestingly, N-(p-tolyl)acetamide (121a) was proved to be a suitable substrate 
as well, although a modest yield was obtained under the optimal conditions. However, among 
a set of varied α,β-unsaturated ketones, the aromatic ketone 41b only delivered the desired 
product 120cb in only low yield, presumably due to a polymerization tendency of the ketone. 
Yet, vinyl alkyl ketones 41c and 41d gave the alkylated products 120dc and 120dd, 
respectively, in relatively high yields.  
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Scheme 5.1. Ruthenium(II)-catalyzed hydroarylation of α,β-unsaturated ketones 41 with 
substituted benzamides 2. 
5.3 Mechanistic Studies 
5.3.1 Comparison of the Directing Group Power 
Intermolecular competition experiments between arenes with different directing groups 
clearly highlighted the amide as directing group is more powerful than the ketone in the 
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chelation-assisted C–H hydroarylation under the standard reaction conditions (Scheme 5.2). 
 
Scheme 5.2. Competition experiments between aromatic amide 2b and ketone 30a. 
5.3.2 Reaction in the Presence of Isotopically Labeled Solvent 
Obvious evidence of H/D exchange on both the reisolated starting material [Dn]-2b and the 
desired profuct [Dn]-120ba was obtained with the deuterated cosolvent D2O (Scheme 5.3), 
which can be rationalized in terms of a reversible C–H bond metalation step in the 
ruthenium(II)-catalyzed C–H hydroarylations. 
 
Scheme 5.3. H/D exchange experiments. 
Moreover, ruthenium(II)-catalyzed hydroarylations with the product compound and the 
isotopically labeled substrate [D5]-2a disclosed a significant kinetic isotope effect (KIE) of 
kH/kD ≈ 1.1 for the intermolecular KIE experiment (Scheme 5.4). This data is in agreement 
with the C–H bond metalation not to be the rate-determining step. 
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Scheme 5.4. Kinetic isotope effect (KIE) studies. 
5.4 Scope of the Oxidative Annulation with α,β-Unsaturated Ketone 
Thereafter, inspired by our previous work on oxidative alkenylations,5,7,100 we probed the 
oxidative annulation of differently decorated acetanilides 121 in the presence of cocatalytic 
AgSbF6 and stoichimetric Cu(OAc)2 (Scheme 5.5). Importantly, the catalytic system was not 
limited to the use of electron-rich N-phenyleacetanilides 121a–121c, but also allowed for the 
transformation of electron-poor substrates. Valuable electrophilic functional groups, such as 
fluoro, chloro, bromo, trifluoro and ester substituents, were well tolerated by the ruthenium(II) 
catalytic system when utilizing substituted acetanilides 121d–121h. Upon intramolecular 
competition experiment with substrate 121i bearing a meta-methyl substituent, the cyclization 
was governed by steric interaction to deliver the product 122ia in a good yield. However, 
substrates 121j and 121k bearing an ortho-substituent provided the desired products 122ja 
and 122ka, respectively, in lower yields. Phenyl vinyl ketone ketone (41b) demonstrated 
again a lower reactivity.  
 
Ruthenium(II)-Catalyzed C–H Bond Hydroarylation and Oxidative Annulation with α,β-Unsaturated Ketones  via 
Monodentate Directing Group 
60 
 
Scheme 5.5. Scope of oxidative annulations with substituted N-phenylacetanilides 121. [a] 
[RuCl2(p-cymene)]2 (5.0 mol %), AgSbF6 (20 mol %). 
5.5 Proposed Catalytic Cycle 
Based on our previous work,7, 107  we propose the initial C–H ruthenation formed 
cycloruthenated complex 134b then followed by a migratory insertion with alkene 41 to 
generate the intermediate 134c. Subsequently, β-hydrideelimination furnish the product of 
oxidative alkenylation 134d, the catalytically active ruthenium(II) complex is regenerated 
after reductive elimination and reoxidation, while the desired product 122 is obtained through 
an intramolecular nucleophilic addition of compound 134d, followed by elimination of acetic 
acid to furnish desired product 122. 
                                                                 
107 L. Ackermann, L. Wang, R. Wolfram, A. V. Lygin , Org. Lett. 2012, 14, 728-731. 
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In summary, we have developed the first ruthenium(II)-catalyzed hydroarylation and 
oxidative annulation of α,β-unsaturated ketones 41 with easily accessible monodentate 
benzamides 2, acetanilides 121 under simple reaction conditions. Furthermore, inexpensive, 
non-toxic H2O was proved to be the suitable reaction medium in the C–H bond 
ortho-alkylation. This methodology highlighted the fact that monodentate directing groups 
can be used to achieve these challenging transformations. The latter proceeded only with 
difficulty when traditional methods were used and represent the utilization of α,β-unsaturated 
ketones 41 in the ruthenium(II)-catalyzed direct C–H bond hydroarylation, which was only 
realized with bidentate directing groups as of yet. Detailed KIE experiments indicated C–H 
metalation to be not the rate-determining step. Moreover, novel oxidative annulations of 
N-phenylacetanilides 121 with α,β-unsaturated ketones 41 to deliver decorated quinolines 122 
were also viable with the versatile ruthenium(II) catalyst. 
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6 Cobalt-Catalyzed C–H Arylation with Weakly-Coordinating Amides and 
Tetrazoles: Expedient Route to Angiotensin-II-Receptor Blockers 
Angiotensin-II-Receptor Blockers (ARBs), such as Valsartan, Losartanare or Candesartan, are 
important antihypertensives.108,5e As of yet, the biaryl moieties in ARBs were predominantly 
synthesized through palladium-catalyzed cross-coupling reactions. 109 A significant advance 
to access these building blocks has been accomplished with ruthenium(II) catalysts through 
direct C–H bond arylation reactions.5e,110 In consideration of the progress in cobalt-catalyzed 
direct C–H bond arylation,67,75 we devised cobalt-catalyzed C–H bond arylations with 
weakly-coordinating7b benzamides 2 as well as direct arylations of aryl tetrazoles 123. Our 
strategy for the synthesis of derivatives 139 as ARBs constituents is depicted in scheme 6.1.111  
 
Scheme 6.1. Strategies for the synthesis of derivatives 124 as ARBs building blocks. 
6.1 Optimization 
6.1.1 Optimization Studies 
We initialed our studies by probing different reaction conditions for the envisioned C–H bond 
                                                                 
108 a) J. H. Kim, J. H. Lee, S. H. Paik, J. H. Kim, Y. H. Chi, Arch. Pharmacal Res. 2012, 35, 1123–1126; b) A. R. De 
Caterina, A. R. Harper, F. Cuculi , Vasc. Health Risk Manage. 2012, 8, 299–305. 
109 a) S. Aalla, G. Gilla, Y. Bojja , R. R. Anumula, P. R. Vummenthala, P. R. Padi , Org. Process Res. Dev. 2012, 16, 
682–686; b) G. Wang, B. Sun, C. Peng, Org. Process Res. Dev. 2011, 15, 986–988. 
110
 a) M. Seki, ACS Catal. 2014, 4, 4047–4050; b) E. Diers, N. Y. P. Kumar, T. Mejuch, I . Marek, L. Ackermann, 
Tetrahedron 2013, 69, 4445–4453; c) M. Seki , M. Nagahama, J. Org. Chem. 2011, 76, 10198–10206. 
111 J. Li , L. Ackermann, Chem. Eur. J. 2015, 21, 5718–5722. 
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arylation of weakly-coordinating benzamide 2a with inexpensive p-tolylchloride (88a) (Table 
6.1). 
Table 6.1. Optimization of cobalt-catalyzed C–H bond arylation.[a]  
 
Entry [Co(acac)2] [mol %] Ligand Yield[b] [%] 
1 10.0 IMesHCl (140a) 23[c] 
2 10.0 IPrHCl (140b) <5[c] 
3 10.0 sIMesHCl (140c) 16[c] 
4 10.0 sIPrHCl (140d) 0[c] 
5 10.0 PPh3 13[c] 
6 10.0 140e 29[c] 
7 10.0 140f <5[c] 
8 10.0 140g 47[c] 
9 5.0 140g 78 
10 -- 140g 0 
11 5.0 140h 32 
12 5.0 140i <5 
13 5.0 140j 26 
[a] General reaction conditions: 2a (0.5 mmol), 88a (0.6 mmol), cat. Co(acac)2, ligand (5 mol %), 
CyMgCl (3.0 equiv), DMPU (1.0 mL), 60 °C, 16 h. [b] Yield of isolated product. [c] 88a (0.75 
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mmol), ligand (20 mol %).  
Thus far, all reported cobalt-catalyzed direct arylations with organic (pseudo)halides were 
accomplished with one of the two N-heterocyclic carbene (NHC)112–113 preligands IMesHCl 
(140a) or IPrHCl (140b).67,75 However, preligands 140a and 140b delivered the desired 
product 139aa in only unsatisfactory low yields, even with a relatively high catalyst loading 
of 10 mol % (entries 1 and 2). A similar observation was made when employing the saturated 
analogues sIMesHCl (140c), and sIPrHCl (140d) (entries 3 and 4), or the tertiary phosphine 
PPh3 (entry 5). Cobalt catalysts derived from isopropyl-substituted NHC 140e were 
previously shown to be effective for direct alkylations,65c but proved unsuitable for the C–H 
bond arylation with benzamides 2a (entries 6 and 7), thus highlighting the challenge 
associated with the use of weakly-coordinating amides. In contrast, among various NHC 
precursors, ICyHCl (140g) proved to be optimal with an ideal ligand to cobalt ratio of 1:1 
(entries 8 and 9). Under these reaction conditions the catalyst loading could also be 
significantly reduced (entry 9). The more electron-rich pre-NHC 140h, the bidentate 
derivative 140i and the unsymmetrically substituted pre-NHC 140j failed to improve the 
catalytic efficacy (entries 10–13). 
6.1.2 Effect of the Directing Groups 
Notably, we also tried the cobalt-catalyzed C–H bond arylation with differently substituted 
aryl amides 141a–141f (Scheme 6.2). These test reactions under the optimized reaction 
conditions verified the crucial importance of the amide directing group. For substrates without 
free N–H moieties or with sterically demanding directing group, no catalytic reaction was 
observed. The same result was obtained with benzenesulfonamide 141c or with substrate 141f 
bearing a bidentate-type directing groups as well.  
                                                                 
112 M. N. Hopkinson, C. Richter, M. Schedler, F. Glorius , Nature 2014, 510, 485–496. 
113 S. Díez-González, N. Marion, S. P. Nolan, Chem. Rev. 2009, 109, 3612–3676. 
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Scheme 6.2. Screening of directing groups for the arylation reactions. 
6.2 Scope and Limitations 
Having identified a highly effective catalyst for the selective arylation of N-methylbenzamide 
(2a) with 4-chlorotoluene (88a), we further extended the reaction scope to include other 
benzamides with a broad range of aryl chlorides (Scheme 6.3). In order to test the efficiency 
of the cobalt-catalyzed direct arylation, we subsequently set up a 10 mmol scale reaction of 
2a with 88a which provided biaryl product 139aa in 64% yield when employing 2.0 mol % of 
Co(acac)2 and ICyHCl in DMPU at 60 °C  for 16 h. Notably, various aryl chlorides 88a–88g 
were successfully employed. The TBS-protected (4-chlorophenyl)methanol 88d and 
4-chlorophenol 88f were readily converted to the corresponding biaryl products 139ad and 
139of in good yields of 57% and 70%, respectively. The arylation with sterically more 
demanding ortho substituent o-tolylchloride afforded the target product 139ac as well, albeit 
in a modest yield (55%). Similarly lower yields were observed for benzamides 2s , 2f, and 2p 
with electron-deficient functional groups, even when employing an increased loading of 
Co(acac)2 and carbene preligand. Likewise, we exploited the use of the amide group for the 
direct arylation of the biologically active indole 114 derivatives, delivering the desired products 
139ua, 139ra and 139rg were isolated in good yields. Upon arylation of meta-substituted 
benzamide 2m, an influence of the secondary directing group chelation effect102 was minor.  
                                                                 
114 Modern Heterocyclic Chemistry (Eds .: J. Alvarez-Builla, J. J. Vaquero, J. Barluenga,), Wiley-VCH, Weinheim, 
2011. 





Scheme 6.3. Substrate scope of cobalt-catalyzed C–H bond arylation. [a] 0.5 h. [b] Co(acac)2 (2.0 
mol %), 140g (2.0 mol %). [c] Co(acac)2 (10 mol %), 140g (10 mol %). 
Thereafter, the substrate scope was extended to competition experiments of various 
benzamides 2 (Scheme 6.4). Remarkably, the cobalt-catalyzed C–H functionalizations 
occurred on the benzamides 2 with excellent chemo-selectivity. Both electron-donating and 
electron-withdrawing substituents on the aryl chloride 88 were tolerated selectively delivering 
the mono-arylated biaryls 139va–139xd in good yields. Moreover, chlorobenzenes with 
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sterically hindered substituents in the ortho-position also delivered the desired products 139 
with high catalytic efficacy. 
 
 
Scheme 6.4. Cobalt-catalyzed direct C–H bond arylation of anilides 2. [a]: 0.5 h. 
6.3 Mechanistic Studies 
The results of a set of intermolecular competition experiments revealed electron-deficient 
benzamides 2 and electron-deficient aryl chlorides 88 to be more reactive than their 
electron-rich counterparts (Scheme 6.5). 
Thereafter, we performed studies to delineate the catalyst working mode. Independent 
experiments with isotopically labeled substrates indicated the C–H bond cobaltation not to be 
kinetically relevant (KIE ≈ 1.0), and provided evidence for a reversible D/H exchange 
reaction (Scheme 6.6). 




Scheme 6.5. (a) Competition experiments between aryl chlorides 88, (b) and different aryl amides 
2. 
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Scheme 6.6. (a) Kinetic isotope effect (KIE) study. (b, c) Cobalt-catalyzed H/D exchange 
experiments with deuterated 2a. 
6.4 Synthesis of Biaryl Tetrazoles  
As discussed above, benzamides can be easy transformed into phenyl tetrazoles according to 
the previously published protocols. 115 Consequently, a simple route to synthesize ARBs 
building blocks and derivatives 124a–124d was designed via initial cobalt-catalyzed direct 
C–H bond arylation by weak assistance of amides group in substrates 2 (Scheme 6.3) 
followed by the transformation of the amido substituent into the tetrazole moiety (Scheme 
6.7). 
 
Scheme 6.7. Facile preparation of biaryl tetrazoles 124. 
Alternatively, we explored the possibility of devising an even more step-economical approach 
to biaryl tetrazoles 124 through the unprecedented cobalt-catalyzed C–H bond activation by 
tetrazole assistance in substrates 123. Intriguingly, a low-valent cobalt catalyst derived from 
preligand 140a proved effective here, thereby chemo-selectively delivering the desired 
products 124. It is noteworthy that the tetrazole-assisted C–H bond arylation proceeded by 
C–H/C–O bonds cleavages with challenging aryl carbamates 86 as the electrophiles (Scheme 
6.8), although the products 124 were obtained in rather modest yields. 
                                                                 
115 S. N. Rao, T. Ravisankar, J. Latha, K. S. Babu, Pharma Chem. 2012, 4, 1093–1103. 





Scheme 6.8. Tetrazole-assisted C–H bond arylation with carbamates 86. 
6.5 Oxidative Annulation 
Finally, we successfully exploited the products of direct arylation 139 for the synthesis of 
substituted phenanthridin-6(5H)-ones 143a and 143b, which were obtained in 83 and 64% 
yield, respectively (Scheme 6.9). 
 
Scheme 6.9. Oxidative annulations of 139 to phenanthridin-6(5H)-ones 143. 
6.6 Conclusion 
In summary, we have developed novel strategies for cobalt-catalyzed syntheses of biaryl 
tetrazoles 124 through C–H bond functionalization. Thus, NHC-ligated low-valent cobalt 
catalysts enabled the first direct arylation assisted by weak coordination. The arylated 
benzamides 139 were formed with high site- and chemo-selectivities as well as ample scope. 
This reaction provided expedient access to biaryl tetrazoles, which represent key scaffolds of 
ARB blockbuster drugs. The results of mechanistic studies were in line with a reversible C–H 
bond cobaltation and a rate-determining reductive elimination. The power of the user-friendly 
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cobalt catalysis was further illustrated by unprecedented tetrazole-assisted C–H bond 
activations with 3d transition metal complexes, thus constituting an alternative approach to 
ARBs building blocks.  
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7 Cobalt(III)-Catalyzed C–H Bond Cyanation of Arenes and Heteroarenes 
Functionalizations of otherwise inert C–H bonds provide an approach for improving the 
atom- and step-economy in organic synthesis. While most of the achievements were 
accomplished with expensive second-row transition-metal catalysts, largely focused on 
ruthenium, rhodium and palladium complexes, further applications of these methods are 
limited.5,7,116 Inexpensive cobalt catalysts, for C–H bonds activations have been recognized as 
an increasingly viable tool for organic syntheses, also in the field of C–H bond activation 
including arylations, alkylations, alkenylations, benzylations and hydroarylations.5j–5k The 
general cobalt catalytic systems for most of these studies were assisted by phosphine or 
N-heterocyclic carbene (NHC) ligands, along with a strong base. Grignard reagents were used 
as base and reductants to generate the reactive low-valent cobalt-catalysts, which devised 
methods for new C–C bonds formation. Although several functional groups can be tolerated, 
the Grignard reagents could induce some other undesirable byproducts. Therefore, in order to 
avoid these kinds of disadvantages, the research groups of Kanai, Ackermann, Daugulis and 
Song developed other mild reaction systems with cobalt catalysts, including high-valent 
[Cp*Co(III)] derivatives, which allowed for the oxidative alkyne annulations, oxidative 
alkenylations and alkoxylation under mild reaction conditions without Grignard 
reagents.68,79,82–84,86 Based on this progress, we hence became interested in developing 
unprecedented cobalt(III)-catalyzed C–H bond cyanations of arenes and heteroarenes, which 
are discussed below in this Chapter.89 
7.1 Optimization Studies  
Initially we probed various reaction conditions for the desired cobalt-catalyzed C–H bond 
functionalization utilizing 2-phenylpyridine (28a) and N-cyano-N-phenyl-
p-toluenesulfonamide (125, NCTS) as the cyanating reagent. Preliminary experiments 
identified [Cp*CoI2(CO)] to be the efficient metal catalyst of choice, along with AgSbF6 and 
NaOAc as the cocatalytic additives (Table 7.1, entries 1-4, 10). Experiments without this 
additive or with AgOAc instead of AgSbF6 inhibited the reaction immediately (entries 6 and 
                                                                 
116 L. Ackermann, Top. Curr. Chem. 2010, 292, 211–229, and references  ci ted therein. 
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8). Among a representative set of acetate source, KOAc provided optimal yields (entries 1, 5, 
7 and 9). A C–H bond cyanation with an excess of substrate 125 formed the monocyanated 
product 126a as the sole product (entry 11), which unraveled the prominent chemoselectivity 
of the cobalt(III) catalyst.  
Table 7.1 Optimization of cobalt-catalyzed C–H bond cyanation.[a]  
 
Entry  [Co] Additive A Additive B Yield (%)[b] 
1 [Cp*CoI2(CO)] AgSbF6 NaOAc 83 
2 CoI2 AgSbF6 NaOAc 0 
3 Co(acac)2 AgSbF6 NaOAc 0 
4 [Cp*CoCl2]2 AgSbF6 NaOAc 30 
5 [Cp*CoI2(CO)] AgSbF6 KOAc 90 
6 [Cp*CoI2(CO)] AgOAc NaOAc 0 
7 [Cp*CoI2(CO)] AgSbF6 AgOAc 66 
8 [Cp*CoI2(CO)] -- KOAc 0 
9 [Cp*CoI2(CO)] AgSbF6 -- 33 
10 -- AgSbF6 KOAc 0 
11 [Cp*CoI2(CO)] AgSbF6 KOAc 93[c]  
12 [Cp*CoI2(CO)] AgSbF6 KOAc 39[d] 
[a] Reaction conditions: 28a (0.5 mmol), 2 (0.75 mmol), [Cp*CoI2(CO)] (112, 2.5 mol %), 
additive A (5.0 mol %), additive B (5.0 mol %), DCE (2.0 mL), 120 °C , 16 h. [b] Yield of isolated 
product. [c] 125 (1.5 mmol). [d] 4.0 h.  
7.2 Scope and Limitations 
7.2.1 Substrate Scope of Cobalt-Catalyzed C–H Bond Cyanation 
With the optimized catalytic system in hand, the scope of the cyanation was evaluated 
(Scheme 7.1).  




Scheme 7.1. Substrate scope of cobalt-catalyzed C–H bond cyanation. 
The chelation-assisted C–H bond functionalization of meta-disubstituted arenes 28a–28c 
proceeded with excellent site-selectivity at the less sterically hindered position. Significantly, 
the cobalt(III) catalyst displayed a remarkable chemo-selectivity, and a number of valuable 
electrophilic groups such as esters (126d) or ketones (126e  and 126h) were well tolerated. 
Cyanation of the substrate 28i with a fluorine substituent featured a considerable secondary 
directing group effect,102 thereby leading to the site-selectively afforded the more sterically 
hindered compound 126i as the sole product in good yield.103 However, the 
3,4,5-trifluorosubstituted substrate 28j delivered the corresponding product 126j with an 
inferior result. Subsequently, a variation of the substitution pattern on the Lewis-basic 
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pyridine moiety proved to be viable, but did not significantly alter the catalytic efficacy. We 
were delighted to observe that synthetically useful substrates substituted with heterocyclic 
moieties, such as pyridyl (py), pyrimidinyl (pym), and pyrazolyl, could be utilized as the 
selectivity-ensuring entities. In contrast, other directing groups, such as oximes or esters, have 
been thus far not been suitable substrates. 
7.2.2 Scope of the C–H Bond Cyanation with Indoles 
Thereafter, we examined the use of the removable pyrimidine directing group for the 
cyanation of biologically active indole 117 derivatives 7118 (Scheme 7.2). 
 
 
Scheme 7.2. Cobalt-catalyzed C–H bond cyanation of indoles 7. [a] [Cp*CoI2(CO)] (112, 5.0 
mol %), AgSbF6 (10 mol %), KOAc (10 mol %). 
Applying this method, the parent compound 127a was synthesized in virtually quantitative 
yield. Remarkably, 5-substituted indoles bearing various functional groups, such as methoxy 
(7b), bromo (7c) or amido (7e), were efficiently cyanated, which allowed the synthesis of 
serotonin derivatives in a step-economical fashion. Unfortunately, the reaction with 5-nitro 
                                                                 
117
 Modern Heterocyclic Chemistry (Eds .: J. Alvarez-Builla, J. J. Vaquero, J. Barluenga), Wiley-VCH, Weinheim, 
2011. 
118 L. Ackermann, A. V. Lygin, Org. Lett. 2011, 13, 3332–3335. 
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substituted indole 7d was not successful. Generally, substitution on the carbocyclic moiety of 
the substrates 7 was well tolerated by the C–H bond functionalization catalyst. Interestingly, 
the sterically more congested 3-methyl indole derivative 7h delivered the desired cyanated 
product 127h in excellent isolated yield as well. Even the sensitive ketone functionality on the 
tetrahydroindolone 7i was cyanated with remarkably high efficacy. 
7.2.3 Scope of the C–H Bond Cyanation with Heteroarenes 
The versatile cobalt(III) catalyst was not limited to cyanations on the indole heterocycle. 
Indeed, the direct C–H bond cyanation of pyrroles (144, Scheme 7.3a) and thiophenes (146, 
Scheme 7.3b) occurred with excellent levels of efficacy and positional selectivity as well.  
 
Scheme 7.3. Cobalt-catalyzed C–H bond cyanation of the heteroarenes 144 and 146. 
7.3 Mechanistic Studies 
7.3.1 Intermolecular Competition Experiments  
Intrigued by the outstanding activity of the cobalt catalyst through for cobalt mechanistically 
unusual carboxylate assistance, we sought to unravel the mode of action. To this end, 
intermolecular competition experiments between the differently substituted arenes 28b and 
28c highlighted a slight preference in the C–H bond cyanation for the more electron-rich 
substrate (Scheme 7.4). 
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Scheme 7.4. Competition experiment between differently substituted arenes 28b and 28c. 
7.3.2 Reactions with Isotopically Labelled Reagents 
The use of a deuterated cosolvent clearly indicated a significant H/D exchange solely 
occurring in the ortho position of arene 28a (Scheme 7.5a).  
 
Scheme 7.5. Cobalt-catalyzed H/D exchange and determination of KIE values with arene 28a. 
Accordingly, cobalt-catalyzed C–H bond cyanations with isotopically labeled substrates led to 
a minor kinetic isotope effect (KIE) values of kH/kD ≈ 1.0 and kH/kD ≈ 1.1 for the inter- and 
intramolecular KIE-determination experiments, respectively (Scheme 7.5b and Scheme 7.5c). 
These data were in agreement with the C–H bond metalation step not being rate-determining. 
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Moreover, a Hammett plot correlation 119  (See Chapter 10) indicated a change in the 
rate-determining reaction step depending on the substitution pattern of the arene. 
7.3.3 Proposed Catalytic Cycle 
 
Scheme 7.6. Proposed catalytic cycle. 
Based on our mechanistic studies, we proposed the catalytic cycle initiated by a reversible 
carboxylate-assisted C–H bond metalation, thus yielding the cyclometalated complex 149 
(Scheme 7.6). Subsequent coordination and insertion of 125 furnished the key intermediates 
150 and 151, respectively. Finally, β-elimination provides the desired product 126, while 
proto-demetalation regenerates the catalytically active cobalt(III) carboxylate catalyst 148. 
7.4 Application 
To illustrate the unique potential of the cobalt(III)-catalyzed cyanation protocol, we removed 
the directing group on the indole 127a (Scheme 7.7a),118 and devised a reaction sequence 
which resulted in the formal direct carboxylation of unactivated C–H bonds.120 Thus, a 
                                                                 
119 a) L. P. Hammett, J. Am. Chem. Soc, 1937, 59, 96–103; b) Y. Aihara, N. Chatani, Chem. Sci. 2011, 4, 664–670. 
120
 a) B. Yu, L.-N. He, ChemSusChem 2015, 8, 52–62; b) M. T. Johnson, O. F. Wendt, J. Organomet. Chem. 2014, 
751, 213–220; c) L. Ackermann, Angew. Chem. Int. Ed. 2011, 50, 3842–3844; d) K. Huang, C.-L. Sunwa, Z.-J. Shi, 
Chem. Soc. Rev. 2011, 40, 2435–2452. 
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one-pot procedure initiated by the cobalt-catalyzed C–H bond cyanation, along with a facile 
base-mediated saponification, delivered the desired carboxylic acid 152 in high yield (Scheme 
7.7b). 
 
Scheme 7.7. (a) Removal of directing group. (b) Cobalt-catalyzed one-pot synthesis of the 
carboxylic acid 152. 
Finally, we exploited the cobalt-catalyzed C–H bond cyanation for the synthesis of the 
functionalized indoles 153–155 (Scheme 7.8).118, 121  Particularly, the high-yielding 
preparation of the 2-tetrazolyl derivative 153 should prove instrumental for the design of 
novel bioactive drugs. 
 
Scheme 7.8. Cobalt-catalyzed C–H bond activation towards substituted indoles. 
7.5 Conclusion 
In summary, we have reported on the first cobalt-catalyzed cyanation of unactivated C–H 
                                                                 
121
 a) M. Chaitanya, D. Yadagiri, P. Anbarasan, Org. Lett. 2013, 15, 4960–4963; b) S. M. Kim, J. H. Park, Y. K. Kang, Y. 
K. Chung, Angew. Chem. Int. Ed. 2009, 48, 4543–4545; c) D. Amantini , R. Beleggia, F. Fringuelli, F. Pizzo, L. Vaccaro, 
J. Org. Chem. 2004, 69, 2896–2898. 
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bonds in arenes 28 and heteroarenes 7, 144 and 146. Thus, carboxylate assistance led to an 
enhanced activity of cationic cobalt(III) catalyst towards the direct cyanation of arenes and 
heteroarenes with ample scope. The optimized catalytic system tolerated various functional 
groups and proved applicable with removable directing groups. Mechanistic studies revealed 
an effecient cobalt-catalyzed site-selective ortho deuteration of heteroarylarenes by reversible 
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8 Cobalt(III)-Catalyzed Aryl- and Alkenyl-C–H Bond Aminocarbonylation 
with Isocyanates and Acyl Azides  
In recent years, transition-metal-catalyzed direct insertion of isocyanates into C–H bonds is in 
high demand, because they efficiently provide synthetically valuable amide moieties.122 
Theoretically, acyl azides can be employed as precursors for isocyanates via the "Curtius 
rearrangement" at elevated temperature.123 To the best of our knowledge, acyl azides were 
only found to work as amino sources in the iridium- and ruthenium-catalyzed amidation.124–125 
Another sole example of the use of acyl azides was developed applying rhodium catalysts.125 
However, further application of acyl azides was strongly limited by the difficulty in 
controlling their dual reactivity, leading to a mixture of products with C–C and C–N bond 
formation. Described herein is the first cobalt(III)-catalyzed C–H bond aminocarbonylation 
with isocyanates and acyl azides.126 
8.1 Optimization  
We commenced our studies by exploring the reaction conditions for the cobalt(III)-catalyzed 
C–H bond aminocarbonylations of 1-phenylpyrazole (128a) with phenyl isocyanate (129a) 
(Table 8.1). With a combination of AgNTf2 or AgPF6 and AgOAc, the desired product 130aa 
was obtained in low yields (entries 1–2). Among a set of representative carboxylate salts, 
AgOPiv provided the optimal results (entries 3–9). The nature of the silver salts appeared to 
be crucial, and both AgSbF6 and AgNTf2 combined with AgOPiv gave the best yields (entries 
10–13). Moreover, omission of either of the catalyst's components or replacement of the 
[Cp*CoI2(CO)]85–86 by other cobalt sources failed to deliver the desired product (entries 
14–19), whereas reducing the amount of isocyanate 129a or changing the reaction media 
resulted in significantly reduced yields or inhibited the reaction (entries 20–22). 
Table 8.1. Optimization of cobalt(III)-catalyzed C–H bond aminocarbonylation.[a] 
                                                                 
122 a) S. D. Sarkar, L. Ackermann, Chem. Eur. J. 2014, 20, 13932–13936; b) B. Zhou, W. Hou, Y. Yang, Y. Li , Chem. Eur. 
J. 2013, 19, 4701–4706; c) K. D. Hesp, R. G. Bergman, J. Ellman, J. Am. Chem. Soc. 2013, 135, 11430–11433; d) K. 
Murali rajan, K. Parthasarathy, C. H. Cheng, Org. Lett. 2012, 14, 4262–4265; e) Y. Kuninobu, Y. Tokunaga, A. Kawata, 
K. Takai, J. Am. Chem. Soc. 2006, 128, 202–209. 
123 T. Curtius , Ber. Dtsch. Chem. Ges. 1890, 23, 3023–3033. 
124
 J. Ryu, J. Kwak, K. Shin, D. Lee, S. Chang, J. Am. Chem. Soc. 2013, 135, 12861–12868. 
125 K. Shin, J. Ryu, S. Chang, Org. Lett. 2014, 16, 2022–2025. 
126 J. Li , L. Ackermann, Angew. Chem. Int. Ed. 2015, 54, (DOI: 10.1002/anie.201501926). 
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Entry [Co] Additive 1  Additive 2  Yield (% )[b] 
1 [Cp*CoI2(CO)] AgNTf2 AgOAc 35 
2 [Cp*CoI2(CO)] AgPF6 AgOAc 23 
3 [Cp*CoI2(CO)] AgPF6 AgCO2Ad 25 
4 [Cp*CoI2(CO)] AgPF6 AgOPiv  42 
5 [Cp*CoI2(CO)] AgPF6 KOAc 24 
6 [Cp*CoI2(CO)] KPF6  AgOAc 0 
7 [Cp*CoI2(CO)] AgPF6 CsOAc 0 
8 [Cp*CoI2(CO)] AgPF6 KOPiv  0 
9 [Cp*CoI2(CO)] AgPF6 NaOPiv  0 
10 [Cp*CoI2(CO)] AgSbF6 AgOPiv  46 
11 [Cp*CoI2(CO)] AgNTf2 AgOPiv  57 
12 [Cp*CoI2(CO)] AgPF6 AgOPiv  64[c]  
13 [Cp*CoI2(CO)] AgSbF6 AgOPiv 67[c] 
14 [Cp*CoI2(CO)] AgPF6 -- 0 
15 [Cp*CoI2(CO)] -- AgOPiv  0 
16 -- AgPF6 AgOPiv  0 
17 CoI2 AgSbF6 AgOPiv  0 
18 Co(OAc)2 AgSbF6 AgOPiv  0 
19 Co(acac)2 AgSbF6 AgOPiv  0 
20 [Cp*CoI2(CO)] AgSbF6 AgOPiv  53[c,d] 
21 [Cp*CoI2(CO)] AgPF6 AgOPiv  0[e] 
22 [Cp*CoI2(CO)] AgPF6 AgOPiv  0[f]  
[a] General reaction conditions: 128a (0.5 mmol), 129a (1.0 mmol), Cp*CoI2(CO) (112, 2.5 
mol %), AgSbF6 (5.0 mol %), KOAc (5.0 mol %), DCE (2.0 mL), 70 °C, 16 h. [b] Isolated yields. 
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[c] [Cp*CoI2(CO)] (5.0 mol %), additives (10 mol %). [d] 129a (0.75 mmol). [e] NMP (2.0 mL). 
[f] PhMe (2.0 mL). 
8.2 Scope and Limitations 
8.2.1 Scope of Aminocarbonylation with Substrates 128 
With the optimized cobalt(III) catalytic system in hand, we explored its substrate scope with 
various N-heteroarenes (Scheme 8.1). 
 
Scheme 8.1. Scope of cobalt-catalyzed aminocarbonylation of C–H bonds. [a] [Cp*CoI2(CO)] (10 
mol %), AgSbF6 (20 mol %), AgOPiv (20 mol %). [b] [Cp*CoI2(CO)] (10 mol %), AgNTf2 (20 
mol %), AgOPiv (20 mol %). 
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Notably, the chelation-assisted C–H bond aminocarbonylation proved to be broadly 
applicable. Both electron-rich as well as electron-deficient arylpyrazoles were converted into 
nitriles with moderate to high isolated yields 130aa–130ea. Importantly, the cobalt(III) 
catalyst displayed an excellent chemoselectivity, wherein a number of valuable electrophilic 
groups, such as ketones or esters, were well tolerated. Interestingly, a certain amount of 
disubstituted products like 130fa' were also isolated. Furthermore, a set of more sterically 
hindered substrates bearing an ortho-methyl, fluoro or bromo group generated the desired 
products in good yields 130ha–130ja. We were delighted to observe that synthetically useful 
indazoles 28k could be utilized as the selectivity ensuring entity. In intramolecular 
competition experiments with meta-substituted arenes 28l and 28m, the site-selectivities were 
largely governed by steric interactions. The widely applicable cobalt catalyst was not limited 
to transformations of only aromatic pyrazoles. Indeed, heteroaromatic thiophene, indole and 
furan derivatives 128n–128p also led to site-selective C–H bond aminocarbonylations. 
8.2.2 Scope of Aminocarbonylation with Decorated Isocyanates 129 
Next, we were pleased to observe that isocyanates 129b–129f bearing various functional 
groups were well tolerated by the cobalt catalyst (Scheme 8.2).  
 
 
Scheme 8.2. Cobalt-catalyzed aminocarbonylation of C–H bonds. 
Acceptable yields were obtained with electron-rich substituted isocyanates 129b and 129c, 
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whereas electron-deficient reagents 129d were found to be most reactive, and the desired 
product 130hd was produced in virtually quantitative yield. Likewise a chloro substituent in 
isocyanate 129e was also found to be tolerated by the catalytic system, which can be useful 
for further functionalizations by cross-coupling chemistry.  
8.2.3 Scope of Aminocarbonylation with Acyl Azides 131 
As discussed above, acyl azides 131 can either be employed as aminocarbonylation reagents 
or precursors for isocyanates 129. Yet, the synthetic approach to acyl azides is much simpler 
than those to isocyanates. Thus, we were delighted to explore that a wide substrate scope was 
observed to be competent when employing differently decorated acyl azides 131 (Scheme 
8.3). Good yields were obtained with para-substituted electron-rich acyl azides 131b, 131c 
and 131g as well as with azides 130ah and 130ai bearing electron-withdrawing substituents. 
Finally, meta- and ortho-substituted acyl azides 131f and 131j were tested, delivering the 
desired products 130af and 130aj, respectively, in high isolated yields.  
 
 
Scheme 8.3. Cobalt-catalyzed C–H bond aminocarbonylation with acyl azides 131. 
8.2.4 Scope of Aminocarbonylation with Vinyl Pyrazole 132 
Interestingly, cobalt(III)-catalyzed aminocarbonylation was not only applicable on 
(hetero)arenes, but also successfully on olefins via alkenyl C–H bond activation (Scheme 8.4). 
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Both (E)-1-styryl-1H-pyrazole (132a) and 1-(1-phenylvinyl)-1H-pyrazole (132b) as well as 
un- or para-substituted aryl isocyanates showed good reactivity in direct aminocarbonylations 
under remarkable mild reaction conditions , thereby furnishing the thermodynamically less 
stable Z-olefins as the sole products 133. 
 
 
Scheme 8.4. Cobalt-catalyzed C–H bond aminocarbonylation with vinyl pyrazoles 133. 
8.3 Mechanistic Studies 
8.3.1 H/D Exchange Experiments and Kinetic Isotope Experiments  
Intrigued by the outstanding catalytic activity of this cobalt catalyst through for cobalt 
mechanistically unusual carboxylate assistance, we performed studies to delineate its working 
mode. To this end, an experiment with deuterated substrate [D5]-128a clearly demonstrated a 
significant H/D exchange solely occurring in the ortho position of [Dn]-128a and [Dn]-130aa 
(Scheme 8.5a). 
Independent experiments with isotopically labeled substrates indicated the C–H bond 
cobaltation can be characterized with a kinetic isotope effect (KIE) value of kH/kD = 1.4 
(Scheme 8.5b). A similar KIE value was also obtained in the intramolecular 
KIE-determination experiment (Scheme 8.5c). 
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Scheme 8.5. Mechanistic studies. (a) H/D exchange reaction. (b) Intermolecular competition 
experiment: Determination of kinetic isotope effect (KIE). (c) Intramolecular competition 
experiment: Determination of kinetic isotope effect (KIE). 
8.3.2 Competition Experiments  
A set of intermolecular competition experiments between the differently substituted arenes 
128 revealed a distinct preference in the C–H bond aminocarbonylation for the more 
electron-rich substrate 128b (Scheme 8.6a). On the contrary, the results from the competition 
experiments between differently substituted isocyanates 129 showed the latter as an 
electron-deficient one to be more reactive than its electron-rich counterparts (Scheme 8.6b). 
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Scheme 8.6. (a) Competition experiment with different arenes 128. (b) Competition experiment 
with different isocyanates 129. 
8.3.3 Proposed Catalytic Cycle 
Based on our mechanistic studies, we proposed the catalytic cycle to be initiated by a 
reversible C–H bond metalation, thus yielding the cyclometalated complex 157 (Scheme 8.7). 
Subsequent coordination and insertion of isocyanate 129 furnish the key intermediates 158 
and 159, respectively. Finally, proto-demetalation regenerates the catalytically active 
cobalt(III) carboxylate catalyst 156 and provides the desired product 130. 
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Scheme 8.7. Proposed catalytic cycle. 
8.4 Applications 
To demonstrate the synthetic versatility of the products synthesized by this method, several 
derivatization reactions were performed (Scheme 8.8). 
 
Scheme 8.8. Derivatization of products 130 obtained by cobalt-catalyzed C–H bond 
aminocarbonylation.  
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Oxidative annulation of 130aa afforded the heterocyclic product 160. Direct C–H bond 
benzylation 127 and arylation 128  using ruthenium(II) catalysts delivered the corresponding 
products 161 and 162 in modest to good yields, respectively.  
8.5 Conclusion 
In summary, we have established the first cobalt-catalyzed aminocarbonylation of unactivated 
C–H bonds with isocyanates 129 and acyl azides 131. Thus, carboxylate assistance led to a 
highly active cationic cobalt(III) catalyst for the direct aminocarbonylation of arenes 128 and 
alkenes 132 with ample scope. The optimized catalytic system tolerated various functional 
groups and proved applicable to olefins via alkenyl C–H bond activation. Mechanistic studies 
revealed an effective site-selective cobalt catalyst for the site-selective ortho deuteration of 






                                                                 
127 L. Ackermann, P. Novák, Org. Lett. 2009, 11, 4966–4969. 
128 L. Ackermann, R. Vicente, H. K. Potukuchi , V. Pi rovano, Org. Lett. 2010, 12, 5032-5035. 
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9 Summary and Outlook 
To improve the atom- and step-economy of organic syntheses, major efforts have been made 
on transformations of inert carbon–hydrogen (C–H) bonds into carbon–carbon (C–C) or 
carbon–heteroatom (C–N, C–O, C–Hal) bonds. Significant advances in organometallic 
chemistry have set the stage for the development of increasingly viable metal catalysts for 
C–H bond activation reactions and their applications in the preparation of pharmaceutical, 
agrochemical and functional materials. Thus, the work presented within this thesis focused on 
the development of versatile ruthenium- and cobalt-catalyzed direct C–H bond 
functionalizations. 
In the first project, an effective protocol for the oxidative annulation of ketimines 73 with 
internal alkynes 1 was established, and the catalytic system consisting of [RuCl2(p-cymene)]2, 
AgSbF6 and Cu(OAc)2·H2O tolerated well various functional groups (Scheme 9.1). 
 
Scheme 9.1. Oxidative C–H bond functionalization with decorated ketimines and alkynes. 
In order to access the corresponding reduced 1,2-dihydroisoquinolines 116, we subsequently 
devised a two-step reaction sequence consisting of an initial ruthenium(II)-catalyzed C–H 
bond activation followed by palladium-catalyzed hydrogenation (Scheme 9.2). 
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Scheme 9.2. Multicatalytic synthesis of 1,2-dihydroisoquinolines 116. 
Based on the above findings, we managed to expand the scope of aromatic substrates to 
particularly challenging (hetero)aryl amidines 117. A method for ruthenium(II)-catalyzed 
oxidative C–H bond annulations was developed by employing amidines and internal alkynes 
1. The reaction provided expedient access to differently decorated aminoisoquinolines 118 
with ample scope. In addition, intramolecular competition experiments with substrates 
bearing meta-methyl or meta-trifluoromethyl substituents proceeded with excellent levels of 
site selectivity, producing aminoisoquinolines substituted at the less sterically hindered 
position (Scheme 9.3) 
 
Scheme 9.3. Substrates scope for ruthenium(II)-catalyzed oxidative C–H bond annulations. 
Inspired by the successful synthesis of aminoisoquinolines 118, we subsequently became 
interesting in developing novel oxidative twofold C–H bond functionalizations with alkenes 
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20. The reaction proceeded not only with excellent chemo-, site-, and regio-selectivities, but 
also with perfect diastereoselectivity (Scheme 9.4). 
 
Scheme 9.4. Ruthenium(II)-catalyzed oxidative C–H bond alkenylation.  
We subsequently established ruthenium(II)-catalyzed direct hydroarylation of α,β-unsaturated 
ketones 41 with aromatic amides 2 through monodentate coordination (Scheme 9.5). 
Meanwhile, oxidative annulations of α,β-unsaturated ketones 41 with acetanilides 121 
furnished decorated quinolines 122 (Scheme 9.6). 
 
Scheme 9.5. Direct C–H bond hydroarylation of α,β-unsaturated ketones 41 with decorated 
amides 2. 
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Scheme 9.6. Oxidative annulations of α,β-unsaturated ketones 41 with acetanilides 121. 
Thereafter, we developed cobalt-catalyzed direct C–H bond arylation with 
weakly-coordinating benzamides. Various aryl chlorides 88 as well as un- or para-substituted 
benzamides 2 were identified as viable substrates for direct arylations under remarkably mild 
reaction conditions. Moreover, the unique synthetic utility of this reaction was illustrated by 
the facile transformation of the ortho-arylated benzamides 139 to the desired biaryl tetrazoles 
124 (Scheme 9.7). 
 
Scheme 9.7. Scope of cobalt-catalyzed C–H bond arylation and facile transformation of arylated 
benzamides 139 to biaryl tetrazoles 124. 
Very recently, inexpensive high-valent [Cp*Co(III)] derivatives have been identified as 
efficient catalysts for the site-selective functionalization of unactivated C–H bonds. We 
developed first cobalt(III)-catalyzed C–H bond cyanation of arenes and heteroarenes. The 
chelation-assisted C–H bond cyanation proceeded with excellent site- and chemo-selectivity, 
and a wide range of functional groups, such as halogens, ketones, esters and amides, were 
tolerated under the optimized reaction conditions (Scheme 9.8). 
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Scheme 9.8. Cobalt-catalyzed C–H bond cyanation. 
Finally, described herein is the first cobalt(III)-catalyzed C–H bond aminocarbonylation with 
isocyanates 129 or acyl azides 131 as an electrophilic partner (Scheme 9.9). Notably, a broad 
scope of isocyanates 129 or acyl azides 131 makes this strategy especially attractive. 
 
Scheme 9.9. Cobalt-catalyzed aminocarbonylation of C–H bonds. 
In summary, major efforts in this thesis were focused on step- and atom-economical synthetic 
strategies based on transition-metal-catalyzed direct C–H bond functionalizations. In this 
context, we have developed ruthenium- and cobalt-catalyzed chelation-assisted direct C–H 
bond annulations, hydroarylations, arylations, cyanations and aminocarbonylations. 
Considering the rapid expansion of transition-metal-catalyzed C–H bond functionalizations, 
the researches towards further applications of the cobalt(III) is actively undertaken in the 
Ackermann group, more exciting progress is expected. 
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10 Experimental Section 
10.1 General Remarks 
Unless otherwise noted, all reactions were performed under N2 or Ar atmosphere using 
pre-dried glassware and standard Schlenk techniques. 
Solvents  
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and 
stored under an inert atmosphere (Ar or N2) according to the following standard procedures. 
1,2-Dimethoxyether (DME) and tert-amylalcohol (t-AmOH) were used as supplied by 
Merck or stirred over sodium chips for 5 h at 120 °C and then distilled at ambient pressure.  
Water (H2O) was degassed before its use applying repeated freeze-pump-thaw degassing 
procedure.  
1,2-Dichloroethane  (DCE) and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
(DMPU) were dried over CaH2 for 8 h, degassed and distilled under reduced pressure.  
Dichloromethane  (DCM), N,N-dimethylformamide  (DMF) and tetrahydrofuran (THF) 
were purified using a solvent purification system (SPS) from MBRAUN. 
N-Methyl-2-pyrrolidone (NMP) was dried over CaH2 for 4 h at 150 °C and subsequently 
distilled under reduced pressure.  
Methanol (MeOH) was distilled from magnesium methanolate.  
Toluene was pre-dried over KH followed by distillation from sodium benzophenone ketyl.  
1,4-Dioxane was dried over sodium benzophenone ketyl and distilled afterwards.  
Vacuum  
The following pressures were measured on the used vacuum pump and were not corrected: 
membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar.  
Melting Points (M. p.) 
Melting points were measured using a Stuart®  Melting Point Apparatus SMP3 from 
BARLOWORLD SCIENTIFIC. Reported values are uncorrected.  
Chromatography  
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plates 
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(Merck) with 254 nm fluorescent indicator from MERCK. Plates were visualized under 
UV-light or developed by treatment with a KMnO4 solution followed by carefully heating. 
Chromatographic purification of products was accomplished by flash column chromatography 
on MERCK silica gel, grade 60 (0.040–0.063 mm and 0.063–0.200 mm).  
Gas Chromatography (GC) 
The conversion of the reactions was monitored by coupled gas chromatography/mass 
spectrometry using G1760C GCDplus with mass detector HP 5971, 5890 Series II with mass 
detector HP 5972 from HEWLETT-PACKARD and 7890A GC-System with mass detector 
5975C (Triplex-Axis-Detector) from AGILENT TECHNOLOGIES equipped with HP-5MS 
columns (30 m × 0.25 mm, Ø 0.25 m).  
High Performance Liquid Chromatography (HPLC) 
Preparative and analytical separations were performed on an HPLC-System from KNAUER 
(Smartline Pump 100, Dynamic Mixing Chamber, Injection- and Control-Valve, Smartline 
UV Detector 2500). Separation normal phase column (250 × 10 mm) from 
MACHEREY-NAGEL (MN) was used. Organic solvents of HPLC grade were employed. All 
samples were filtered through Polytetrafluoroethylene Filter from ROTH (Ø 25 mm, 0.2 μm) 
or VWR (Ø 13 mm, 0.2 μm) prior to separation.  
Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectroscopy was performed at 300, 400, 500 or 600 
MHz (1H NMR), 75, 100 or 125 MHz (13C NMR, APT) and 282 MHz (19F NMR) on 
BRUKER AM 250, VARIAN Unity-300 and Inova 500 instruments. Chemical shifts are 
reported as δ-values in ppm relative to the residual proton peak of the deuterated solvent or its 
carbon atom, respectively, or the standard trimethylsilyl (TMS) peak. For characterization of 
the observed resonance multiplicities the following abbreviations were applied: s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), dt (doublet of triplet), 
or analogue representations. The coupling constants J are reported in Hertz (Hz).  
Infrared Spectroscopy (IR) 
Infrared spectra were recorded on a BRUKER Alpha-P ATR-spectrometer. Liquid probes 
have been measured as films between the plates of NaCl and solid probes neat applying 
Attenuated Total Reflection (ATR) technique which enables the samples to be examined 
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directly. Analysis of the spectral data has been done by using the OPUS 3.1 software from 
BRUKER, respectively OPUS 6. Absorption (ṽ) is given in wave numbers (cm–1). Spectra 
were recorded in the range of 4000 to 400 cm–1.  
Mass Spectrometry (MS) 
MS (EI) and HR-MS (EI) were measured on a Time-of-Flight mass spectrometer AccuTOF 
from JOEL. ESI-mass spectra were recorded on an Ion-Trap mass spectrometer LCQ from 
FINNIGAN or on a Time-of-Flight mass spectrometer microTOF from BRUKER. 
ESI-HR-MS spectra were recorded on a BRUKER APEX IV or a BRUKER DALTONIC {7T, 
Fourier Transform Ion Cyclotron Resonance (FTICR)} mass spectrometer. The ratios of mass 
to charge (m/z) are indicated, intensities relative to the base peak (I = 100) are written in 
parentheses.  
Reagents  
Chemicals obtained from commercial sources with purity above 95% were used without 
further purification.  
10.2 Synthesis of the Starting Materials  
The following starting materials were synthesized according to previously described methods: 
ketimines 73a–73i;129 alkynes 1b–1d, 1d–1g, 1h–1k, 1i; amidines 117a–117r;130 aryl amides 
2a–2z, [D5]-2a; 131  acetanilides 121a–121k; 132  α,β-unsaturated ketones 41b–41c; 133  aryl 
tetrazoles 123a–123b;110c aryl chlorides 88d, 88f; 134  carbamates 86;135  phenylpyridines 
28a–28e , 28g–28l, 146, phenyl pyrimidines 28m–28n;136 (pyrimidin-2-yl)-1H-indoles 7a–7h, 
144; 137  N-cyano-N-phenyl-p-toluenesulfonamide (125, NCTS); 138  2-[D]-phenylpyridine 
[D1]-28a; 139  Cp*CoIIII2(CO) (112);85,86 aryl pyrazoles 128b–128i, 128k–128n, 128p, 
                                                                 
129 G. Ghattas, D. Chen, F. Pan, J. Klankermayer, Dalton Trans. 2012, 41, 9026–9028. 
130 a) X. H. Wei , M. Zhao, Z. Y. Du, X. W. Li , Org. Lett. 2011, 13, 4636–4639; b) Y. Wang, H. G. Wang, J. L. Peng, Q. 
Zhu, Org. Lett. 2011, 13, 4604–4607. 
131
 Q. Tang, D. Xia , X. Jin, Q. Zhang, X.-Q. Sun, C. Wang, J. Am. Chem. Soc. 2013, 135, 4628–4631. 
132 S. Ueda, H. Nagasawa, J. Org. Chem. 2009, 74, 4272–4277. 
133 A. Bugarin, K. D. Jones , B. T. Connell , Chem. Commun. 2010, 46, 1715–1717. 
134 H. M. L. Davies , S. J. Hedley, B. R. Bohall, J. Org. Chem. 2005, 70, 10737–10742. 
135 X. Sun, Y. Sun, C. Zhang, Y. Rao, Chem. Commun. 2014, 50, 1262–1264. 
136 V. P. W. Böhm, T. Weskamp, C. W. K. Gstöttmayr, W. A. Herrmann, Angew. Chem. Int. Ed. 2000, 39, 1602–1604. 
137
 L. Ackermann, A. V. Lygin, Org. Lett. 2011, 13, 3332–3335. 
138 P. Anbarasan, H. Neumann, M. Beller, Chem. Eur. J. 2011, 17, 4217–4222. 
139 C. Xu, Q. Shen, Org. Lett. 2014, 16, 2046–2049. 
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[D5]-128a; 140  128j; 141  128o; 142  132a; 143  132b; 144  2-[D]-1-phenyl-1H-pyrazole 
([D1]-128a);141,139 isocyanates 129b–129c, 129e-129f and acyl azides 131.145 
10.3 General Procedures 
General procedure A for the ruthenium(II)-catalyzed oxidative alkyne annulation with 
ketimines 
A suspension of ketimine 73 (0.50 mmol), alkyne 1 (1.00 mmol), [RuCl2(p-cymene)]2 (15.3 
mg, 5.0 mol %), AgSbF6 (34.4 mg, 20.0 mol %), and Cu(OAc)2∙H2O (99.5 mg, 0.50 mmol) in 
DCE (2.0 mL) was stirred at 100 °C  for 20 h under an atmosphere of air. After cooling down 
to ambient temperature, the reaction mixture was extracted with EtOAc (3 × 20 mL), washed 
with brine (20 mL) and dried over Na2SO4. The solvent was evaporated under reduced 
pressure, and the residue was purified by column chromatography (n-hexane/EtOAc/Et3N) to 
afford product 115. 
General procedure B for Multicatalytic Synthesis of Dihydroisoquinolines 
A suspension of ketimine 73 (0.50 mmol), alkyne 1 (1.00 mmol), [RuCl2(p-cymene)]2 (15.3 
mg, 5.0 mol %), AgSbF6 (34.4 mg, 20.0 mol %), and Cu(OAc)2∙H2O (99.5 mg, 0.50 mmol) in 
DCE (2.0 mL) was stirred at 100 °C  for 20 h under an atmosphere of air. After cooling to 
ambient temperature, the reaction mixture was filtrated, and Pd/C (10 % w/w) was added. The 
reaction mixture was stirred at ambient temperature for 24 h under an atmosphere of H2. The 
reaction mixture was extracted with EtOAc (3 × 20 mL), washed with brine (20 mL) and 
dried over Na2SO4. The solvent was evaporated under reduced pressure, and the residue was 
purified by column chromatography (n-hexane/EtOAc) to afford product 116. 
General procedure C for the ruthenium(II)-catalyzed oxidative alkyne annulation with 
amidines  
A suspension of amidine 117 (0.50 mmol), alkyne 1 (1.00 mmol), [RuCl2(p-cymene)]2 (15.3 
mg, 5.0 mol %), KPF6 (27.6 mg, 30 mol %) and Cu(OAc)2·H2O (199 mg, 1.00 mmol) in DME 
(2.0 mL) was stirred at 120 °C for 22 h under an atmosphere of N2. At ambient temperature, 
                                                                 
140 A. Correa, C. Bolm, Adv. Synth. Catal. 2007, 349, 2673–2676. 
141 F. Diness, D. P. Fai rlie, Angew. Chem. Int. Ed. 2012, 51, 8102–8106. 
142 W.-B. Wu, J.-M. Huang, Org. Lett. 2012, 14, 5832–5835. 
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 J. Mao, Q. Hua, J. Guo, D. Shi , S. Ji , Synlett 2008, 13, 2011–2016. 
144 Q. Liao, Y. Wang, L. Zhang, C. Xi , J. Org. Chem. 2009, 74, 6371–6373. 
145 K. Shi , J. Ryu, S. Chang, Org. Lett. 2014, 16, 2022–2025. 
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H2O (20 mL) was added, and the reaction mixture was extracted with EtOAc (3 × 20 mL). 
The combined organic layers were washed with brine (20 mL) and dried over Na 2SO4. The 
solvent was evaporated in vacuo, and the residue was purified by column chromatography on 
silica gel (n-hexane/EtOAc) to yield products 118. 
General procedure D for the ruthenium(II)-catalyzed oxidative alkenylation of amidines  
A suspension of amidine 117 (0.50 mmol), alkene 20 (0.75 mmol), [RuCl2(p-cymene)]2 
(7.7−15.3 mg, 2.5−5.0 mol %), AgOAc (41.5 mg, 50 mol %) and Cu(OAc)2·H2O (199 mg, 
1.00 mmol) in DCE (2.0 mL) was stirred at 100−120 °C for 22 h under an atmosphere of N2. 
At ambient temperature, the reaction mixture was extracted with EtOAc (3 × 20 mL), washed 
with brine (20 mL) and dried over Na2SO4. The solvent was evaporated in vacuo, and the 
residue was purified by column chromatography on silica gel (n-hexane/EtOAc) to yield 
products 119. 
General procedure E for the ruthenium(II)-catalyzed C−H hydroarylation with 
aromatic amides 
A suspension of aryl amides 2 or acetanilides 121 (0.50 mmol), α,β-unsaturated ketones 41 
(1.00 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), MesCO2K (30.3 mg, 30 mol %) and 
MesCO2H (82 mg, 1.0 equiv) in degassed H2O (2.0 mL) was stirred at 120 °C for 20 h under 
an atmosphere of N2. At ambient temperature, aq. Sat. NaCl solution (15 mL) was added, the 
reaction mixture was extracted with EtOAc (3 × 20 mL) and the combined organic phases 
were dried over Na2SO4. Evaporation of the solvents in vacuo and purification of the residue 
by column chromatography on silica gel (n-hexane/EtOAc) yielded products 120. 
General procedure F for the ruthenium(II)-catalyzed oxidative annulation by 
acetanilides 
A suspension of respective acetanilide 121 (0.50 mmol), α,β-unsaturated ketone 41 (1.00 
mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), AgSbF6 (17.2 mg, 20 mol %) and Cu(OAc)2 
(190.0 mg, 2.1 equiv) in 1,4-dioxane (2,0 mL) was stirred at 140 °C for 20 h under an 
atmosphere of N2. At ambient temperature, H2O (15 mL) was added. The reaction mixture 
was extracted with EtOAc (3 × 20 mL). The combined organic phases were washed with 
brine (20 mL) and dried over Na2SO4. Evaporation of the solvents in vacuo and purification 




General procedure G for the cobalt-catalyzed C−H bond arylation by aromatic amides  
A suspension of Co(acac)2 (6.5 mg, 5.0 mol %), ICyHCl (6.8 mg, 5.0 mol %), aryl amide 2 
(0.50 mmol) and DMPU (1.0 mL) was stirred for 5 min at 0 °C. To this mixture, a 2-Me-THF 
solution of CyMgCl (1.0 M  solution in 2-Me-THF, 1.5 mL, 3.0 equiv) was added dropwise at 
the same temperature, followed by addition of aryl chloride 88 (1.2 equiv). Then the mixture 
was stirred at 60 °C for 16 h (or for 30 min in the indicated cases) under an atmosphere of 
argon. At ambient temperature, aq. sat. NH4Cl solution (2.0 mL) and H2O (15 mL) were 
added. The reaction mixture was extracted with MTBE (3 × 20 mL), the combined organic 
phases were washed with brine (20 mL) and dried over Na2SO4. Evaporation of the solvents 
in vacuo and purification of the residue by column chromatography on silica gel 
(n-hexane/EtOAc) yielded products 139. 
General procedure H for the cobalt-catalyzed C−H bond arylation in aryl tetrazoles 
A suspension of Co(acac)2 (12.9 mg, 10.0 mol %), IMesHCl (34.0 mg, 20.0 mol %), aryl 
tetrazole 123 (0.50 mmol), aryl carbamate 86 (1.2 equiv) and DMPU (1.0 mL) was stirred for 
5 min at 0 °C. To this mixture, a 2-Me-THF solution of CyMgCl (1.0 M  solution in 
2-Me-THF, 0.8 mL, 1.6 equiv) was added dropwise at the same temperature. Then the 
mixture was stirred at 60 °C for 16 h under an atmosphere of argon. At ambient temperature, 
aq. Sat. NH4Cl solution (2.0 mL) and H2O (15 mL) were added. The reaction mixture was 
extracted with MTBE (3 × 20 mL), the combined organic phases were washed with brine (20 
mL) and dried over Na2SO4. Evaporation of the solvents in vacuo and purification of the 
residue by column chromatography on silica gel (n-hexane/EtOAc) yielded products 124. 
General procedure I for the cobalt-catalyzed C−H bond cyanation by (hetero)arenes 
A suspension of 28 or 7 (0.50 mmol), NCTS (125) (204 mg, 0.75 mmol), [Cp*CoI2(CO)] 
(112, 6.0 mg, 2.5 mol %), AgSbF6 (8.6 mg, 5.0 mol %) and KOAc (2.5 mg, 5.0 mol %) in 
DCE (2.0 mL) was stirred at 120 °C for 16 h under an atmosphere of argon. At ambient 
temperature, the solvent was evaporated in vacuo, and the residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc/ CH2Cl2/Et3N) to yield products 126 or 127. 
General procedure J for the cobalt-catalyzed C−H bond carbonylation by isocyanates 
A suspension of 128 (0.50 mmol), aryl isocyanate 129 (1.00 mmol), [Cp*CoI2(CO)] (112, 
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12.0 mg, 5.0 mol %), AgSbF6 (17.2 mg, 10.0 mol %) and AgOPiv (10.4 mg, 10.0 mol %) in 
DCE (2.0 mL) was stirred at 70 °C for 16 h under an atmosphere of argon. At ambient 
temperature, the solvent was evaporated in vacuo, and the residue was purified by column 
chromatography on silica gel (n-hexane/CH2Cl2/EtOAc/Et3N) to yield products 130. 
General procedure K for the cobalt-catalyzed C−H bond carbonylation by acyl azides 
A suspension of 128 (0.50 mmol), acyl azide 131 (1.0 mmol), Cp*CoI2(CO) (112, 12.0 mg, 
5.0 mol %), AgNTf2 (19.9 mg, 10.0 mol %) and AgOPiv (10.4 mg, 10.0 mol %) in DCE (2.0 
mL) was stirred at 80 °C for 16 h under an atmosphere of argon. At ambient temperature, the 
solvent was evaporated in vacuo, and the residue was purified by column chromatography on 
silica gel (n-hexane/ CH2Cl2/EtOAc/Et3N) to yield products 130. 
10.4 Analytical Data  
10.4.1 Analytical Data for the Product of Ruthenium(II)-Catalyzed 




The general procedure A was followed using 73a (119.5 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178.0 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc/Et3N: 2:1:0.05) yielded 115aa (147 mg, 71%) as a yellow solid. M. p.: 
190–192 °C. 
1H-NMR (300 MHz, DMSO-d6): δ = 7.66 (d, J = 8.2 Hz, 1H), 7.14 (m, 2H),7.01–7.04 (m, 
6H), 6.84–6.94 (m, 5H), 6.76 (d, J = 8.8 Hz, 2H), 6.41 (s, 1H), 4.46 (s, 1H), 3.63 (s, 3H), 3.07 
(s, 1H), 2.13 (s, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 157.5 (Cq), 147.2 (Cq), 142.0 (Cq), 138.0 (Cq), 137.4 (Cq), 
135.9 (Cq), 134.8 (Cq), 133.6 (Cq), 131.8 (CH), 131.6 (CH), 130.7 (CH), 127.7 (CH), 127.1 
(CH), 126.7 (CH), 126.5 (CH), 125.9 (CH), 124.7 (Cq), 124.0 (CH), 123.8 (CH), 114.3 (CH), 
112.1 (Cq), 79.2 (CH2), 55.0 (CH3), 20.9 (CH3).  
Experimental Section 
103 
IR (ATR): 3024, 1654, 1507, 1245, 1028, 697 cm-1.  
MS (EI) m/z (relative intensity) 415 (55) [M+], 414 (100), 400 (45), 383 (15), 370 (10), 294 
(10).  




The general procedure A was followed using 73b (112.5 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc/Et3N: 2:1:0.02) yielded 115ba (122 mg, 61%) as an off white solid. M. p.: 
189–190 °C. 
1H-NMR (300 MHz, DMSO-d6): δ = 7.76 (m, 1H), 7.20–6.85 (m, 14H), 6.77 (d, J = 8.7 Hz, 
2H), 6.61 (m, 1H), 4.52 (s, 1H), 3.63 (s, 3H), 3.13 (s, 1H).  
13C-NMR (75 MHz, DMSO-d6): δ = 157.3 (Cq), 147.0 (Cq), 141.8 (Cq), 137.2 (Cq), 135.5 (Cq), 
134.6 (Cq), 133.4 (Cq), 131.6 (CH), 131.4 (CH), 130.5 (CH), 128.7 (CH), 127.6 (CH), 127.0 
(Cq), 126.6 (CH), 126.4 (CH), 125.9 (CH), 125.8 (CH), 123.8 (CH), 123.6 (CH), 114.3 (CH), 
112.1 (Cq), 80.1 (CH2), 54.9 (CH3).  
IR (ATR): 2993, 1621, 1507, 1244, 758, 699 cm-1.  
MS (EI) m/z (relative intensity) 401 (50) [M+], 400 (100), 388 (10), 356 (5), 209 (10). 







The general procedure A was followed using 73d (118.5 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc/Et3N: 5:1:0.01→5:1:0.02) yielded 115da (125 mg, 62%) as an off white 
solid. M. p.: 194–196 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.65 (d, J = 8.3 Hz, 1H), 7.17–7.00 (m, 6H), 6.94–6.83 
(m, 5H), 6.72 (br s, 3H), 6.41 (s, 1H), 4,45 (s, 1H), 3.12 (s, 1H), 2.14 (s, 3H), 2.10 (s, 6H). 
13C-NMR (75 MHz, DMSO-d6): δ = 146.6 (Cq), 141.8 (Cq), 141.6 (Cq), 138.0 (Cq), 137.8 (Cq), 
137.4 (Cq), 135.7 (Cq), 133.5 (Cq), 131.7 (CH), 130.6 (CH), 128.1 (CH), 127.9 (CH), 127.6 
(CH), 127.0 (CH), 126.4 (CH), 126.3 (CH), 125.8 (CH), 124.7 (Cq), 123.9 (CH), 123.6 (CH), 
112.1 (Cq), 79.6 (CH2), 20.7 (CH3), 20.3 (CH3).  
IR (ATR): 3011, 1738, 1600, 1481, 1302, 698 cm-1.  
MS (EI) m/z (relative intensity) 413 (5) [M+], 400 (10), 291 (5).131 (5), 69 (30), 44 (100). 





The general procedure A was followed using 73e (119.5 mg, 0.50mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc/Et3N: 3:1:0.02) yielded 115ea (94 mg, 45%) as a yellow solid. M. p.: 
186–188 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.08–7.18 (m, 5H), 7.02 (d, J = 8.7 Hz, 2H), 7.00–6.97 
(m, 2H), 6.91–6.89 (m, 5H), 6.75 (d, J = 8.7 Hz, 2H), 6.42 (dd, J = 7.6, 1.5 Hz, 1H), 4,31 (s, 
1H), 3.92 (s, 1H), 3.65 (s, 3H), 2.52 (s, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 157.1 (Cq), 146.3 (Cq), 142.1 (Cq), 137.9 (Cq), 135.8 (Cq), 
135.7 (Cq), 135.1 (Cq), 133.8 (Cq), 131.7 (CH), 131.1 (CH), 130.3 (CH), 129.2 (CH), 127.6 
(CH), 127.3 (CH), 126.8 (Cq), 126.6 (CH), 126.3 (CH), 125.7 (CH), 120.7 (CH), 114.1 (CH), 
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113.7 (Cq), 96.1 (CH2), 54.9 (CH3), 22.5 (CH3).  
IR (ATR): 2959, 1616, 1507, 1239, 1034, 760 cm-1.  
MS (EI) m/z (relative intensity) 415 (75) [M+], 400 (100), 369 (10), 294 (5), 279 (5), 121 (10). 





The general procedure A was followed using 73f (119.5 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc/Et3N: 1:1:0.01→1:1:0.03) yielded 115fa (148 mg, 71%) as an off white 
solid. M. p.: 148–150 °C. 
1H-NMR (300 MHz, DMSO-d6): δ = 7.60 (s, 1H), 7.12 (d, J = 7.3 Hz, 2H), 7.07–6.84 (m, 
11H), 6.77 (d, J = 8.6 Hz, 2H), 6.53 (d, J = 8.0 Hz, 1H), 4,50 (s, 1H), 3.64 (s, 3H), 3.11 (s, 
1H), 2.31 (s, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 157.5 (Cq), 147.1 (Cq), 141.0 (Cq), 137.5 (Cq), 135.9 (Cq), 
135.3 (Cq), 134.9 (Cq), 131.7 (CH), 131.6 (CH), 131.1 (Cq), 130.7 (CH), 129.7 (Cq), 127.7 
(CH), 127.0 (Cq), 126.7 (CH), 126.4 (CH), 125.9 (CH), 124.0 (CH), 123.8 (CH), 114.4 (CH), 
112.1 (Cq), 79.7 (CH2), 55.0 (CH3), 20.8 (CH3).  
IR (ATR): 2997, 1621, 1507, 1244, 1030, 698 cm-1.  
MS (EI) m/z (relative intensity) 415 (100) [M+], 414 (85), 400 (45), 383 (10), 369 (10), 306 
(5).  






The general procedure A was followed using 73a (119.5 mg, 0.50 mmol) and 
1,2-bis(4-methoxyphenyl)acetylene (1b) (238 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc/Et3N: 2:1:0→2:1:0.05) yielded 115ab (142 mg, 60%) as a 
yellow solid. M. p.: 125–126 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.63 (d, J = 8.5 Hz, 1H), 7.01 (d, J = 8.9 Hz, 3H), 6.93 
(d, J = 8.9 Hz, 2H), 6.84 (d, J = 8.9 Hz, 2H), 6.78 (d, J = 8.9 Hz, 2H), 6.72 (d, J = 8.9 Hz, 2H), 
6.44 (d, J = 8.9 Hz, 2H), 6.42 (s, 1H), 4,42 (s, 1H), 3.67 (s, 3H), 3.66 (s, 3H), 3.52 (s, 3H), 
3.01 (s, 1H), 2.14 (s, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 157.4 (Cq), 157.1 (Cq), 157.0 (Cq), 147.3 (Cq), 141.9 (Cq), 
137.9 (Cq), 135.1 (Cq), 134.1 (Cq), 132.7 (CH), 131.8 (CH), 131.5 (CH), 129.7 (Cq), 128.5 
(Cq), 126.9 (CH), 124.7 (Cq), 124.0 (CH), 123.7 (CH), 114.4 (CH), 113.2 (CH), 112.2 (CH), 
111.8 (Cq), 79.0 (CH2), 55.0 (CH3), 54.7 (CH3), 54.5 (CH3), 20.9 (CH3).  
IR (ATR): 2955, 1737, 1605, 1506, 1235, 807 cm-1.  
MS (EI) m/z (relative intensity) 475 (65) [M+], 474 (100), 460 (20), 443 (5), 366 (5), 240 (5). 





The general procedure A was followed using 73a (119.5 mg, 0.50 mmol) and 
1,2-bis(4-methylphenyl)ethylne (1c) (206 mg, 1.00 mmol). Purification by column 
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chromatography (n-hexane/EtOAc/Et3N: 1:1:0→1:1:0.03) yielded 115ac (134 mg, 61%) as a 
yellow solid. M. p.: 163–165 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.63 (d, J = 8.3 Hz, 1H), 7.01 (d, J = 8.8 Hz, 2H), 6.96 
(m, 1H), 6.95 (d, J = 8.1 Hz, 2H), 6.90 (d, J = 8.1 Hz, 2H), 6.81 (d, J = 7.8 Hz, 2H), 6.76 (d, J 
= 8.8 Hz, 2H), 6.68 (d, J = 8.1 Hz, 2H), 6.41 (s, 1H), 4,43 (s, 1H), 3.63 (s, 3H), 3.03 (s, 1H), 
2.18 (s, 3H), 2.12 (s, H), 1.99 (s, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 157.4 (Cq), 147.3 (Cq), 141.9 (Cq), 137.9 (Cq), 135.2 (Cq), 
135.0 (Cq), 134.6 (Cq), 134.5 (Cq), 133.9 (Cq), 133.2 (Cq), 131.6 (CH), 131.5 (CH), 130.5 
(CH), 128.4 (CH), 127.4 (CH), 126.9 (CH), 124.7 (Cq), 124.0 (CH), 123.7 (CH), 114.3 (CH), 
112.0 (Cq), 79.1 (CH2), 54.9 (CH3), 20.9 (CH3), 20.6 (CH3), 20.5 (CH3).  
IR (ATR): 2956, 1606, 1506, 1239, 1033, 804 cm-1.  
MS (EI) m/z (relative intensity) 443 (40) [M+], 430 (100), 411 (5), 386 (5), 342 (15), 237 (60). 
HR-MS (EI) m/z calcd for C32H28NO [M-H+] 442.2171, found 442.2179. 





The general procedure A was followed using 73a (119.5 mg, 0.50 mmol) and 
1,2-bis(4-fluorophenyl)ethyne (1d) (214 mg, 1.00 mmol) at 120 °C. Purification by column 
chromatography (n-hexane/EtOAc/Et3N: 2:1:0→2:1:0.05) yielded 115ad (122 mg, 54%) as 
an off white solid. M. p.: 196–198 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.67 (d, J = 8.1 Hz, 1H), 7.06–6.97 (m, 9H), 6.79 (d, J = 
8.9 Hz, 2H), 6.73 (t, J = 8.9 Hz, 2H), 6.40 (s, 1H), 4,48 (s, 1H), 3.65 (s, 3H), 3.08 (s, 1H), 
2.15 (s, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 160.9 (Cq, JC-F = 243.0 Hz), 159.8 (Cq, JC-F = 243.0 Hz), 
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157.6 (Cq), 147.0 (Cq), 141.3 (Cq), 138.2 (Cq), 134.7 (Cq), 133.6 (CH, JC-F = 8.2 Hz), 133.5 
(Cq), 132.8 (CH, JC-F = 8.2 Hz), 132.3 (Cq), 132.3 (Cq), 131.5 (CH), 127.3 (CH), 124.7 (Cq), 
123.9 (CH), 123.8 (CH), 114.7 (CH, JC-F = 21.1 Hz), 114.5 (CH), 113.7 (CH, JC-F = 21.7 Hz), 
111.3 (Cq), 79.4 (CH2), 55.0 (CH3), 20.8 (CH3).  
19F-NMR (282 MHz, DMSO-d6): δ = -109.9, -111.4.  
IR (ATR): 2971, 1601, 1505, 1213, 828 cm-1.  
MS (EI) m/z (relative intensity) 451 (75) [M+], 450 (100), 436 (45), 419 (15), 406 (5), 330 (5). 





The general procedure A was followed using 73a (119.5 mg, 0.50 mmol) and oct-4-yne (1e) 
(110 mg, 1.00 mmol). Purification by column chromatography (n-hexane/EtOAc/Et3N: 
3:1:0.01→3:1:0.05) yielded 115ae  (77 mg, 44%) as a yellow oil.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.50 (d, J = 8.1 Hz, 1H), 7.15 (d, J = 8.9 Hz, 2H), 7.08 
(d, J = 8.9 Hz, 2H), 7.04 (s, 1H), 6.93 (d, J = 8.1 Hz, 1H), 4.24 (s, 1H), 3.81 (s, 3H), 2.81 (s, 
1H), 2.43–2.38 (m, 2H), 2.31 (s, 3H), 2.06–2.00 (m, 2H), 1.52–1.44 (m, 2H), 1.33–1.25 (m, 
2H), 1.00 (t, J = 7.8 Hz, 3H), 0.62 (t, J = 8.0 Hz, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 158.3 (Cq), 147.4 (Cq), 140.4 (Cq), 138.0 (Cq), 134.7 (Cq), 
132.7 (Cq), 131.0 (CH), 126.1 (CH), 124.8 (Cq), 132.7 (CH), 121.9 (CH), 115.1 (CH), 106.1 
(Cq), 78.1 (CH2), 55.2 (CH3), 31.6 (CH2), 28.9 (CH2), 22.8 (CH2), 21.9 (CH2), 21.1 (CH3), 
14.1 (CH2), 14.0 (CH3).  
IR (ATR): 2957, 1650, 1506, 1241, 1031, 827 cm-1.  
MS (EI) m/z (relative intensity) 347 (55) [M+], 334 (65), 320 (100), 304 (50), 291 (45), 176 
(45).  







The general procedure A was followed using 73a (119.5 mg, 0.50 mmol) and 
prop-1-yn-1-ylbenzene (1f) (116 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc/Et3N: 1:2:0→1:2:0.03) yielded 115af (125 mg, 69%) as an off white solid. 
M. p.: 121–123 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.62 (d, J = 8.9 Hz, 1H), 7.17–7.05 (m, 7H), 6.97 (d, J = 
8.9 Hz, 2H), 6.95 (d, J = 8.9 Hz, 2H), 4,35 (s, 1H), 3.64 (s, 3H), 2.96 (s, 1H), 2.34 (s, 3H) ), 
1.66 (s, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 157.4 (Cq), 147.1 (Cq), 141.0 (Cq), 138.3 (Cq), 136.6 (Cq), 
135.2 (Cq), 133.3 (Cq), 131.7 (CH), 130.1 (CH), 127.5 (CH), 127.0 (CH), 126.9 (CH), 125.2 
(Cq), 123.5 (CH), 122.6 (CH), 114.2 (CH), 102.5 (Cq), 78.1 (CH2), 55.0 (CH3), 21.0 (CH3), 
14.4 (CH3).  
IR (ATR): 2920, 1609, 1506, 1298, 1242, 698 cm-1.  
MS (EI) m/z (relative intensity) 353 (45) [M+], 352 (100), 340 (40), 321 (10), 244 (15), 217 
(15).  





The general procedure A was followed using 73a (119.5 mg, 0.50 mmol) and 
but-1-yn-1-ylbenzene (1g) (130 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc/Et3N: 1:1:0→1:1:0.03) yielded 115ag (116 mg, 63%) as an off white solid. 
M. p.: 199–201 °C.  
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1H-NMR (300 MHz, DMSO-d6): δ = 7.62 (d, J = 8.5 Hz, 1H), 7.18–7.08 (m, 6H), 7.02 (d, J = 
8.5 Hz, 1H), 6.96 (d, J = 9.0 Hz, 2H), 6.74 (d, J = 9.0 Hz, 2H), 4,33 (s, 1H), 3.63 (s, 3H), 2.92 
(s, 1H), 2.34 (s, 3H), 2.08 (q, J = 7.1 Hz, 2H), 0.92 (t, J = 7.1 Hz, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 157.4 (Cq), 147.2 (Cq), 141.0 (Cq), 138.2 (Cq), 136.3 (Cq), 
135.1 (Cq), 132.0 (Cq), 131.7 (CH), 129.9 (CH), 127.5 (CH), 127.1 (CH), 126.8 (CH), 125.5 
(Cq), 123.9 (CH), 122.4 (CH), 114.2 (CH), 108.8 (Cq), 78.0 (CH2), 54.9 (CH3), 21.0 (CH3), 
20.6 (CH2), 14.3 (CH3).  
IR (ATR): 2970, 1737, 1584, 1508, 1229, 1027, 736 cm-1.  
MS (EI) m/z (relative intensity) 367 (50) [M+], 366 (100), 352 (25), 336 (5), 320 (5), 244 (5). 





The general procedure A was followed using 73a (119.5 mg, 0.50 mmol) and 
1-(hex-1-yn-1-yl)-4-methoxybenzene (1h) (188 mg, 1.00 mmol). Purification by column 
chromatography (n-hexane/EtOAc/Et3N: 3:1:0.01→3:1:0.05) yielded 115ah (125 mg, 59%) 
as an off white solid. M. p.: 133–133 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.60 (d, J = 8.3 Hz, 1H), 7.10 (s, 1H), 6.99 (m, 1H), 
6.99 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 6.76 (d, J = 8.8 Hz, 2H), 6.71 (d, J = 8.8 Hz, 
2H), 4,31 (s, 1H), 3.65 (s, 6H), 2.90 (s, 1H), 2.33 (s, 3H), 2.05 (t, J = 7.3 Hz, 2H), 1.34 (m, 
2H), 1.16 (m, 2H), 0.71 (t, J = 7.3 Hz, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 157.6 (Cq), 157.1 (Cq), 147.1 (Cq), 140.9 (Cq), 138.0 (Cq), 
135.3 (Cq), 132.3 (Cq), 131.5 (CH), 131.1 (CH), 128.5 (Cq), 126.6 (CH), 125.3 (Cq), 123.7 
(CH), 122.3 (CH), 114.2 (CH), 112.7 (CH), 108.0 (Cq), 77.9 (CH2), 54.9 (CH3), 54.7 (CH3), 
31.6 (CH2), 27.2 (CH2), 22.1 (CH2), 21.1 (CH3), 13.4 (CH3).  
IR (ATR): 2928, 1737, 1507, 1240, 1033, 829 cm-1.  
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MS (EI) m/z (relative intensity) 425 (65) [M+], 424 (100), 412 (25), 384 (75), 274 (5), 240 
(10).  





The general procedure A was followed using 73a (119.5 mg, 0.50 mmol) and 
1-fluoro-4-(hex-1-yn-1-yl)benzene (1i) (176 mg, 1.00 mmol) at 120 °C. Purification by 
column chromatography (n-hexane/EtOAc/Et3N: 3:1:0→3:1:0.05) yielded 115ai (148 mg, 
72%) as an off white solid. M. p.: 96–98 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.62 (d, J = 8.4 Hz, 1H), 7.16–7.11 (m, 3H), 7.02–6.96 
(m, 5H), 6.77 (d, J = 8.8 Hz, 2H), 4,34 (s, 1H), 3.65 (s, 3H), 2.93 (s, 1H), 2.34 (s, 3H), 2.04 (t, 
J = 7.2 Hz, 2H), 1.34 (m, 2H), 1.15 (m, 2H), 0.70 (t, J = 7.2 Hz, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 160.6 (Cq JC-F = 245 Hz), 157.3 (Cq), 147.0 (Cq), 140.0 
(Cq), 138.1 (Cq), 135.0 (Cq), 132.6 (Cq, JC-F = 3.5 Hz), 132.4 (Cq), 132.3 (CH, JC-F = 8.0 Hz), 
131.5 (CH), 126.8 (CH), 125.3 (Cq), 123.7 (CH), 122.4 (CH), 114.3 (CH, JC-F = 21.5 Hz), 
114.2 (CH), 108.0 (Cq), 78.1 (CH2), 55.0 (CH3), 31.5 (CH2), 27.1 (CH2), 22.0 (CH2), 20.9 
(CH3), 13.4 (CH3).  
19F-NMR (282 MHz, DMSO-d6): δ = -114.4.  
IR (ATR): 2954, 1599, 1507, 1243, 1033, 825 cm-1.  
MS (EI) m/z (relative intensity) 413 (50) [M+], 412 (100), 398 (20), 372 (40), 354 (10), 262 
(10).  







The general procedure A was followed using 73a (119.5 mg, 0.50 mmol) and ethyl 
4-(hex-1-ynyl)benzoate (1j) (230 mg, 1.00 mmol) at 120 °C. Purification by column 
chromatography (n-hexane/EtOAc/Et3N: 3:1:0→3:1:0.05) yielded 115aj (116 mg, 50%) as an 
off white solid. M. p.: 151–153 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.75 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 8.4 Hz, 1H), 7.26 
(d, J = 8.4 Hz, 2H), 7.13 (s, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.99 (d, J = 9.0 Hz, 2H), 6.75 (d, J 
= 9.0 Hz, 2H), 4,36 (s, 1H), 4.26 (q, J = 7.2 Hz, 2H), 3.63 (s, 3H), 2.98 (s, 1H), 2.35 (s, 3H), 
2.02 (m, 2H), 1.34 (m, 2H), 1.29 (t, J = 7.2 Hz, 3H), 1.12 (m, 2H), 0.68 (t, J = 7.2 Hz, 3H). 
13C-NMR (75 MHz, DMSO-d6): δ = 165.1 (Cq), 157.5 (Cq), 147.0 (Cq), 141.1 (Cq), 140.0 (Cq), 
138.1 (Cq), 134.8 (Cq), 132.0 (Cq), 131.6 (CH), 130.5 (CH), 128.3 (Cq), 128.1 (CH), 127.0 
(CH), 125.5 (Cq), 123.8 (CH), 122.4 (CH), 114.3 (CH), 107.9 (Cq), 78.3 (CH2), 60.5 (CH2), 
54.9 (CH3), 31.4 (CH2), 26.9 (CH2), 21.8 (CH2), 20.9 (CH3), 13.8 (CH3), 13.2 (CH3).  
IR (ATR): 2928, 1718, 1507, 1272, 1098, 747 cm-1.  
MS (EI) m/z (relative intensity) 467 (60) [M+], 466 (100), 452 (20), 438 (20), 424 (10), 394 
(10).  





The general procedure A was followed using 73a (119.5 mg, 0.50 mmol) and 
1-(4-(hex-1-ynyl)phenyl)ethanone (1k) (200 mg, 1.00 mmol) at 120 °C. Purification by 
column chromatography (n-hexane/EtOAc/Et3N: 3:1:0.01→3:1:0.03) yielded 115ak (125 mg, 
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57%) as an off white solid. M. p.: 129–131 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.75 (d, J = 8.3 Hz, 2H), 7.56 (s, 1H), 7.27 (d, J = 8.3 
Hz, 2H), 7.26 (d, J = 8.5 Hz, 1H), 7.22 (d, J = 8.5 Hz, 1H), 7.01 (d, J = 8.4 Hz, 2H), 6.76 (d, J 
= 8.4 Hz, 2H), 4,41 (s, 1H), 3.63 (s, 3H), 3.00 (s, 1H), 2.49 (s, 3H), 2.33 (s, 3H), 1.98 (m, 2H), 
1.33 (m, 2H), 1.11 (m, 2H), 0.68 (t, J = 7.6 Hz, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 197.3 (Cq), 157.5 (Cq), 147.1 (Cq), 141.2 (Cq), 139.2 (Cq), 
135.3 (Cq), 135.2 (Cq), 135.0 (Cq), 131.7 (CH), 130.6 (CH), 130.0 (CH), 129.6 (Cq), 127.9 
(Cq), 127.3 (CH), 124.1 (CH), 122.5 (CH), 114.4 (CH), 108.0 (Cq), 79.0 (CH2), 55.0 (CH3), 
31.6 (CH2), 27.2 (CH2), 26.5 (CH3), 22.0 (CH2), 20.8 (CH2), 13.4 (CH3).  
IR (ATR): 2929, 1681, 1507, 1243, 1028, 830 cm-1.  
MS (EI) m/z (relative intensity) 437 (60) [M+], 436 (85), 424 (100), 408 (10), 396 (20), 354 
(90).  




The general procedure B was followed using 73a (119.5 mg, 0.50 mmol) and 1a (178 mg, 1.00 
mmol). Purification by column chromatography (n-hexane/EtOAc: 120:1) yielded 116aa (83 
mg, 40%) as a white solid. M. P.: 168–170 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.32–7.24 (m, 4H), 7.24–7.05 (m, 4H), 6.99–6.91 (m, 5H), 
6.90–6.86 (m, 2H), 6.63–6.57 (m, 2H), 5.02 (q, J = 6.8 Hz, 1H), 3.65 (d, J = 0.9 Hz, 3H), 2.26 (s, 
3H), 1.67 (d, J = 6.8 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 154.6 (Cq), 140.9 (Cq), 138.6 (Cq), 137.8 (Cq), 137.6 (Cq), 
136.2 (Cq), 132.1 (Cq), 132.1 (CH), 131.0 (CH), 130.7 (Cq), 127.8 (CH), 127.0 (CH), 126.9 
(CH), 126.6 (CH), 126.0 (CH), 124.8 (CH), 123.8 (CH), 123.6 (CH), 121.7 (Cq), 113.6 (CH), 
60.2 (CH), 55.3 (CH3), 22.5 (CH3), 21.5 (CH3).  
IR (ATR): 2980, 1755, 1510, 1243, 1027, 750 cm-1.  
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MS (EI) m/z (relative intensity) 417 (10) [M+], 402 (100), 387 (5), 358 (10), 294 (5).  




The general procedure B was followed using 73a (119.5 mg, 0.50 mmol) and 
prop-1-ynylbenzene (1f) (116 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 100:1) yielded 116af (87 mg, 49%) as a white solid. M. p.: 150–152 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.42 (dd, J = 8.0, 1.5 Hz, 2H), 7.16–7.28 (m, 4H), 7.00 (d, J 
= 8.0 Hz, 1H), 6.90 (d, J = 7.6 Hz, 1H), 6.78 (d, J = 8.7 Hz, 2H), 6.57 (d, J = 8.7 Hz, 2H), 
4.90 (q, J = 7.0 Hz, 1H), 3.63 (s, 3H), 2.40 (s, 3H), 2.23 (s, 3H), 1.50 (d, J = 7.0 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 154.3 (Cq), 141.5 (Cq), 137.9 (Cq), 136.2 (Cq), 136.1 (Cq), 
133.7 (Cq), 132.1 (Cq), 130.8 (CH), 127.5 (CH), 127.1 (CH), 126.8 (CH), 124.5 (CH), 123.3 
(CH), 122.9 (CH), 113.9 (Cq), 113.6 (CH), 60.1 (CH), 55.3 (CH3), 22.0 (CH3), 21.5 (CH3), 
15.3 (CH3).  
IR (ATR): 2964, 1738, 1505, 1229, 1033, 772 cm-1.  
MS (EI) m/z (relative intensity) 355 (15) [M+], 340 (100), 325 (5), 296 (10), 282 (5).  




The general procedure B was followed using 73a (119.5 mg, 0.50 mmol) and oct-4-yne (1e) 
(110 mg, 1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 50:1) 
yielded 116ae  (75 mg, 42%) as a green oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.08 (s, 1H), 6.91 (d, J = 7.6 Hz, 1H), 6.87 (d, J = 9.2 Hz, 
2H), 6.78 (d, J = 7.6 Hz, 1H), 6.75 (d, J = 9.2 Hz, 2H), 4.60 (q, J = 6.8 Hz, 1H), 3.74 (s, 3H), 
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2.70–2.47 (m, 2H), 2.42–2.34 (m, 1H), 2.34 (s, 3H), 2.16–2.06 (m, 1H), 1.41-1.68 (m, 4H), 
1.32 (d, J = 6.8 Hz, 3H), 1.05 (t, J = 7.4 Hz, 3H), 0.87 (t, J = 7.4 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 155.0 (Cq), 141.5 (Cq), 137.6 (Cq), 135.8 (Cq), 132.0 (Cq), 
131.7 (Cq), 126.0 (CH), 124.7 (CH), 124.0 (CH), 121.9 (CH), 118.3 (Cq), 113.9 (CH), 60.3 
(CH), 55.4 (CH3), 31.4 (CH2), 29.8 (CH2), 23.4 (CH2), 22.1 (CH3), 22.1 (CH2), 21.6 (CH3), 
14.6 (CH3), 14.2 (CH3).  
IR (ATR): 2958, 2869, 1505, 1237, 1035, 827cm-1.  
MS (EI) m/z (relative intensity) 349 (10) [M+], 334 (100), 320 (10), 304 (5), 290 (5), 276 (5). 




The general procedure B was followed using 73f (119.5 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 100:1) yielded 116fa (94 mg, 45%) as an off white solid. M. p.: 
160–163 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.25 (d, J = 4.4 Hz, 4H), 7.22–7.09 (m, 4H), 7.00–6.89 (m, 
4H), 6.86 (d, J = 8.9 Hz, 3H), 6.86 (s, 1H), 6.58 (d, J = 8.9 Hz, 2H), 4.98 (q, J = 6.7 Hz, 1H), 
2.29 (s, 3H), 1.65 (d, J = 6.7 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 154.5 (Cq), 141.0 (Cq), 138.7 (Cq), 137.6 (Cq), 136.8 (Cq), 
135.9 (Cq), 133.6 (Cq), 131.9 (CH), 131.0 (CH), 129.7 (Cq), 127.8 (CH), 127.5 (CH), 127.0 
(CH), 126.5 (CH), 126.0 (CH), 125.5 (CH), 123.5 (CH), 123.3 (CH), 122.1 (Cq), 113.7 (CH), 
60.4 (CH), 55.3 (CH3), 22.4 (CH3), 21.1 (CH3).  
IR (ATR): 2972, 1756, 1509, 1243, 1027, 749 cm-1.  
MS (EI) m/z (relative intensity) 417 (10) [M+], 402 (100), 387 (5), 358 (10), 294 (5).  






The general procedure B was followed using 73h (119.5 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 100:1) yielded 116ha (116 mg, 56%) as an off white solid. M. p.: 
100–103 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.32–7.27 (m, 5H), 7.22–7.14 (m, 5H), 6.99-6.89 (m, 6H), 
6.60 (dd, J = 9.0, 1.3 Hz, 2H), 4.68 (dd, J = 6.9, 6.9 Hz, 1H), 3.65 (d, J = 1.4 Hz, 3H), 
2.18–2.08 (m, 1H), 1.92–1.83 (m, 1H), 1.23 (t, J = 7.6 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 154.7 (Cq), 141.2 (Cq), 138.6 (Cq), 138.5 (Cq), 137.6 (Cq), 
132.4 (Cq), 131.9 (CH), 131.8 (Cq), 131.3 (CH), 127.8 (CH), 127.0 (CH), 126.7 (CH), 126.7 
(CH), 126.1 (CH), 125.8 (CH), 125.8 (CH), 124.1 (CH), 123.2 (CH), 112.7 (Cq), 113.7 (CH), 
67.0 (CH), 55.3 (CH3), 28.6 (CH2), 11.2 (CH3).  
IR (ATR): 2953, 1738, 1505, 1229, 1028, 700 cm-1.  
MS (EI) m/z (relative intensity) 417 (65) [M+], 388 (100), 372 (5), 344 (10), 280 (5), 252 (5). 





The general procedure B was followed using 73i (157.5 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 100:1) yielded 116ia (118 mg, 48%) as an off white solid. M. p.: 
138–140 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.38–7.33 (m, 2H), 7.29–7.24 (m, 2H), 7.17–7.07 (m, 2H), 
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7.07–7.00 (m, 1H), 7.00–6.89 (m, 3H), 6.86 (d, J = 9.0 Hz, 2H), 6.59 (d, J = 8.9 Hz, 2H), 6.39 
(s, 1H), 4.91 (q, J = 6.7 Hz, 1H), 3.81 (s, 3H), 3.75 (s, 3H), 3.63 (s, 3H), 2.99 (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 154.3 (Cq), 152.3 (Cq), 150.5 (Cq), 141.8 (Cq), 140.7 (Cq), 
140.5 (Cq), 137.4 (Cq), 137.3 (Cq), 132.4 (CH), 132.1 (Cq), 131.1 (CH), 126.8 (CH), 126.7 
(CH), 126.3 (CH), 125.5 (CH), 122.6 (CH), 121.8 (Cq), 120.5 (Cq), 113.7 (CH), 103.9 (CH), 
60.5 (CH), 60.2 (CH3), 59.7 (CH3), 55.9 (CH3), 55.3 (CH3), 21.9 (CH3).  
IR (ATR): 2987, 1742, 1511, 1226, 708 cm-1.  
MS (EI) m/z (relative intensity) 493 (5) [M+], 478 (100), 463 (5), 448 (10), 417 (5).  
HR-MS (EI) m/z calcd for C32H31NO4 [M+] 493.2253, found 493.2259. 
 
Intermolecular Competition Experiment Between Alkynes Substrates 1a and 1l: 
 
A suspension of (E)-4-methoxy-N-[1-(p-tolyl)ethylidene]aniline (73a) (120 mg, 0.50 mmol), 
1,2-diphenylethyne (1a) (178 mg, 1.00 mmol), hex-3-yne (1l) (82.0 mg, 1.00 mmol), 
[RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O 
(100 mg, 0.50 mmol) in DCE (2.0 mL) was stirred at 100 °C  for 20 h under an atmosphere of 
air. At ambient temperature, H2O (20 mL) was added, and the mixture was extracted with 
EtOAc (3 × 20 mL). The combined organic layers were washed with brine (20 mL) and dried 
over Na2SO4. The solvent was evaporated in vacuo, and the residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc/Et3N: 20:1:0.05) to yield 115aa (78 mg, 42%) 
as the sole product. 
 
Ruthenium(II)-Catalyzed H/D Exchange with Substrate 73a in [D4]-MeOH as the 




A suspension of (E)-4-methoxy-N-[1-(p-tolyl)ethylidene]aniline (73a) (120 mg, 0.50 mmol), 
oct-4-yne (1e) (110 mg, 1.00 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), AgSbF6 
(34.4 mg, 20 mol %) and Cu(OAc)2·H2O (100 mg, 0.50 mmol) in a solvent mixture of DCE 
and [D4]-MeOH (1.8/0.2 mL) was stirred at 100 °C  for 20 h under an atmosphere of air. At 
ambient temperature, H2O (20 mL) was added, and the mixture was extracted with EtOAc (3 
× 20 mL). The combined organic layers were washed with brine (20 mL) and dried over 
Na2SO4. The solvent was evaporated in vacuo, and the residue was purified by column 
chromatography (n-hexane/EtOAc/Et3N: 1:2:0.03) to yield [Dn]-115ae (32.0 mg, 21%) as an 
off white solid. The D-incorporation in [Dn]-115ae was estimated by 1H-NMR spectroscopy. 
10.4.2 Analytical Data for the Products of the Ruthenium(II)-Catalyzed 
Oxidative C-H Activation with Internal Alkynes and Acrylates 
N-(tert-Butyl)-3,4-diphenylisoquinolin-1-amine (118aa) 
 
The general procedure C was followed using 117a (88.0 mg, 0.50 mmol) and 1a (178 mg, 
1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 100:1) yielded 118aa 
(141 mg, 80%) as a yellow solid. M. p.: 139−142 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.76 (d, J = 7.9 Hz, 1H), 7.55 (d, J = 7.3 Hz, 1H), 
7.48−7.41 (m, 4H), 7.35−7.30 (m, 3H), 7.26−7.23 (m, 2H), 7.18−7.16 (m, 3H), 5.23 (s, 1H), 
1.66 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 153.3 (Cq), 148.0 (Cq), 141.9 (Cq), 138.8 (Cq), 137.4 (Cq), 
132.1 (CH), 130.4 (CH), 129.1 (CH), 128.2 (CH), 127.1 (CH), 126.5 (CH), 126.4 (CH), 126.3 
(CH), 125.2 (CH), 121.0 (CH), 120.2 (Cq), 117.0 (Cq), 51.9 (Cq), 29.4 (CH3).  
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IR (ATR): 3437, 2956, 1515, 1416, 1210, 697 cm-1.  
MS (EI) m/z (relative intensity) 352 (30) [M+], 337 (15), 296 (100), 278 (25), 190 (10), 165 
(10).  
HR-MS (EI) m/z calcd for C25H24N2 [M+] 352.1939, found 352.1934.  




The general procedure C was followed using 117a (88.0 mg, 0.50 mmol) and 1b (238 mg, 
1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 100/1→50/1) yielded 
118ab (131 mg, 64%) as a white solid. M. p.: 176−179 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.72 (d, J = 8.4 Hz, 1H), 7.53 (d, J = 7.8 Hz, 1H), 7.55 (d, J 
= 6.9, 1.4 Hz, 1H), 7.41−7.35 (m, 3H), 7.12 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 8.9 Hz, 2H), 6.71 
(d, J = 8.4 Hz, 2H), 5.16 (s, 1H), 3.83 (s, 3H), 3.76 (s, 3H), 1.63 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 158.2 (Cq), 158.1 (Cq), 153.1 (Cq), 147.6 (Cq), 137.9 (Cq), 
134.5 (Cq), 133.0 (CH), 131.6 (CH), 131.2 (Cq), 129.0 (CH), 126.2 (CH), 124.9 (CH), 121.0 
(CH), 119.2 (Cq), 116.9 (Cq), 113.8 (CH), 112.6 (CH), 55.2 (CH3), 55.1 (CH3), 51.8 (Cq), 29.4 
(CH3).  
IR (ATR): 3439, 2949, 1512, 1417, 1234, 763 cm-1.  
MS (EI) m/z (relative intensity) 412 (30) [M+], 397 (15), 356 (100), 341 (10), 312 (10). 
HR-MS (EI) m/z calcd for C27H28N2O2 [M+] 412.2151, found 412.2141. 
 
N-(tert-Butyl)-3,4-di-p-tolylisoquinolin-1-amine (118ac) 
                                                                 




The general procedure C was followed using 117a (88.0 mg, 0.50 mmol) and 1c (206 mg, 
1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 150/1) yielded 118ac 
(171 mg, 90%) as a white solid. M. p.: 173−174 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.73 (d, J = 8.0 Hz, 1H), 7.53 (dd, J = 8.1, 2.1 Hz, 1H), 
7.46−7.39 (m, 2H), 7.34 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 8.2 Hz, 2H), 7.11 (d, J = 8.2 Hz, 2H), 
6.98 (d, J = 8.1 Hz, 2H), 5.18 (s, 1H), 2.39 (s, 3H), 2.31 (s, 3H), 1.64 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 153.0 (Cq), 147.7 (Cq), 139.0 (Cq), 137.6 (Cq), 135.9 (Cq), 
135.9 (Cq), 135.8 (Cq), 131.6 (CH), 130.0 (CH), 129.0 (CH), 128.9 (CH), 127.7 (CH), 126.2 
(CH), 124.7 (CH), 121.0 (CH), 119.8 (Cq), 116.9 (Cq), 51.8 (Cq), 29.5 (CH3), 21.4 (CH3), 21.3 
(CH3).  
IR (ATR): 3452, 2989, 1573, 1512, 1210, 762 cm-1.  
MS (EI) m/z (relative intensity) 380 (35) [M+], 365 (15), 324 (100), 308 (10), 291 (5). 




The general procedure C was followed using 117a (88.0 mg, 0.50 mmol) and 1d (214 mg, 
1.00 mmol) at 140 °C. Purification by column chromatography (n-hexane/EtOAc: 120/1) 
yielded 118ad (131 mg, 68%) as a yellow solid. M. p.: 195−198 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.76 (d, J = 7.9 Hz, 1H), 7.49−7.40 (m, 3H), 7.36−7.31 (m, 
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2H), 7.17−7.12 (m, 2H), 7.06 (t, J = 8.8 Hz, 2H), 6.88 (t, J = 8.8 Hz, 2H), 5.24 (s, 1H), 1.64 (s, 
9H).  
13C-NMR (75 MHz, CDCl3): δ = 161.9 (Cq, JC-F = 245.5 Hz), 161.2 (Cq, JC-F = 245.5 Hz), 
153.3 (Cq), 147.2 (Cq), 137.7 (Cq, JC-F = 3.5 Hz), 137.3 (Cq), 134.4 (Cq, JC-F = 3.5 Hz), 133.4 
(CH, JC-F =7.9 Hz), 131.9 (CH, JC-F = 7.9 Hz), 129.3 (CH), 125.9 (CH), 125.3 (CH), 121.1 
(CH), 118.8 (Cq), 117.0 (Cq), 115.3 (CH, JC-F = 21.4 Hz), 114.1 (CH, JC-F = 21.4 Hz), 51.9 
(Cq), 29.4 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = −(115.75−115.83) (m), −(115.85−116.00) (m).  
IR (ATR): 3472, 2963, 1506, 1417, 1214, 825 cm-1.  
MS (EI) m/z (relative intensity) 388 (30) [M+], 373 (15), 332 (100), 331 (95), 314 (20), 294 
(5).  
HR-MS (EI) m/z calcd for C25H22N2F2 [M+] 388.1751, found 388.1746. 
 
N-tert-Butyl-3,4-bis(4-chlorophenyl)isoquinolin-1-amine  (118am) 
 
The general procedure C was followed using 117a (88.0 mg, 0.50 mmol) and 1m (246 mg, 
1.00 mmol) at 140 °C. Purification by column chromatography (n-hexane/EtOAc: 120/1) 
yielded 118am (76 mg, 36%) as an off white solid. M. p.: 198−200 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.74 (m, 1H, ArH), 7.41−7.47 (m, 3H), 7.27−7.33 (m, 4H), 
7.12−7.17 (m, 4H), 5.24 (s, 1H), 1.61 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 153.5 (Cq), 147.0 (Cq), 140.1 (Cq), 137.1 (Cq), 137.0 (Cq), 
133.3 (CH), 132.7 (Cq), 132.6 (Cq), 131.6 (CH), 129.5 (CH), 128.6 (CH), 127.5 (CH), 125.9 
(CH), 125.6 (CH), 121.2 (CH), 118.9 (Cq), 117.1 (Cq), 51.9 (Cq), 29.3 (CH3).  
IR (ATR): 3450, 2952, 1517, 1418, 1088, 763 cm-1.  








The general procedure C was followed using 117a (88.0 mg, 0.50 mmol) and 1n (190 mg, 
1.00 mmol) at 140 °C. Purification by column chromatography (n-hexane/EtOAc: 120/1) 
yielded 118an (142 mg, 75%) as an off white solid. M. p.: 165−168 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.67 (d, J = 8.2 Hz, 1H), 7.55 (dd, J = 5.2, 1.2 Hz, 1H), 
7.48−7.44 (m, 2H), 7.41−7.36 (m, 1H), 7.27−7.25 (m, 2H), 7.03 (dd, J = 3.8, 1.2 Hz, 1H), 
6.89−6.86 (m, 1H), 6.46 (dd, J = 3.8, 1.2 Hz, 1H), 5.30 (s, 1H), 1.70 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 153.2 (Cq), 146.9 (Cq), 143.0 (Cq), 139.5 (Cq), 139.0 (Cq), 
129.7 (CH), 128.9 (CH), 127.8 (CH), 127.8 (CH), 127.1 (CH), 126.9 (CH), 126.4 (CH), 126.1 
(CH), 125.2 (CH), 120.9 (CH), 117.1 (Cq), 109.4 (Cq), 52.0 (Cq), 29.0 (CH3).  
IR (ATR): 3444, 2962, 1513, 1426, 1223, 699 cm-1.  
MS (EI) m/z (relative intensity) 364 (60) [M+], 349 (20), 308 (100), 290 (10), 275 (40), 263 
(10).  




The general procedure C was followed using 117a (88.0 mg, 0.50 mmol) and 1e  (110 mg, 
1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 150/1) yielded 118ae 
(112 mg, 78%) as a green oil.  
1H-NMR (300 MHz, CDCl3) δ = 7.83 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.58−7.52 
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(m, 1H), 7.38−7.32 (m, 1H), 4.95 (s, 1H), 2.87−2.75 (m, 4H), 1.89−1.79 (m, 2H), 1.66−1.57 
(m, 2H), 1.60 (s, 9H), 1.07 (t, J = 7.3 Hz, 3H), 1.01 (t, J = 7.3 Hz, 3H).  
13C-NMR (75 MHz, CDCl3) δ = 152.3 (Cq), 150.4 (Cq), 136.7 (Cq), 128.7 (CH), 123.8 (CH), 
123.7 (CH), 121.6 (CH), 117.1 (Cq), 116.5 (Cq), 51.5 (Cq), 37.1 (CH2), 29.5 (CH2), 29.4 (CH3), 
24.1 (CH2), 22.7 (CH2), 14.6 (CH3), 14.4 (CH3).  
IR (ATR): 3482, 2957, 1518, 1416, 1209, 758 cm-1.  
MS (EI) m/z (relative intensity) 284 (20) [M+], 269 (15), 255 (10), 228 (25), 213 (10), 199 
(100).  




The general procedure C was followed using 117a (88.0 mg, 0.50 mmol) and 1l (82 mg, 1.00 
mmol). Purification by column chromatography (n-hexane/EtOAc: 100/1) yielded 118al (107 
mg, 84%) as a green oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.83 (d, J = 8.5 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H,), 7.53 
(ddd, J = 8.5, 6.8, 1.1 Hz, 1H), 7.33 (ddd, J = 8.5, 6.8, 1.1 Hz, 1H), 4.94 (s, 1H), 2.89 (q, J = 
7.6 Hz, 2H), 2.81 (q, J = 7.6 Hz, 2H), 1.58 (s, 9H), 1.33 (t, J = 7.6 Hz, 3H), 1.21 (t, J = 7.6 Hz, 
3H).  
13C-NMR (75 MHz, CDCl3): δ = 152.4 (Cq), 151.2 (Cq), 136.4 (Cq), 128.8 (CH), 123.8 (CH), 
123.4 (CH), 121.6 (CH), 117.3 (Cq), 117.1 (Cq), 51.5 (Cq), 29.3 (CH3), 28.0 (CH2), 20.2 (CH2), 
15.2 (CH3), 14.1 (CH3).  
IR (ATR): 3458, 2961, 1518, 1417, 1210, 758 cm-1.  
MS (EI) m/z (relative intensity) 256 (20) [M+], 241 (20), 228 (10), 200 (45), 185 (100), 171 
(60).  






The general procedure C was followed using 117a (88.0 mg, 0.50 mmol) and 1h (188 mg, 
1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 100/1) yielded 118ah 
(83 mg, 46%) as a white solid. M. p.: 115−117 °C.  
1H-NMR (300 MHz, CDCl3):δ = 7.99 (d, J = 8.8 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.59 (dd, 
J = 8.8, 7.2 Hz, 1H), 7.52 (d, J = 8.4, 7.2 Hz, 2H), 7.41 (d, J = 7.8 Hz, 1H), 6.97 (d, J = 8.6 
Hz, 2H), 5.01 (s, 1H), 3.87 (s, 3H), 2.93−2.87 (m, 2H), 1.69−1.56 (m, 2H), 1.55 (s, 9H), 
1.42−1.35 (m, 2H), 0.99 (t, J = 7.3 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 158.5 (Cq), 152.0 (Cq), 149.0 (Cq), 136.9 (Cq), 135.4 (Cq), 
130.4 (CH), 128.7 (CH), 124.6 (CH), 124.4 (CH), 121.4 (CH), 117.8 (Cq), 117.3 (Cq), 112.9 
(CH), 55.2 (CH3), 51.4 (Cq), 33.4 (CH2), 29.4 (CH3), 27.8 (CH2), 22.8 (CH2), 14.0 (CH3).  
IR (ATR): 3448, 2953, 1510, 1419, 1228, 830 cm-1.  
MS (EI) m/z (relative intensity) 362 (30) [M+], 347 (10), 319 (10), 306 (35), 263 (100), 248 
(20).  




The general procedure C was followed using 117a (88.0 mg, 0.50 mmol) and 1f (116 mg, 
1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 150/1) yielded 118af 
(105 mg, 72%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.93 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 
7.70−7.66 (m, 2H), 7.65−7.62 (m, 1H), 7.49−7.43 (m, 3H), 7.40−7.34 (m, 1H), 5.05 (s, 1H), 
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2.53 (s, 3H), 1.60 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 152.2 (Cq), 149.0 (Cq), 142.5 (Cq), 137.7 (Cq), 130.1 (CH), 
129.2 (CH), 127.5 (CH), 126.8 (CH), 124.9 (CH), 124.4 (CH), 121.5 (CH), 117.6 (Cq), 112.2 
(Cq), 51.7 (Cq), 29.4 (CH3), 15.2 (CH3).  
IR (ATR): 3452, 2960, 1517, 1421, 1211, 699 cm-1.  
MS (EI) m/z (relative intensity) 290 (25) [M+], 275 (15), 273 (95), 234 (100), 216 (20). 




The general procedure C was followed using 117b (95.0 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 150/1) yielded 118ba (131 mg, 72%) as a yellow solid. M. p.: 92−95 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.64 (d, J = 8.9 Hz, 1H), 7.40−7.25 (m, 7H), 7.22−7.12 (m, 
5H), 5.15 (s, 1H), 2.36 (s, 3H), 1.63 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 153.3 (Cq), 148.1 (Cq), 142.1 (Cq), 139.2 (Cq), 139.0 (Cq), 
137.6 (Cq), 132.1 (CH), 130.3 (CH), 128.1 (CH), 127.1 (CH), 127.0 (CH), 126.4 (CH), 126.3 
(CH), 125.3 (CH), 121.0 (CH), 120.0 (Cq), 115.2 (Cq), 51.9 (Cq), 29.4 (CH3), 21.9 (CH3).  
IR (ATR): 3456, 2957, 1573, 1415, 1206, 697 cm-1.  
MS (EI) m/z (relative intensity) 366 (40) [M+], 351 (20), 310 (100), 309 (95), 292 (20), 277 
(20).  






The general procedure C was followed using 117c (103 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 100/1) yielded 118ca (133 mg, 70%) as a white solid. M. p.: 138−139 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.66 (d, J = 9.4 Hz, 1H), 7.40−7.38 (m, 1H), 7.37 (d, J = 
1.5 Hz, 1H), 7.34−7.25 (m, 3H), 7.22−7.19 (m, 2H), 7.16−7.12 (m, 3H), 7.03 (dd, J = 9.0, 2.6 
Hz, 1H), 6.85 (d, J = 2.6 Hz, 1H), 5.08 (s, 1H), 3.68 (s, 3H), 1.62 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 160.1 (Cq), 153.3 (Cq), 148.7 (Cq), 142.0 (Cq), 139.4 (Cq), 
139.0 (Cq), 132.0 (CH), 130.4 (CH), 128.2 (CH), 127.0 (CH), 126.5 (CH), 126.4 (CH), 123.0 
(CH), 120.0 (Cq), 116.3 (CH), 112.1 (Cq), 105.6 (CH), 55.1 (CH3), 51.8 (Cq), 29.5 (CH3).  
IR (ATR): 3426, 2954, 1610, 1515, 1417, 1213, 703 cm-1.  
MS (EI) m/z (relative intensity) 382 (25) [M+], 367 (15), 326 (100), 308 (10), 293 (10), 282 
(15).  
HR-MS (EI) m/z calcd for C26H26N2O [M+] 382.2045, found 382.2047.  




The general procedure C was followed using 117d (97.0 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 120/1) yielded 118da (142 mg, 77%) as a yellow solid. M. p.: 175−176 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.77−7.72 (m, 1H), 7.40−7.37 (m, 2H), 7.37−7.28 (m, 3H), 
7.20−7.12 (m, 7H), 5.15 (s, 1H), 1.63 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 163.0 (Cq, JC-F = 249.0 Hz), 153.1 (Cq), 149.2 (Cq), 141.5 
(Cq), 139.7 (Cq, JC-F = 9.1 Hz), 138.3 (Cq), 131.9 (CH), 130.3 (CH), 128.4 (CH), 127.1 (CH), 
126.8 (CH), 126.7 (CH), 123.9 (CH, JC-F = 8.1 Hz), 120.0 (Cq), 114.6 (CH, JC-F = 24.8 Hz), 
114.0 (Cq), 110.2 (CH, JC-F = 22.2 Hz), 52.0 (Cq), 29.4 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = −(109.9−110.0), (m).  
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IR (ATR): 3432, 2970, 1575, 1519, 1208, 696 cm-1.  
MS (EI) m/z (relative intensity) 370 (30) [M+], 355 (15), 314 (95), 313 (100), 296 (20), 208 
(5).  




The general procedure C was followed using 117e (105 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 120/1) yielded 118ea (152 mg, 79%) as a yellow solid. M. p.: 175−176 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.67 (d, J = 8.8 Hz, 1H), 7.49 (d, J = 2.1 Hz, 1H), 
7.39−7.29 (m, 6H), 7.20−7.13 (m, 5H), 5.15 (s, 1H), 1.62 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 153.1 (Cq), 149.4 (Cq),141.5 (Cq), 138.8 (Cq), 138.1 (Cq), 
135.6 (Cq), 131.9 (CH), 130.3 (CH), 128.4 (CH), 127.2 (CH), 126.8 (CH), 126.7 (CH), 125.8 
(CH), 125.2 (CH), 122.9 (CH), 119.5 (Cq), 115.2 (Cq), 52.1 (Cq), 29.4 (CH3).  
IR (ATR): 3465, 2963, 1571, 1414, 1211, 695 cm-1.  
MS (EI) m/z (relative intensity) 386 (35) [M+], 371 (15), 330 (100), 312 (25), 277 (20), 199 
(5).  
HR-MS (EI) m/z calcd for C25H23ClN2 [M+] 386.1550, found 386.1538.  




The general procedure C was followed using 117f (127 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
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(n-hexane/EtOAc: 150/1) yielded 118fa (154 mg, 72%) as a yellow solid. M. p.: 176−178 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.69 (d, J = 1.8 Hz, 1H), 7.62 (d, J = 8.8 Hz, 1H), 7.50 (dd, 
J = 8.8, 1.8 Hz, 1H), 7.40−7.31 (m, 5H), 7.21−7.15 (m, 5H), 5.17 (s, 1H), 1.64 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 153.2 (Cq), 149.4 (Cq), 141.5 (Cq), 139.0 (Cq), 138.0 (Cq), 
131.9 (CH), 130.3 (CH), 128.4 (CH), 128.4 (CH), 128.4 (CH), 127.2 (CH), 126.8 (CH), 126.7 
(CH), 124.1 (Cq), 122.9 (CH), 119.3 (Cq), 115.5 (Cq), 52.1 (Cq), 29.3 (CH3).  
IR (ATR): 3443, 2965, 1568, 1414, 1211, 695 cm-1.  
MS (EI) m/z (relative intensity) 430, 432 (30) [M+], 415, 417 (15), 374, 376 (100), 356, 358 
(10), 293, 295 (10), 277 (25).  




The general procedure C was followed using 117g (151 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 120/1) yielded 118ga (105 mg, 44%) as white solid. M. p.: 179−181 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.89 (d, J = 1.8 Hz, 1H), 7.67 (dd, J = 8.8, 1.8 Hz, 1H), 
7.44 (dd, J = 8.8 Hz, 1H), 7.38−7.29 (m, 5H), 7.19−7.13 (m, 5H), 5.15 (s, 1H), 1.62 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 153.3 (Cq), 149.2 (Cq), 141.5 (Cq), 139.2 (Cq), 138.0 (Cq), 
135.0 (CH), 133.8 (CH), 132.0 (CH), 130.3 (CH), 128.4 (CH), 127.1 (CH), 126.8 (CH), 126.7 
(CH), 122.7 (CH), 119.0 (Cq), 115.8 (Cq), 96.5 (Cq), 52.0 (Cq), 29.3 (CH3).  
IR (ATR): 3452, 2958, 1566, 1413, 1210, 693 cm-1.  
MS (EI) m/z (relative intensity) 478 (50) [M+], 463 (15), 422 (100), 421 (90), 404 (5), 277 
(20).  






The general procedure C was followed using 117h (111 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 80/1) yielded 118ha (99 mg, 59%) as a red solid. M. p.: 200−202 °C. 
1H-NMR (300 MHz, CDCl3): δ = 8.44 (d, J = 2.3 Hz, 1H), 8.14 (dd, J = 9.0, 2.3 Hz, 1H), 
7.88 (d, J = 9.0 Hz, 1H), 7.39−7.33 (m, 5H), 7.20−7.16 (m, 5H), 5.32 (s, 1H), 1.64 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 152.9 (Cq), 148.1 (Cq), 140.9 (Cq), 137.6 (Cq), 137.2 (Cq), 
131.8 (CH), 130.3 (CH), 128.7 (CH), 127.4 (CH), 127.3 (CH), 127.1 (CH), 123.3 (CH), 122.9 
(Cq), 122.4 (CH), 121.0 (Cq), 119.0 (Cq), 118.5 (CH), 52.4 (Cq), 29.2 (CH3).  
IR (ATR): 3444, 2916, 1530, 1342, 1210, 697 cm-1.  
MS (EI) m/z (relative intensity) 397 (30) [M+], 382 (10), 341 (100), 311 (20), 294 (30), 277 
(20).  




The general procedure C was followed using 117i (95.0 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 100/1) yielded 118ia (113 mg, 62%) as a white solid. M. p.: 215−217 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.50 (s, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.41−7.38 (m, 2H), 
7.34−7.27 (m, 4H), 7.22−7.19 (m, 2H), 7.16−7.11 (m, 3H), 5.15 (s, 1H), 2.51 (s, 3H), 1.64 (s, 
9H).  
13C-NMR (75 MHz, CDCl3): δ = 152.9 (Cq), 147.0 (Cq), 141.9 (Cq), 139.0 (Cq), 135.4 (Cq), 
135.0 (Cq), 132.0 (CH), 131.0 (CH), 130.3 (CH), 128.1 (CH), 127.1 (CH), 126.4 (CH), 126.3 
(CH), 126.2 (CH), 120.3 (CH), 120.2 (Cq), 117.1 (Cq), 51.8 (Cq), 29.4 (CH3), 21.7 (CH3).  
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IR (ATR): 3461, 2953, 1570, 1419, 1205, 694 cm-1.  
MS (EI) m/z (relative intensity) 366 (30) [M+], 351 (15), 310 (100), 309 (80), 292 (15), 277 
(15).  
HR-MS (EI) m/z calcd for C26H26N2 [M+] 366.2096, found 366.2078.  




The general procedure C was followed using 117j (122 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 150/1) yielded 118ja (149 mg, 71%) as a yellow solid. M. p.: 176−177 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.98 (s, 1H), 7.65−7.58 (m, 2H), 7.40−7.37 (m, 2H), 
7.34−7.29 (m, 3H), 7.19 (d, J = 2.1 Hz, 1H), 7.17 (d, J = 2.0 Hz, 2H), 7.15 (d, J = 2.8 Hz, 2H), 
5.24 (s, 1H), 1.64 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 153.4 (Cq), 150.3 (Cq), 141.2 (Cq), 139.3 (Cq), 138.0 (Cq), 
131.8 (CH), 130.3 (CH), 128.3 (CH), 127.2 (CH, JC-F = 6.0 Hz), 127.2 (CH), 126.8 (CH), 
126.8 (CH), 126.2 (Cq, JC-F = 32.0 Hz), 124.8 (CH, JC-F = 3.5 Hz), 124.5 (Cq, JC-F = 271.3 Hz), 
119.9 (Cq), 118.9 (CH, JC-F = 4.5 Hz), 115.9 (Cq), 52.3 (Cq), 29.4 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = −61.96 (s).  
IR (ATR): 3474, 2960, 1524, 1303, 1105, 692 cm-1.  
MS (EI) m/z (relative intensity) 420 (30) [M+], 405 (15), 364 (100), 363 (95), 346 (15), 277 
(10).  






The general procedure C was followed using 117k (110 mg, 0.50 mmol) and 4-octyne (1e) 
(110 mg, 1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 
100/1→80/1) yielded 118ke (100 mg, 60%) and 118ke' (10 mg, 7%) as a green oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.22 (d, J = 8.9 Hz, 1H), 6.97 (d, J = 8.9 Hz, 1H), 6.04 (s, 
2H), 4.79 (s, 1H), 2.90−2.85 (m, 2H), 2.72−2.67 (m, 2H), 1.85−1.73 (m, 2H), 1.58−1.50 (m, 
2H), 1.54 (s, 9H), 0.99 (t, J = 7.3 Hz, 6H).  
13C-NMR (75 MHz, CDCl3): δ = 151.9 (Cq), 151.0 (Cq), 146.3 (Cq), 141.4 (Cq), 124.4 (Cq), 
116.2 (CH), 114.6 (Cq), 114.1 (Cq), 107.7 (CH), 100.7 (CH2), 51.6 (Cq), 36.5 (CH2), 30.7 
(CH2), 29.4 (CH3), 25.1 (CH2), 22.8 (CH2), 14.4 (CH3), 14.4 (CH3).  
IR (ATR): 3459, 2958, 1525, 1442, 1210, 738 cm-1.  
MS (EI) m/z (relative intensity) 328 (55) [M+], 313 (15), 299 (25), 272 (30), 243 (100), 227 
(5).  




1H-NMR (300 MHz, CDCl3): δ = 7.11 (s, 1H), 6.97 (s, 1H), 5.99 (s, 2H), 4.50 (s, 1H), 
2.75−2.68 (m, 4H), 1.83−1.76 (m, 2H), 1.60−1.50 (m, 2H), 1.53 (s, 9H), 1.03 (t, J = 7.2 Hz, 
3H), 0.99 (t, J = 7.2 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 151.7 (Cq), 149.6 (Cq), 149.4 (Cq), 145.8 (Cq), 134.4 (Cq), 
116.9 (Cq), 112.6 (Cq), 101.1 (CH2), 100.8 (CH), 98.9 (CH), 51.5 (Cq), 37.0 (CH2), 30.0 (CH2), 
29.5 (CH3), 23.9 (CH2), 22.8 (CH2), 14.6 (CH3), 14.4 (CH3).  
IR (ATR): 3444, 2929, 1634, 1357, 1056, 694 cm-1.  








The general procedure C was followed using 117l (95.0 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol) in H2O. Purification by column chromatography 
(n-hexane/EtOAc: 200/1) yielded 118la (83 mg, 45%) as an off white solid. M. p.: 
136−139 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.42−7.38 (m, 2H), 7.36−7.26 (m, 4H), 7.24−7.20 (m, 2H), 
7.19-7.12 (m, 5H), 5.57 (s, 1H), 2.96 (s, 3H), 1.63 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 154.4 (Cq), 147.5 (Cq), 141.8 (Cq), 139.5 (Cq), 139.4 (Cq), 
132.5 (Cq), 132.2 (CH), 130.3 (CH), 129.1 (CH), 128.3 (CH), 128.2 (CH), 127.1 (CH), 126.4 
(CH), 126.4 (CH), 124.6 (CH), 120.2 (Cq), 117.8 (Cq), 52.3 (Cq), 29.4 (CH3), 25.0 (CH3).  
IR (ATR): 3510, 2963, 1503, 1406, 1222, 705 cm-1.  
MS (EI) m/z (relative intensity) 366 (20) [M+], 351 (10), 310 (100), 309 (65), 292 (20), 277 
(10).  




The general procedure C was followed using 117m (95.0 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 100/1) yielded 118ma (110 mg, 60%) as a yellow solid. M. p.: 83−86 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.73 (d, J = 8.4 Hz, 1H), 7.41−7.30 (m, 7H), 7.23−7.20 (m, 
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2H), 7.16−7.13 (m, 3H), 5.31 (t, J = 5.6 Hz, 1H), 3.56−3.52 (m, 2H), 2.38 (s, 3H), 2.13−2.04 
(m, 1H), 1.07 (d, J = 6.5 Hz, 6H). 
13C-NMR (75 MHz, CDCl3): δ = 153.9 (Cq), 148.3 (Cq), 141.7 (Cq), 139.4 (Cq), 138.8 (Cq), 
137.6 (Cq), 132.0 (CH), 130.3 (CH), 128.1 (CH), 127.2 (CH), 127.2 (CH), 127.1 (CH), 126.4 
(CH), 125.3 (CH), 120.8 (CH), 120.2 (Cq), 114.8 (Cq), 49.2 (CH2), 28.6 (CH), 22.0 (CH3), 
20.7 (CH3).  
IR (ATR): 2957, 1573, 1318, 1055, 697 cm-1.  
MS (EI) m/z (relative intensity) 366 (15) [M +], 351 (15), 323 (20), 310 (55), 293 (70), 222 
(55), 105 (100).  




The general procedure C was followed using 117n (95.0 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 100/1) yielded 117na (88 mg, 48%) as a yellow solid. M. p.: 93−96 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.69 (d, J = 8.5 Hz, 1H), 7.41−7.39 (m, 1H), 7.32−7.27 (d, 
J = 1.9 Hz, 1H), 7.31 (m, 5H), 7.21−7.18 (m, 2H), 7.16−7.11 (m, 3H), 5.20 (s, 1H), 3.74−3.68 
(m, 2H), 2.36 (s, 3H), 1.80−1.70 (m, 2H), 1.57−1.44 (m, 2H), 0.99 (t, J = 7.3 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 153.9 (Cq), 148.3 (Cq), 141.7 (Cq), 139.4 (Cq), 138.8 (Cq), 
137.5 (Cq), 132.0 (CH), 130.3 (CH), 128.0 (CH), 127.2 (CH), 127.1 (CH), 126.5 (CH), 126.4 
(CH), 125.2 (CH), 120.9 (CH), 120.3 (Cq), 114.8 (Cq), 41.4 (CH2), 32.1 (CH2), 22.0 (CH3), 
20.5 (CH2), 14.1 (CH3).  
IR (ATR): 2958, 1599, 1573, 1448, 1318, 697 cm-1.  
MS (EI) m/z (relative intensity) 366 (15) [M+], 351 (20), 323 (30), 310 (100), 294 (25). 






The general procedure C was followed using 117o (80.0 mg, 0.50 mmol) and 
diphenylacetylene (1a) (178 mg, 1.00 mmol). Purification by column chromatography 
(n-hexane/EtOAc/Et3N: 3/1/0→3/1/0.1) yielded 118oa (105 mg, 62%) as an off white solid. 
M. p.: 234−237 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.14 (d, J = 8.1 Hz, 1H), 7.26 (d, J = 1.5 Hz, 1H), 
7.21−7.14 (m, 8H), 7.07−7.04 (m, 2H), 6.82 (s, 1H), 3.99 (t, J = 9.5 Hz, 2H), 3.74 (t, J = 9.5 
Hz, 2H), 2.28 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 157.2 (Cq), 141.9 (Cq), 139.1 (Cq), 137.0 (Cq), 136.4 (Cq), 
134.8 (Cq), 131.8 (CH), 129.4 (CH), 128.1 (CH), 128.0 (CH), 127.9 (CH), 127.9 (CH), 126.5 
(CH), 126.3 (CH), 125.2 (CH), 119.0 (Cq), 113.6 (Cq), 51.6 (CH2), 50.4 (CH2), 22.0 (CH3).  
IR (ATR): 3045, 2869, 1623, 1419, 1274, 699 cm-1.  
MS (EI) m/z (relative intensity) 336 (80) [M+], 335 (100) [M-H-].  




The general procedure C was followed using 117p (108 mg, 0.50 mmol) and 4-octyne (1e) 
(110 mg, 1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 10/1) 
yielded 118pe (68 mg, 42%) as a yellow solid. M. p.: 88−91 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.96 (br s, 1H), 7.73 (d, J = 7.7 Hz, 1H), 7.42 (d, J = 8.0 Hz, 
1H), 7.35−7.29 (m, 1H), 7.27−7.21 (m, 1H), 4.67 (s, 1H), 2.79−2.70 (m, 4H), 1.92−1.80 (m, 
2H), 1.71−1.58 (m, 2H), 1.65 (s, 9H), 1.07−0.98 (m, 6H).  
13C-NMR (75 MHz, CDCl3): δ = 153.4 (Cq), 151.6 (Cq), 145.2 (Cq), 138.3 (CH), 123.6 (CH), 
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122.5 (Cq), 120.0 (CH), 119.3 (CH), 110.3 (CH), 107.2 (Cq), 102.5 (Cq), 51.7 (Cq), 36.4 (CH2), 
29.9 (CH3), 29.1 (CH2), 23.5 (CH2), 22.8 (CH2), 14.4 (CH3), 14.3 (CH3).  
IR (ATR): 3448, 2957, 1582, 1439, 1238, 733 cm-1.  
MS (EI) m/z (relative intensity) 323 (60) [M+], 308 (70), 267 (100), 252 (60), 238 (100), 224 
(35), 211 (80).  




The general procedure C was followed using 117q (91.0 mg, 0.50 mmol) and 4-octyne (1e) 
(110 mg, 1.00 mmol) in H2O. Purification by column chromatography (n-hexane/EtOAc: 
120/1→100/1) yielded 118qe (83 mg, 57%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.18 (d, J = 5.5 Hz, 1H), 7.10 (d, J = 5.5 Hz, 1H), 4.43 (s, 
1H), 2.73−2.67 (m, 4H), 1.85−1.77 (m, 2H), 1.69−1.61 (m, 2H), 1.53 (s, 9H), 1.03−0.96 (m, 
6H). 13C-NMR (75 MHz, CDCl3): δ = 150.8 (Cq), 150.8 (Cq), 149.3 (Cq), 122.8 (CH), 120.8 
(Cq), 119.9 (CH), 117.2 (Cq), 51.6 (Cq), 36.1 (CH2), 33.2 (CH2), 29.5 (CH3), 22.9 (CH2), 22.7 
(CH2), 14.5 (CH3), 14.3 (CH3).  
IR (ATR): 3443, 2957, 1556, 1489, 1419, 1215, 686 cm-1.  
MS (EI) m/z (relative intensity) 290 (60) [M+], 275 (75), 234 (75), 219 (35), 205 (100), 178 
(40).  







The general procedure C was followed using 118r (127 mg, 0.50 mmol) and oct-4-yne (1e) 
(110 mg, 1.00 mmol). Purification by column chromatography (n-hexane/EtOAc: 100/1) 
yielded 118re (150 mg, 64%) as a yellow solid. M. p.: 107−108 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 7.07 (d, J = 8.6 Hz, 2H), 6.92 (s, 1H), 6.83 (d, J = 8.6 
Hz, 2H), 6.70 (s, 1H), 5.44 (br s, 2H), 3.68 (s, 3H), 2.64−2.43 (m, 8H), 2.40 (s, 3H), 
1.61−1.45 (m, 8H), 1.02−0.92 (m, 9H), 0.80 (t, J = 7.4 Hz, 3H).  
13C-NMR (75 MHz, DMSO-d6): δ = 157.9 (Cq), 150.9 (Cq), 149.5 (Cq), 141.3 (Cq), 140.7 (Cq), 
138.1 (Cq), 135.4 (Cq), 130.7 (Cq), 127.2 (CH), 117.4 (Cq), 116.3 (Cq), 113.9 (CH), 113.7 
(CH), 112.5 (CH), 112.1 (Cq), 54.9 (CH3), 45.7 (CH2), 36.0 (CH2), 30.7 (CH2), 29.1 (CH2), 
28.8 (CH2), 22.6 (CH2), 22.4 (CH3), 21.8 (CH2), 21.7 (CH2), 20.9 (CH2), 14.1 (CH3), 14.0 
(CH3), 13.9 (CH3), 13.8 (CH3).  
IR (ATR): 2954, 1624, 1513, 1345, 1252, 829 cm-1.  
MS (EI) m/z (relative intensity) 470 (40) [M+], 441 (5), 349 (45), 306 (10), 277 (10), 121 
(100).  
HR-MS (EI) m/z calcd for C32H42N2O [M+] 470.3297, found 470.3293.  
 
N-(4-Methoxybenzyl)-6-methyl-3,4-diphenylisoquinolin-1-amine  (118ra) 
  
The general procedure C was followed using 117r (127 mg, 0.50 mmol) and 1a (178 mg, 1.00 
mmol). Purification by column chromatography (n-hexane/EtOAc: 100/1) yielded 118ra (73 
mg, 34%) as a yellow solid. M. p.: 97−98 °C.  
1H-NMR (CDCl3, 300 MHz): δ7.70 (d, J = 8.8 Hz, 2H), 7.44−7.27 (m, 9H), 7.25−7.13 (m, 
5H), 6.92 (dd, J = 8.3, 2.4 Hz, 2H), 5.42 (t, J = 5.0 Hz, 1H), 4.86 (d, J = 5.0 Hz, 2H), 3.82 (s, 
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3H), 2.38 (s, 3H).  
13C-NMR (CDCl3, 75 MHz): δ = 158.8 (Cq), 153.5 (Cq), 148.2 (Cq), 141.6 (Cq), 139.6 (Cq), 
138.7 (Cq), 132.1 (Cq), 132.0 (CH), 130.3 (CH), 129.5 (CH), 128.1 (CH), 127.3 (CH), 127.1 
(CH), 126.5 (CH), 126.4 (CH), 125.3 (CH), 121.0 (CH), 120.9 (Cq), 114.8 (Cq), 113.9 (CH), 
55.4 (CH3), 45.5 (CH2), 22.0 (CH3).  
IR (ATR): 3436, 2910, 1573, 1509, 1245, 699 cm-1.  
MS (EI) m/z (relative intensity) 430 (100) [M+], 415 (20), 309 (15), 294 (30), 136 (35), 121 
(70).  
HR-MS (EI) m/z calcd for C30H26N2O [M+] 430.2045, found 430.2051. 
 
Intermolecular Competition Experiment between Substrates 117c and 117e:  
 
A suspension of 1,2-di-p-tolylethyne (1c) (103 mg, 0.50 mmol), 
N-(tert-butyl)-4-methoxybenzimidamide (117c) (206 mg, 1.00 mmol), 
N-(tert-butyl)-4-chlorobenzimidamide (117e) (210 mg, 1.00 mmol), [RuCl2(p-cymene)]2 
(15.3 mg, 5.0 mol %), KPF6 (27.6 mg, 30 mol %) and Cu(OAc)2·H2O (199 mg, 1.00 mmol) in 
DME (2.0 mL) was stirred at 120 °C  for 22 h under an atmosphere of N2. At ambient 
temperature, H2O (20 mL) was added, and the mixture was extracted with EtOAc (3 × 20 mL). 
The combined organic layers were washed with brine (20 mL) and dried over Na2SO4. The 
solvent was evaporated in vacuo, and the residue was purified by column chromatography on 
silica gel (n-hexane/EtOAc: 100/1) to yield a mixture of 118cc and 118ec (21 mg, 10%) as a 
solid. The ratio was estimated by 1H-NMR spectroscopy. 
 




A suspension of N-(tert-butyl)-4-methylbenzimidamide (117b) (95.0 mg, 0.50 mmol), 
1,2-bis(4-fluorophenyl)ethyne (1d) (214 mg, 1.00 mmol), 4-octyne (1e) (110 mg, 1.00 mmol), 
[RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), KPF6 (27.6 mg, 30 mol %) and Cu(OAc)2·H2O 
(199 mg, 1.00 mmol) in DME (2.0 mL) was stirred at 120 °C  for 22 h under an atmosphere of 
N2. At ambient temperature, H2O (20 mL) was added, and the mixture was extracted with 
EtOAc (3 × 20 mL). The combined organic layers were washed with brine (20 mL) and dried 
over Na2SO4. The solvent was evaporated in vacuo, and the residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc: 150:1→120:1) to yield a mixture products of 
118bd and 118be (141 mg, 75%) as a solid. The ratio was estimated by 1H-NMR 
spectroscopy. 
 
Ruthenium(II)-Catalyzed H/D Exchange in Substrate 117b with D2O as the Cosolvent in 
the Absence of Alkyne:  
 
A suspension of N-(tert-butyl)-4-methylbenzimidamide (117b) (95.0 mg, 0.50 mmol), 
[RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), KPF6 (27.6 mg, 30 mol %) and Cu(OAc)2·H2O 
(199 mg, 1.00 mmol) in a solvent mixture of DME and D2O (1.8/0.2 mL) was stirred at 
120 °C  for 0.5 h under an atmosphere of N2. At ambient temperature, H2O (20 mL) was added, 
and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were 
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washed with brine (20 mL) and dried over Na2SO4. The solvent was evaporated in vacuo, and 
the residue was purified by column chromatography (n-hexane/EtOAc/Et3N: 1/1/0.02) to 
yield [Dn]-117b (55.0 mg, 58%) as a white solid. The D-incorporation in [Dn]-117b was 
estimated by 1H-NMR spectroscopy. 
 
Ruthenium-Catalyzed H/D Exchange in Substrate 117b with D2O as the Cosolvent in the 
Presence of Alkyne: 
 
A suspension of N-(tert-butyl)-4-methylbenzimidamide (117b) (95.0 mg, 0.50 mmol), 
oct-4-yne (1e) (110 mg, 1.00 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), KPF6 (27.6 
mg, 30 mol %) and Cu(OAc)2·H2O (199 mg, 1.00 mmol) in a solvent mixture of DME and 
D2O (1.8/0.2 mL) was stirred at 120 °C  for 22 h under an atmosphere of N2. At ambient 
temperature, H2O (20 mL) was added, and the mixture was extracted with EtOAc (3×20 mL). 
The combined organic layers were washed with brine (20 mL) and dried over Na 2SO4. The 
solvent was evaporated in vacuo, and the residue was purified by column chromatography on 
silica gel (n-hexane/EtOAc: 100/1) to yield [Dn]-118be (131 mg, 88%) as a green oil. The 
D-incorporation in [Dn]-118be was estimated by 1H-NMR spectroscopy. 
 
Analytical Data for the Products of the Ruthenium(II)-Catalyzed Oxidative C–H 
Bond Activation with Acrylates 
Ethyl (E)-2-(3-imino-2-isobutyl-6-methylisoindolin-1-ylidene)acetate (119'ma) 
 
The general procedure D was followed using 117m (95.0 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
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mmol) and [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 8/1) yielded 119'ma (110 mg, 77%) as a white solid. M.p.: 
68−71 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.96 (s, 1H), 7.68 (br s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.31 
(d, J = 7.9 Hz, 1H), 5.42 (s, 1H), 4.21 (q, J = 7.0 Hz, 2H), 3.66 (d, J = 7.7 Hz, 2H), 2.45 (s, 
3H), 2.24−2.15 (m, 1H), 1.31 (t, J = 7.0 Hz, 3H), 0.93 (d, J = 6.8 Hz, 6H).  
13C-NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 162.3 (Cq), 151.4 (Cq), 142.2 (Cq), 133.0 (Cq), 
131.2 (CH), 128.3 (CH), 127.9 (Cq), 120.4 (CH), 93.5 (CH), 59.9 (CH2), 47.2 (CH2), 26.9 
(CH), 22.0 (CH3), 20.1 (CH3), 14.4 (CH3).  
IR (ATR): 3385, 3228, 2961, 1640, 1157, 1069, 826 cm-1. 
MS (EI) m/z (relative intensity) 286 (20) [M+], 241 (15), 213 (100), 197 (15), 185 (15), 158 
(35), 142 (10).  
HR-MS (EI) m/z calcd for C17H22N2O2 [M+] 286.1681, found 286.1678. 
 
Ethyl (E)-2-(2-n-butyl-6-methylisoindolin-3-imino-1-ylidene)acetate (119'na) 
 
The general procedure D was followed using 117n (95.0 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 8/1) yielded 119'na (64 mg, 45%) as a white solid. M. p.: 
101−102 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.97 (s, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.32 (d, J = 7.6 Hz, 
1H), 5.43 (s, 1H), 4.23 (q, J = 7.2 Hz, 2H), 3.81 (t, J = 7.7 Hz, 2H), 2.46 (s, 3H), 1.68−1.57 
(m, 2H), 1.45−1.30 (m, 2H), 1.33 (t, J = 7.2 Hz, 3H), 0.94 (t, J = 7.3 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 166.9 (Cq), 161.8 (Cq), 151.0 (Cq), 142.2 (Cq), 133.2 (Cq), 
131.1 (CH), 128.4 (CH), 128.0 (Cq), 120.3 (CH), 93.1 (CH), 59.9 (CH2), 40.0 (CH2), 29.3 
(CH2), 22.1 (CH3), 20.2 (CH2), 14.4 (CH3), 13.8 (CH3).  
IR (ATR): 3235, 2934, 1598, 1153, 1069, 822 cm-1.  
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MS (EI) m/z (relative intensity) 286 (5) [M+], 241 (10), 213 (100), 185 (15), 158 (20), 142 
(10).  
HR-MS (EI) m/z calcd for C17H22N2O2 [M+] 286.1681, found 286.1684. 
 
Ethyl (E)-2-{3-imino-2-(4-methoxybenzyl)-6-methylisoindolin-1-ylidene}acetate (119'ra) 
 
The general procedure D was followed using 117r (127 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 117'ra (129 mg, 74%) as a white solid. M. p.: 
165−166 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.99 (s, 1H), 7.58 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 7.9 Hz, 
1H), 7.15 (d, J = 8.9 Hz, 2H), 6.82 (d, J = 8.9 Hz, 2H), 5.44 (s, 1H), 5.03 (s, 2H), 4.17 (q, J = 
7.1 Hz, 2H), 3.75 (s, 3H), 2.49 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 166.7 (Cq), 162.1 (Cq), 158.7 (Cq), 150.8 (Cq), 142.5 (Cq), 
142.5 (Cq), 133.3 (Cq), 131.4 (CH), 128.6 (CH), 128.3 (Cq), 127.9 (CH), 120.6 (CH), 114.1 
(CH), 94.4 (CH), 59.9 (CH2), 55.2 (CH3), 43.2 (CH2), 22.1 (CH3), 14.4 (CH3).  
IR (ATR): 3261, 2955, 1604, 1115, 1035, 819 cm-1.  
MS (EI) m/z (relative intensity) 350 (70) [M+], 335 (5), 277 (60), 185 (100), 121 (45).  







The general procedure D was followed using 117r (127 mg, 0.50 mmol), 20b (96.0 mg, 0.75 
mmol) [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 5/1) to afford 119'rb (140 mg, 74%) as a white solid. 
M.p.: 111−113 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.99 (s, 1H), 7.58 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 7.9 Hz, 
1H), 7.15 (d, J = 8.9 Hz, 2H), 6.82 (d, J = 8.9 Hz, 2H), 5.44 (s, 1H), 5.03 (s, 2H), 4.17 (q, J = 
6.8 Hz, 2H), 3.75 (s, 3H), 2.49 (s, 3H), 1.65 (m, 2H), 1.39 (m, 2H), 0.94 (t, J =7.1 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 166.8 (Cq), 162.1 (Cq), 158.8 (Cq), 150.8 (Cq), 142.5 (Cq), 
142.0 (Cq), 133.4 (Cq), 131.5 (CH), 128.6 (CH), 128.3 (Cq), 127.9 (CH), 120.6 (CH), 114.1 
(CH), 94.5 (CH), 64.0 (CH2), 55.2 (CH3), 43.2 (CH2), 30.8 (CH2), 22.1 (CH3), 19.2 (CH2), 
13.8 (CH3).  
IR (ATR): 3250, 2965, 1596, 1247, 1097, 822 cm-1.  
MS (EI) m/z (relative intensity) 378 (55) [M+], 363 (5), 277 (45), 185 (100), 121 (65). 





The general procedure D was followed using 117r (127 mg, 0.50 mmol), 20c (122 mg, 0.75 
mmol) [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 119'rc (142 mg, 69%) as a white solid. M. p.: 
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136−137 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.99 (s, 1H), 7.58 (d, J = 7.7 Hz, 1H), 7.30−7.39 (m, 6H), 
7.13 (d, J = 8.8 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 5.50 (s, 1H), 5.17 (s, 2H), 5.03 (s, 2H), 3.75 
(s, 3H), 2.48 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 166.5 (Cq), 162.1 (Cq), 158.8 (Cq), 151.3 (Cq), 142.6 (Cq), 
136.4 (Cq), 133.3 (Cq), 131.5 (CH), 128.7 (CH), 128.5 (CH), 128.2 (CH), 128.2 (Cq), 128.2 
(Cq), 128.1 (CH), 127.9 (CH), 120.6 (CH), 114.1 (CH), 93.9 (CH), 65.8 (CH2), 55.2 (CH3), 
43.2 (CH2), 22.1 (CH3).  
IR (ATR): 3255, 2832, 1707, 1637, 1120, 824 cm-1.  
MS (EI) m/z (relative intensity) 412 (10) [M+], 321 (10), 277 (25), 185 (100), 142 (5), 121 
(45).  
HR-MS (EI) m/z calcd for C26H24N2O3 [M+] 412.1787, found 412.1790.  
 
Ethyl 2-{(1Z,3Z)-3-(tert-Butylimino)-6-methylisoindolin-1-ylidene}acetate (119ba) 
 
The general procedure D was followed using 119b (95.0 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C. Purification by column 
chromatography (n-hexane/EtOAc: 12/1) yielded 119ba (105 mg, 73%) as a white solid. M.p.: 
142−144 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.88 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.39 (s, 1H), 7.32 (d, 
J = 7.8 Hz, 1H), 5.45 (s, 1H), 4.25 (q, J = 7.2 Hz, 2H), 2.44 (s, 3H), 1.46 (s, 9H), 1.34 (t, J = 
7.2 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.6 (Cq), 151.9 (Cq), 148.0 (Cq), 140.7 (Cq), 134.5 (Cq), 
132.9 (Cq), 132.1 (CH), 122.4 (CH), 120.9 (CH), 84.0 (CH), 59.9 (Cq), 54.1 (CH2), 30.5 
(CH3), 21.7 (CH3), 14.5 (CH3).  
IR (ATR): 3397, 2969, 1637, 1193, 1053, 801 cm-1.  




HR-MS (EI) m/z calcd for C17H22N2O2 [M+] 286.1681, found 286.1676. 
 
n-Butyl 2-{(1Z,3Z)-3-(tert-Butylimino)-6-methylisoindolin-1-ylidene}acetate (119bb) 
 
The general procedure D was followed using 119b (95.0 mg, 0.50 mmol), 20b (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 15/1) yielded 119bb (100 mg, 64%) as a white solid. M.p.: 
75−78 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.87 (s, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.38 (s, 1H), 7.30 (d, 
J = 7.9 Hz, 1H), 5.45 (s, 1H), 4.17 (t, J = 6.7 Hz, 2H), 2.43 (s, 3H), 1.72−1.62 (m, 2H), 1.45 
(s, 9H), 1.50−1.36 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.7 (Cq), 151.9 (Cq), 148.0 (Cq), 140.7 (Cq), 134.5 (Cq), 
132.8 (Cq), 132.1 (CH), 122.4 (CH), 120.9 (CH), 84.0 (CH), 63.9 (Cq), 54.0 (CH2), 30.8 
(CH2), 30.4 (CH3), 21.7 (CH3), 19.2 (CH2), 13.7 (CH3).  
IR (ATR): 3396, 2968, 1634, 1189, 1051, 702 cm-1.  
MS (EI) m/z (relative intensity) 314 (10) [M+], 299 (100), 285 (5), 225 (85), 185 (20), 158 
(25).  
HR-MS (EI) m/z calcd for C19H26N2O2 [M+] 314.1994, found 314.1996. 
 
Benzyl 2-{(1Z,3Z)-3-(tert-Butylimino)-6-methylisoindolin-1-ylidene}acetate (119bc) 
 
The general procedure D was followed using 117b (95.0 mg, 0.50 mmol), 20c (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 119bc (119 mg, 68%) as a white solid. M. p.: 
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126−127 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.82 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.42−7.30 (m, 7H), 
5.52 (s, 1H), 5.25 (s, 2H), 2.42 (s, 3H), 1.44 (s, 9H).  
13C-NMR (75 MHz, CDCl3): δ = 169.1 (Cq), 152.2 (Cq), 147.9 (Cq), 140.7 (Cq), 136.2 (Cq), 
134.4 (Cq), 132.8 (Cq), 132.2 (CH), 128.6 (CH), 128.2 (CH), 128.1 (CH), 122.4 (CH), 120.9 
(CH), 83.6 (CH), 65.8 (Cq), 54.1 (CH2), 30.4 (CH3), 21.7 (CH3).  
IR (ATR): 3396, 2968, 1634, 1189, 1050, 754 cm-1.  
MS (EI) m/z (relative intensity) 348 (10) [M+], 333 (100), 225 (80), 185 (15), 158 (25), 91 
(60).  
HR-MS (EI) m/z calcd for C22H24N2O2 [M+] 348.1838, found 348.1831. 
 
Ethyl 2-{(1Z,3Z)-3-(tert-Butylimino)isoindolin-1-ylidene}acetate (119aa)  
 
The general procedure D was followed using 117a (88.0 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 12/1) yielded 119aa (79 mg, 58%) as a white solid. M. p.: 
68−70 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.92 (s, 1H), 7.85−7.82 (m, 1H), 7.58−7.56 (m, 1H), 
7.51−7.42 (m, 2H), 5.47 (s, 1H), 4.22 (q, J = 7.2 Hz, 2H), 1.45 (s, 9H), 1.31 (t, J = 7.2 Hz, 
3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.4 (Cq), 151.7 (Cq), 147.8 (Cq), 135.3 (Cq), 134.2 (Cq), 
131.0 (CH), 130.2 (CH), 122.6 (CH), 120.5 (CH), 84.2 (CH), 59.9 (Cq), 54.1 (CH2), 30.4 
(CH3), 14.4 (CH3).  
IR (ATR): 3387, 2971, 1656, 1179, 1058, 808 cm-1.  
MS (EI) m/z (relative intensity) 272 (15) [M+], 257 (100), 211 (95), 170 (35), 144 (40), 128 
(20).  




Ethyl 2-{(1Z,3Z)-3-(tert-Butylimino)-6-methoxyisoindolin-1-ylidene}acetate (119ca) 
 
The general procedure D was followed using 117c (103 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) at 120 °C . Purification by column 
chromatography (n-hexane/EtOAc: 4/1) yielded 119ca (127 mg, 84%) as a white solid. M. p.: 
100−101 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.81 (s, 1H), 7.72 (d, J = 9.2 Hz, 1H), 7.02 (d, J = 2.2 Hz, 
1H), 7.00 (dd, J = 9.2, 2.2 Hz, 1H), 5.41 (s, 1H), 4.22 (q, J = 7.2 Hz, 2H), 3.82 (s, 3H), 1.43 (s, 
9H), 1.30 (t, J = 7.2 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.4 (Cq), 161.8 (Cq), 151.6 (Cq), 147.6 (Cq), 135.9 (Cq), 
128.0 (Cq), 123.8 (CH), 118.0 (CH), 104.6 (CH), 84.0 (CH), 59.9 (Cq), 55.6 (CH3), 54.0 (CH2), 
30.5 (CH3), 14.4 (CH3).  
IR (ATR): 3418, 2969, 1634, 1490, 1282, 1057, 800 cm-1.  
MS (EI) m/z (relative intensity) 302 (15) [M+], 287 (100), 241 (90), 200 (30), 174 (40), 158 
(20).  
HR-MS (EI) m/z calcd for C17H22N2O3 [M+] 302.1630, found 302.1636. 
 
Ethyl 2-{(1Z,3Z)-3-(tert-Butylimino)-6-fluoroisoindolin-1-ylidene}acetate (119da) 
 
The general procedure D was followed using 117d (97.0 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) at 120 °C . Purification by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 119da (105 mg, 72%) as a white solid. M.p.: 
87−88 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.90 (s, 1H), 7.81 (dd, J = 8.4, 5.0 Hz, 1H), 7.23 (dd, J = 
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8.4, 2.1 Hz, 1H), 7.17 (dd, J = 8.4, 2.1 Hz, 1H), 5.42 (s, 1H), 4.23 (q, J = 7.2 Hz, 2H), 1.44 (s, 
9H), 1.32 (t, J = 7.2 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.3 (Cq), 164.3 (Cq, JC-F = 250.2 Hz), 150.6 (Cq, JC-F = 4.1 
Hz), 146.8 (Cq), 136.2 (Cq, JC-F = 10.0 Hz), 131.3 (Cq), 124.5 (CH, JC-F = 9.4 Hz), 118.6 (CH, 
JC-F = 23.6 Hz), 107.5 (CH, JC-F = 24.6 Hz), 84.7 (CH), 60.1 (Cq), 54.2 (CH2), 30.4 (CH3), 
14.2 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = -(109.5−109.6). (m). IR (ATR): 3391, 2970, 1667, 1210, 
1054, 799 cm-1.  
MS (EI) m/z (relative intensity) 290 (5) [M+], 275 (100), 229 (90), 188 (25), 162 (35), 146 
(20).  
HR-MS (EI) m/z calcd for C16H19N2O2F [M+] 290.1431, found 290.1423. 
 
Ethyl 2-{(1Z,3Z)-6-Bromo-3-(tert-butylimino)isoindolin-1-ylidene}acetate (119fa) 
 
The general procedure D was followed using 119f (127 mg, 0.50 mmol), ethyl acrylate (20a) 
(75.0 mg, 0.75 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) at 120 °C . Purification 
by column chromatography (n-hexane/EtOAc: 20/1) yielded 119fa (112 mg, 64%) as a white 
solid. M. p.: 115−116 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.92 (s, 1H), 7.75−7.72 (m, 2H), 7.64 (d, J = 8.1 Hz, 1H), 
5.46 (s, 1H), 4.26 (q, J = 6.8 Hz, 2H), 1.46 (s, 9H), 1.34 (t, J = 6.8 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.3 (Cq), 150.3 (Cq), 146.9 (Cq), 136.1 (Cq), 134.2 (CH), 
134.0 (Cq), 124.5 (CH), 124.1 (Cq), 123.7 (CH), 85.1 (CH), 60.1 (Cq), 54.3 (CH2), 30.4 (CH3), 
14.4 (CH3).  
IR (ATR): 3382, 2970, 1647, 1197, 1046, 799 cm-1.  
MS (EI) m/z (relative intensity) 350; 352 (5) [M+], 335; 337 (100), 289; 291 (70), 222; 224 
(20), 207; 209 (15).  





Ethyl 2-{(1Z,3Z)-3-(tert-Butylimino)-6-nitroisoindolin-1-ylidene}acetate (119ha) 
 
The general procedure D was followed using 117h (111 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) at 120 °C . Purification by column 
chromatography (n-Hexane/EtOAc: 20/1) yielded 119ha (42 mg, 26%) as a white solid. M. p.: 
190−191 °C.  
1H-NMR (300 MHz, CDCl3): δ = 10.09 (s, 1H), 8.44 (d, J = 1.9 Hz, 1H), 8.35 (dd, J = 8.6, 
1.9 Hz, 1H), 7.99 (d, J = 8.6 Hz, 1H), 5.60 (s, 1H), 4.26 (q, J = 7.2 Hz, 2H), 1.45 (s, 9H), 1.33 
(t, J = 7.2 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.1 (Cq), 149.5 (Cq), 149.5 (Cq), 145.8 (Cq), 140.4 (Cq), 
135.2 (Cq), 125.9 (CH), 123.7 (CH), 116.3 (CH), 86.3 (CH), 60.4 (Cq), 54.8 (CH2), 30.2 (CH3), 
14.4 (CH3).  
IR (ATR): 3339, 2966, 1623, 1259, 1030, 800 cm-1.  
MS (EI) m/z (relative intensity) 317 (10) [M+], 302 (100), 272 (30), 256 (75), 226 (20), 189 
(20), 57 (25).  
HR-MS (ESI) m/z calcd for C16H20N3O4 [M+H+] 318.1454, found 318.1449. 
 
n-Butyl 2-{(1Z,3Z)-3-(tert-Butylimino)-6-methoxyisoindolin-1-ylidene}acetate (119cb) 
 
The general procedure D was followed using 117c (103 mg, 0.50 mmol), 20b (96.0 mg, 0.75 
mmol) [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 8/1) yielded 119cb (117 mg, 71%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 9.83 (s, 1H), 7.74 (d, J = 8.6 Hz, 1H), 7.06−7.02 (m, 2H), 
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5.45 (s, 1H), 4.17 (t, J = 6.6 Hz, 2H), 3.85 (s, 3H), 1.72−1.62 (m, 2H), 1.44 (s, 9H), 1.49−1.36 
(m, 2H), 1.31 (t, J = 7.4 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.6 (Cq), 161.8 (Cq), 151.7 (Cq), 147.7 (Cq), 135.9 (Cq), 
128.1 (Cq), 123.8 (CH), 118.1 (CH), 104.6 (CH), 84.1 (CH), 63.9 (Cq), 55.7 (CH3), 54.0 (CH2), 
30.9 (CH2), 30.5 (CH3), 19.2 (CH2), 13.8 (CH3).  
IR (ATR): 3399, 2962, 1621, 1157, 1053, 800 cm-1.  
MS (EI) m/z (relative intensity) 330 (10) [M+], 315 (100), 274 (5), 241 (75), 200 (25), 174 
(30), 158 (20).  
HR-MS (EI) m/z calcd for C19H26N2O3 [M+] 330.1943, found 330.1947. 
 
Ethyl 2-{(1Z,3Z)-3-(tert-Butylimino)-6-chloroisoindolin-1-ylidene}acetate (119ea) 
 
The general procedure D was followed using 117e (105 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) at 120 °C . Purification by column 
chromatography (n-hexane/EtOAc: 15/1) yielded 119ea (107 mg, 70%) as a white solid. M. p.: 
120−121 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.91 (s, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.54 (d, J = 1.8 Hz, 
1H), 7.45 (dd, J = 8.1, 1.8 Hz, 1H), 5.44 (s, 1H), 4.23 (q, J = 7.2 Hz, 2H), 1.44 (s, 9H), 1.32 (t, 
J = 7.2 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.2 (Cq), 150.4 (Cq), 146.8 (Cq), 136.5 (Cq), 135.8 (Cq), 
133.7 (Cq), 131.2 (CH), 123.9 (CH), 120.7 (CH), 85.1 (CH), 60.1 (Cq), 54.3 (CH2), 30.3 
(CH3), 14.4 (CH3).  
IR (ATR): 3382, 2967, 1643, 1176, 1049, 800 cm-1.  
MS (EI) m/z (relative intensity) 306 (5) [M+], 291 (85), 245 (60), 204 (20), 178 (25), 43 (100). 
HR-MS (ESI) m/z calcd for C16H19N2O235Cl [M+] 306.1135, found 306.1096.  
 




The general procedure D was followed using 117e (105 mg, 0.50 mmol), 20b (96.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) at 120 °C . Purification by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 119eb (123 mg, 74%) as a white solid. M. p.: 
81−82 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.91 (s, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.54 (d, J = 1.9 Hz, 
1H), 7.45 (dd, J = 8.2, 1.9 Hz, 1H), 5.45 (s, 1H), 4.17 (t, J = 6.6 Hz, 2H), 1.72−1.62 (m, 2H), 
1.44 (s, 9H), 1.45−1.37 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.4 (Cq), 150.4 (Cq), 146.9(Cq), 136.5 (Cq), 135.8 (Cq), 
133.7 (Cq), 131.2 (CH), 124.0 (CH), 120.7 (CH), 85.1 (CH), 64.1 (Cq), 54.3 (CH2), 30.8 
(CH2), 30.3 (CH3), 19.2 (CH2), 13.7 (CH3).  
IR (ATR): 3367, 2958, 1651, 1172, 1061, 828 cm-1.  
MS (EI) m/z (relative intensity) 334 (5) [M+], 319 (100), 245 (75), 204 (20), 178 (20), 163 
(15).  
HR-MS (EI) m/z calcd for C18H23N2O235Cl [M+] 334.1448, found 334.1445. 
 
Benzyl 2-{(1Z,3Z)-3-(tert-Butylimino)-6-chloroisoindolin-1-ylidene}acetate (119ec) 
 
The general procedure D was followed using 117e (105 mg, 0.50 mmol), 20c (122 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) at 120 °C . Purification by column 
chromatography (n-hexane/EtOAc: 15/1) yielded 119ec (130 mg, 71%) as a white solid. M. p.: 
114−116 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.85 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 1.8 Hz, 
1H), 7.47 (dd, J = 8.4, 1.8 Hz, 1H), 7.41−7.33 (m, 5H), 5.51 (s, 1H), 5.23 (s, 2H), 1.42 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 168.9 (Cq), 150.8 (Cq), 146.7 (Cq), 136.5 (Cq), 136.0 (Cq), 
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135.7 (Cq), 133.7 (Cq), 131.3 (CH), 128.6 (CH), 128.3 (CH), 128.2 (CH), 123.9 (CH), 120.8 
(CH), 84.7 (CH), 66.0 (Cq), 54.3 (CH2), 30.8 (CH3).  
IR (ATR): 3385, 2970, 1638, 1161, 1048, 602 cm-1.  
MS (EI) m/z (relative intensity) 368 (10) [M+], 353 (100), 309 (5), 245 (80), 205 (20), 178 
(20).  
HR-MS (EI) m/z calcd for C21H21N2O2Cl [M+] 368.1292, found 368.1297.  
 
Ethyl 2-{(1Z,3Z)-3-(tert-Butylimino)-4-methylisoindolin-1-ylidene}acetate (119la) 
 
The general procedure D was followed using 117l (95.0 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 119la (91 mg, 64%) as a white solid. M. p.: 
91−92 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.85 (s, 1H), 7.42 (dd, J = 9.0, 3.0 Hz, 1H), 7.31 (dd, J = 
9.0, 9.0 Hz, 1H), 7.25 (dd, J = 9.0, 3.0 Hz, 1H), 5.42 (s, 1H), 4.23 (q, J = 6.0 Hz, 2H), 2.69 (s, 
3H), 1.44 (s, 9H), 1.32 (t, J = 6.0 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.7 (Cq), 152.1 (Cq), 148.3 (Cq), 137.3 (Cq), 134.8 (Cq), 
133.6 (CH), 131.8 (Cq), 129.3 (CH), 118.1 (CH), 82.7 (CH), 59.8 (Cq), 54.4 (CH2), 30.3 (CH3), 
18.4 (CH3), 14.5 (CH3).  
IR (ATR): 3400, 2965, 1618, 1178, 1054, 780 cm-1.  
MS (EI) m/z (relative intensity) 286 (55) [M+], 271 (50), 225 (100), 184 (90), 156 (30), 142 
(15).  
HR-MS (EI) m/z calcd for C17H22N2O2 [M+] 286.1681, found 286.1685. 
 




The general procedure D was followed using 117i (95.0 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 119ia (114 mg, 80%) as a white solid. M. p.: 
79−81 °C. 
1H-NMR (300 MHz, CDCl3): δ = 9.88 (br s, 1H), 7.65 (s, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.35 
(d, J = 8.0 Hz, 1H), 5.42 (s, 1H), 4.22 (q, J = 7.1 Hz, 2H), 2.41 (s, 3H), 1.45 (s, 9H), 1.31 (t, J 
= 7.1 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.6 (Cq), 151.9 (Cq), 148.1 (Cq), 141.7 (Cq), 135.5 (Cq), 
131.7 (Cq), 131.3 (CH), 122.8 (CH), 120.4 (CH), 83.8 (CH), 59.9 (CH2), 54.0 (Cq), 30.4 
(CH3), 21.6 (CH3), 14.4 (CH3).  
IR (ATR): 3406, 2962, 1214, 1161, 1030, 796 cm-1.  
MS (EI) m/z (relative intensity) 286 (10) [M+], 271 (100), 225 (90), 185 (25), 158 (30). 





The general procedure D was followed using 117j (122 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) at 120 °C . Purification by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 119ja (85 mg, 50%) as a white solid. M. p.: 
139−140 °C.  
1H-NMR (300 MHz, CDCl3): δ = 10.0 (br s, 1H), 8.13 (s, 1H), 7.74 (dd, J = 8.0, 1.0 Hz, 1H), 
7.69 (d, J = 8.0 Hz, 1H), 5.55 (s, 1H), 4.25 (q, J = 7.2 Hz, 2H), 1.46 (s, 9H), 1.33 (t, J = 7.2 
Hz, 3H).  
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13C-NMR (75 MHz, CDCl3): δ = 169.2 (Cq), 150.3 (Cq), 146.5 (Cq), 137.2 (Cq), 136.0 (Cq), 
133.1 (Cq, JC-F = 32.8 Hz), 127.2 (CH, JC-F = 7.4 Hz), 123.8 (Cq, JC-F = 273.0 Hz), 121.1 (CH), 
120.1 (CH, JC-F = 7.6 Hz), 85.8 (CH), 60.3 (CH2), 54.5 (Cq), 30.3 (CH3), 14.4 (CH3).  
IR (ATR): 3278, 2942, 1725, 1642, 1184, 1050, 778 cm-1. 
MS (EI) m/z (relative intensity) 340 (10) [M+], 325 (80), 279 (85), 238 (15), 212 (15), 43 
(100). 
HR-MS (ESI) m/z calcd for C17H20F3N2O2 [M+H+] 341.1477 found 341.1471. 
 
Ethyl 2-{(1Z,3Z)-3-(tert-Butylimino)-7-fluoroisoindolin-1-ylidene}acetate (119sa) 
 
The general procedure D was followed using 117s (97.0 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) at 120 °C . Purification by column 
chromatography (n-hexane/EtOAc: 15/1) yielded 119sa (71 mg, 49%) and 119sa' (7 mg, 5%) 
as a white solids. 119sa: M. p.: 101−102 °C.  
1H{19F}-NMR (300 MHz, CDCl3): δ = 10.10 (s, 1H), 7.74 (d, J = 7.6 Hz, 1H), 7.53 (dd, J = 
8.2, 7.6 Hz, 1H), 7.23 (d, J = 8.2 Hz, 1H), 5.80 (s, 1H), 4.32 (q, J = 7.2 Hz, 2H), 1.53 (s, 9H), 
1.41 (t, J = 7.2 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.6 (Cq), 158.3 (Cq, JC-F = 256.7 Hz), 148.6 (Cq, JC-F = 3.6 
Hz), 147.1 (Cq, JC-F = 2.7 Hz), 138.2 (Cq, JC-F = 3.3 Hz), 132.4 (CH, JC-F = 7.5 Hz), 121.3 (Cq, 
JC-F = 14.1 Hz), 118.6 (CH, JC-F = 3.6 Hz), 117.4 (CH, JC-F = 19.8 Hz), 89.1 (CH, JC-F = 7.3 
Hz), 60.1 (Cq), 54.2 (CH2), 30.2 (CH3), 14.4 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = -(116.9−117.0). (m).  
IR (ATR): 3388, 2970, 1634, 1210, 1073, 812 cm-1.  
MS (EI) m/z (relative intensity) 290 (10) [M+], 275 (90), 229 (100), 188 (30), 162 (30), 147 
(15).  




Ethyl 2-{(1Z,3Z)-3-(tert-Butylimino)-5-fluoroisoindolin-1-ylidene}acetate (119sa') 
 
M. p.: 96−97 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.99 (s, 1H), 7.58 (dd, J = 8.4, 4.6 Hz, 2H), 7.19 (td, J = 8.6, 
2.4 Hz, 1H), 5.45 (s, 1H), 4.27 (q, J = 7.1 Hz, 2H), 1.48 (s, 9H), 1.34 (t, J = 7.1 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 169.4 (Cq), 165.3 (Cq, JC-F = 251.7 Hz), 150.9 (Cq), 146.7 
(Cq), 138.0 (Cq), 129.0 (Cq), 122.4 (CH, JC-F = 9.5 Hz), 118.2 (CH, JC-F = 28.2 Hz), 109.5 (CH, 
JC-F = 23.0 Hz), 84.0 (CH), 60.1 (Cq), 54.3 (CH2), 30.3 (CH3), 14.4 (CH3).  
IR (ATR): 3382, 2967, 1628, 1207, 1053, 798 cm-1.  
MS (EI) m/z (relative intensity) 290 (10) [M+], 275 (100), 229 (95), 188 (30), 162 (30), 147 
(15).  





The general procedure D was followed using 117k (110 mg, 0.50 mmol), 20a (75.0 mg, 0.75 
mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) at 100 °C . Purification by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 119ka (108 mg, 68%) as a white solid. M. p.: 
181−182 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.79 (s, 1H), 7.37 (d, J = 8.0 Hz, 1H), 6.92 (d, J = 8.0 Hz, 
1H), 6.11 (s, 2H), 5.52 (s, 1H), 4.24 (q, J = 7.2 Hz, 2H), 1.43 (s, 9H), 1.31 (t, J = 7.2 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 169.5 (Cq), 150.1 (Cq), 148.9 (Cq), 147.4 (Cq), 142.4 (Cq), 
129.6 (Cq), 116.3 (CH), 116.1 (Cq), 110.5 (CH), 102.7 (C H2), 87.6 (CH), 59.9 (Cq), 54.0 
(CH2), 30.4 (CH3), 14.4 (CH3).  
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IR (ATR): 3400, 2981, 1620, 1178, 1036, 800 cm-1.  
MS (EI) m/z (relative intensity) 316 (15) [M+], 301 (95), 255 (100), 214 (35), 188 (45), 173 
(10).  
HR-MS (EI) m/z calcd for C17H20N2O4 [M+] 316.1423, found 316.1424. 
 
Ethyl 2-{3-(tert-Butylamino)-6-methoxy-1H-isoindol-1-yl}acetate (135ca) 
 
A suspension of N-(tert-butyl)-4-methoxybenzimidamide (117c) (15.30 mg, 0.075 mmol), 20a 
(7.500 mg, 0.075 mmol), [RuCl2(p-cymene)]2 (23.0 mg, 50.0 mol %) and AgOAc (12.50 mg, 
0.075 mmol) in DCE (1.0 mL) was stirred at 60 °C for 22 h under an atmosphere of N2. At 
ambient temperature, the reaction mixture was extracted with EtOAc (3 × 10 mL), washed 
with brine (20 mL) and dried over Na2SO4. The solvent was evaporated under reduced 
pressure, and the residue was purified by column chromatography on silica gel 
(n-hexane/EtOAc/Et3N: 5/1/0.05) to afford 135ca (10 mg, 44%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.17 (d, J = 8.9 Hz, 1H), 7.02 (d, J = 2.0 Hz, 1H), 6.86 (dd, 
J = 8.9, 2.0 Hz, 1H), 5.06 (dd, J = 8.5, 6.4 Hz, 1H), 4.41 (br s, 1H), 4.19−4.11 (m, 2H), 3.82 
(s, 3H), 2.99 (dd, J = 15.6, 6.2 Hz, 1H), 2.48 (dd, J = 15.6, 8.6 Hz, 1H), 1.48 (s, 9H), 1.24 (t, J 
= 7.2 Hz, 1H).  
13C-NMR (75 MHz, CDCl3): δ = 171.9 (Cq), 160.5 (Cq), 160.1 (Cq), 154.2 (Cq), 128.8 (Cq), 
118.8 (CH), 113.4 (CH), 107.7 (CH), 66.7 (CH), 60.3 (Cq), 55.5 (CH3), 51.4 (CH2), 39.7 
(CH2), 29.0 (CH3), 14.2 (CH3).  
IR (film): 3402, 2965, 1725, 1605, 1480, 1242, 1023 cm-1.  
MS (ESI) m/z (relative intensity) 305 (90) [M+H+], 291 (100), 249 (5), 235 (10), 161 (5). 
HR-MS (ESI) m/z calcd for C17H25N2O3 [M+H+] 305.1865, found 305.1862. 
 




A suspension of N-(tert-butyl)-4-methylbenzimidamide (117b) (190 mg, 1.00 mmol), 
N-(tert-butyl)-4-fluorobenzimidamide (117d) (194 mg, 1.00 mmol), 20a (50.0 mg, 0.50 
mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), AgOAc (41.5 mg, 50 mol %) and 
Cu(OAc)2·H2O (199 mg, 1.00 mmol) in DCE (2.0 mL) was stirred at 100 °C for 22 h under 
an atmosphere of N2. At ambient temperature, the reaction mixture was extracted with EtOAc 
(3 × 20 mL), washed with brine (20 mL) and dried over Na2SO4. The solvent was evaporated 
under reduced pressure and the residue was purified by column chromatography on silica gel 
(n-hexane/EtOAc: 15/1→10/1) to yield 119ba (21.0 mg, 15%) and 119da (11.0 mg, 8%) as 
colorless solids. 
 
Ruthenium(II)-Catalyzed H/D Exchange with Substrate 117c in CD3OD as the 
Cosolvent: A suspension of N-(tert-butyl)-4-methoxybenzimidamide (117c) (103 mg, 0.50 
mmol), ethyl acrylate (20a) (100 mg, 0.75 mmol), [RuCl2(p-cymene)]2 (7.7 mg, 2.5 mol %), 
AgOAc (41.5 mg, 50 mol %) and Cu(OAc)2·H2O (199 mg, 1.00 mmol) was stirred at 100 °C 
for 22 h in a solvent mixture of DCE and CD3OD (1.8/0.2 mL) as the solvent under an 
atmosphere of N2. At ambient temperature, the reaction mixture was extracted with EtOAc (3 
× 20 mL), washed with brine (20 mL) and dried over Na2SO4. The solvent was evaporated 
under reduced pressure, and the residue was purified by column chromatography on silica gel 
(n-hexane/EtOAc/Et3N: 5/1/0→1/1/0.02) yielded [Dn]-119ca (71.0 mg, 47%) as a green oil, 
[Dn]-135ca (26.0 mg, 17%) as a green oil and reisolated starting material [Dn]-117c (11.0 mg, 
11%) as a colorless solid. The D-incorporation in [Dn]-119ca, [Dn]-135ca and [Dn]-117c was 




10.4.3 Analytical Data for the Products of Ruthenium(II)-Catalyzed C–H 
Bond Hydroarylation and Oxidative Annulation with 
α,β-Unsaturated Ketones via Monodentate Coordination 
N-Methyl-2-(3-oxobutyl)benzamide (120aa) 
 
The general procedure E was followed using 2a (68 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
1:1→1:2) yielded 120aa (82 mg, 80%) as a colorless solid. M. p.: = 117−119 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.36–7.27 (m, 2H), 7.21–7.13 (m, 2H), 6.36 (br s, 1H), 2.96 
(d, J = 4.9 Hz, 3H), 2.93 (t, J = 6.0 Hz, 2H), 2.87 (t, J = 6.0 Hz, 2H), 2.10 (s, 3H).  
13C-NMR (125MHz, CDCl3): δ = 208.6 (Cq), 170.6 (Cq), 138.9 (Cq), 136.7 (Cq), 129.9 (CH), 
129.7 (CH), 127.2 (CH), 126.2 (CH), 45.2 (CH2), 30.0 (CH3), 27.2 (CH2), 26.6 (CH3).  
IR (ATR): 3290, 1707, 1631, 1368, 1166, 661 cm-1.  
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MS (EI) m/z (relative intensity) 205 (10) [M+], 175 (10), 162 (100), 144 (10), 131 (45), 103 (5). 




The general procedure E was followed using 2b (75 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
2:1→1:1) yielded 120ba (77 mg, 70%) as a colorless solid. M. p.: = 108−109 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.24 (dd, J = 7.1, 1.4 Hz, 1H), 7.00 (s, 1H), 6.99 (d, J = 7.1 
Hz, 1H), 6.26 (br s, 1H), 2.96 (d, J = 4.9 Hz, 3H), 2.90 (t, J = 6.0 Hz, 2H), 2.89 (t, J = 6.0 Hz, 
2H), 2.30 (s, 3H), 2.11 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 208.5 (Cq), 170.5 (Cq), 139.9 (Cq), 139.0 (Cq), 133.6 (Cq), 
130.5 (CH), 127.1 (CH), 126.8 (CH), 45.4 (CH2), 30.0 (CH3), 27.3 (CH2), 26.7 (CH3), 21.3 
(CH3).  
IR (ATR): 3287, 1710, 1632, 1542, 1164, 693 cm-1.  
MS (EI) m/z (relative intensity) 219 (10) [M+], 189 (5), 176 (100), 161 (10), 145 (45), 115 
(15).  




The general procedure E was followed using 2c (83 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
1:1→1:2) yielded 120ca (94 mg, 80%) as a colorless solid. M. p.: = 107−109 °C.  
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1H-NMR (300 MHz, CDCl3): δ = 7.29 (dd, J = 8.1, 0.8 Hz, 1H), 6.70 (s, 1H), 6.66 (d, J = 8.1 
Hz, 1H), 6.34 (br s, 1H), 3.76 (s, 3H), 2.93 (d, J = 5.1 Hz, 3H), 2.93 (t, J = 6.4 Hz, 2H), 2.86 (t, 
J = 6.4 Hz, 2H), 2.10 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 208.6 (Cq), 170.3 (Cq), 160.6 (Cq), 141.4 (Cq), 128.9 (Cq), 
128.9 (CH), 115.4 (CH), 111.2 (CH), 55.2 (CH3), 45.2 (CH2), 29.9 (CH3), 27.5 (CH2), 26.6 
(CH3).  
IR (ATR): 3288, 1705, 1543, 1247, 1157, 696 cm-1.  
MS (EI) m/z (relative intensity) 235 (15) [M+], 205 (10), 192 (100), 177 (5), 161 (60), 135 (10). 
HR-MS (EI) m/z calcd for C13H17NO3 [M+] 235.1208, found 235.1206. 
 
N-Methyl-3-(3-oxobutyl)-[1,1'-biphenyl]-4-carboxamide  (120da) 
 
The general procedure E was followed using 2d (106 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
1:1→1:2) yielded 120da (111 mg, 79%) as a colorless solid. M. p.: = 153−155 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.60–7.48 (m, 2H), 7.48–7.38 (m, 5H), 7.38–7.28 (m, 1H), 
6.42 (br s, 1H), 3.10–3.00 (m, 2H), 2.98 (d, J = 4.9 Hz, 3H), 2.96–2.83 (m, 2H), 2.12 (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 208.5 (Cq), 170.4 (Cq), 142.8 (Cq), 140.1 (Cq), 139.6 (Cq), 
135.3 (Cq), 128.8 (CH), 128.6 (CH), 127.7 (CH), 127.7 (CH), 127.1 (CH), 124.9 (CH), 45.3 
(CH2), 29.9 (CH3), 27.4 (CH2), 26.6 (CH3).  
IR (ATR): 3287, 1709, 1630, 1543, 1160, 697 cm-1.  
MS (EI) m/z (relative intensity) 281 (15) [M+], 250 (5), 238 (100), 207 (40), 178 (20), 165 (15). 
HR-MS (EI) m/z calcd for C18H19NO2 [M+] 281.1416, found 281.1417. 
 




The general procedure E was followed using 2e (107 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
2:1→1:1) yielded 120ea (113 mg, 81%) as a colorless solid. M. p.: = 132−134 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.40–7.29 (m, 2H), 7.27–7.21 (m, 1H), 6.52 (br s, 1H), 
2.99–2.92 (m, 4H), 2.92 (d, J = 1.6 Hz, 3H), 2.15 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 208.0 (Cq), 169.5 (Cq), 141.1 (Cq), 135.6 (Cq), 132.4 (CH), 
129.3 (CH), 128.8 (CH), 124.0 (Cq), 44.8 (CH2), 30.0 (CH3), 26.8 (CH2), 26.8 (CH3).  
IR (ATR): 3287, 1705, 1639, 1543, 1167, 686 cm-1.  
MS (EI) m/z (relative intensity) 283 (5) [M+], 240 (100), 225 (10), 211 (35), 183 (10), 102 (20). 
HR-MS (ESI) m/z calcd for C12H14NO279Br [M+] 283.0208, found 283.0210. 
 
N-Methyl-2-(3-oxobutyl)-4-(trifluoromethyl)benzamide  (120fa) 
 
The general procedure E was followed using 2f (102 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
1:1→1:2) yielded 120fa (99 mg, 73%) as a colorless solid. M. p.: = 117−119 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.45 (s, 3H), 6.58 (br s, 1H), 2.99 (d, J = 4.9 Hz, 3H), 2.96 (t, 
J = 5.0 Hz, 2H), 2.94 (t, J = 5.0 Hz, 2H), 2.13 (s, 3H).  
13C-NMR (100 MHz, CDCl3,): δ = 207.9 (Cq), 169.2 (Cq), 140.1 (Cq), 139.6 (Cq), 131.8 (Cq, 
JC-F = 32.4 Hz), 127.8 (CH), 126.2 (CH, JC-F = 3.7 Hz), 124.0 (Cq, JC-F = 271.5 Hz), 123.1 (CH, 
J = 3.7 Hz), 44.68 (CH2), 30.02 (CH3), 26.8 (CH2), 26.8 (CH3).  
19F-NMR (CDCl3, 282 MHz): δ -62.9 (s).  
IR (ATR): 3294, 1713, 1550, 1333, 1114, 696 cm-1.  
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MS (EI) m/z (relative intensity) 273 (5) [M+], 254 (5), 230 (60), 199 (20), 151 (10), 43 (100). 




The general procedure E was followed using 2g (121 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
2:1) yielded 120ga (106 mg, 68%) as a colorless solid. M. p.: = 131−133 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.37–7.31 (m, 5H), 7.32–7.25 (m, 1H), 6.74 (d, J = 2.5 Hz, 
1H), 6.70 (dd, J = 8.4, 2.6 Hz, 1H), 6.44 (br s, 1H), 4.59 (d, J = 5.8 Hz, 2H), 3.78 (s, 3H), 2.99 
(t, J = 7.1 Hz, 2H), 2.86 (t, J = 7.1 Hz, 2H), 2.09 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 208.3 (Cq), 169.4 (Cq), 160.8 (Cq), 141.9 (Cq), 138.3 (Cq), 
128.8 (CH), 128.8 (CH), 128.6 (Cq), 127.8 (CH), 127.5 (CH), 115.7 (CH), 111.3 (CH), 55.3 
(CH3), 45.3 (CH2), 44.0 (CH2), 29.9 (CH3), 27.7 (CH2).  
IR (ATR): 3280, 1706, 1628, 1268, 1025, 694 cm-1.  
MS (EI) m/z (relative intensity) 311 (15) [M+], 268 (45), 205 (20), 161 (30), 106 (25), 91 (100). 
HR-MS (ESI) m/z calcd for C19H22NO3 [M+H+] 312.1600, found 312.1600. 




The general procedure E was followed using 2h (115 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
5:1→2:1) yielded 120ha (109 mg, 73%) as a colorless solid. M. p.: = 112−114 °C.  
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1H-NMR (300 MHz, CDCl3): δ = 7.40–7.25 (m, 6H), 6.93–6.81 (m, 2H), 6.74 (t, J = 5.8 Hz, 
1H), 4.57 (d, J = 5.8 Hz, 2H), 2.94 (t, J = 6.6 Hz, 2H), 2.83 (t, J = 6.6 Hz, 2H), 2.07 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 208.0 (Cq), 168.9 (Cq), 163.4 (Cq, JC-F = 249.7 Hz), 142.3 (Cq, 
JC-F = 7.8 Hz), 138.1 (Cq), 132.5 (Cq, JC-F = 3.1 Hz), 129.3 (CH, JC-F = 8.8 Hz), 128.8 (CH), 
127.8 (CH), 127.6 (CH), 116.6 (CH, JC-F = 21.4 Hz), 113.2 (CH, JC-F = 21.6 Hz), 44.7 (CH2), 
44.0 (CH2), 29.9 (CH3), 27.1 (CH2, JC-F = 1.6 Hz).  
19F-NMR (282 MHz, CDCl3): δ = -110.4 (ddd, J = 9.8, 8.1, 5.8 Hz).  
IR (ATR): 3281, 1709, 1635, 1234, 1168, 694 cm-1.  
MS (EI) m/z (relative intensity) 299 (10) [M+], 256 (30), 193 (10), 149 (25), 106 (65), 91 (100). 
HR-MS (EI) m/z calcd for C18H18FNO2 [M+] 299.1322, found 299.1323. 
 
N-Benzyl-4-chloro-2-(3-oxobutyl)benzamide  (120ia) 
 
The general procedure E was followed using 2i (123 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
2:1) yielded 120ia (97 mg, 62%) as a colorless solid. M. p.: = 125−126 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.37–7.25 (m, 6H), 7.20–7.18 (m, 1H), 7.16 (dd, J = 8.1, 2.1 
Hz, 1H), 6.67 (d, J = 6.4 Hz, 1H), 4.59 (d, J = 5.8 Hz, 2H), 2.93 (t, J = 6.6 Hz, 2H), 2.85 (t, J = 
6.6 Hz, 2H), 2.09 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 207.7 (Cq), 168.6 (Cq), 141.2 (Cq), 137.9 (Cq), 135.8 (Cq), 
134.7 (Cq), 129.8 (CH), 128.7 (CH), 128.6 (CH), 127.8 (CH), 127.6 (CH), 126.4 (CH), 44.8 
(CH2), 44.1 (CH2), 30.0 (CH3), 27.0 (CH2).  
IR (ATR): 3279, 1708, 1637, 1541, 1163, 692 cm-1.  
MS (EI) m/z (relative intensity) 315 (10) [M+], 272 (30), 209 (5), 165 (15), 106 (75), 91 (100). 
HR-MS (EI) m/z calcd for C18H18N35ClO2 [M+] 315.1026, found 315.1030. 
 




The general procedure E was followed using 2j (109 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
3:1) yielded 120ja (100 mg, 70%) as a colorless solid. M. p.: = 143−145 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.30–7.20 (m, 1H), 7.02 (s, 1H), 7.01 (d, J = 6.8 Hz, 1H), 
6.04 (d, J = 8.2 Hz, 1H), 4.13–3.82 (m, 1H), 2.96 (t, J = 6.2 Hz, 2H), 2.87 (t, J = 6.2 Hz, 2H), 
2.32 (s, 3H), 2.12 (s, 3H), 2.13–2.02 (m, 2H), 1.88–1.69 (m, 3H), 1.54–1.32 (m, 2H), 1.31–1.09 
(m, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 208.2 (Cq), 169.0 (Cq), 139.8 (Cq), 138.9 (Cq), 134.1 (Cq), 
130.5 (CH), 127.0 (CH), 126.8 (CH), 48.6 (CH), 45.4 (CH2), 33.2 (CH2), 30.0 (CH3), 27.4 
(CH2), 25.6 (CH2), 25.0 (CH2), 21.3 (CH3).  
IR (ATR): 3278, 2923, 1712, 1631, 1537, 699 cm-1.  
MS (EI) m/z (relative intensity) 287 (35) [M+], 244 (100), 189 (70), 162 (70), 145 (60).  




The general procedure E was followed using 2k (97 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
1:1→1:2) yielded 120ka (76 mg, 58%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.25 (d, J = 7.7 Hz, 1H), 7.01 (s, 1H), 7.00 (d, J = 7.7 Hz, 1H), 
6.40 (br s, 1H), 3.60 (dt, J = 7.8, 1.7 Hz, 2H), 3.53 (dt, J = 7.8, 1.7 Hz, 2H), 3.35 (s, 3H), 2.95 
(dt, J = 6.0, 1.3 Hz, 2H), 2.83 (dt, J = 6.0, 1.3 Hz, 2H), 2.31 (s, 3H), 2.11 (s, 3H).  
Experimental Section 
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13C-NMR (125 MHz, CDCl3): δ = 208.1 (Cq), 169.8 (Cq), 140.1 (Cq), 139.3 (Cq), 133.4 (Cq), 
130.8 (CH), 127.1 (CH), 126.8 (CH), 71.2 (CH2), 58.8 (CH3), 45.6 (CH2), 39.6 (CH2), 30.0 
(CH3), 27.6 (CH2), 21.3 (CH3).  
IR (ATR): 3313, 2928, 1640, 1530, 1302, 1121 cm-1.  
MS (EI) m/z (relative intensity) 263 (5) [M+], 248 (10), 231 (10), 220 (30), 189 (75), 145 (100). 
HR-MS (EI) m/z calcd for C15H21NO3 [M+] 263.1521, found 263.1524. 
 
N-Methyl-2-(3-oxobutyl)-1-naphthamide  (120la) 
 
The general procedure E was followed using 2l (93 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
2:1) yielded 120la (57 mg, 45%) as a colorless solid. M. p.: = 153−155 °C.  
1H-NMR (500 MHz, CDCl3): δ = 7.91–7.62 (m, 3H), 7.54–7.35 (m, 2H), 7.25 (d, J = 8.3 Hz, 
1H), 6.46 (br s, 1H), 3.08 (d, J = 5.4 Hz, 3H), 3.01–2.78 (m, 4H), 2.09 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 208.0 (Cq), 170.1 (Cq), 134.6 (Cq), 134.1 (Cq), 131.8 (Cq), 
130.2 (Cq), 129.1 (CH), 127.8 (CH), 126.8 (CH), 126.3 (CH), 125.6 (CH), 124.8 (CH), 44.7 
(CH2), 30.1 (CH3), 27.4 (CH2), 26.6 (CH3).  
IR (ATR): 3261, 1704, 1627, 1260, 745, 448 cm-1.  
MS (EI) m/z (relative intensity) 255 (20) [M+], 224 (10), 212 (100), 197 (20), 181 (50), 155 
(25).  






The general procedure E was followed using 2m (90 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
1:1→1:2) yielded 120ma (100 mg, 80%) as a colorless solid. M. p.: = 139−141 °C.  
1H-NMR (300 MHz, CDCl3): δ = 6.93 (d, J = 8.0 Hz, 1H), 6.64 (d, J = 8.0 Hz, 1H), 6.47 (br s, 
1H), 5.95 (s, 2H), 2.94 (d, J = 4.9 Hz, 3H), 2.94–2.88 (m, 4H), 2.15 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 208.7 (Cq), 169.5 (Cq), 148.1 (Cq), 146.2 (Cq), 131.0 (Cq), 
121.5 (CH), 121.1 (Cq), 106.2 (CH), 101.1 (CH2), 43.0 (CH2), 29.9 (CH3), 26.7 (CH3), 21.7 
(CH2).  
IR (ATR): 3301, 1706, 1543, 1251, 1040, 705 cm-1.  
MS (EI) m/z (relative intensity) 249 (25) [M+], 218 (15), 206 (100), 188 (5), 175 (65), 149 (15). 




The general procedure E was followed using 2n (77 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
1:1) yielded 120na (86 mg, 70%) as a colorless solid. M. p.: = 123−125 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.21–7.11 (m, 2H), 7.09–6.93 (m, 1H), 6.55 (br s, 1H), 2.96 
(d, J = 4.9 Hz, 3H), 2.94 (t, J = 5.4 Hz, 2H), 2.89 (t, J = 5.4 Hz, 2H), 2.12 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 208.7 (Cq), 169.3 (Cq, J = 3.2 Hz), 161.4 (Cq, J = 246.1 Hz), 
139.1 (Cq, J = 4.3 Hz), 127.8 (CH, J = 8.9 Hz), 126.1 (Cq, J = 16.7 Hz), 122.9 (CH, J = 3.4 Hz), 
116.7 (CH, J = 23.0 Hz), 43.5 (CH2, J = 2.4 Hz), 29.8 (CH3), 26.7 (CH3), 21.1 (CH2, J = 2.9 Hz). 
19F-NMR (282 MHz, CDCl3): δ = -116.1 (dd, J = 10.2, 4.4 Hz).  
IR (ATR): 3291, 1703, 1547, 1319, 1163, 710 cm-1.  
MS (EI) m/z (relative intensity) 223 (10) [M+], 180 (100), 165 (15), 149 (60), 121 (15), 101 
(15).  






The general procedure E was followed using 2o (75 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
2:1→1:1) yielded 120oa (68 mg, 62%) as a colorless solid. M. p.: = 112−114 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.15 (d, J = 1.8 Hz, 1H), 7.10 (dd, J = 7.9, 1.8 Hz, 1H), 7.07 
(d, J = 7.9 Hz, 1H), 6.41 (br s, 1H), 2.98 (d, J = 4.9 Hz, 3H), 2.89 (t, J = 5.0 Hz, 2H), 2.87 (t, J 
= 5.0 Hz, 2H), 2.30 (s, 3H), 2.12 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 208.6 (Cq), 170.6 (Cq), 136.4 (Cq), 135.8 (Cq), 135.6 (Cq), 
130.6 (CH), 129.5 (CH), 127.8 (CH), 45.3 (CH2), 30.1 (CH3), 26.7 (CH2), 26.7 (CH3), 20.9 
(CH3).  
IR (ATR): 3285, 1709, 1541, 1319, 1160, 697 cm-1.  
MS (EI) m/z (relative intensity) 219 (15) [M+], 189 (5), 176 (100), 161 (10), 145 (60), 117 (15). 




The general procedure E was followed using 2p (102 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
1:1→1:2) yielded 120pa (85 mg, 62%) as a colorless solid. M. p.: = 96−98 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.60 (dt, J = 1.6, 0.7 Hz, 1H), 7.56–7.49 (m, 1H), 7.32 (dt, 
J = 8.3, 0.8 Hz, 1H), 6.61 (br s, 1H), 2.98 (d, J = 5.2 Hz, 3H), 2.97 (t, J = 5.8 Hz, 2H), 2.89 (t, 
J = 5.8 Hz, 2H), 2.11 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 207.9 (Cq), 169.0 (Cq), 142.9 (Cq, JC-F = 1.7 Hz), 137.2 
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(Cq), 130.1 (CH), 128.6 (Cq, JC-F = 32.8 Hz), 126.4 (CH, JC-F = 3.7 Hz), 124.3 (CH, JC-F = 3.8 
Hz), 123.2 (Cq, JC-F = 271.5 Hz), 44.7 (CH2), 30.0 (CH3), 26.9 (CH2), 26.8 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = -62.6 (s).  
IR (ATR): 3286, 1705, 1552, 1311, 1115, 641 cm-1.  
MS (EI) m/z (relative intensity) 273 (5) [M+], 243 (5), 230 (100), 215 (10), 199 (35), 189 (10). 




The general procedure E was followed using 2q (113 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
2:1) yielded 120qa (94 mg, 64%) as a colorless solid. M. p.: = 130−132 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.43–7.25 (m, 5H), 7.17 (d, J = 0.9 Hz, 1H), 7.14–7.06 (m, 
2H), 6.52 (br s, 1H), 4.60 (d, J = 5.8 Hz, 2H), 3.01 (dt, J = 6.8, 1.5 Hz, 2H),, 2.82 (dt, J = 6.8, 1.5 
Hz, 2H), 2.29 (s, 3H), 2.07 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 208.5 (Cq), 169.9 (Cq), 138.2 (Cq), 136.2 (Cq), 136.0 (Cq), 
136.0 (Cq), 130.8 (CH), 129.9 (CH), 128.8 (CH), 127.9 (CH), 127.7 (CH), 127.6 (CH), 45.4 
(CH2), 44.0 (CH2), 29.9 (CH3), 26.9 (CH2), 20.8 (CH3).  
IR (ATR): 3242, 1707, 1634, 1311, 821, 702 cm-1.  
MS (EI) m/z (relative intensity) 295 (20) [M+], 252 (40), 189 (5), 145 (20), 106 (30), 91 (100). 






The general procedure E was followed using 2r (94 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
2:1→1:1) yielded 120ra (65 mg, 50%) as a colorless solid. M. p.: = 151−153 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.67 (m, 1H), 7.35–7.29 (m, 1H), 7.26–7.15 (m, 2H), 6.08 (br 
s, 1H), 3.74 (s, 3H), 3.35 (t, J = 7.5 Hz, 2H), 3.04 (d, J = 4.9 Hz, 3H), 2.93 (t, J = 7.5 Hz, 2H),, 
2.15 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 207.8 (Cq), 166.6 (Cq), 144.9 (Cq), 136.6 (Cq), 124.8 (Cq), 
121.8 (CH), 121.2 (CH), 118.4 (CH), 110.0 (CH), 107.6 (Cq), 43.3 (CH2), 29.9 (CH3), 29.6 
(CH3), 26.3 (CH3), 19.8 (CH2).  
IR (ATR): 3293, 1711, 1619, 1539, 1167, 734 cm-1.  
MS (EI) m/z (relative intensity) 258 (55) [M+], 227 (15), 215 (80), 200 (10), 184 (100), 172 
(15), 158 (85).  




The general procedure E was followed using 2c (83 mg, 0.5 mmol) and 41b (132 mg, 1.0 mmol) 
for 20 h. Purification by column chromatography (n-hexane/EtOAc 1:1→1:2) yielded 120cb 
(31 mg, 21%) as a colorless solid. M. p.: = 130−132 °C .  
1H-NMR (300 MHz, CDCl3): δ = 7.97–7.88 (m, 2H), 7.51 (ddt, J = 8.3, 6.6, 1.4 Hz, 1H), 
7.45–7.36 (m, 2H), 7.31 (d, J = 8.5 Hz, 1H), 6.77 (d, J = 2.6 Hz, 1H), 6.69 (dd, J = 8.5, 2.6 Hz, 
1H), 6.38 (br s, 1H), 3.75 (s, 3H), 3.42 (t, J = 7.3 Hz, 2H), 3.12 (t, J = 7.3 Hz, 2H), 2.94 (d, J = 
4.9 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 199.8 (Cq), 170.4 (Cq), 160.6 (Cq), 141.6 (Cq), 136.8 (Cq), 
133.0 (CH), 129.1 (Cq), 128.9 (CH), 128.5 (CH), 128.1 (CH), 115.5 (CH), 111.3 (CH), 55.2 
(CH3), 40.5 (CH2), 28.1 (CH2), 26.7 (CH3).  
IR (ATR): 3277, 1681, 1545, 1277, 1039, 690 cm-1.  
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MS (EI) m/z (relative intensity) 297 (15) [M+], 266 (10), 223 (10), 192 (100), 177 (30), 161 
(35).  
HR-MS (ESI) m/z calcd for C18H20NO3 [M+H+] 298.1443, found 298.1437. 
 
3-(3-Cyclohexyl-3-oxopropyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide  (120dc) 
 
The general procedure E was followed using 2d (106 mg, 0.5 mmol) and 41c (138 mg, 1.0 
mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 1:1→1:2) yielded 
120dc (79 mg, 45%) as a colorless solid. M. p.: = 155−157 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.55 (d, J = 7.4 Hz, 2H), 7.50–7.30 (m, 6H), 6.56 (br s, J = 4.9 
Hz, 1H), 3.00 (d, J = 4.9 Hz, 3H), 2.99 (t, J = 5.7 Hz, 2H), 2.94 (t, J = 5.7 Hz, 2H), 2.34 – 2.25 
(m, 1H), 1.82 – 1.68 (m, 4H), 1.34–1.10 (m, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 213.7 (Cq), 170.3 (Cq), 142.6 (Cq), 140.2 (Cq), 139.6 (Cq), 
135.4 (Cq), 128.7 (CH), 128.3 (CH), 127.8 (CH), 127.6 (CH), 127.0 (CH), 124.8 (CH), 50.9 
(CH), 42.2 (CH2), 28.5 (CH2), 27.3 (CH2), 26.8 (CH3), 25.9 (CH2), 25.7 (CH2).  
IR (ATR): 3289, 2927, 1699, 1630, 1538, 1312, 697 cm-1.  
MS (EI) m/z (relative intensity) 349 (20) [M+], 318 (5), 238 (100), 209 (40), 178 (15), 165 (15). 




The general procedure E was followed using 2d (106 mg, 0.5 mmol) and 41d (126 mg, 1.0 
mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 1:1) yielded 120dd 
(84 mg, 50%) as a colorless solid. M. p.: = 128−130 °C.  
Experimental Section 
170 
1H-NMR (CDCl3, 500 MHz): δ = 7.57–7.50 (m, 2H), 7.46–7.38 (m, 5H), 7.37–7.32 (m, 1H), 
6.46 (br s, J = 4.9 Hz, 1H), 3.03 (t, J = 7.2 Hz, 2H), 3.00 (d, J = 4.9 Hz, 3H), 2.90 (t, J = 7.2 Hz, 
2H), 2.36 (t, J = 7.5 Hz, 2H), 1.52 (p, J = 7.5 Hz, 2H), 1.31–1.13 (m, 4H), 0.83 (t, J = 7.1 Hz, 
3H).  
13C-NMR (CDCl3, 125 MHz): δ = 211.1 (Cq), 170.4 (Cq), 142.8 (Cq), 140.2 (Cq), 139.6 (Cq), 
135.5 (Cq), 128.8 (CH), 128.5 (CH), 127.9 (CH), 127.7 (CH), 127.1 (CH), 124.9 (CH), 44.2 
(CH2), 43.0 (CH2), 31.4 (CH2), 27.3 (CH2), 26.7 (CH3), 23.5 (CH2), 22.4 (CH2), 13.9 (CH3). 
IR (ATR): 3287, 1710, 1632, 1542, 1164, 693 cm-1.  
MS (EI) m/z (relative intensity) 337 (5) [M+], 281 (25), 238 (100), 223 (5), 207 (35), 178 (15). 
HR-MS (EI) m/z calcd for C22H27NO2 [M+] 337.2042, found 337.2048. 
 
N-(4-Methyl-2-(3-oxobutyl)phenyl)acetamide  (139aa) 
 
The general procedure E was followed using 121a (75 mg, 0.5 mmol), methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) and KO2CMes (51 mg, 50 mol %) for 20 h. Purification by column 
chromatography (n-hexane/EtOAc 2:1→1:1) yielded 139aa (51 mg, 47%) as a colorless solid. 
M. p.: = 124−126 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.84 (br s, 1H), 7.62 (d, J = 8.2 Hz, 1H), 6.99 (dd, J = 8.0, 2.0 
Hz, 1H), 6.89 (d, J = 2.1 Hz, 1H), 2.87 (dt, J = 6.0, 1.5 Hz, 2H), 2.75 (dt, J = 6.0, 1.5 Hz, 2H), 
2.26 (s, 3H), 2.24 (s, 3H), 2.12 (s, 3H).  
13C-NMR (CDCl3, 75 MHz): δ = 210.3 (Cq), 168.8 (Cq), 134.7 (Cq), 133.0 (Cq), 132.6 (Cq), 
130.3 (CH), 127.7 (CH), 124.4 (CH), 45.3 (CH2), 29.9 (CH3), 24.2 (CH3), 23.8 (CH2), 20.8 
(CH3).  
IR (ATR): 3282, 1709, 1641, 1522, 1287, 811 cm-1.  
MS (EI) m/z (relative intensity) 219 (60) [M+], 176 (75), 162 (40), 134 (100), 120 (85), 107 
(10).  




Intermolecular Competition Experiments Between Arenes with Different Directing 
Groups: 
 
A suspension of MVK (41a) (35 mg, 0.5 mmol), N,4-dimethylbenzamide (2b) (75 mg, 0.5 
mmol), 1-(p-tolyl)ethanone (30a) (67 mg, 0.5 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 
mol %), MesCO2K (30.3 mg, 30.0 mol %) and MesCO2H (82 mg, 1.0 equiv) in H2O (2.0 mL) 
was stirred at 120 °C for 20 h under an atmosphere of Ar. At ambient temperature, aq. sat. 
NaCl (15 mL) was added. The reaction mixture was extracted with EtOAc (3 × 20 mL). The 
combined organic phases were dried over Na2SO4. Evaporation of the solvents in vacuo and 
purification of the residue by column chromatography on silica gel (n-hexane/EtOAc 1:1) 
yielded products 120ba (43 mg, 39%) as the sole product. 
 
H/D Exchange Experiments: 




A suspension of MVK (41a) (70 mg, 1.0 mmol), N,4-dimethylbenzamide (2b) (75 mg, 0.5 
mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), MesCO2K (30.3 mg, 30.0 mol %) and 
MesCO2H (82 mg, 1.0 equiv) in a solvent mixture of H2O and D2O (1.0/1.0 mL) was stirred at 
120 °C for 20 h under an atmosphere of Ar. At ambient temperature, aq. sat. NaCl (15 mL) 
was added. The reaction mixture was extracted with EtOAc (3 × 20 mL). The combined 
organic phases were dried over Na2SO4. Evaporation of the solvents in vacuo and purification 
of the residue by column chromatography on silica gel (n-hexane/EtOAc 1:1→1:2) yielded 
product [Dn]-120ba (88 mg, 80%) as a colorless solid, and reisolated starting material [Dn]-2b 
(11 mg, 14%) as a colorless solid. The D-incorporation in [Dn]-120ba and [Dn]-2b was 
estimated by 1H-NMR spectroscopy. 
 




Two independent reactions with 2a or deuterated substrate [D5]-2a under the standard 
conditions were performed: Suspensions of MVK (41a) (70 mg, 1.0 mmol), substrates 2a (68 
mg, 0.5 mmol) or [D5]-2a (70 mg, 0.5 mmol), [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), 
MesCO2K (30.3 mg, 30.0 mol %) and MesCO2H (82 mg, 0.5 mmol) in H2O (2.0 mL) were 
stirred at 110 °C for 0.5 h, 1.5 h, 2.0 h, 2.5 h, 3.5 h, 4.5 h, 5.0 h under an atmosphere of argon, 
respectively. The consumption of substrate 2a or [D5]-2a and the appearance of the products 
120aa or [Dn]-120aa were monitored by GC analysis. These experiments indicated that the 
C–H bond activation is not the turnover-limiting step of the ruthenium(II)-catalyzed C–H 
alkylation reaction. 
 
t/(h) 0.5 1.5 2.0 2.5 3.5 4.5 5.0 
120aa 0.23 0.39 0.57 0.45 0.66 0.73 0.76 
2a 0.77 0.61 0.43 0.55 0.34 0.27 0.24 
 
t/(h) 0.5 1.5 2.0 2.5 3.5 4.5 5.0 
[Dn]-120aa  0.04 0.17 0.22 0.24 0.31 0.42 0.60 
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,6-Dimethylquinoline  (122aa) 
 
The general procedure F was followed using 121a (75 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
6:1) yielded 122aa (52 mg, 66%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.91 (d, J = 8.7 Hz, 1H), 7.89 (d, J = 9.0 Hz, 1H), 7.49 (s, 
1H), 7.48 (dd, J = 7.6, 1.8 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H), 2.69 (s, 3H), 2.48 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 157.9 (Cq), 146.4 (Cq), 135.5 (CH), 135.3 (Cq), 131.6 (CH), 
128.2 (CH), 126.4 (Cq), 126.3 (CH), 121.9 (CH), 25.2 (CH3), 21.4 (CH3).  
IR (film): 2917, 1601, 1495, 1119, 825, 592 cm-1.  
MS (EI) m/z (relative intensity) 157 (100) [M+], 142 (20), 128 (10), 115 (20), 89 (10), 77 (10). 
HR-MS (EI) m/z calcd for C11H11N [M+] 157.0891, found 157.0884. 




The general procedure F was followed using 121b (83 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
3:1) yielded III-6ba (60 mg, 69%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.94–7.90 (m, 1H), 7.89–7.85 (m, 1H), 7.30 (dd, J = 9.2, 2.8 
Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 7.01 (d, J = 2.8 Hz, 1H), 3.88 (s, 3H), 2.67 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 157.1 (Cq), 156.3 (Cq), 143.9 (Cq), 135.0 (CH), 130.0 (CH), 
127.3 (Cq), 122.2 (CH), 121.8 (CH), 105.2 (CH), 55.4 (CH3), 25.0 (CH3).  
IR (ATR): 2937, 1602, 1498, 1229, 1029, 830 cm-1.  
                                                                 
148 a). Y. Matsubara, S. Hirakawa, Y. Yamaguchi , Z.-i . Yoshida, Angew. Chem. Int. Ed., 2011, 50, 7670–7673; b) V. 
Sridharan, C. Avendaño, J. C. Menéndez, Tetrahedron, 2007, 63, 673–681. 
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MS (EI) m/z (relative intensity) 173 (100) [M+], 158 (50), 143 (5), 130 (80), 115 (5), 103 (20). 
HR-MS (ESI) m/z calcd for C11H12NO [M+H+] 174.0919, found 174.0921. 
The spectral data were in accordance with those reported in the literature.148 
 
2-Methyl-6-phenylquinoline  (122ca) 
 
The general procedure F was followed using 121c (106 mg, 0.5 mmol) and methyl vinyl 
ketone (41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography 
(n-hexane/EtOAc 5:1) yielded 122ca (57 mg, 52%) as an off white solid. M. p.: = 92−93 °C . 
1H-NMR (300 MHz, CDCl3): δ = 8.09 (dd, J = 8.9, 2.1 Hz, 2H), 7.99–7.91 (m, 2H), 7.76–7.65 
(m, 2H), 7.50 (d, J = 7.5 Hz, 1H), 7.48 (d, J = 6.6 Hz, 1H), 7.43–7.35 (m, 1H), 7.31 (d, J = 8.4 
Hz, 1H), 2.77 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 159.0 (Cq), 147.3 (Cq), 140.5 (Cq), 138.4 (Cq), 136.3 (CH), 
129.1 (CH), 129.0 (CH), 128.9 (CH), 127.5 (CH), 127.4 (CH), 126.6 (Cq), 125.2 (CH), 122.4 
(CH), 25.4 (CH3).  
IR (ATR): 2998, 1595, 1488, 1314, 892, 764 cm-1.  
MS (EI) m/z (relative intensity) 219 (100) [M+], 204 (5), 191 (5), 176 (5), 152 (5).  
HR-MS (EI) m/z calcd for C16H13N [M+] 219.1048, found 219.1049. 




The general procedure E was followed using 121d (77 mg, 0.5 mmol), methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) for 20 h. Purification 
by column chromatography (n-hexane/EtOAc 5:1) yielded 122da (47 mg, 58%) as an off white 
solid. M. p.: = 51−53 °C .  
                                                                 
149 F. Mongin, L. Mojovic, B. Guillamet, F. Trécourt, G. Quéguiner, J. Org. Chem., 2002, 67, 8991–8994. 
Experimental Section 
176 
1H-NMR (300 MHz, CDCl3): δ = 8.05–7.91 (m, 2H), 7.42 (ddd, J = 9.1, 8.4, 2.8 Hz, 1H), 7.36 
(dd, J = 8.9, 2.8 Hz, 1H), 7.27 (dd, J = 8.4, 0.8 Hz, 1H), 2.71 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 159.9 (Cq, JC-F = 250.1 Hz), 158.3 (Cq), 144.9 (Cq), 135.5 (CH, 
JC-F = 5.1 Hz), 131.0 (CH, JC-F = 9.0 Hz), 126.9 (Cq, JC-F = 10.1 Hz), 122.7 (CH), 119.4 (CH, JC-F 
= 25.6 Hz), 110.5 (CH, JC-F = 21.8 Hz), 25.2 (CH3). 
19F-NMR (CDCl3, 282 MHz): δ -115.0 (td, J = 8.6, 5.3 Hz).  
IR (ATR): 3058, 1652, 1439, 1329, 749, 509 cm-1.  
MS (EI) m/z (relative intensity) 161 (100) [M+], 146 (5), 133 (10).  
HR-MS (EI) m/z calcd for C10H8NF [M+] 161.0641, found 161.0638. 
The spectral data were in accordance with those reported in the literature.148a,150 
 
6-Chloro-2-methylquinoline  (122ea) 
 
The general procedure F was followed using 121e (85 mg, 0.5 mmol), methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) for 20 h. Purification 
by column chromatography (n-hexane/EtOAc 5:1) yielded 122ea (53 mg, 60%) as an off white 
solid. M. p.: = 95−97 °C .  
1H-NMR (300 MHz, CDCl3): δ = 7.9 (d, J = 8.6 Hz, 2H), 7.7 (d, J = 2.4 Hz, 1H), 7.57 (dd, J = 
9.0, 2.3 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H), 2.70 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 159.3 (Cq), 146.2 (Cq), 135.2 (CH), 131.2 (Cq), 130.2 (CH), 
130.2 (CH), 127.0 (Cq), 126.1 (CH), 122.8 (CH), 25.3 (CH3).  
IR (ATR): 3050, 1597, 1468, 1067, 830, 641 cm-1.  
MS (EI) m/z (relative intensity) 177 (100) [M+], 162 (10), 142 (15), 133 (15), 115 (15), 105 (5). 
HR-MS (EI) m/z calcd for C10H8NCl [M+] 177.0345, found 177.0341. 
The spectral data were in accordance with those reported in the literature.148a,150 
 
6-Bromo-2-methylquinoline (122fa) 
                                                                 




The general procedure F was followed using 121f (107 mg, 0.5 mmol), methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) for 20 h. Purification 
by column chromatography (n-hexane/EtOAc 5:1) yielded 122fa (56 mg, 51%) as an off white 
solid. M. p.: = 98−100 °C .  
1H-NMR (300 MHz, CDCl3): δ = 7.95–7.90 (m, 1H), 7.89 (d, J = 2.2 Hz, 1H), 7.87–7.82 (m, 
1H), 7.71 (dd, J = 9.0, 2.2 Hz, 1H), 7.27 (d, J = 8.5 Hz, 1H), 2.70 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 159.5 (Cq), 146.4 (Cq), 135.1 (CH), 132.8 (CH), 130.4 (CH), 
129.5 (CH), 127.6 (Cq), 122.8 (CH), 119.3 (Cq), 25.4 (CH3).  
IR (ATR): 3048, 1594, 1488, 1300, 1071, 828 cm-1.  
MS (EI) m/z (relative intensity) 221 (100) [M+], 205 (5), 142 (20), 115 (30).  
HR-MS (EI) m/z calcd for C10H8N79Br [M+] 220.9840, found 220.9838. 
The spectral data were in accordance with those reported in the literature.148a,150 
 
2-Methyl-6-(trifluoromethyl)quinoline  (122ga) 
 
The general procedure F was followed using 121g (101 mg, 0.5 mmol), methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) for 20 h. Purification 
by column chromatography (n-hexane/EtOAc 5:1) yielded 122ga (30 mg, 28%) as a yellow 
oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.21–8.04 (m, 3H), 7.83 (dd, J = 8.8, 2.1 Hz, 1H), 7.37 (d, J 
= 8.4 Hz, 1H), 2.77 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 161.5 (Cq), 148.9 (Cq), 136.8 (CH), 129.8 (CH), 127.6 (Cq, 
JC-F = 32.5 Hz), 124.1 (Cq, JC-F = 273.3 Hz), 125.5 (CH, JC-F = 4.4 Hz), 125.4 (Cq), 125.1 (CH, 
JC-F = 3.2 Hz), 123.2 (CH), 25.5 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = -62.2 (s).  
IR (ATR): 1605, 1484, 1291, 1109, 903, 705 cm-1.  
MS (EI) m/z (relative intensity) 211 (100) [M+], 193 (5), 168 (5).  
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HR-MS (ESI) m/z calcd for C11H9NF3 [M+H+] 212.0687, found 212.0687.  
The spectral data were in accordance with those reported in the literature.151 
 
2-Methylquinolin-6-yl acetate (122ha)  
 
The general procedure F was followed using 121h (97 mg, 0.5 mmol), methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) for 20 h. Purification 
by column chromatography (n-hexane/EtOAc 3:1) yielded 122ha (51 mg, 51%) as a yellow oil.   
1H-NMR (300 MHz, CDCl3): δ = 7.99 (d, = 8.8 Hz, 1H), 7.96 (d, = 8.5 Hz, 1H), 7.48 (d, J = 2.5 
Hz, 1H), 7.38 (dd, J = 9.0, 2.6 Hz, 1H), 7.28–7.22 (m, 1H), 2.71 (s, 3H), 2.32 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 169.4 (Cq), 158.8 (Cq), 147.8 (Cq), 145.8 (Cq), 135.8 (CH), 
130.1 (CH), 126.6 (Cq), 124.4 (CH), 122.5 (CH), 118.1 (CH), 25.2 (CH3), 21.1 (CH3).  
IR (ATR): 1713, 1598, 1504, 1429, 1234, 832 cm-1.  
MS (EI) m/z (relative intensity) 201 (5) [M+], 159 (100), 130 (10), 103 (5).  
HR-MS (EI) m/z calcd for C12H11NO2 [M+] 201.0790, found 201.0789. 




The general procedure F was followed using 121i (75 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
5:1) yielded 122ia (49 mg, 62%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.96 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 0.8 Hz, 1H), 7.63 (d, J 
= 8.3 Hz, 1H), 7.29 (dd, J = 8.3, 1.7 Hz, 1H), 7.19 (d, J = 8.4 Hz, 1H), 2.70 (s, 3H), 2.52 (s, 
3H).  
13C-NMR (75 MHz, CDCl3): δ = 158.9 (Cq), 148.1 (Cq), 139.6 (Cq), 135.8 (CH), 127.8 (CH), 
                                                                 
151 K. K. H. Chandrashekarappa, K. M. Mahadevan, K. B. Manjappa, Tetrahedron Letters 2013, 54, 1368–1370. 
152 K. Jyothish, R. R. Avirah, D. Ramaiah, Org. Lett. 2006, 8, 111–114. 
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127.7 (CH), 127.1 (CH), 124.5 (Cq), 121.1 (CH), 25.3 (CH3), 21.9 (CH3).  
IR (ATR): 2916, 1601, 1505, 1305, 835, 776 cm-1.  
MS (EI) m/z (relative intensity) 157 (100) [M+], 142 (20), 128 (5), 115 (15), 89 (5).  
HR-MS (EI) m/z calcd for C11H11N [M+] 157.0891, found 157.0889. 




The general procedure E was followed using 121j (75 mg, 0.5 mmol) and methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) for 20 h. Purification by column chromatography (n-hexane/EtOAc 
5:1) yielded 122ja (27 mg, 34%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.98 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 8.4, 1H), 7.51 (ddd, J  
= 7.0, 1.6, 0.9 Hz, 1H), 7.34 (dd, J = 8.0, 7.0 Hz, 1H), 7.25 (d, J = 8.4 Hz, 1H), 2.80 (s, 3H), 
2.75 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 157.8 (Cq), 146.9 (Cq), 136.5 (Cq), 136.2 (CH), 129.4 (CH), 
126.3 (Cq), 125.4 (CH), 125.2 (CH), 121.6 (CH), 25.6 (CH3), 17.9 (CH3).  
IR (ATR): 2919, 1604, 1500, 1424, 829, 758 cm-1.  
MS (EI) m/z (relative intensity) 157 (100) [M+], 142 (20), 128 (5), 115 (15), 89 (5).  
HR-MS (EI) m/z calcd for C11H11N [M+] 157.0891, found 157.0883. 
The spectral data were in accordance with those reported in the literature.149 
 
8-Fluoro-2-methylquinoline  (122ka) 
 
The general procedure F was followed using 121k (77 mg, 0.5 mmol), methyl vinyl ketone 
(41a) (70 mg, 1.0 mmol) and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) for 20 h. Purification 
by column chromatography (n-hexane/EtOAc 5:1) yielded 122ka (24 mg, 30%) as a yellow oil.   
Experimental Section 
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1H-NMR (300 MHz, CDCl3): δ = 8.03 (dd, J = 8.5, 1.6 Hz, 1H), 7.58–7.48 (m, 1H), 7.44–7.34 
(m, 2H), 7.32 (d, J = 8.6 Hz, 1H), 2.77 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 159.5 (Cq, JC-F = 1.6 Hz), 157.6 (Cq, JC-F = 255.3 Hz), 138.0 
(Cq, JC-F = 11.2 Hz), 135.8 (CH, JC-F = 3.2 Hz), 128.1 (Cq, JC-F = 2.7 Hz), 125.3 (CH, JC-F = 8.0 
Hz), 123.1 (CH, JC-F = 4.8 Hz), 123.0 (CH), 113.5 (CH, JC-F = 19.2 Hz), 25.5 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = -126.4 (ddd, J = 9.9, 5.3, 1.6 Hz).  
IR (ATR): 3057, 1606, 1503, 1234, 1081, 831 cm-1.  
MS (EI) m/z (relative intensity) 161 (100) [M+], 146 (10), 132 (5).  
HR-MS (EI) m/z calcd for C10H8NF [M+] 161.0641, found 161.0645. 
The spectral data were in accordance with those reported in the literature.151 
 
6-Methoxy-2-phenylquinoline  (122bb) 
 
The general procedure F was followed using 121b (83 mg, 0.5 mmol), 41b (132 mg, 1.0 mmol) 
and [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %) for 20 h. Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 122bb (33 mg, 28%) as a colorless solid. M. p.: 
= 129−131 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.15–8.00 (m, 4H), 7.81 (d, J = 8.6 Hz, 1H), 7.62–7.46 (m, 
2H), 7.46–7.41 (m, 1H), 7.37 (dd, J = 9.2, 2.8 Hz, 1H), 7.07 (d, J = 2.8 Hz, 1H), 3.93 (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 157.6 (Cq), 155.0 (Cq), 144.3 (Cq), 139.8 (Cq), 135.5 (CH), 
131.2 (CH), 128.9 (CH), 128.8 (CH), 128.1 (Cq), 127.2 (CH), 122.3 (CH), 119.2 (CH), 105.0 
(CH), 55.5 (CH3). 
IR (ATR): 1596, 1490, 1227, 1020, 831, 699 cm-1.  
MS (EI) m/z (relative intensity) 235 (100) [M+], 220 (35), 192 (60), 165 (5).  
HR-MS (EI) m/z calcd for C16H13NO [M+] 235.0997, found 235.1000. 
The spectral data were in accordance with those reported in the literature.153 
 
                                                                 
153 K. A. Reynolds , D. J. Young, W. A. Loughlin, Synthesis 2010, 3645–3648. 
Experimental Section 
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10.4.4 Analytically Data for the Products of Cobalt-Catalyzed Direct 
Arylation of Aromatic Amides 
N,4'-Dimethylbiphenyl-2-carboxamide (139aa) 
 
The general procedure G was followed using 2a (68 mg, 0.5 mmol) and 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol) for 16 h (or 0.5 h). Purification by column chromatography 
(n-hexane/EtOAc 10:1→2:1) yielded 139aa (88 mg, 78%) and 139aa' (14 mg, 9%) as colorless 
solids, (or 81 mg, 72% yield of 139aa as the sole product). 139aa: M. p.: = 108−110 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.67 (ddd, J = 7.5, 1.6, 0.6 Hz, 1H), 7.49–7.40 (m, 1H), 
7.40–7.35 (m, 1H), 7.33 (ddd, J = 7.2, 1.6, 0.6 Hz, 1H), 7.28 (d, J = 8.1 Hz, 2H), 7.20 (d, J = 8.1 
Hz, 2H), 5.20 (s, 1H), 2.67 (d, J = 5.0 Hz, 3H), 2.37 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 170.3 (Cq), 139.3 (Cq), 137.5 (Cq), 137.1 (Cq), 135.5 (Cq), 
130.1 (CH), 130.1 (CH), 129.3 (CH), 128.8 (CH), 128.5 (CH), 127.3 (CH), 26.7 (CH3), 21.2 
(CH3).  
IR (ATR): 3252, 2921, 1625, 1564, 1020, 801 cm-1.  
MS (EI) m/z (relative intensity) 225 (40) [M+], 208 (15), 195 (100), 165 (50), 152 (45), 115 (5). 




M. p.: = 223−225 °C.  
1H-NMR (400 MHz, CDCl3): δ = 7.43 (dd, J = 8.3, 7.0 Hz, 1H), 7.34 (d, J = 8.1 Hz, 4H), 7.31 
(dd, J = 7.7, 0.6 Hz, 2H), 7.20–7.15 (m, 4H), 5.21 (s, 1H), 2.49 (d, J = 5.0 Hz, 3H), 2.36 (s, 6H). 
13C-NMR (125 MHz, CDCl3): δ = 169.9 (Cq), 140.0 (Cq), 137.5 (Cq), 137.0 (Cq), 135.6 (Cq), 
128.9 (CH), 128.9 (CH), 128.9 (CH), 128.3 (CH), 26.6 (CH3), 21.3 (CH3).  
Experimental Section 
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IR (ATR): 3253, 2921, 1625, 1564, 1020, 801 cm-1.  
MS (EI) m/z (relative intensity) 315 (40) [M+], 298 (5), 285 (100), 267 (10), 242 (20), 226 (10). 




The general procedure G was followed using 2a (68 mg, 0.5 mmol) and 3-chlorotoluene (88b) 
(76 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 
10:1→2:1) yielded 139ab (73 mg, 65%) as a colorless solid. M. p.: = 144−146 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.67 (dd, J = 7.4, 1.5 Hz, 1H), 7.46–7.31 (m, 3H), 7.27 (d, J = 
7.4 Hz, 1H), 7.20–7.14 (m, 3H), 5.20 (s, 1H), 2.66 (d, J = 5.1 Hz, 3H), 2.37 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 170.1 (Cq), 140.0 (Cq), 139.3 (Cq), 138.2 (Cq), 135.5 (Cq), 
130.0 (CH), 129.9 (CH), 129.2 (CH), 128.8 (CH), 128.4 (CH), 128.4 (CH), 127.4 (CH), 125.6 
(CH), 26.7 (CH3), 21.5 (CH3).  
IR (ATR): 3284, 1632, 1313, 757, 700, 449 cm-1.  
MS (EI) m/z (relative intensity) 225 (35) [M+], 208 (10), 195 (100), 165 (50), 152 (45), 115 (5). 




The general procedure G was followed using 2a (68 mg, 0.5 mmol) and 2-chlorotoluene (88c) 
(76 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 
10:1→2:1) yielded 139ac (62 mg, 55%) as a colorless solid. M. p.: = 95−96 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.92–7.88 (m, 1H), 7.52–7.37 (m, 2H), 7.32–7.22 (m, 3H), 
7.20–7.12 (m, 2H), 5.22 (s, 1H), 2.60 (d, J = 4.9 Hz, 3H), 2.09 (s, 3H).  
Experimental Section 
183 
13C-NMR (125 MHz, CDCl3): δ = 168.7 (Cq), 140.1 (Cq), 139.0 (Cq), 136.0 (Cq), 134.7 (Cq), 
130.3 (CH), 130.2 (CH), 130.2 (CH), 129.2 (CH), 129.0 (CH), 128.1 (CH), 127.6 (CH), 126.1 
(CH), 26.7 (CH3), 20.1 (CH3).  
IR (ATR): 3318, 1629, 1548, 1310, 755, 467 cm-1.  
MS (EI) m/z (relative intensity) 225 (15) [M+], 210 (20), 195 (100), 165 (50), 152 (25), 139 (5). 





The general procedure G was followed using 2a (68 mg, 0.5 mmol) and 
tert-butyl{(4-chlorobenzyl)oxy}dimethylsilane (88d) (154 mg, 0.6 mmol) for 0.5 h. 
Purification by column chromatography (n-hexane/EtOAc 10:1→2:1) yielded 139ad (102 mg, 
57%) as a colorless solid. M. p.: = 91−93 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.68 (ddd, J = 7.6, 1.5, 0.5 Hz, 1H), 7.44 (td, J = 7.5, 1.5 Hz, 
1H), 7.38 (dd, J = 7.5, 1.5 Hz, 1H), 7.36 (s, 4H), 7.34 (ddd, J = 7.6, 1.5, 0.5 Hz, 1H), 5.16 (d, J 
= 5.0 Hz, 1H), 4.77 (s, 2H), 2.65 (d, J = 5.0 Hz, 3H), 0.93 (s, 9H), 0.09 (s, 6H).  
13C-NMR (125 MHz, CDCl3): δ = 170.3 (Cq), 141.1 (Cq), 139.2 (Cq), 138.7 (Cq), 135.6 (Cq), 
130.1 (CH), 130.1 (CH), 128.9 (CH), 128.5 (CH), 127.5 (CH), 126.2 (CH), 64.7 (CH2), 26.7 
(CH3), 25.9 (CH3), 18.4 (Cq), -5.2 (CH3).  
IR (ATR): 3304, 2929, 1630, 1252, 834, 759 cm-1.  
MS (EI) m/z (relative intensity) 355 (5) [M+], 340 (5), 298 (100), 224 (35), 195 (10), 165 (20). 






The general procedure G was followed using 2c (83 mg, 0.5 mmol) and 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 
10:1→3:2) yielded 139ca (72 mg, 56%) as a colorless solid. M. p.: = 128−129 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.68 (d, J = 8.6 Hz, 1H), 7.27 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 
8.0 Hz, 2H), 6.88 (dd, J = 8.6, 2.6 Hz, 1H), 6.80 (d, J = 2.6 Hz, 1H), 5.15 (s, 1H), 3.82 (s, 3H), 
2.64 (d, J = 4.9 Hz, 3H), 2.37 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 169.6 (Cq), 160.5 (Cq), 141.1 (Cq), 137.6 (Cq), 137.2 (Cq), 
130.8 (CH), 129.2 (CH), 128.4 (CH), 127.8 (Cq), 115.3 (CH), 112.7 (CH), 55.4 (CH3), 26.7 
(CH3), 21.2 (CH3).  
IR (ATR): 3304, 1633, 1536, 1287, 1179, 824 cm-1.  
MS (EI) m/z (relative intensity) 255 (35) [M+], 238 (5), 225 (100), 210 (5), 182 (15), 165 (10). 
HR-MS (EI) m/z calcd for C16H17NO2 [M+] 255.1259, found 255.1263. 
 
N,4',5-Trimethylbiphenyl-2-carboxamide  (139ba) 
 
The general procedure G was followed using 2b (75 mg, 0.5 mmol) and 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol) for 0.5 h. Purification by column chromatography (n-hexane/EtOAc 
10:1→2:1) yielded 139ba (78 mg, 65%) as a colorless solid. M. p.: = 137−139 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.59 (d, J = 7.8 Hz, 1H), 7.27 (d, J = 8.1 Hz, 2H), 7.21–7.10 
(m, 4H), 5.16 (d, J = 5.0 Hz, 1H), 2.66 (d, J = 4.9 Hz, 3H), 2.38 (s, 3H), 2.37 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 170.3 (Cq), 140.2 (Cq), 139.3 (Cq), 137.4 (Cq), 137.3 (Cq), 
132.6 (Cq), 130.8 (CH), 129.2 (CH), 129.0 (CH), 128.5 (CH), 128.1 (CH), 26.7 (CH3), 21.3 
(CH3), 21.2 (CH3).  
Experimental Section 
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IR (ATR): 3243, 1627, 1563, 1322, 841, 519 cm-1.  
MS (EI) m/z (relative intensity) 239 (40) [M+], 222 (10), 209 (100), 181 (15), 165 (45), 152 (5). 




The general procedure G was followed using 2d (106 mg, 0.5 mmol), 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol), Co(acac)2 (12.9 mg, 10 mol %) and ICyHCl (13.5 mg, 10 mol %) for 0.5 h. 
Purification by column chromatography (n-hexane/EtOAc 10:1→3:2) yielded 139da (102 mg, 
68%) as a colorless solid. M. p.: = 170−172 °C.  
1H-NMR (500 MHz, CDCl3): δ = 7.76 (d, J = 8.0 Hz, 1H), 7.64–7.57 (m, 3H), 7.55 (d, J = 1.8 
Hz, 1H), 7.43 (ddd, J = 7.7, 6.7, 1.2 Hz, 2H), 7.39–7.35 (m, 1H), 7.34 (d, J = 8.0 Hz, 2H), 
7.26–7.21 (m, 2H), 5.28 (d, J = 4.9 Hz, 1H), 2.70 (d, J = 4.9 Hz, 3H), 2.39 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 169.9 (Cq), 142.8 (Cq), 140.0 (Cq), 139.7 (Cq), 137.6 (Cq), 
137.1 (Cq), 134.1 (Cq), 129.4 (CH), 129.3 (CH), 128.8 (CH), 128.8 (CH), 128.5 (CH), 127.8 
(CH), 127.1 (CH), 125.9 (CH), 26.7 (CH3), 21.3 (CH3).  
IR (ATR): 3301, 1639, 1530, 1304, 757, 719 cm-1.  
MS (EI) m/z (relative intensity) 301 (40) [M+], 284 (10), 271 (100), 241 (10), 228 (30), 165 
(10).  
HR-MS (EI) m/z calcd for C21H19NO [M+] 301.1467, found 301.1460.  
 




The general procedure G was followed using 2s (77 mg, 0.5 mmol), 4-chlorotoluene (88a) (76 
mg, 0.6 mmol), Co(acac)2 (12.9 mg, 10 mol %) and ICyHCl (13.5 mg, 10 mol %) for 0.5 h. 
Purification by column chromatography (n-hexane/EtOAc 3:1→1:1) yielded 139sa (64 mg, 
53%) as a colorless solid. M. p.: = 144−145 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.70 (dd, J = 8.4, 6.0 Hz, 1H), 7.29 (d, J = 8.1 Hz, 2H), 7.23 
(d, J = 8.1 Hz, 2H), 7.11–7.02 (m, 2H), 5.17 (s, 1H), 2.68 (d, J = 4.8 Hz, 3H), 2.40 (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 169.2 (Cq), 163.1 (Cq, JC-F = 250.0 Hz), 141.8 (Cq, JC-F = 8.3 
Hz), 138.1 (Cq), 136.0 (Cq, JC-F = 1.8 Hz), 131.5 (Cq, JC-F = 3.2 Hz), 131.2 (CH, JC-F = 9.0 Hz), 
129.4 (CH), 128.3 (CH), 116.7 (CH, JC-F = 22.1 Hz), 114.3 (CH, JC-F = 22.1 Hz), 26.8 (CH3), 
21.3 (CH3).  
19F-NMR (CDCl3, 376 MHz): δ -110.4 – -110.5 (m).  
IR (ATR): 3243, 1630, 1557, 1176, 835, 607 cm-1. 
MS (EI) m/z (relative intensity) 243 (5) [M+], 213 (20), 183 (5), 165 (5), 58 (25), 43 (100). 
HR-MS (EI) m/z calcd for C15H14NFO [M+] 243.1059, found 243.1065.  
 
N,4'-Dimethyl-5-(trifluoromethyl)biphenyl-2-carboxamide  (139fa) 
 
The general procedure G was followed using 2f (102 mg, 0.5 mmol), 4-chlorotoluene (88a) (76 
mg, 0.6 mmol), Co(acac)2 (12.9 mg, 10 mol %) and ICyHCl (13.5 mg, 10 mol %) for 0.5 h. 
Purification by column chromatography (n-hexane/EtOAc 6:1→2:1) yielded 139fa (93 mg, 
63%) as a colorless solid. M. p.: = 157−159 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.74 (d, J = 8.6 Hz, 1H), 7.61 (d, J = 8.6 Hz, 1H), 7.60 (s, 1H), 
7.29 (d, J = 8.1 Hz, 2H), 7.23 (d, J = 8.1 Hz, 2H), 5.31 (s, 1H), 2.69 (d, J = 4.9 Hz, 3H), 2.38 (s, 
3H).  
13C-NMR (125 MHz, CDCl3): δ = 168.9 (Cq), 139.9 (Cq), 138.6 (Cq), 138.3 (Cq), 135.6 (Cq), 
131.9 (Cq, JC-F = 32.8 Hz), 129.5 (CH), 129.3 (CH), 128.3 (CH), 126.9 (CH, JC-F = 7.5 Hz), 
124.0 (CH, JC-F = 7.5 Hz), 123.5 (Cq, JC-F = 271.9 Hz), 26.8 (CH3), 21.3 (CH3). 
Experimental Section 
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19F-NMR (376 MHz, CDCl3): δ = -62.9 (s).  
IR (ATR): 3280, 1643, 1335, 1117, 814, 545 cm-1.  
MS (EI) m/z (relative intensity) 293 (35) [M+], 263 (100), 235 (10), 215 (20), 165 (30).  
HR-MS (EI) m/z calcd for C16H14NOF3 [M+] 293.1027, found 293.1034. 
 
N,4,4'-Trimethylbiphenyl-2-carboxamide  (139oa) 
 
The general procedure G was followed using 2o (75 mg, 0.5 mmol) and 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol) for 0.5 h. Purification by column chromatography (n-hexane/EtOAc 2:1) 
yielded 139oa (93 mg, 78%) as a colorless solid. M. p.: = 144−146 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.48 (s, 1H), 7.27 (d, J = 8.2 Hz, 2H), 7.22 (d, J = 8.2 Hz, 2H), 
7.19 (d, J = 8.2 Hz, 2H), 5.18 (s, 1H), 2.66 (d, J = 4.9 Hz, 3H), 2.37 (s, 3H), 2.36 (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 170.5 (Cq), 137.3 (Cq), 137.2 (Cq), 137.1 (Cq), 136.4 (Cq), 
135.3 (Cq), 130.8 (CH), 130.1 (CH), 129.4 (CH), 129.2 (CH), 128.5 (CH), 26.6 (CH3), 21.1 
(CH3), 20.9 (CH3).  
IR (ATR): 3320, 1633, 1533, 1309, 810, 531 cm-1.  
MS (EI) m/z (relative intensity) 239 (45) [M+], 222 (10), 209 (100), 181 (15), 165 (50), 152 (5). 




The general procedure G was followed using 2o (75 mg, 0.5 mmol) and 
4-chloro-1,2-dimethylbenzene (88e) (84 mg, 0.6 mmol) for 0.5 h. Purification by column 
chromatography (n-hexane/EtOAc 3:1) yielded 139oe (82 mg, 64%) as a colorless solid. M. p.: 
= 123−125 °C.  
Experimental Section 
188 
1H-NMR (300 MHz, CDCl3): δ = 7.77–7.71 (m, 1H), 7.29–7.26 (m, 1H), 7.14 (d, J = 7.8 Hz, 
1H), 7.07 (dd, J = 7.5, 1.4 Hz, 1H), 7.05 (d, J = 7.7 Hz, 1H), 6.98 (s, 1H), 5.24 (s, 1H), 2.60 (d, 
J = 4.9 Hz, 3H), 2.40 (s, 3H), 2.32 (s, 3H), 2.03 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 168.9 (Cq), 139.9 (Cq), 137.3 (Cq), 136.2 (Cq), 135.6 (Cq), 
134.2 (Cq), 133.0 (Cq), 131.0 (CH), 130.2 (CH), 130.2 (CH), 129.8 (CH), 129.8 (CH), 128.7 
(CH), 26.8 (CH3), 21.1 (CH3), 21.0 (CH3), 19.5 (CH3).  
IR (ATR): 3281, 1634, 1551, 1319, 823, 468 cm-1.  
MS (EI) m/z (relative intensity) 253 (40) [M+], 238 (70), 222 (100), 208 (15), 195 (50), 179 
(55).  




The general procedure G was followed using 2o (75 mg, 0.5 mmol) and 
tert-butyl(4-chlorophenoxy)dimethylsilane (88f) (145 mg, 0.6 mmol) for 0.5 h. Purification by 
column chromatography (n-hexane/EtOAc 2:1) yielded 139of (125 mg, 70%) as a colorless 
solid. M. p.: = 70−72 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.49 (d, J = 1.5 Hz, 1H), 7.23–7.21 (m, 4H), 6.85 (dd, J = 8.6, 
0.6 Hz, 2H), 5.10 (d, J = 5.0 Hz, 1H), 2.65 (d, J = 5.0 Hz, 3H), 2.37 (d, J = 0.7 Hz, 3H), 0.98 (s, 
9H), 0.20 (s, 6H).  
13C-NMR (125 MHz, CDCl3): δ = 170.5 (Cq), 155.4 (Cq), 137.1 (Cq), 136.1 (Cq), 135.3 (Cq), 
133.1 (Cq), 130.8 (CH), 129.9 (CH), 129.8 (CH), 129.5 (CH), 120.2 (CH), 26.6 (CH3), 25.7 
(CH3), 20.9 (CH3), 18.3 (Cq), -4.4 (CH3).  
IR (ATR): 3251, 2930, 1621, 1254, 911, 777 cm-1. 
MS (EI) m/z (relative intensity) 355 (45) [M+], 298 (35), 267 (100), 239 (5), 211 (5), 165 (10). 




N,4'-Dimethyl-4-(trifluoromethyl)biphenyl-2-carboxamide  (139pa) 
 
The general procedure G was followed using 2p (102 mg, 0.5 mmol) 4-chlorotoluene (88a) (76 
mg, 0.6 mmol), Co(acac)2 (12.9 mg, 10 mol %) and ICyHCl (13.5 mg, 10 mol %) for 0.5 h. 
Purification by column chromatography (n-hexane/EtOAc 3:1) yielded 139pa (78 mg, 53%) as 
a colorless solid. M. p.: = 161−163 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.96  (s, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 8.4 Hz, 
1H), 7.31 (d, J = 7.9 Hz, 2H), 7.26 (d, J = 7.9 Hz, 2H), 5.26 (s, 1H), 2.72 (d, J = 4.8 Hz, 3H), 
2.41 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 168.7 (Cq), 142.7 (Cq), 138.4 (Cq), 136.0 (Cq), 135.7 (Cq), 
130.6 (CH), 129.6 (Cq, JC-F = 32.6 Hz), 129.5 (CH), 128.3 (CH), 126.6 (CH, JC-F = 7.2 Hz), 
126.0 (CH, JC-F = 7.2 Hz), 123.7 (Cq, JC-F = 272.4 Hz), 26.8 (CH3), 21.3 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = -62.7 (s).  
IR (ATR): 3241, 1633, 1364, 1263, 1125, 825 cm-1.  
MS (EI) m/z (relative intensity) 293 (30) [M+], 263 (100), 249 (5), 235 (10), 215 (20), 165 (35). 




general procedure G was followed using 2m (90 mg, 0.5 mmol) and 4-chlorotoluene (88a) (76 
mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 10:1→2:1) 
yielded 139ma (93 mg, 59%) and 139ma' (23 mg, 17%) as colorless solids. IV-5ia: M. p.: = 
166−168 °C.  
Experimental Section 
190 
1H-NMR (300 MHz, CDCl3): δ = 7.30 (d, J = 8.1 Hz, 2H), 7.28 (d, J = 7.9 Hz, 1H), 7.21 (d, J = 
8.1 Hz, 2H), 6.79 (d, J = 7.9 Hz, 1H), 5.97 (s, 2H), 5.25 (s, 1H), 2.63 (d, J = 4.9 Hz, 3H), 2.36 (s, 
3H).  
13C-NMR (125 MHz, CDCl3): δ = 168.9 (Cq), 148.6 (Cq), 145.2 (Cq), 138.0 (Cq), 130.5 (Cq), 
129.5 (Cq), 129.2 (CH), 129.0 (CH), 123.5 (CH), 121.4 (Cq), 107.3 (CH), 101.3 (CH2), 26.7 
(CH3), 21.3 (CH3).  
IR (ATR): 3238, 1637, 1443, 1243, 830, 526 cm-1. 
MS (EI) m/z (relative intensity) 269 (55) [M+], 252 (10), 239 (100), 209 (20), 181 (40), 153 
(35).  




M. p.: = 190−192 °C.  
1H-NMR (500 MHz, CDCl3): δ = 7.22 (d, J = 8.2 Hz, 2H), 7.18 (d, J = 8.2 Hz, 3H), 7.18 (s, 1H), 
6.00 (s, 2H), 5.07 (d, J = 4.9 Hz, 1H), 2.61 (d, J = 4.9 Hz, 3H), 2.36 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 169.4 (Cq), 148.9 (Cq), 146.9 (Cq), 137.4 (Cq), 137.0 (Cq), 
134.3 (Cq), 129.2 (CH), 129.2 (Cq), 128.5 (CH), 109.9 (CH), 109.1 (CH), 101.6 (CH2), 26.8 
(CH3), 21.2 (CH3).  
IR (ATR): 3341, 1635, 1480, 1232, 820, 577 cm-1.  
MS (EI) m/z (relative intensity) 269 (100) [M+], 252 (25), 239 (100), 224 (10), 209 (55), 181 
(60).  
HR-MS (ESI) m/z calcd for C16H16NO3 [M+H+] 270.1130, found 270.1127. 
 




The general procedure G was followed using 2l (93 mg, 0.5 mmol) and 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol) for 0.5 h. Purification by column chromatography (n-hexane/EtOAc 4:1) 
yielded 139la (78 mg, 57%) as a colorless solid. M. p.: = 196−198 °C.  
1H-NMR (400 MHz, CDCl3): δ = 8.08–7.97 (m, 1H), 7.90–7.87 (d, J = 8.8 Hz, 1H), 7.86–7.82 
(m, 1H), 7.57–7.46 (m, 3H), 7.46–7.43 (m, 2H), 7.25–7.21 (m, 2H), 5.40 (d, J = 5.0 Hz, 1H), 
2.77 (d, J = 5.0 Hz, 3H), 2.39 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 170.3 (Cq), 137.4 (Cq), 137.4 (Cq), 136.3 (Cq), 133.3 (Cq), 
132.4 (Cq), 130.4 (Cq), 129.4 (CH), 129.2 (CH), 128.6 (CH), 127.9 (CH), 127.5 (CH), 127.2 
(CH), 126.2 (CH), 125.6 (CH), 26.8 (CH3), 21.2 (CH3).  
IR (ATR): 3280, 1632, 1538, 1292, 811, 548 cm-1.  
MS (EI) m/z (relative intensity) 275 (50) [M+], 258 (5), 245 (100), 230 (5), 215 (25), 202 (55). 
HR-MS (EI) m/z calcd for C19H17NO [M+] 275.1310, found 275.1305.  
 
2-(4-Methoxyphenyl)-N-methyl-1-naphthamide  (139lg) 
 
The general procedure G was followed using 2l (93 mg, 0.5 mmol) and 
1-chloro-4-methoxybenzene (88g) (85 mg, 0.6 mmol) for 0.5 h. Purification by column 
chromatography (n-hexane/EtOAc 2:1) yielded 139lg (81 mg, 56%) as a colorless solid. M. p.: 
= 190−191 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.04 (d, J = 8.5 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.80 (dd, J 
= 8.5, 1.6 Hz, 1H), 7.61–7.37 (m, 5H), 6.95 (d, J = 8.5 Hz, 2H), 5.45 (d, J = 5.1 Hz, 1H), 3.83 (s, 
3H), 2.77 (d, J = 5.1 Hz, 3H).  
Experimental Section 
192 
13C-NMR (125 MHz, CDCl3): δ = 170.3 (Cq), 159.1 (Cq), 135.8 (Cq), 133.0 (Cq), 132.6 (Cq), 
132.1 (Cq), 130.4 (Cq), 129.8 (CH), 129.3 (CH), 127.8 (CH), 127.4 (CH), 127.1 (CH), 126.1 
(CH), 125.4 (CH), 113.9 (CH), 55.3 (CH3), 26.8 (CH3).  
IR (ATR): 3288, 1633, 1541, 1243, 820, 555 cm-1.  
MS (EI) m/z (relative intensity) 291 (60) [M+], 274 (5), 261 (100), 218 (15), 202 (10), 189 (35). 
HR-MS (EI) m/z calcd for C19H17NO2 [M+] 291.1259, found 291.1264. 
 
N,3,4'Trimethylbiphenyl-2-carboxamide  (139ta) 
 
The general procedure G was followed using 2t (75 mg, 0.5 mmol) and 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 2:1) 
yielded 139ta (64 mg, 54%) as a colorless solid. M. p.: = 185−186 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.31 (d, J = 8.1 Hz, 2H), 7.27 (d, J = 7.6 Hz, 1H), 
7.20–7.14 (m, 4H), 5.23 (d, J = 6.0 Hz, 1H), 2.64 (d, J = 4.9 Hz, 3H), 2.39 (s, 3H), 2.35 (s, 
3H).  
13C-NMR (125 MHz, CDCl3): δ = 170.6 (Cq), 138.9 (Cq), 137.4 (Cq), 137.0 (Cq), 136.2 (Cq), 
135.6 (Cq), 129.0 (CH), 129.0 (CH), 128.8 (CH), 128.2 (CH), 127.1 (CH), 26.5 (CH3), 21.2 
(CH3), 19.6 (CH3).  
IR (ATR): 3228, 1625, 1543, 786, 710, 543 cm-1.  
MS (EI) m/z (relative intensity) 239 (65) [M+], 224 (10), 209 (100), 195 (5), 181 (20), 165 
(65). 
HR-MS (ESI) m/z calcd for C16H18NO [M+H+] 240.1388, found 240.1380.  
 




The general procedure G was followed using 2u (94 mg, 0.5 mmol) and 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 2:1) 
yielded 139ua (100 mg, 72%) as a colorless solid. M. p.: = 167−169 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.56 (d, J = 8.1 Hz, 1H), 7.41–7.38 (m, 1H), 7.36 (d, J = 8.0 
Hz, 2H), 7.31 (dd, J = 8.1, 1.2 Hz, 1H), 7.27 (d, J = 8.0 Hz, 2H), 7.12 (dd, J = 8.1, 1.2 Hz, 1H), 
5.64 (s, 1H), 4.02 (s, 3H), 2.77 (d, J = 5.1 Hz, 3H), 2.42 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 163.2 (Cq), 137.7 (Cq), 136.9 (Cq), 130.7 (Cq), 129.9 (CH), 
129.5 (CH), 129.1 (Cq), 126.2 (Cq), 124.1 (CH), 120.6 (CH), 120.4 (CH), 118.2 (Cq), 109.9 
(CH), 31.6 (CH3), 26.4 (CH3), 21.3 (CH3).  
IR (ATR): 3242, 1639, 1567, 1365, 751, 517 cm-1.  
MS (EI) m/z (relative intensity) 278 (100) [M+], 262 (5), 248 (30), 233 (15), 221 (15), 204 (20). 
HR-MS (EI) m/z calcd for C18H18N2O [M+] 278.1419, found 278.1414. 
 
N,1-Dimethyl-2-p-tolyl-1H-indole-3-carboxamide  (139ra) 
 
The general procedure G was followed using 2r (94 mg, 0.5 mmol) and 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 
2:1→1:1) yielded 139ra (80 mg, 58%) as a colorless solid. M. p.: = 170−171 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.36 (d, J = 7.3 Hz, 1H), 7.35 (d, J = 7.9 Hz, 2H), 7.32 (d, J = 
7.9 Hz, 2H), 7.31 (m, 1H), 7.29 (dd, J = 6.8, 1.5 Hz, 1H), 7.26 (m, 1H), 5.24 (s, 1H), 3.49 (s, 
3H), 2.73 (d, J = 4.7 Hz, 3H), 2.46 (s, 3H).  
Experimental Section 
194 
13C-NMR (125 MHz, CDCl3): δ = 166.0 (Cq), 140.9 (Cq), 139.8 (Cq), 136.6 (Cq), 130.4 (CH), 
129.8 (CH), 127.9 (Cq), 127.0 (Cq), 122.6 (CH), 122.0 (CH), 121.5 (CH), 109.3 (CH), 108.9 
(Cq), 30.6 (CH3), 26.0 (CH3), 21.4 (CH3). 
IR (ATR): 3338, 1623, 1524, 1222, 750, 511 cm-1.  
MS (EI) m/z (relative intensity) 278 (30) [M+], 248 (100), 233 (5), 218 (5), 204 (10), 190 (5). 
HR-MS (EI) m/z calcd for C18H18N2O [M+] 278.1419, found 278.1422. 
 
2-(4-Methoxyphenyl)-N,1-dimethyl-1H-indole-3-carboxamide  (139rg) 
 
The general procedure G was followed using 2r (94 mg, 0.5 mmol) and 
1-chloro-4-methoxybenzene (88g) (85 mg, 0.6 mmol) for 16 h. Purification by column 
chromatography (n-hexane/EtOAc 3:2) yielded 139rg (87 mg, 59%) as a colorless solid. M. p.: 
= 146−147 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.41–8.30 (m, 1H), 7.36 (d, J = 8.7 Hz, 2H), 7.33–7.19 (m, 
3H), 7.06 (d, J = 8.7 Hz, 2H), 5.28 (s, 1H), 3.89 (s, 3H), 3.49 (s, 3H), 2.74 (d, J = 4.8 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 165.9 (Cq), 160.4 (Cq), 140.6 (Cq), 136.5 (Cq), 131.8 (CH), 
126.9 (Cq), 122.8 (Cq), 122.6 (CH), 121.9 (CH), 121.5 (CH), 114.5 (CH), 109.2 (CH), 108.8 
(Cq), 55.4 (CH3), 30.6 (CH3), 26.1 (CH3).  
IR (ATR): 3338, 1619, 1542, 1247, 752, 531 cm-1.  
MS (EI) m/z (relative intensity) 294 (45) [M+], 264 (100), 249 (5), 234 (5), 221 (5), 192 (10). 






The general procedure G was followed using 2v (99 mg, 0.5 mmol) and 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 10:1) 
yielded 139va (103 mg, 72%) as a colorless solid. M. p.: = 154−155 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.86 (dd, J = 7.5, 1.5 Hz, 1H), 7.64–7.37 (m, 3H), 7.35 (d, J 
= 8.1 Hz, 2H), 7.24–7.16 (m, 4H), 7.11 (dd, J = 8.1, 1.5 Hz, 2H), 7.08–6.98 (m, 1H), 6.92 (s, 
1H), 2.37 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 167.0 (Cq), 139.5 (Cq), 137.9 (Cq), 137.5 (Cq), 136.9 (Cq), 
135.1 (Cq), 130.6 (CH), 130.3 (CH), 129.6 (CH), 129.5 (CH), 128.7 (CH), 128.6 (CH), 127.6 
(CH), 124.2 (CH), 119.8 (CH), 21.2 (CH3).  
IR (ATR): 3058, 1652, 1439, 1329, 749, 509 cm-1.  
MS (EI) m/z (relative intensity) 287 (35) [M+], 195 (100), 165 (40), 152 (40).  
HR-MS (EI) m/z calcd for C20H17NO [M+] 287.1310, found 287.1304.  




The general procedure G was followed using 2v (99 mg, 0.5 mmol) and 
1-chloro-4-methoxybenzene (88g) (85 mg, 0.6 mmol) for 16 h. Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 139vg (112 mg, 74%) as a colorless solid. 
M.p.: = 146−148 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.84 (dd, J = 7.5, 1.4 Hz, 1H), 7.53–7.37 (m, 5H), 
7.25–7.13 (m, 4H), 7.07–7.01 (m, 1H), 6.97–6.91 (d, J = 8.8 Hz, 3H), 3.81 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 167.3 (Cq), 159.5 (Cq), 139.1 (Cq), 137.6 (Cq), 135.1 (Cq), 
132.1 (Cq), 130.6 (CH), 130.4 (CH), 130.0 (CH), 129.4 (CH), 128.8 (CH), 127.4 (CH), 124.3 
(CH), 119.9 (CH), 114.4 (CH), 55.4 (CH3).  
IR (ATR): 3238, 1653, 1434, 1238, 755, 526 cm-1.  
                                                                 
154 S. E. Havlik, J. M. Simmons, V. J. Winton, J. B. Johnson, J. Org. Chem. 2011, 76, 3588–3593. 
Experimental Section 
196 
MS (EI) m/z (relative intensity) 303 (20) [M+], 211 (100), 196 (5), 183 (5), 168 (20), 152 (5). 
HR-MS (EI) m/z calcd for C20H17NO2 [M+] 303.1259, found 303.1260. 
The spectral data were in accordance with those reported in the literature.154 
 
N-Phenyl-[1,1'-biphenyl]-2-carboxamide  (139vh)  
 
The general procedure G was followed using 2v (99 mg, 0.5 mmol) and chlorobenzene (88h) 
(67 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 10:1) 
and recrystallization (n-hexane/EtOAc) yielded 139vh (78 mg, 57%) as a colorless solid. M. p. : 
= 111−113 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.88 (dd, J = 7.2, 1.6 Hz, 1H), 7.60–7.37 (m, 8H), 7.22 (d, J = 
8.5 Hz, 1H), 7.19 (d, J = 7.2 Hz, 1H), 7.13–6.95 (m, 3H), 6.88 (s, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 166.9 (Cq), 139.8 (Cq), 139.4 (Cq), 137.4 (Cq), 135.2 (Cq), 
130.6 (CH), 130.2 (CH), 129.5 (CH), 128.9 (CH), 128.7 (CH), 128.7 (CH), 128.0 (CH), 127.8 
(CH), 124.3 (CH), 119.8 (CH).  
IR (ATR): 3331, 1664, 1516, 1433, 741, 688 cm-1.  
MS (EI) m/z (relative intensity) 273 (50) [M+], 181 (100), 152 (60), 127 (5).  
HR-MS (EI) m/z calcd for C19H15NO [M+] 273.1154, found 273.1153.  
The spectral data were in accordance with those reported in the literature.154 
 
2'-Methyl-N-phenylbiphenyl-2-carboxamide  (139vc) 
 
The general procedure G was followed using 2v (99 mg, 0.5 mmol) and 2-chlorotoluene (88c) 
(76 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 10:1) 
yielded 139vc (118 mg, 82%) as a colorless solid. M. p.: = 134−136 °C.  
Experimental Section 
197 
1H-NMR (300 MHz, CDCl3): δ = 8.12 (dd, J = 7.1, 2.0 Hz, 1H), 7.57–7.48 (m, 2H), 7.41–7.30 
(m, 4H), 7.26 (dd, J = 7.3, 2.1 Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 7.17 (d, J = 7.1 Hz, 1H), 7.10 
(s, 1H), 7.01 (d, J = 6.9 Hz, 2H), 7.00–6.98 (m, 1H), 2.11 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 165.5 (Cq), 139.9 (Cq), 138.9 (Cq), 137.5 (Cq), 136.5 (Cq), 
134.2 (Cq), 130.9 (CH), 130.8 (CH), 130.4 (CH), 130.1 (CH), 129.2 (CH), 128.7 (CH), 128.6 
(CH), 128.0 (CH), 126.6 (CH), 124.1 (CH), 119.6 (CH), 20.1 (CH3).  
IR (ATR): 3063, 1647, 1546, 1329, 752, 512 cm-1.  
MS (EI) m/z (relative intensity) 287 (5) [M+], 195 (100), 165 (20), 152 (15), 93 (25).  




The general procedure G was followed using 2v (99 mg, 0.5 mmol) and 
1-chloro-2-methoxybenzene (88i) (85 mg, 0.6 mmol) for 16 h. Purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 139vi (99 mg, 65%) as a colorless solid. M. p.: 
= 139−141 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.90 (dd, J = 7.3, 1.8 Hz, 1H), 7.59–7.42 (m, 2H), 7.41–7.27 
(m, 4H), 7.24–7.12 (m, 4H), 7.08 (td, J = 7.5, 1.1 Hz, 1H), 7.05–6.98 (m, 1H), 6.90 (dd, J = 8.2, 
1.0 Hz, 1H), 3.65 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 166.7 (Cq), 156.2 (Cq), 137.8 (Cq), 137.8 (Cq), 135.9 (Cq), 
135.7 (Cq), 130.9 (CH), 130.6 (CH), 130.6 (CH), 129.8 (CH), 128.9 (CH), 128.7 (CH), 127.8 
(CH), 123.9 (CH), 121.2 (CH), 119.4 (CH), 111.0 (CH), 55.6 (CH3).  
IR (ATR): 3237, 1653, 1434, 1238, 756, 515 cm-1.  
MS (EI) m/z (relative intensity) 303 (5) [M+], 272 (10), 211 (100), 196 (20), 168 (10), 139 (10). 
HR-MS (EI) m/z calcd for C20H17NO2 [M+] 303.1259, found 303.1255. 






The general procedure G was followed using 2w (105 mg, 0.5 mmol) and 4-chlorotoluene 
(88a) (76 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 
10:1) yielded 139wa (120 mg, 80%) as a colorless solid. M. p.: = 134−136 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.87 (dd, J = 7.5, 1.5 Hz, 1H), 7.55–7.45 (m, 2H), 
7.42–7.39 (m, 1H), 7.37 (d, J = 8.1 Hz, 2H), 7.24 (d, J = 8.1 Hz, 2H), 7.03 (s, 4H), 6.91 (s, 
1H), 2.39 (s, 3H), 2.28 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 167.0 (Cq), 139.4 (Cq), 137.8 (Cq), 136. 9 (Cq), 135.2 (Cq), 
134.9 (Cq), 133.9 (Cq), 130.4 (CH), 130.2 (CH), 129.5 (CH), 129.4 (CH), 129.2 (CH), 128.6 
(CH), 127.5 (CH), 119. 9 (CH), 21.2 (CH3), 20.9 (CH3).  
IR (ATR): 3044, 1649, 1510, 1327, 755, 510 cm-1.  
MS (EI) m/z (relative intensity) 301 (15) [M+], 285 (5), 195 (100), 165 (20), 152 (20). 
HR-MS (EI) m/z calcd for C21H19NO [M+] 301.1467, found 301.1478.  
The spectral data were in accordance with those reported in the literature.155 
 
N-(4-Methoxyphenyl)-4'-methyl-[1,1'-biphenyl]-2-carboxamide  (139xa) 
 
The general procedure G was followed using 2x (114 mg, 0.5 mmol) and 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 10:1) 
yielded 139xa (115 mg, 72%) as a colorless solid. M. p.: = 152−154 °C.  
1H-NMR (400 MHz, CDCl3): δ = 7.84 (ddd, J = 7.6, 1.6, 0.5 Hz, 1H), 7.50 (td, J = 7.5, 1.5 Hz, 
1H), 7.43 (td, J = 7.5, 1.5 Hz, 1H), 7.38 (ddd, J = 7.6, 1.5, 0.5 Hz, 1H), 7.35 (d, J = 8.1 Hz, 2H), 
                                                                 
155 U. A. Shah, N. K. Wagh,.H. S. Deokar, S. S. Kadam, V. M. Kulkarni , Int. J. Pharm. Bio Sci. 2010, 1, 501–511. 
Experimental Section 
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7.22 (d, J = 8.1 Hz, 2H), 7.02 (d, J = 9.0 Hz, 2H), 6.81 (s, 1H), 6.75 (d, J = 9.0 Hz, 2H), 3.74 (s, 
3H), 2.38 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 167.0 (Cq), 156.3 (Cq), 139.4 (Cq), 137.8 (Cq), 137.0 (Cq), 
135.2 (Cq), 130.7 (Cq), 130.4 (CH), 130.2 (CH), 129.5 (CH), 129.4 (CH), 128.6 (CH), 127.5 
(CH), 121.7 (CH), 113.9 (CH), 55.5 (CH3), 21.5 (CH3). 
IR (ATR): 3250, 1650, 1506, 1239, 836, 515 cm-1.  
MS (EI) m/z (relative intensity) 317 (40) [M+], 195 (100), 165 (30), 152 (35), 122 (5).  
HR-MS (EI) m/z calcd for C21H19NO2 [M+] 317.1416, found 317.1408. 




The general procedure G was followed using 2y (108 mg, 0.5 mmol) and 4-chlorotoluene (88a) 
(76 mg, 0.6 mmol) for 16 h. Purification by column chromatography (n-hexane/EtOAc 8:1) 
yielded 139ya (134 mg, 88%) as a colorless solid. M. p.: = 160−162 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.84 (dd, J = 7.5, 1.6 Hz, 1H), 7.54–7.38 (m, 3H), 7.34 (d, J = 
8.1 Hz, 2H), 7.23 (d, J = 8.1 Hz, 2H), 7.07–7.03 (m, 2H), 6.93–6.87 (m, 3H), 2.39 (s, 3H), 2.38 
(s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 167.1 (Cq), 159.3 (Cq, JC-F = 243.0 Hz), 139.4 (Cq), 137.9 
(Cq), 136.9 (Cq), 134.9 (Cq), 133.5 (Cq, JC-F = 2.7 Hz), 130.6 (CH), 130.3 (CH), 129.6 (CH), 
129.5 (CH), 128.6 (CH), 127.6 (CH), 121.6 (CH, JC-F = 7.9 Hz), 115.4 (CH, JC-F = 22.5 Hz), 
21.2 (CH3).  
19F-NMR (CDCl3, 282 MHz): δ -117.9 – -118.0 (m).  
IR (ATR): 3026, 1650, 1505, 1212, 755, 514 cm-1.  
MS (EI) m/z (relative intensity) 305 (20) [M+], 267 (5), 239 (5), 195 (100), 165 (40), 152 (40). 
HR-MS (EI) m/z calcd for C20H16NFO [M+] 305.1216, found 305.1209.  




2-(Benzo[d][1,3]dioxol-5-yl)-N-(4-fluorophenyl)benzamide  (139zj) 
 
The general procedure G was followed using 2z (108 mg, 0.5 mmol) and 
5-chlorobenzo[d][1,3]dioxole (88j) (94 mg, 0.6 mmol) for 16 h. Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 139zj (92 mg, 55%) as a colorless solid. M. p.: 
= 123−125 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.80 (dd, J = 7.5, 1.5 Hz, 1H), 7.63–7.40 (m, 2H), 7.38 (dd, J 
= 7.5, 1.5 Hz, 1H), 7.18 (m, 2H), 7.03 (br s, 1H), 7.00–6.81 (m, 5H), 5.98 (s, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 167.2 (Cq), 159.3 (Cq, JC-F = 245.4 Hz), 148.0 (Cq), 147.5 
(Cq), 139.0 (Cq), 135.0 (Cq), 133.7 (Cq), 133.5 (Cq, JC-F = 2.8 Hz), 130.6 (CH), 130.2 (CH), 
129.2 (CH), 127.6 (CH), 122.2 (CH), 121.7 (CH, JC-F = 7.9 Hz), 115.5 (CH, JC-F = 22.6 Hz), 
109.2 (CH), 108.6 (CH), 101.3 (CH2).  
19F-NMR (376 MHz, CDCl3): δ = -117.7 – -117.8 (m).  
IR (ATR): 3235, 1646, 1505, 1223, 761, 517 cm-1.  
MS (EI) m/z (relative intensity) 335 (40) [M+], 278 (40), 248 (15), 225 (40), 195 (100), 167 
(40).  
HR-MS (EI) m/z calcd for C20H14NO3 [M+] 335.0958, found 335.0962. 
 
4'-{[(tert-Butyldimethylsilyl)oxy]methyl}-N-(4-methoxyphenyl)-[1,1'-biphenyl]-2-carbox
amide  (139xd) 
 
The general procedure G was followed using 2x (114 mg, 0.5 mmol) and 
tert-butyl{(4-chlorobenzyl)oxy}dimethylsilane (88d) (154 mg, 0.6 mmol) for 16 h (or 0.5 h). 
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Purification by column chromatography (n-hexane/EtOAc 5:1) yielded 139xd (143 mg, 64%; 
or 152 mg, 68%) as a colorless solid. M. p.: = 97−99 °C.  
1H-NMR (500 MHz, CDCl3): δ = 7.84 (ddd, J = 7.6, 1.5, 0.5 Hz, 1H), 7.50 (td, J = 7.5, 1.5 Hz, 
1H), 7.46–7.41 (m, 3H), 7.41–7.36 (m, 3H), 7.00 (d, J = 8.9 Hz, 2H), 6.80 (s, 1H), 6.74 (d, J = 
9.0 Hz, 2H), 4.76 (t, J = 0.8 Hz, 2H), 3.73 (s, 3H), 0.93 (s, 9H), 0.09 (s, 6H).  
13C-NMR (125 MHz, CDCl3): δ = 167.1 (Cq), 156.5 (Cq), 141.4 (Cq), 139.3 (Cq), 138.5 (Cq), 
135.4 (Cq), 130.6 (Cq), 130.5 (CH), 130.3 (CH), 129.5 (CH), 128.7 (CH), 127.7 (CH), 126.5 
(CH), 121.8 (CH), 114.0 (CH), 64.6 (CH2), 55.4 (CH3), 25.9 (CH3), 18.4 (Cq), -5.3 (CH3).  
IR (ATR): 3312, 2928, 1646, 1509, 1243, 1087, 823 cm-1.  
MS (EI) m/z (relative intensity) 447 (20) [M+], 390 (100), 375 (5), 316 (15), 195 (10), 165 (30). 
HR-MS (EI) m/z calcd for C27H33NO3Si [M+] 447.2230, found 447.2223. 
 
a) Intermolecular Competition Experiment between Substrates 88k and 88a:  
 
A suspension of N-methylbenzamide (2a) (68 mg, 0.5 mmol), 4-chlorotoluene (88a) (76 mg, 
0.6 mmol), 1-chloro-4-fluorobenzene (88k) (78 mg, 0.6 mmol), Co(acac)2 (6.5 mg, 5.0 
mol %), and ICyHCl (140g) (6.8 mg, 5.0 mol %) in DMPU (1.0 mL) was stirred for 5 min at 
0 °C. To this mixture, a 1.0 M solution of CyMgCl in THF (1.5 mL, 3.0 equiv) was added 
dropwise at the same temperature. The reaction mixture was stirred at 60 °C for 16 h under an 
atmosphere of Ar. At ambient temperature, aq. sat. NH4Cl solution (2.0 mL) and H2O (15 mL) 
were added, and the resulting mixture was extracted with MTBE (3 × 20 mL). The combined 
organic phases were washed with brine (20 mL) and dried over Na2SO4. Evaporation of the 
solvents in vacuo and purification of the residue by column chromatography on silica gel 





4'-Fluoro-N-methyl-[1,1'-biphenyl]-2-carboxamide  (139ak) 
 
M. p.: = 131−133 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.61 (ddd, J = 7.4, 1.6, 0.5 Hz, 1H), 7.45 (td, J = 7.4, 1.6 Hz, 
1H), 7.41–7.33 (m, 3H), 7.33–7.29 (m, 1H), 7.08 (t, J = 8.7 Hz, 2H), 5.26 (s, 1H), 2.69 (d, J = 
4.9 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 170.0 (Cq), 162.3 (Cq, JC-F = 246.9 Hz), 138.2 (Cq), 136.0 (Cq, 
JC-F = 3.4 Hz), 135.8 (Cq), 130.1 (CH, JC-F = 8.1 Hz), 130.0 (CH), 130.0 (CH), 128.5 (CH), 
127.6 (CH), 115.5 (CH, JC-F = 21.4 Hz), 26.7 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = -114.49 – -114.62 (m).  
IR (ATR): 3320, 1633, 1533, 1309, 810, 531 cm-1.  
MS (EI) m/z (relative intensity) 229 (30) [M+], 212 (5), 199 (100), 170 (55), 151 (10).  
HR-MS (EI) m/z calcd for C14H12NFO [M+] 229.0903, found 229.0906.  
 
b) Intermolecular Competition Experiment between Substrates 2c and 2s:  
 
A suspension of 4-methoxy-N-methylbenzamide (2c) (99 mg, 0.6 mmol), 
4-fluoro-N-methylbenzamide (2s) (92 mg, 0.6 mmol), 4-chlorotoluene (88a) (63 mg, 0.5 
mmol), Co(acac)2 (6.5 mg, 5.0 mol %), and ICyHCl (140g) (6.8 mg, 5.0 mol %) in DMPU 
(1.0 mL) was stirred for 5 min at 0 °C. To this mixture, a 1.0 M solution of CyMgCl in THF 
(2.2 mL, 4.4 equiv) was added dropwise at the same temperature. Then the reaction mixture 
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was stirred at 60 °C for 16 h under an atmosphere of Ar. At ambient temperature, aq. sat. 
NH4Cl solution (2.0 mL) and H2O (15 mL) were added and the reaction mixture was 
extracted with MTBE (3 × 20 mL). The combined organic phases were washed with brine (20 
mL) and dried over Na2SO4. Evaporation of the solvents in vacuo and purification of the 
residue by column chromatography on silica gel (n-hexane/EtOAc 2:1→1:1) yielded 139ca (6 
mg, 5%) and 139sa (23 mg, 19%) as colorless solids. 
 
Cobalt-Catalyzed H/D Exchange in Substrate [D5]-2a under the Standard Reaction 
Conditions: 
 
A suspension of Co(acac)2 (6.5 mg, 5.0 mol %), ICyHCl (140g) (6.8 mg, 5.0 mol %), [D5]-2a 
(70 mg, 0.5 mmol) and DMPU (1.0 mL) was stirred for 5 min at 0 °C. To this mixture, a 1.0 
M  solution of CyMgCl in THF (1.5 mL, 3.0 equiv) was added dropwise at the same 
temperature followed by 4-chlorotoluene 88a (76 mg, 1.2 equiv). Then the reaction mixture 
was stirred at 60 °C for 30 min under an atmosphere of Ar. At ambient temperature, aq. sat. 
NH4Cl solution (2.0 mL) and H2O (15 mL) were added. The reaction mixture was extracted 
with MTBE (3 × 20 mL). The combined organic phases were washed with brine (20 mL) and 
dried over Na2SO4. Evaporation of the solvents in vacuo and purification of the residue by 
column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded product [Dn]-139aa (81 
mg, 70%) and starting material [Dn]-2a (18 mg, 25%) as colorless solids. The D-incorporation 




Under the same reaction conditions, from [D5]-2a (140 mg, 1.0 mmol) and 4-chlorotoluene 
88a (63 mg, 0.5 mmol) trated with 1.0 M  solution of CyMgCl in THF (2.0 mL, 4.0 equiv) in 
the presence of Co(acac)2 (6.5 mg, 5.0 mol %) and ICyHCl (140g) (6.8 mg, 5.0 mol %) in 
DMPU (1.0 mL), product [Dn]-139aa (89 mg, 78%) and starting material [Dn]-2a (76 mg, 
54%) were obtained as colorless solids after the same workup and column chromatography on 
silica gel (n-hexane/EtOAc 2:1). The degree of deuterium incorporation in [Dn]-139aa and 
[Dn]-2a were estimated by 1H-NMR spectroscopy. 
 
KIE Determination Experiments with 2a and [D5]-2a as Substrates :  
 
Two parallel reactions with substrate 2a and deuterated substrate [D5]-2a were performed 
under the standard conditions G: In each case, a suspension of 4-chlorotoluene (88a) (151 mg, 
1.2 mmol), substrates 2a (135 mg, 1.0 mmol) or [D5]-2a (140 mg, 1.0 mmol), respectively, 
Co(acac)2 (12.9 mg, 5.0 mol %), ICyHCl (140g) (13.5 mg, 5.0 mol %) and 
1,3,5-trimethoxybenzene (168 mg, 1.0 mmol) in DMPU (2.0 mL) was stirred for 5 min at 
0 °C. To each mixture was added a 1.0 M solution of CyMgCl in THF (3.0 mL, 3.0 equiv) 
dropwise at the same temperature, and then the reaction mixtures were stirred at 23 °C for 2.0 
h. For both reactions, an aliquot (0.2 mL) was removed by syringe every 10 min. The 
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consumption of substrate 2a or [D5]-2a and the appearance of the product 139aa or 
[Dn]-139aa were monitored by GC analysis. These experiments indicated that the C–H bond 









Time/(min) 10 20 30 40 50 60 70 80 90 100 110 120 
139aa 0.02 0.1 0.26 0.4 0.56 0.62 0.63 0.66 0.69 0.69 0.71 0.74 
2a 0.98 0.9 0.74 0.6 0.44 0.38 0.37 0.34 0.31 0.31 0.29 0.26 
 
Time/(min) 10 20 30 40 50 60 70 80 90 100 110 120 
[Dn]-139aa 0.01 0.11 0.28 0.4 0.56 0.64 0.65 0.7 0.72 0.75 0.77 0.79 
[D5]-2a 0.99 0.89 0.72 0.6 0.44 0.36 0.35 0.3 0.28 0.25 0.23 0.21 
 
Synthesis of Biaryl Tetrazoles 



















































initial rate of 2a   
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To a stirred solution of compound 139vh (205 mg, 0.75 mmol) in CCl4 (10 mL) was added 
PCl5 (312 mg, 1.5 mmol) under an atmosphere of Ar. The reaction mixture was stirred at 
80 °C for 3 h. After completion of the reaction, the solvent was removed under reduced 
pressure. To the residue was added DMF (5.0 mL) at 0 °C under an atmosphere of Ar, and the 
mixture was stirred for 10 min to get a clear solution. The obtained iminoyl chloride solution 
was added dropwise to the stirred suspension of NaN3 (153 mg, 2.35 mmol) in DMF (5.0 mL) 
at 0 °C, then the mixture was stirred at 23 °C overnight. After completion of the reaction as 
was indicated by TLC monitoring, the reaction mixture was cooled to 0 °C, diluted with H2O 
(15.0 mL)115 and extracted with EtOAc (3 × 20 mL) and the combined organic phases were 
washed with brine (20 mL) and dried over Na2SO4. Evaporation of the solvents in vacuo and 
purification of the residue by column chromatography on silica gel (n-hexane/EtOAc 5:1) 
yielded product 124a (197 mg, 88%) as a colorless solid. M. p.: = 124−126 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.79 (ddd, J = 7.4, 1.6, 0.5 Hz, 1H), 7.63–7.51 (m, 2H), 
7.31 (ddd, J = 7.6, 1.5, 0.5 Hz, 1H), 7.27–7.21 (m, 1H), 7.16–7.06 (m, 3H), 7.03–6.95 (m, 
2H), 6.66–6.51 (m, 4H).  
13C-NMR (125 MHz, CDCl3): δ = 153.9 (Cq), 141.7 (Cq), 138.6 (Cq), 133.5 (Cq), 131.5 (CH), 
131.2 (CH), 130.3 (CH), 128.9 (CH), 128.9 (CH), 128.3 (CH), 128.1 (CH), 127.9 (CH), 127.1 
(CH), 123.2 (CH), 122.7 (Cq).  
IR (ATR): 1503, 1454, 1103, 760, 684, 550 cm-1.  
MS (EI) m/z (relative intensity) 298 (15) [M+], 297 (55), 269 (100), 241 (5), 178 (5), 152 (15). 




From the compound 139xa (222 mg, 0.70 mmol) in CCl4 (10 mL) was added PCl5 (292 mg, 
1.40 mmol) and NaN3 (137 mg, 2.10 mmol), product 124b (202 mg, 84%) was obtained as a 
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colorless solid after column chromatography on silica gel (n-hexane/EtOAc 4:1) applying the 
same protocol as indicated above. M. p.: = 143−145 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.74 (dd, J = 7.5, 1.6 Hz, 1H), 7.56 (td, J = 7.5, 1.6 Hz, 1H), 
7.49 (td, J = 7.5, 1.6 Hz, 1H), 7.30 (dd, J = 7.5, 1.6 Hz, 1H), 6.85 (d, J = 8.0 Hz, 2H), 6.59 (d, J 
= 9.0 Hz, 2H), 6.55–6.44 (m, 4H), 3.75 (s, 3H), 2.26 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 159.8 (Cq), 154.0 (Cq), 141.8 (Cq), 137.0 (Cq), 135.9 (Cq), 
131.3 (CH), 131.1 (CH), 130.1 (CH), 128.9 (CH), 128.0 (CH), 127.6 (CH), 126.6 (Cq), 124.7 
(CH), 122.8 (Cq), 113.9 (CH), 55.6 (CH3), 21.1 (CH3).  
IR (ATR): 2919, 1515, 1252, 1103, 831, 756 cm-1.  
MS (EI) m/z (relative intensity) 342 (10) [M+], 313 (95), 299 (100), 284 (10), 271 (10), 192 
(45).  




From the compound 139xd (224 mg, 0.50 mmol), PCl5 (312 mg, 1.50 mmol) and NaN3 (102 
mg, 1.60 mmol), product 124c (142 mg, 79%) was obtained as a colorless oil after column 
chromatography on silica gel (n-hexane/EtOAc 4:1) applying the same protocol as indicated 
above.  
1H-NMR (500 MHz, CDCl3): δ = 7.77 (dd, J = 7.6, 1.5 Hz, 1H), 7.59 (tdd, J = 7.6, 1.5, 0.4 Hz, 
1H), 7.54 (tdd, J = 7.6, 1.4, 0.4 Hz, 1H), 7.31 (dd, J = 7.6, 1.5 Hz, 1H), 7.01 (d, J = 8.2 Hz, 2H), 
6.63 (d, J = 8.2 Hz, 2H), 6.61 (d, J = 9.0 Hz, 2H), 6.51 (d, J = 9.0 Hz, 2H), 4.23 (s, 2H), 3.75 (s, 
3H).  
13C-NMR (125 MHz, CDCl3): δ = 160.0 (Cq), 153.8 (Cq), 141.1 (Cq), 139.0 (Cq), 134.6 (Cq), 
131.5 (CH), 131.4 (CH), 130.3 (CH), 128.6 (CH), 128.3 (CH), 128.2 (CH), 126.6 (Cq), 124.6 
(CH), 122.9 (Cq), 114.2 (CH), 55.6 (CH3), 54.3 (CH2).  
IR (ATR): 2099, 1512, 1250, 1025, 831, 694 cm-1.  
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MS (EI) m/z (relative intensity) 358 (20) [M+], 357 (100), 329 (20), 311 (10), 300 (10), 270 
(10).  




To a solution of compound 139ad (178 mg, 0.50 mmol) in CH2Cl2 (10 mL) was added 
phosphorous pentachloride (125 mg, 0.60 mmol) at –18 to –20 °C under an atmosphere of Ar, 
then the reaction mixture was warmed to 23 °C for 1 h. The solvent was removed under 
reduced pressure (bath temperature under 23 °C). The residue was dissolved in DCM (10 mL), 
and TMSN3 (98.0 mg, 0.85 mmol) was added dropwise to this solution at –18 to –20 °C under 
stirring. The reaction mixture was stirred at 23 °C for 18 h, the reaction was quenched by 
careful addition of aq. sat. NaHCO3 solution (15 mL).110c After extraction with DCM (3 × 20 
mL), the combined organic phases were washed with brine (20 mL) and dried over Na 2SO4. 
The solvent was evaporated in vacuo, and the residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc 1:1) to yield products 124d (87.0 mg, 65%) as 
a colorless solid. M. p.: = 143−145 °C.  
1H-NMR (500 MHz, CDCl3): δ = 7.63 (ddd, J = 7.6, 1.5, 0.5 Hz, 1H), 7.58–7.53 (m, 2H), 
7.49 (td, J = 7.5, 1.4 Hz, 1H), 7.25 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.5 Hz, 2H), 4.65 (s, 2H), 
3.21 (s, 3H), 2.53 (s, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 155.1 (Cq), 141.5 (Cq), 141.1 (Cq), 137.9 (Cq), 131.7 (CH), 
131.3 (CH), 130.3 (CH), 128.5 (CH), 127.9 (CH), 127.3 (CH), 122.2 (Cq), 64.3 (CH2), 33.5 
(CH3). 
IR (ATR): 3390, 1474, 1206, 1006, 780, 526 cm-1.  
MS (EI) m/z (relative intensity) 266 (20) [M+], 265 (100), 237 (45), 219 (10), 208 (20), 178 
(20).  







The general procedure H was followed using 123a (133 mg, 0.5 mmol) and 
4-{(4-methoxybenzyloxy)methyl}phenyl dimethylcarbamate (86a) (189 mg, 0.6 mmol). 
Purification by column chromatography (n-hexane/EtOAc 5:1) yielded 124e (107 mg, 43%) as 
a colorless oil.  
1H-NMR (500 MHz, CDCl3): δ = 7.61 (ddd, J = 7.8, 6.4, 2.3 Hz, 1H), 7.54 (ddd, J = 7.8, 1.3, 
0.7 Hz, 1H), 7.46–7.39 (m, 2H), 7.27 (ddd, J = 8.6, 8.2, 0.6 Hz, 4H), 7.17 (ddd, J = 8.3, 7.3, 1.9 
Hz, 1H), 7.12–7.08 (m, 2H), 6.88 (d, J = 8.7 Hz, 2H), 6.77 (ddd, J = 7.6, 1.9, 0.4 Hz, 1H), 6.73 
(td, J = 7.4, 1.1 Hz, 1H), 6.68–6.63 (m, 1H), 4.71 (s, 2H), 4.49 (s, 2H), 4.49 (s, 2H), 3.80 (s, 3H), 
3.48 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 159.2 (Cq), 156.7 (Cq), 154.6 (Cq), 141.5 (Cq), 138.2 (Cq), 
138.2 (Cq), 138.2 (Cq), 131.1 (CH), 131.1 (CH), 130.1 (CH), 130.0 (CH), 129.9 (CH), 129.3 
(CH), 128.6 (CH), 128.0 (CH), 127.4 (CH), 123.1 (Cq), 121.5 (Cq), 120.4 (CH), 113.8 (CH), 
110.2 (CH), 72.1 (CH2), 71.2 (CH2), 55.3 (CH3), 55.1 (CH3), 46.1 (CH2).  
IR (ATR): 2962, 1720, 1257, 1083, 1022, 795 cm-1.  
MS (EI) m/z (relative intensity) 492 (5) [M+], 356 (30), 250 (10), 235 (10), 207 (20), 121 (100). 







The general procedure H was followed using 123b (133 mg, 0.5 mmol) and 
4-{(methoxymethoxy)methyl}phenyl dimethylcarbamate (84b) (143 mg, 0.6 mmol). 
Purification by column chromatography (n-hexane/EtOAc 4:1) yielded 124f (85 mg, 41%) as a 
colorless solid. M. p.: = 98−100 °C.  
1H-NMR (500 MHz, CDCl3): δ = 7.61 (ddd, J = 7.8, 6.7, 2.0 Hz, 1H), 7.54 (ddd, J = 7.8, 1.3, 
0.6 Hz, 1H), 7.47–7.38 (m, 2H), 7.30–7.25 (m, 2H), 7.17 (ddd, J = 8.4, 7.4, 1.9 Hz, 1H), 7.10 (d, 
J = 8.4 Hz, 2H), 6.78 (ddd, J = 7.5, 1.9, 0.5 Hz, 1H), 6.74 (td, J = 7.4, 1.0 Hz, 1H), 6.69–6.64 (m, 
1H), 4.72 (s, 2H), 4.70 (s, 2H), 4.56 (s, 2H), 3.49 (s, 3H), 3.40 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 156.6 (Cq), 154.6 (Cq), 141.5 (Cq), 138.3 (Cq), 137.7 (Cq), 
131.1 (CH), 131.1 (CH), 130.1 (CH), 130.0 (CH), 129.9 (CH), 128.6 (CH), 128.1 (CH), 127.5 
(CH), 123.1 (Cq), 121.5 (Cq), 120.4 (CH), 110.2 (CH), 95.9 (CH2), 68.7 (CH2), 55.5 (CH3), 55.1 
(CH3), 46.1 (CH2).  
IR (ATR): 2950, 1728, 1496, 1249, 1040, 769 cm-1.  
MS (EI) m/z (relative intensity) 416 (20) [M+], 415 (30), 355 (10), 298 (5), 205 (30), 121 (100). 
HR-MS (ESI) m/z calcd for C24H25N4O3 [M+H+] 417.1927, found 417.1917.  
 
1-Benzyl-5-(4'-methyl-[1,1'-biphenyl]-2-yl)-1H-tetrazole  (124g) 
 
The general procedure H was followed using 123c (118 mg, 0.5 mmol) and p-tolyl 
dimethylcarbamate (84c) (107 mg, 0.6 mmol). Purification by column chromatography 
(n-hexane/EtOAc 5:1) and recrystallization (n-hexane) yielded 124g (83 mg, 51%) as a 
colorless solid. M. p.: = 109−111 °C.  
1H-NMR (300 MHz, CDCl3): δ = 7.66–7.47 (m, 2H), 7.44–7.27 (m, 2H), 7.22–7.10 (m, 3H), 




13C-NMR (125 MHz, CDCl3): δ = 154.6 (Cq), 141.5 (Cq), 137.9 (Cq), 135.8 (Cq), 133.1 (Cq), 
131.4 (CH), 131.2 (CH), 130.1 (CH), 129.6 (CH), 128.6 (CH), 128.4 (CH), 128.4 (CH), 127.7 
(CH), 127.5 (CH), 122.6 (Cq), 50.8 (CH2), 21.2 (CH3).  
IR (ATR): 1435, 1240, 1095, 839, 721, 533 cm-1.  
MS (EI) m/z (relative intensity) 326 (55) [M+], 325 (100), 297 (45), 192 (30), 178 (35), 91 (85). 
HR-MS (ESI) m/z calcd for C21H19N4 [M+H+] 327.1610, found 327.1609.  




A suspension of N,4'-dimethyl-[1,1'-biphenyl]-2-carboxamide (139aa) (113 mg, 0.5 mmol) and 
K2S2O8 (270 mg, 1.0 mmol) in H2O (5.0 mL) was stirred at 105 °C for 2.0 h. After completion 
of the reaction, at ambient temperature the reaction mixture was extracted with MTBE (3 × 20 
mL) at ambient temperature. The combined organic layers were dried over Na2SO4 and filtered. 
The solvent was concentrated in vacuo and purification by column chromatography 
(n-Hexane/EtOAc 4:1) yielded 143a (93 mg, 83%) as a colorless solid. M. p.: = 123−125 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.53 (dd, J = 8.1, 0.7 Hz, 1H), 8.22 (d, J = 8.2 Hz, 1H), 8.14 
(dd, J = 8.3, 1.1 Hz, 1H), 7.73 (ddt, J = 8.4, 7.1, 1.4 Hz, 1H), 7.55 (ddt, J = 7.3, 5.8, 1.3 Hz, 1H), 
7.29–7.17 (m, 1H), 7.13 (ddd, J = 8.1, 1.6, 0.8 Hz, 1H), 3.80 (d, J = 1.2 Hz, 3H), 2.51 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 161.6 (Cq), 139.8 (Cq), 137.9 (Cq), 133.6 (Cq), 132.2 (CH), 
128.8 (CH), 127.3 (CH), 125.1 (Cq), 123.5 (CH), 123.0 (CH), 121.3 (CH), 116.8 (Cq), 115.3 
(CH), 30.0 (CH3), 22.0 (CH3). 
IR (ATR): 1644, 1606, 1310, 1098, 769 cm-1. 
MS (EI) m/z (relative intensity) 223 (100) [M+], 208 (10), 192 (20), 178 (5), 165 (15), 152 (10). 
HR-MS (EI) m/z calcd for C15H13NO [M+] 223.0997, found 223.0994.  
The spectral data were in accordance with those reported in the literature.156 
                                                                 






Under the same conditions as above, from N-methyl-[1,1'-biphenyl]-2-carboxamide (139ah) 
(106.0 mg, 0.50 mmol) and K2S2O8 (270.0 mg, 1.00 mmol), compound 143b (6.0 mg, 64%) 
was obtained as a colorless solid after column chromatography (n-hexane/EtOAc 4:1). M. p.: = 
116−118 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.54 (dd, J = 8.1, 1.3 Hz, 1H), 8.25 (m, 2H), 7.74 (m, 1H), 
7.55 (m, 2H), 7.39 (dd, J = 8.6, 1.1 Hz, 2H), 7.30 (m, 1H), 3.80 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 161.4 (Cq), 137.9 (Cq), 133.4 (Cq), 132.2 (CH), 129.4 (CH), 
128.7 (CH), 127.8 (CH), 125.5 (Cq), 123.1 (CH), 122.3 (CH), 121.5 (CH), 119.1 (Cq), 114.9 
(CH), 30.0 (CH3). 
IR (ATR): 2918, 1639, 1599, 1300, 1088, 723 cm-1. 
MS (EI) m/z (relative intensity) 209 (100) [M+], 178 (40), 166 (5), 152 (25), 139 (10).  
HR-MS (EI) m/z calcd for C14H11NO [M+] 209.0841, found 209.0843.  
The spectral data were in accordance with those reported in the literature.157 
10.4.5 Analytical Data for the Products of Cobalt(III)-Catalyzed C−H Bond 
Cyanation of (Hetero)Arenes 
2-(Pyridin-2-yl)benzonitrile (126a) 
 
The general procedure I was followed using 28a (78 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/EtOAc 6:1) yielded 126a (81 mg, 
90%) as a slight yellow solid. M. p.: = 63−65 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.84–8.71 (m, 1H), 7.91–7.73 (m, 4H), 7.68 (dd, J = 7.5, 
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1.4 Hz, 1H), 7.49 (td, J = 7.6, 1.3 Hz, 1H), 7.34 (ddd, J = 7.2, 4.8, 1.5 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 155.1 (Cq), 149.8 (CH), 143.4 (Cq), 136.7 (CH), 134.0 
(CH), 132.7 (CH), 129.9 (CH), 128.6 (CH), 123.2 (CH), 123.1 (CH), 118.6 (Cq), 111.0 (Cq). 
IR (ATR): 3350, 2224, 1560, 1464, 758, 509 cm-1.  
MS (EI) m/z (relative intensity) 180 (100) [M+], 154 (5), 140 (5), 126 (5), 102 (5), 75 (5). 
HR-MS (EI) m/z calcd for C12H8N2 [M+] 180.0687, found 180.0684. 




The general procedure I was followed using 28b (85 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/CH2Cl2 1:1) yielded 126b (70 mg, 
72%) as a colorless solid. M. p.: = 62−63 °C. 
1H-NMR (300 MHz, CDCl3): δ = 8.76 (dd, J = 5.0, 1.4 Hz, 1H), 8.00–7.74 (m, 2H), 7.68 (d, J 
= 8.0 Hz, 1H), 7.66 (s, 1H), 7.44–7.27 (m, 2H), 2.48 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 155.2 (Cq), 149.8 (CH), 143.7 (Cq), 143.2 (Cq), 136.6 (CH), 
133.9 (CH), 130.6 (CH), 129.4 (CH), 123.2 (CH), 123.1 (CH), 118.9 (Cq), 107.9 (Cq), 21.9 
(CH3).  
IR (ATR): 3002, 2218, 1587, 1462, 791, 586 cm-1.  
MS (EI) m/z (relative intensity) 194 (100) [M+], 179 (10), 167 (30), 152 (5), 140 (10), 114 (5). 
HR-MS (EI) m/z calcd for C13H10N2 [M+] 194.0844, found 194.0849. 
The spectral data were in accordance with those reported in the literature.159 
 
2-(Pyridin-2-yl)-4-(trifluoromethyl)benzonitrile (126c) 
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The general procedure I was followed using 28c (112 mg, 0.5 mmol) and NCTS (204 mg, 
0.75 mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc 
1:1:0→1:1:0.1) yielded 126c (110 mg, 89%) as a colorless oil.  
1H-NMR (300 MHz, CDCl3):δ = 8.79 (dt, J = 4.8, 1.4 Hz, 1H), 8.14 (d, J = 1.8 Hz, 1H), 7.92 
(d, J = 8.1 Hz, 1H), 7.90–7.80 (m, 2H), 7.75 (dd, J = 8.1, 1.8 Hz, 1H), 7.40 (ddd, J = 6.8, 4.8, 
1.8 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 153.6 (Cq), 150.1 (CH), 144.2 (Cq), 137.0 (CH), 134.6 
(CH), 134.6 (Cq, JC-F = 33.0 Hz), 127.0 (CH, JC-F = 3.8 Hz), 125.3 (CH, JC-F = 3.8 Hz), 123.9 
(CH), 123.2 (CH), 123.0 (Cq, JC-F = 253.6 Hz), 117.4 (Cq), 114.3 (Cq, JC-F = 1.5 Hz).  
19F-NMR (282 MHz, CDCl3): δ = -63.43 (s). 
IR (ATR): 3056, 2232, 1568, 1335, 1128, 792 cm-1.  
MS (EI) m/z (relative intensity) 248 (100) [M+], 226 (25), 209 (10), 179 (25), 152 (10). 
HR-MS (EI) m/z calcd for C13H7N2F3 [M+] 248.0561, found 248.0551. 
The spectral data were in accordance with those reported in the literature.160 
 
Methyl 3-cyano-4-(pyridin-2-yl)benzoate (126d) 
 
The general procedure I was followed using 28d (107 mg, 0.5 mmol) and NCTS (204 mg, 
0.75 mmol). Purification by column chromatography (n-hexane/EtOAc 3:1) yielded 126d 
(117 mg, 98%) as a colorless solid. M. p.: = 106−108 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.78 (ddd, J = 4.8, 1.8, 1.1 Hz, 1H), 8.45 (dd, J = 1.8, 0.5 
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Hz, 1H), 8.30 (dd, J = 8.2, 1.8 Hz, 1H), 7.93 (dd, J = 8.2, 0.5 Hz, 1H), 7.89–7.79 (m, 2H), 
7.38 (ddd, J = 6.7, 4.8, 1.8 Hz, 1H), 3.96 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 164.8 (Cq), 154.1 (Cq), 150.0 (CH), 146.8 (Cq), 136.9 (CH), 
135.3 (CH), 133.5 (CH), 130.6 (Cq), 130.2 (CH), 123.8 (CH), 123.3 (CH), 117.8 (Cq), 111.4 
(Cq), 52.7 (CH3).  
IR (ATR): 3085, 2230, 1725, 1448, 1294, 756 cm-1.  
MS (EI) m/z (relative intensity) 238 (85) [M+], 207 (100), 179 (70), 152 (40), 125 (15), 89 
(15).  
HR-MS (EI) m/z calcd for C14H10N2O2 [M+] 238.0742, found 238.0734.  




The general procedure I was followed using 28e (98 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/EtOAc 3:1) yielded 126e  (108 mg, 
97%) as a colorless solid. M. p.: = 107−108 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.79 (ddd, J = 4.8, 1.8, 1.1 Hz, 1H), 8.35 (dd, J = 1.8, 0.6 
Hz, 1H), 8.22 (dd, J = 8.2, 1.8 Hz, 1H), 7.96 (dd, J = 8.2, 0.6 Hz, 1H), 7.90–7.78 (m, 2H), 
7.39 (ddd, J = 6.7, 4.8, 1.8 Hz, 1H), 2.66 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 195.4 (Cq), 154.0 (Cq), 150.0 (CH), 146.8 (Cq), 136.9 (CH), 
136.8 (Cq), 134.1 (CH), 132.0 (CH), 130.4 (CH), 123.9 (CH), 123.3 (CH), 117.9 (Cq), 111.6 
(Cq), 26.7 (CH3).  
IR (ATR): 3077, 2227, 1685, 1467, 1260, 786 cm-1.  
MS (EI) m/z (relative intensity) 222 (70) [M+], 207 (100), 179 (70), 152 (35), 125 (15), 78 
(15).  
HR-MS (EI) m/z calcd for C14H10N2O [M+] 222.0793, found 222.0790. 
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The general procedure I was followed using 28f (90 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:4:1:0.01) 
yielded 126f (84 mg, 82%) as a colorless solid. M. p.: = 138−140 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.13 (dd, J = 4.4, 1.8 Hz, 1H), 8.21 (dd, J = 8.1, 1.8 Hz, 
1H), 8.13 (ddd, J = 11.8, 7.7, 1.4 Hz, 2H), 7.83–7.79 (m, 2H), 7.74 (m, 1H), 7.62 (dd, J = 8.1, 
4.4 Hz, 1H).  
13C-NMR (75 MHz, CDCl3): δ = 148.4 (CH), 144.4 (Cq), 136.2 (CH), 135.7 (CH), 134.0 (Cq), 
132.7 (CH), 130.7 (Cq), 127.3 (CH), 127.2 (CH), 127.1 (CH), 126.9 (Cq), 123.0 (CH), 120.8 
(Cq), 108.9 (Cq).  
IR (ATR): 2207, 1618, 1422, 829, 714, 664 cm-1.  
MS (EI) m/z (relative intensity) 204 (100) [M+], 177 (20), 150 (10), 124 (5), 102 (5).  
HR-MS (EI) m/z calcd for C14H8N2 [M+] 204.0687, found 204.0685.  




The general procedure I was followed using 28g (87 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc 1:1:0.05) yielded 
126g (72 mg, 73%) as a colorless solid. M. p.: = 102−105 °C. 
1H-NMR (300 MHz, CDCl3): δ = 8.61 (d, J = 2.9 Hz, 1H), 7.78 (m, 3H), 7.67 (td, J = 7.7, 1.4 
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Hz, 1H), 7.58–7.42 (m, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 159.1 (Cq, JC-F = 258.5 Hz), 151.3 (Cq, JC-F = 4.3 Hz), 
142.3 (Cq), 138.3 (CH, JC-F = 24.0 Hz), 134.0 (CH), 132.8 (CH), 129.8 (CH), 128.7 (CH), 
124.1 (CH, JC-F = 4.7 Hz), 123.5 (CH, JC-F = 20.8 Hz), 118.5 (Cq), 110.9 (Cq).  
19F-NMR (282 MHz, CDCl3): δ = -126.8 (dd, J = 8.0, 4.3 Hz).  
IR (ATR): 3043, 2220, 1584, 1446, 1223, 750 cm-1.  
MS (EI) m/z (relative intensity) 198 (100) [M+], 179 (5), 171 (10), 151 (5), 128 (5), 99 (5). 




The general procedure I was followed using 28h (99 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-Hexane/CH2Cl2/EtOAc 1:1:0.05) yielded 
126h (72 mg, 65%) as a colorless solid. M. p.: = 124−125 °C.  
1H-NMR (400 MHz, CDCl3): δ = 9.29 (dd, J = 2.3, 0.9 Hz, 1H), 8.36 (dd, J = 8.2, 2.2 Hz, 
1H), 7.91–7.85 (m, 2H), 7.82 (ddd, J = 7.5, 1.4, 0.6 Hz, 1H), 7.71 (dd, J = 7.5, 1.4 Hz, 1H), 
7.55 (td, J = 7.5, 1.4 Hz, 1H), 2.67 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 196.0 (Cq), 158.6 (Cq), 149.9 (CH), 142.1 (Cq), 136.4 (CH), 
134.3 (CH), 132.8 (CH), 131.3 (Cq), 130.0 (CH), 129.5 (CH), 122.9 (CH), 118.3 (Cq), 111.2 
(Cq), 26.9 (CH3).  
IR (ATR): 2224, 1676, 1582, 1370, 1269, 761 cm-1.  
MS (EI) m/z (relative intensity) 222 (70) [M+], 207 (100), 179 (50), 152 (65), 125 (15), 102 
(10).  






The general procedure I was followed using 28i (96 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-Hexane/CH2Cl2/EtOAc 2:1:0.1) yielded 
126i (78 mg, 72%) as a slight yellow solid. M. p.: = 67–68 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.82–8.77 (m, 1H), 7.85 (td, J = 7.8, 1.7 Hz, 1H), 7.61–7.56 
(m, 2H), 7.41 (ddd, J = 7.8, 4.9, 1.2 Hz, 1H), 7.31 (td, J = 8.9, 7.4 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 153.4 (Cq, JC-F = 259.0, 13.4 Hz), 150.1 (CH), 149.3 (Cq, 
JC-F = 2.9 Hz), 148.5 (Cq, JC-F = 259.0, 13.4 Hz), 136.6 (CH), 134.1 (Cq, JC-F = 13.4 Hz), 130.5 
(CH, JC-F = 7.8, 4.7 Hz), 125.2 (CH, JC-F = 3.7 Hz), 124.2 (CH), 117.9 (CH, JC-F = 18.5 Hz), 
116.5 (Cq), 109.5 (Cq, JC-F = 3.7 Hz).  
19F-NMR (282 MHz, CDCl3): δ = -126.9 (m), -138.33 (m).  
IR (ATR): 3089, 2235, 1570, 1426, 1275, 745 cm-1.  
MS (EI) m/z (relative intensity) 216 (100) [M+], 197 (15), 189 (15), 163 (10), 136 (5), 88 (5). 
HR-MS (EI) m/z calcd for C12H6N2F2 [M+] 216.0499, found 216.0492.  
2,3,4-trifluoro-6-(pyridin-2-yl)benzonitrile (126j) 
 
The general procedure I was followed using 28j (105 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-Hexane/CH2Cl2/EtOAc 2:1:0.1) yielded 
126j (47 mg, 40%) as a slight yellow solid. M. p.: = 61–63 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.75 (ddd, J = 4.8, 1.7, 1.0 Hz, 1H), 7.92–7.82 (m, 1H), 7.78 




13C-NMR (125 MHz, CDCl3): δ = 153.6 (Cq, ddd, JC-F = 259.7, 16.5, 3.2 Hz), 153.6 (Cq, ddd, 
JC-F = 260.1, 15.8, 2.2 Hz), 152.1 (Cq), 150.1 (CH), 140.0 (Cq, dd, JC-F = 8.1, 4.3 Hz), 139.7 (Cq, 
ddd, JC-F = 257.6, 15.9, 2.1 Hz), 137.1 (CH), 124.2 (CH), 122.9 (CH), 114.2 (CH, dd, JC-F = 19.8, 
3.3 Hz), 111.8 (Cq, t, JC-F = 2.7 Hz), 98.0 (Cq, dd, JC-F = 13.3, 3.7 Hz).  
19F-NMR (282 MHz, CDCl3): δ = -122.84 – -123.12 (m), -124.79 (ddd, J = 20.0, 11.8, 2.2 Hz), 
-156.60 (ddd, J = 21.3, 19.9, 6.9 Hz).  
IR (ATR): 3068, 2235, 1520, 1397, 1072, 789 cm-1.  
MS (EI) m/z (relative intensity) 234 (100) [M+], 215 (25), 207 (20), 181 (15), 157 (5).  




The general procedure I was followed using 28k (106 mg, 0.5 mmol) and NCTS (204 mg, 
0.75 mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc 
1:1:0→1:1:0.1) yielded 126k (79 mg, 67%) as a colorless solid. M. p.: = 68−71 °C.  
1H-NMR (400 MHz, CDCl3): δ = 8.74 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.83–7.73 (m, 4H), 
7.68 (dd, J = 8.3, 2.1 Hz, 1H), 7.31 (ddd, J = 7.3, 4.8, 1.4 Hz, 1H), 1.34 (s, 9H).  
13C-NMR (100 MHz, CDCl3): δ = 155.2 (Cq), 152.3 (Cq), 149.9 (CH), 140.6 (Cq), 136.7 (CH), 
131.1 (CH), 130.2 (CH), 129.7 (CH), 123.0 (CH), 123.0 (CH), 119.2 (Cq), 110.6 (Cq), 34.8 
(Cq), 31.0 (CH3).  
IR (ATR): 2964, 2223, 1602, 1461, 897, 789 cm-1.  
MS (EI) m/z (relative intensity) 236 (30) [M+], 221 (100), 205 (10), 193 (25), 166 (5), 152 (5). 
HR-MS (EI) m/z calcd for C16H16N2 [M+] 236.1313, found 236.1314.  
The spectral data were in accordance with those reported in the literature.161 
 
                                                                 





The general procedure I was followed using 28l (100 mg, 0.5 mmol) and NCTS (204 mg, 
0.75 mmol). Purification by column chromatography (n-hexane/EtOAc 5:1) yielded 126l (88 
mg, 79%) as a colorless solid. M. p.: = 109−111 °C. 
1H-NMR (400 MHz, CDCl3): δ = 8.55 (dd, J = 5.1, 1.0 Hz, 1H), 7.72 (dd, J = 8.7, 1.0 Hz, 
1H), 7.51 (dt, J = 1.7, 0.8 Hz, 1H), 7.22 (d, J = 2.7 Hz, 1H), 7.16 (dd, J = 8.7, 2.7 Hz, 1H), 
7.09 (ddd, J = 5.1, 1.5, 0.8 Hz, 1H), 3.84 (s, 3H), 2.40 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 159.3 (Cq), 154.8 (Cq), 149.5 (CH), 147.8 (Cq), 136.2 (Cq), 
131.2 (CH), 123.7 (CH), 123.7 (CH), 119.3 (CH), 118.6 (Cq), 118.3 (CH), 111.7 (Cq), 55.7 
(CH3), 21.1 (CH3).  
IR (ATR): 2925, 2225, 1608, 1466, 1276, 820 cm-1.  
MS (EI) m/z (relative intensity) 224 (100) [M+], 209 (25), 194 (10), 181 (60), 166 (20), 154 
(25).  




The general procedure I was followed using 28m (87 mg, 0.5 mmol) and NCTS (204 mg, 
0.75 mmol). Purification by column chromatography (n-hexane/EtOAc 5:1) yielded 126m (60 
mg, 60%) as a colorless solid. M. p.: = 170−171 °C. 
1H-NMR (300 MHz, CDCl3): δ = 8.90 (d, J = 4.9 Hz, 2H), 8.42 (dd, J = 8.9, 5.6 Hz, 1H), 
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7.54 (dd, J = 8.1, 2.7 Hz, 1H), 7.46–7.36 (m, 1H), 7.32 (t, J = 4.9 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 162.9 (Cq, JC-F = 253.4 Hz), 161.8 (Cq), 157.2 (Cq), 136.5 
(CH, JC-F = 3.7 Hz), 132.7 (CH, JC-F = 8.7 Hz), 121.8 (CH, JC-F = 24.8 Hz), 120.0 (CH, JC-F = 
10.5 Hz), 120.0 (CH), 117.6 (Cq, JC-F = 2.7 Hz), 113.5 (Cq, JC-F = 9.4 Hz).  
19F-NMR (282 MHz, CDCl3): δ = -108.8 (td, J = 7.9, 5.5 Hz).  
IR (ATR): 3062, 2231, 1560, 1415, 1227, 810 cm-1.  
MS (EI) m/z (relative intensity) 119 (100) [M+], 172 (15), 146 (90), 119 (25), 100 (10), 75 
(10).  
HR-MS (EI) m/z calcd for C11H6N3F [M+] 199.0546, found 199.0538.  




The general procedure I was followed using 28n (93 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/EtOAc 6:1→4:1) yielded 126n (95 
mg, 90%) as a colorless solid. M. p.: = 127−129 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.84 (d, J = 4.8 Hz, 2H), 8.32 (d, J = 8.9 Hz, 1H), 7.30 (d, J 
= 2.7 Hz, 1H), 7.25–7.22 (m, 1H), 7.19 (dd, J = 8.9, 2.7 Hz, 1H), 3.88 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 162.4 (Cq), 160.6 (Cq), 157.1 (CH), 132.6 (Cq), 131.9 (CH), 
119.7 (CH), 119.4 (CH), 118.8 (Cq), 118.7 (CH), 112.9 (Cq), 55.8 (CH3).  
IR (ATR): 3082, 2222, 1552, 1404, 1288, 803 cm-1.  
MS (EI) m/z (relative intensity) 211 (100) [M+], 196 (15), 168 (10), 158 (40), 128 (10), 115 
(10).  
HR-MS (EI) m/z calcd for C12H9N3O [M+] 211.0746, found 211.0752. 
The spectral data were in accordance with those reported in the literature.162 
                                                                 






The general procedure I was followed using 128a (72 mg, 0.5 mmol) and NCTS (204 mg, 
0.75 mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 
20:7:1:0.01) yielded 126o (83 mg, 98%) as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.13 (d, J = 2.6 Hz, 1H), 7.77 (m, 3H), 7.68 (td, J = 7.6, 1.8 
Hz, 1H), 7.40 (td, J = 7.6, 1.2 Hz, 1H), 6.53 (dd, J = 2.6, 1.8 Hz, 1H).  
13C-NMR (75 MHz, CDCl3): δ = 142.2 (CH), 142.0 (Cq), 134.4 (CH), 134.0 (CH), 129.5 
(CH), 127.2 (CH), 124.3 (CH), 117.0 (Cq), 108.5 (CH), 105.3 (Cq).  
IR (ATR): 3124, 2161, 1700, 1392, 933, 749 cm-1.  
MS (EI) m/z (relative intensity) 169 (100) [M+], 142 (55), 129 (15), 115 (25), 102 (30), 75 
(20).  
HR-MS (EI) m/z calcd for C10H7N3 [M+] 169.0640, found 169.0644.  




The general procedure I was followed using 7a (98 mg, 0.5 mmol) and NCTS (204 mg, 
0.75 mmol). Purification by column chromatography (n-hexane/CH2Cl2 3:2) yielded 127a 
(109 mg, 99%) as a colorless solid. M. p.: = 125−127 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.82 (d, J = 4.8 Hz, 2H), 8.68 (dq, J = 8.6, 0.9 Hz, 1H), 
7.67 (ddd, J = 8.0, 1.3, 0.8 Hz, 1H), 7.49 (ddd, J = 8.5, 7.1, 1.3 Hz, 1H), 7.46 (d, J = 0.8 Hz, 
1H), 7.31 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 7.22 (t, J = 4.8 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 158.2 (CH), 156.4 (Cq), 136.5 (Cq), 127.7 (Cq), 127.4 (CH), 
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123.4 (CH), 121.9 (CH), 120.9 (CH), 117.9 (CH), 116.1 (CH), 114.1 (Cq), 108.9 (Cq).  
IR (ATR): 3100, 2225, 1565, 1423, 1333, 738 cm-1.  
MS (EI) m/z (relative intensity) 220 (100) [M+], 194 (15), 169 (25), 141 (15), 114 (25), 79 
(30).  
HR-MS (ESI) m/z calcd for C13H9N4 [M+H+] 221.0827, found 221.0825.  




The general procedure I was followed using 7b (113 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc 2:1:0.01) yielded 
127b (118 mg, 94%) as a colorless solid. M. p.: = 185−187 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.79 (d, J = 4.8 Hz, 2H), 8.59 (dt, J = 9.3, 0.7 Hz, 1H), 7.36 
(d, J = 0.8 Hz, 1H), 7.19 (t, J = 4.8 Hz, 1H), 7.11 (dd, J = 9.3, 2.6 Hz, 1H), 7.07–7.00 (m, 1H), 
3.86 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 158.1 (CH), 156.4 (Cq), 156.2 (Cq), 131.5 (Cq), 128.4 (Cq), 
120.4 (CH), 117.8 (CH), 117.7 (CH), 117.2 (CH), 114.2 (Cq), 109.0 (Cq), 102.5 (CH), 55.7 
(CH3).  
IR (ATR): 2985, 2219, 1568, 1437, 1211, 805 cm-1.  
MS (EI) m/z (relative intensity) 250 (100) [M+], 235 (80), 207 (75), 180 (15), 154 (5), 79 (40). 
HR-MS (EI) m/z calcd for C14H10N4O [M+] 250.0855, found 250.0850. 






The general procedure I was followed using 7c (137 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:4:1:0.01) 
yielded 127c (140 mg, 94%) as a colorless solid. M. p.: = 234−236 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.80 (d, J = 4.8 Hz, 2H), 8.56 (dt, J = 9.1, 0.7 Hz, 1H), 7.78 
(dd, J = 2.0, 0.7 Hz, 1H), 7.53 (dd, J = 9.1, 2.0 Hz, 1H), 7.35 (d, J = 0.7 Hz, 1H), 7.22 (t, J = 
4.8 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 158.4 (CH), 156.3 (Cq), 135.1 (Cq), 130.4 (CH), 129.3 (Cq), 
124.4 (CH), 119.7 (CH), 118.3 (CH), 117.8 (CH), 116.8 (Cq), 113.6 (Cq), 110.0 (Cq).  
IR (ATR): 3140, 2216, 1576, 1441, 1253, 801 cm-1.  
MS (EI) m/z (relative intensity) 298 (100) [M+], 273 (5), 247 (10), 219 (30), 166 (10), 140 
(30).  
HR-MS (EI) m/z calcd for C13H7N479Br [M+] 297.9854, found 297.9860.  




The general procedure I was followed using 7e (126 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/EtOAc 1:1) yielded 127e (98 mg, 
71%) as an off white solid. M. p.: = 284−286 °C.  
1H-NMR (300 MHz, DMSO-d6): δ= 10.04 (s, 1H), 8.95 (dd, J = 4.9, 0.7 Hz, 2H), 8.64–8.40 
(m, 1H), 8.20 (d, J = 2.2 Hz, 1H), 7.81 (s, 1H), 7.55 (dd, J = 9.2, 2.1 Hz, 1H), 7.49 (td, J = 4.9, 
0.7 Hz, 1H), 2.08 (s, 3H).  
13C-NMR (125 MHz, DMSO-d6): δ = 168.0 (Cq), 158.7 (CH), 155.3 (Cq), 135.0 (Cq), 132.0 
(Cq), 127.4 (Cq), 120.9 (CH), 120.1 (CH), 118.6 (CH), 115.7 (CH), 113.6 (Cq), 110.9 (CH), 
108.1 (Cq), 23.9 (CH3).  
IR (ATR): 3216, 2215, 1659, 1424, 1260, 809 cm-1.  
MS (EI) m/z (relative intensity) 277 (45) [M+], 235 (100), 207 (10), 183 (5), 156 (10), 129 (5). 
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The general procedure I was followed using 7f (112 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/CH2Cl2 2:1) yielded 127f (87 mg, 
70%) as a slight yellow oil.  
1H-NMR (500 MHz, CDCl3): δ = 8.89 (d, J = 4.8 Hz, 2H), 7.54 (d, J = 1.4 Hz, 1H), 7.41 (s, 
1H), 7.39 (t, J = 4.9 Hz, 1H), 7.30–7.27 (m, 1H), 7.26–7.22 (t, J = 7.5 Hz, 1H), 2.53 (q, J = 
7.5 Hz, 2H), 0.95 (t, J = 7.5 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 158.6 (CH), 156.8 (Cq), 135.7 (Cq), 129.6 (Cq), 128.0 (Cq), 
127.5 (CH), 123.2 (CH), 120.1 (CH), 120.0 (CH), 118.5 (CH), 113.4 (Cq), 111.2 (Cq), 26.3 
(CH2), 13.6 (CH3). 
IR (ATR): 2969, 2223, 1561, 1411, 1267, 743 cm-1.  
MS (EI) m/z (relative intensity) 248 (100) [M+], 233 (100), 220 (10), 206 (5), 179 (15), 155 
(25).  




The general procedure I was followed using 7g (119 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/CH2Cl2 1:1) yielded 127g (125 mg, 
95%) as a colorless solid. M. p.: = 170−172 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.80 (d, J = 4.8 Hz, 2H), 8.24–8.09 (m, 1H), 7.59 (t, J = 0.6 
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Hz, 1H), 7.37 (dd, J = 8.6, 7.9 Hz, 1H), 7.20 (t, J = 4.8 Hz, 1H), 6.65 (d, J = 7.9 Hz, 1H), 4.18 
(d, J = 7.0 Hz, 2H), 1.49 (t, J = 7.0 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 158.1 (CH), 156.5 (Cq), 152.7 (Cq), 137.7 (Cq), 128.6 (CH), 
119.1 (Cq), 118.6 (CH), 117.8 (CH), 114.3 (Cq), 108.5 (CH), 107.2 (Cq), 103.6 (CH), 63.8 
(CH2), 14.8 (CH3).  
IR (ATR): 2977, 2221, 1567, 1431, 1348, 769 cm-1.  
MS (EI) m/z (relative intensity) 264 (60) [M+], 236 (100), 210 (10), 207 (35), 180 (10), 79 
(30).  




The general procedure I was followed using 7h (105 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:4:1:0.01) 
yielded 127h (108 mg, 92%) as a colorless solid. M. p.: = 167−169 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.78 (d, J = 4.8 Hz, 2H), 8.69 (dt, J = 8.5, 1.0 Hz, 1H), 7.63 
(ddd, J = 8.0, 1.3, 0.7 Hz, 1H), 7.49 (ddd, J = 8.5, 7.2, 1.3 Hz, 1H), 7.32 (ddd, J = 8.0, 7.2, 1.0 
Hz, 1H), 7.16 (t, J = 4.8 Hz, 1H), 2.57 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 158.1 (CH), 156.5 (Cq), 136.4 (Cq), 131.5 (Cq), 128.6 (Cq), 
127.6 (CH), 123.0 (CH), 120.1 (CH), 117.3 (CH), 116.2 (CH), 113.9 (Cq), 107.2 (Cq), 10.0 
(CH3).  
IR (ATR): 3049, 2215, 1567, 1424, 812, 731 cm-1.  
MS (EI) m/z (relative intensity) 234 (100) [M+], 219 (5), 206 (10), 180 (10), 155 (40), 128 
(15).  
HR-MS (ESI) m/z calcd for C14H11N4 [M+H+] 235.0984, found 235.0978. 
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The general procedure I was followed using 7i (107 mg, 0.5 mmol), NCTS (204 mg, 0.75 
mmol), Cp*CoI2(CO) (112, 12.0 mg, 5.0 mol %), AgSbF6 (17.2 mg, 10.0 mol %) and KOAc 
(5.0 mg, 10 mol %). Purification by column chromatography (n-hexane/EtOAc 1:1) yielded 
127i (108 mg, 91%) as a yellow solid. M. p.: = 238−241 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.83 (d, J = 4.8 Hz, 1H), 7.38 (s, 1H), 7.36 (t, J = 4.8 Hz, 1H), 
3.25 (t, J = 6.2 Hz, 2H), 2.60–2.52 (m, 2H), 2.24–2.12 (m, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 193.3 (Cq), 158.6 (CH), 155.2 (Cq), 147.9 (Cq), 122.8 (Cq), 
120.9 (CH), 119.9 (CH), 113.1 (Cq), 105.5 (Cq), 37.7 (CH2), 25.4 (CH2), 23.3 (CH2).  
IR (ATR): 2963, 2217, 1677, 1577, 1410, 825 cm-1.  
MS (EI) m/z (relative intensity) 238 (80) [M+], 223 (5), 210 (15), 196 (10), 182 (100), 155 (5). 




The general procedure I was followed using 144 (73 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/EtOAc 7:1) yielded 145 (83 mg, 
98%) as a colorless solid. M. p.: = 120−122 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.71 (d, J = 4.8 Hz, 2H), 7.96 (dd, J = 3.2, 1.7 Hz, 1H), 
7.20 (t, J = 4.8 Hz, 1H), 7.05 (dd, J = 3.7, 1.7 Hz, 1H), 6.35 (dd, J = 3.7, 3.2 Hz, 1H).  
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13C-NMR (125 MHz, CDCl3): δ = 158.4 (CH), 155.0 (Cq), 126.0 (CH), 124.9 (CH), 118.8 
(CH), 114.0 (Cq), 111.7 (CH), 102.8 (Cq).  
IR (ATR): 3165, 2219, 1564, 1429, 1177, 742 cm-1. 
MS (EI) m/z (relative intensity) 170 (100) [M+], 144 (10), 118 (10), 91 (5), 79 (40), 52 (20). 
HR-MS (EI) m/z calcd for C9H6N4 [M+] 170.0592, found 170.0589. 




The general procedure I was followed using 146 (81 mg, 0.5 mmol) and NCTS (204 mg, 0.75 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 
2:1:0:0→8:4:1:0.01) yielded 147 (72 mg, 77%) and 147' (22 mg, 21%) as slight yellow solids.  
147: M. p.: = 43–45 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.70 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.02–7.88 (m, 1H), 
7.79 (ddd, J = 8.0, 7.5, 1.8 Hz, 1H), 7.66 (d, J = 5.2 Hz, 1H), 7.59 (d, J = 5.2 Hz, 1H), 7.30 
(ddd, J = 7.5, 4.8, 0.9 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 150.8 (Cq), 149.9 (CH), 149.8 (Cq), 136.9 (CH), 131.6 
(CH), 128.2 (CH), 123.5 (CH), 121.8 (CH), 114.6 (Cq), 106.2 (Cq).  
IR (ATR): 3101, 2210, 1582, 1430, 894, 735 cm-1.  
MS (EI) m/z (relative intensity) 186 (100) [M+], 159 (30), 142 (20), 129 (5), 114 (10), 78 (10). 




M. p.: = 153–155 °C.  
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1H-NMR (300 MHz, CDCl3): δ = 8.85–8.78 (m, 1H), 8.21 (s, 1H), 7.95–7.84 (m, 2H), 7.43 
(ddd, J = 6.4, 4.8, 2.4 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 150.2 (CH), 150.0 (Cq), 148.2 (Cq), 140.8 (CH), 137.2 (CH), 
124.8 (CH), 122.9 (CH), 113.4 (Cq), 112.5 (Cq), 112.2 (Cq), 109.4 (Cq).  
IR (ATR): 3088, 2218, 1586, 1465, 993, 744 cm-1.  
MS (EI) m/z (relative intensity) 211 (100) [M+], 184 (65), 167 (10), 158 (15), 139 (5), 78 (10). 




A mixture of 127a (242 mg, 1.10 mmol), NaOEt (300 mg, 4.40 mmol) and DMSO (6.0 mL) 
was stirred at 110 °C under an Ar atmosphere for 24 h. At ambient temperature, the reaction 
mixture was diluted with EtOAc (30 mL) and washed with brine (30 mL). The aqueous phase 
was extracted with EtOAc (2 × 30 mL), and the combined organic phase was dried over 
Na2SO4. After filtration and evaporation of the solvents in vacuo, the crude product was 
purified by column chromatography on silica gel (n-hexane/EtOAc 10:1) to yield 127j (153 
mg, 98%) as a colorless solid. M. p.: 97–98 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.64 (br s, 1H), 7.66 (dd, J = 8.1, 0.9 Hz, 1H), 7.46–7.32 
(m, 2H), 7.23–7.18 (m, 2H).  
13C-NMR (125 MHz, CDCl3): δ = 136.7 (Cq), 126.2 (CH), 126.1 (Cq), 122.0 (CH), 121.7 
(CH), 114.4 (CH), 114.1 (Cq), 111.6 (CH), 106.2 (Cq). IR (ATR): 3273, 2235, 1521, 1409, 
1224, 806, 732, 652 cm-1.  
MS (EI) m/z (relative intensity) 142 (100) [M+], 115 (40), 98 (5), 89 (10), 74 (5), 63 (10). 
HR-MS (EI) m/z calcd for C9H6N2 [M+] 142.0531, found 142.0528. 
The spectral data were in accordance with those reported in the literature.161 
 




A suspension of NCTS (125) (136 mg, 0.50 mmol), 2-(m-tolyl)pyridine (28b) (127 mg, 0.75 
mmol), 2-{3-(trifluoromethyl)phenyl}pyridine (28c) (167 mg, 0.75 mmol), Cp*CoI2(CO) 
(112, 6.0 mg, 2.5 mol %), AgSbF6 (8.6 mg, 5.0 mol %) and KOAc (2.5 mg, 5.0 mol %) in 
DCE (2.0 mL) was stirred at 120 °C for 8 h under an atmosphere of Ar. At ambient 
temperature, the reaction mixture was evaporated in vacuo and the residue was purified by 
column chromatography on silica gel (n-hexane/CH2Cl2/EtOAc 1:1:0.1) to yield 126b (35 mg, 
36%) and 126c (36 mg, 29%). 
 
Hammett plot of Reactions of 2-(4-R-Phenyl)pyridines 28 with NCTS (125): 
To an oven-dried 25 mL screw-capped vials, respective 2-(4-R-phenyl)pyridines (0.25 mmol), 
NCTS (125, 102 mg, 0.38 mmol), Cp*CoI2(CO) (112, 3.0 mg, 2.5 mol %), AgSbF6 (4.3 mg, 
5.0 mol %) and KOAc (1.3 mg, 5.0 mol %) and DCE (1.0 mL) were added under a gentle 
stream of Ar. The reaction mixtures were stirred for 2 h at 120 °C. After the reaction was 
finished, the screw-capped vials were cooled with an ice bath. The mixtures were filtered 
through a pad of Celite each and concentrated in vacuo. The residues were analyzed by 
1H-NMR spectroscopy. Conversions of starting materials were determined using 
dibromomethane (43.5 mg, 0.25 mmol) as an internal standard. 




 P SM NMR Conv.  σm- Log(conv. X/conv. H) 
R = tBu 13% 85% 15% –0.1 –0.2863  
R = Me 17% 81% 19% –0.07 –0.1836  
R = H 29% 71% 29% 0 0  
R = OMe 25% 74% 26% 0.12 –0.0474 
R = F 44% 53% 47% 0.34 0.2097 
R = CO2Me 29% 69% 31% 0.37 0.0290 
R = COMe 29% 70% 30% 0.38 0.0147 
 
 
Cobalt-Catalyzed H/D Exchange in Substrate 28a with CD3OD as the Cosolvent without 
NCTS: 
 
A suspension of 2-phenylpyridine (28a) (78 mg, 0.50 mmol), Cp*CoI2(CO) (112, 6.0 mg, 2.5 
mol %), AgSbF6 (8.6 mg, 5.0 mol %) and KOAc (2.5 mg, 5.0 mol %) in a solvent mixture of 
DCE and CD3OD (0.9/0.1 mL) was stirred at 120 °C for 16 h under an atmosphere of Ar. At 
ambient temperature, the reaction mixture was evaporated in vacuo and the residue was 
purified by column chromatography on silica gel (n-hexane/EtOAc) to yield [Dn]-28a (72 mg, 
92%) as a slightly yellow oil. The D-incorporation in [Dn]-28a was estimated by 1H-NMR 
spectroscopy. 
 








y = 0.9754x - 0.1181 
R² = 0.8523 
y = -5.14x + 1.952 

























Two parallel reactions with 28a and deuterated substrate [D5]-28a under the standard 
conditions were performed: A suspensions of NCTS (125) (102 mg, 0.38 mmol), substrates 
28a (39.0 mg, 0.25 mmol) or [D5]-28a (40.0 mg, 0.25 mmol), Cp*CoI2(CO) (112, 3.0 mg, 2.5 
mol %), AgSbF6 (4.3 mg, 5.0 mol %) and KOAc (1.3 mg, 5.0 mol %) in DCE (1.0 mL) was 
stirred at 120 °C under an atmosphere of Ar. The consumption of substrates V-1a or [D5]-28a 
and the appearance of the products 126a or [Dn]-126a were monitored by GC analysis (with 
0.25 mmol dodecane as an internal standard) after 0.5 h, 1.0 h, 1.5 h, 2.0 h, 2.5 h, 3.0 h, 3.5 h, 
4.0 h, 5.0 h, respectively. The consumption of substrate 28a or [D5]-28a and the appearance of 
the products 126a or [Dn]-126a were monitored by GC analysis (with 0.25 mmol dodecane as 
an internal standard).  
 
t/(h) 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 
126a 0.13 0.29 0.39 0.43 0.48 0.50 0.53 0.55 0.58 
28a 0.84 0.69 0.56 0.52 0.50 0.45 0.47 0.43 0.42 
 
t/(h) 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5.0 
[Dn]-126a 0.13 0.30 0.35 0.37 0.46 0.48 0.50 0.54 0.55 
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initial rate of 28a   



















initial rate of [D5]-28a 








Intramolecular competition experiment: Kinetic isotope effect (KIE):  
 
A suspension of NCTS (125) (136 mg, 0.50 mmol), 2-[D]-phenylpyridine ([D1]-28a) (156 mg, 
1.0 mmol), Cp*CoI2(CO) (112, 6.0 mg, 2.5 mol %), AgSbF6 (8.6 mg, 5.0 mol %) and KOAc 
(2.5 mg, 5.0 mol %) in DCE (2.0 mL) was stirred at 120 °C for 100 min under an atmosphere 
of Ar. At ambient temperature, the reaction mixture was evaporated in vacuo and the residue 
was purified by column chromatography on silica gel (n-hexane/EtOAc 6:1) to yield 
[Dn]-126a' (16 mg, 18%) as a solid. The D-incorporation in [Dn]-126a' was estimated by 
1H-NMR spectroscopy. 
 
2-(Pyridin-2-yl)benzoic acid (152) 
 
A suspension of 2-(pyridin-2-yl)benzonitrile (126a) (90 mg, 0.5 mmol), which was prepared 
according to the general procedure I as indicated above, and KOH (180 mg, 5.0 mmol, 1.25 
mL of a 4 N aq. solution) was stirred at 105 °C for 12 h. After completion of the reaction, the 
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reaction mixture was neutralized by HCl aq. (2 N, 2.8 mL). Then the reaction was extracted 
with CH2Cl2 (200 mL). The combined organic layers were dried over Na2SO4 and filtered. 
The solvent was concentrated in vacuo and the solid was washed with Et2O (3 × 10 mL) to 
afford product 152 (92 mg, 83%, calculated from 28a) as a colorless solid. M. p. : = 
201–204 °C .  
1H-NMR (500 MHz, CD3OD): δ = 8.53 (ddd, J = 5.1, 1.8, 1.0 Hz, 1H), 7.92 (ddd, J = 7.7, 1.4, 
0.5 Hz, 1H), 7.88 (td, J = 7.7, 1.8 Hz, 1H), 7.62 (td, J = 7.5, 1.4 Hz, 1H), 7.57–7.51 (m, 2H), 
7.50 (ddd, J = 7.6, 1.4, 0.5 Hz, 1H), 7.39 (ddd, J = 7.6, 5.0, 1.1 Hz, 1H).  
13C-NMR (125 MHz, CD3OD): δ = 171.2 (Cq), 160.3 (Cq), 149.1 (CH), 142.0 (Cq), 138.5 (Cq), 
133.1 (CH), 132.4 (CH), 131.3 (CH), 131.2 (CH), 129.7 (CH), 125.2 (CH), 123.7 (CH).  
IR (ATR): 2405, 1715, 1429, 1255, 1004, 797 cm-1.  
MS (EI) m/z (relative intensity) 199 (5) [M+], 182 (10), 155 (100), 127 (20), 115 (5), 102 (5). 
HR-MS (ESI) m/z calcd for C12H8NO2 [M-H+] 198.0555, found 198.0555. 




To a solution of 1-(pyrimidin-2-yl)-1H-indole-2-carbonitrile (127a) (66 mg, 0.3 mmol) in 
tBuOH (5.0 mL) was added KOH (336 mg, 6.0 mmol) in small portions. The reaction mixture 
was stirred at 60 °C for 4 h. Then the reaction was cooled to ambient temperature and 
extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over Na 2SO4, 
filtered, concentrated in vacuo and purified by column chromatography (n-hexane/EtOAc 
1:1→1:2) yielded 153 (52 mg, 72%, calculated from 7a) as a colorless solid. M. p.: = 
254−256 °C.  
1H-NMR (500 MHz, CDCl3): δ = 9.37 (br s, 1H), 8.70 (br s, 1H), 8.68 (d, J = 4.8 Hz, 2H), 
7.69 (dd, J = 8.1, 1.0 Hz, 1H), 7.46 (dd, J = 8.3, 1.1 Hz, 1H), 7.33 (ddd, J = 8.3, 7.0, 1.1 Hz, 
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1H), 7.17 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.12 (dd, J = 2.2, 0.9 Hz, 1H), 7.06 (t, J = 4.8 Hz, 
1H).  
13C-NMR (125 MHz, CDCl3): δ = 158.4 (CH), 158.4 (Cq), 157.3 (Cq), 136.9 (Cq), 130.1 (Cq), 
127.5 (Cq), 125.5 (CH), 122.4 (CH), 121.0 (CH), 116.8 (CH), 112.0 (CH), 104.2 (CH).  
IR (ATR): 3388, 3238, 1688, 1573, 1428, 739 cm-1.  
MS (EI) m/z (relative intensity) 238 (90) [M+], 210 (40), 143 (100), 115 (50), 89 (60). 




To the mixture of 1-methyl-1H-indole-2-carbonitrile (31.0 mg, 0.20 mmol), prepared from 
1H-indole-2-carbonitrile (127j) according to previously described methods in 99% yield, and 
CuI (1.0 mg, 5.2 μmol) in anhydrous THF (5 mL) was added EtMgBr (0.21 mmol, 70 μL of a 
3 N solution in THF), and the reaction mixture was stirred at ambient temperature for 10 h. 
Then 1 N HCl aq. solution (3.0 mL) was added at 0 °C, and the resulting mixture was stirred 
at room temperature for another 4 h. The organic layer was separated, and the aqueous layer 
was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified 
by column chromatography (n-hexane/EtOAc 20:1) yielded 154 (20 mg, 52%, calculated 
from 7a) as a slightly yellow solid. M. p.: = 55−57 °C.  
1H-NMR (500 MHz, CDCl3): δ = 7.71–7.65 (d, J = 8.0 Hz, 1H), 7.40–7.33 (m, 2H), 7.28 (d, J 
= 0.7 Hz, 1H), 7.14 (ddd, J = 8.0, 5.6, 2.2 Hz, 1H), 4.07 (s, 3H), 3.00 (q, J = 7.4 Hz, 2H), 1.23 
(t, J = 7.4 Hz, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 194.9 (Cq), 139.9 (Cq), 134.6 (Cq), 125.7 (Cq), 125.6 (CH), 
122.7 (CH), 120.6 (CH), 110.8 (CH), 110.3 (CH), 33.1 (CH2), 32.2 (CH3), 9.0 (CH3).  
IR (ATR): 2951, 1663, 1511, 1315, 1155, 731 cm-1.  
MS (EI) m/z (relative intensity) 187 (50) [M+], 158 (100), 144 (5), 130 (25), 115 (5), 89 (50). 
HR-MS (EI) m/z calcd for C12H13NO [M+] 187.0997, found 187.0995.  
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To the vial equipped with a magnetic bar, TBAF·3H2O (32 mg, 0.1 mmol), 
1H-indole-2-carbonitrile (29 mg, 0.2 mmol) and TMSN3 (34.5 mg, 0.3 mmol) were added. The 
vial was sealed and heated under vigorous stirring at 120 °C for 18 h. The crude reaction 
mixture was diluted with EtOAc (20 mL) and TBAF was removed by washing the organic 
phase with 1 N aq. HCl aqueous solution (3 × 5 mL). The organic layer was dried over Na2SO4 
and concentrated under reduced pressure. The crude solid was washed with a 2:1 
n-hexane/Et2O mixture (2 × 10 mL) to afford 155 (36 mg, 94%, calculated from 7a) as a 
colorless solid. M. p.: = 232−234 °C. 
1H-NMR (500 MHz, CD3OD): δ = 7.63 (dt, J = 8.0, 1.0 Hz, 1H), 7.49 (dd, J = 8.3, 0.9 Hz, 
1H), 7.23 (ddd, J = 8.3, 7.0, 1.0 Hz, 1H), 7.12 (d, J = 0.9 Hz, 1H), 7.09 (ddd, J = 8.0, 7.0, 1.0 
Hz, 1H).  
13C-NMR (125 MHz, CD3OD): δ = 152.3 (Cq), 139.1 (Cq), 129.4 (Cq), 125.1 (CH), 122.9 (Cq), 
122.3 (CH), 121.5 (CH), 113.0 (CH), 105.1 (CH).  
IR (ATR): 3226, 1618, 1339, 1084, 924, 744 cm-1.  
MS (EI) m/z (relative intensity) 185 (70) [M+], 157 (100), 142 (35), 130 (40), 115 (20), 103 
(70).  
HR-MS (EI) m/z calcd for C9H7N5 [M+] 185.0701, found 185.0705. 
The spectral data were in accordance with those reported in the literature.161 
10.4.6 Analytical Data for the Products of Cobalt(III)-Catalyzed Aryl and 
Alkenyl C−H Bond Aminocarbonylation with Isocyanates and Acyl 
Azides 
N-Phenyl-2-(1H-pyrazol-1-yl)benzamide (130aa) 
                                                                 




The general procedure J was followed using 128a (72 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:1%) 
yielded 130aa (88 mg, 67%) as a colorless solid. M. p.: = 167−169 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.47 (br s, 1H), 7.93–7.86 (m, 1H), 7.79–7.74 (m, 1H), 7.69 
(d, J = 2.4 Hz, 1H), 7.57–7.48 (m, 2H), 7.45–7.35 (m, 3H), 7.25 (t, J = 7.6 Hz, 2H), 7.06 (ddt, J 
= 7.8, 6.9, 1.2 Hz, 1H), 6.44 (t, J = 2.2 Hz, 1H). 
13C-NMR (100 MHz, CDCl3): δ = 164.4 (Cq), 141.4 (CH), 137.8 (Cq), 137.2 (Cq), 133.0 (Cq), 
131.9 (CH), 131.3 (CH), 130.6 (CH), 129.1 (CH), 128.8 (CH), 126.7 (CH), 124.4 (CH), 120.0 
(CH), 107.8 (CH).  
IR (ATR): 3245, 1650, 1541, 1326, 942, 755 cm-1.  
MS (EI) m/z (relative intensity) 263 (5) [M+], 171 (100), 144 (5), 130 (5), 116 (20), 89 (5). 
HR-MS (EI) m/z calcd for C16H13N3O [M+] 263.1059, found 263.1061. 




The general procedure J was followed using 128b (79 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:1%) 
yielded 130ba (84 mg, 61%) as a colorless solid. M. p.: = 168−170 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.33 (br s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.80–7.75 (m, 1H), 
7.67 (d, J = 2.4 Hz, 1H), 7.40 (d, J = 7.3 Hz, 2H), 7.36–7.31 (m, 1H), 7.28–7.24 (m, 2H), 
7.22–7.21 (m, 1H), 7.09–6.96 (m, 1H), 6.44 (t, J = 2.1 Hz, 1H), 2.43 (s, 3H).  
                                                                 
166 K. Murali rajan, K. Parthasarathy, C.-H. Cheng, Org. Lett. 2012, 14, 4262–4265. 
Experimental Section 
238 
13C-NMR (125 MHz, CDCl3): δ = 164.3 (Cq), 142.2 (Cq), 141.3 (CH), 138.0 (Cq), 137.1 (Cq), 
132.1 (CH), 130.8 (CH), 130.2 (Cq), 130.0 (CH), 128.8 (CH), 127.6 (CH), 124.3 (CH), 120.0 
(CH), 107.7 (CH), 21.1 (CH3).  
IR (ATR): 3244, 1650, 1543, 1325, 952, 757 cm-1.  
MS (EI) m/z (relative intensity) 277 (5) [M+], 185 (100), 167 (5), 142 (5), 130 (10), 103 (10). 
HR-MS (EI) m/z calcd for C17H15N3O [M+] 277.1215, found 277.1216. 
 
5-Methoxy-N-phenyl-2-(1H-pyrazol-1-yl)benzamide  (130ca) 
 
The general procedure J was followed using 128c (87 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:1:1:1%) 
yielded 130ca (92 mg, 63%) as a colorless solid. M. p.: = 122−124 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.54 (br s, 1H), 7.78 (dd, J = 1.9, 0.7 Hz, 1H), 7.62 (dd, J = 
2.4, 0.7 Hz, 1H), 7.45 (d, J = 3.0 Hz, 1H), 7.43–7.37 (m, 2H), 7.28 (d, J = 8.7 Hz, 1H), 
7.27–7.23 (m, 2H), 7.08–7.05 (m, 1H), 7.05–7.02 (m, 1H), 6.42 (t, J = 2.2 Hz, 1H), 3.88 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 163.9 (Cq), 160.0 (Cq), 141.2 (CH), 137.8 (Cq), 134.5 (Cq), 
132.6 (CH), 130.2 (Cq), 128.8 (CH), 128.7 (CH), 124.4 (CH), 120.0 (CH), 117.7 (CH), 114.7 
(CH), 107.5 (CH), 55.8 (CH3).  
IR (ATR): 3244, 1653, 1555, 1444, 1037, 753 cm-1.  
MS (EI) m/z (relative intensity) 293 (5) [M+], 201 (100), 186 (15), 174 (5), 158 (10), 146 (5). 






The general procedure J was followed using 128d (81 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:1%) 
yielded 130da (91 mg, 65%) as a colorless solid. M. p.: = 142−144 °C.  
1H-NMR (400 MHz, CDCl3): δ = 8.53 (br s, 1H), 7.80 (dd, J = 2.0, 0.6 Hz, 1H), 7.71–7.57 (m, 
2H), 7.45–7.32 (m, 3H), 7.31–7.16 (m, 3H), 7.11–7.02 (m, 1H), 6.46 (dd, J = 2.4, 1.9 Hz, 1H). 
13C-NMR (100 MHz, CDCl3): δ = 165.0 (Cq, JC-F = 251.6 Hz), 162.7 (Cq), 141.6 (CH), 137.6 
(Cq), 135.3 (Cq, JC-F = 7.8 Hz), 133.4 (Cq, J = 3.4 Hz), 132.4 (CH), 129.3 (CH, JC-F = 8.5 Hz), 
128.9 (CH), 124.7 (CH), 120.1 (CH), 118.4 (CH, JC-F = 22.8 Hz), 117.9 (CH, JC-F = 24.6 Hz), 
108.0 (CH).  
19F-NMR (376 MHz, CDCl3): δ = –(110.2 – 110.3) (m).  
IR (ATR): 3270, 1650, 1490, 1326, 1045, 732 cm-1.  
MS (EI) m/z (relative intensity) 281 (5) [M+], 189 (100), 162 (5), 148 (5), 134 (10), 107 (10). 




The general procedure J was followed using 128e (89 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:1%) 
yielded 130ea (106 mg, 71%) as a colorless solid. M. p.: = 137−139 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.63 (br s, 1H), 7.85 (d, J = 2.2 Hz, 1H), 7.78–7.75 (m, 1H), 
7.68 (dd, J = 2.4, 0.7 Hz, 1H), 7.47 (dd, J = 8.6, 2.5 Hz, 1H), 7.39 (dd, J = 8.6, 1.2 Hz, 2H), 
7.32 (d, J = 8.6 Hz, 2H), 7.28–7.21 (m, 1H), 7.13–7.01 (m, 1H), 6.45 (dd, J = 2.2, 1.8 Hz, 1H). 
13C-NMR (125 MHz, CDCl3): δ = 163.1 (Cq), 141.7 (CH), 137.6 (Cq), 135.7 (Cq), 135.0 (Cq), 
134.2 (Cq), 131.9 (CH), 131.3 (CH), 130.6 (CH), 128.9 (CH), 127.9 (CH), 124.7 (CH), 120.1 
(CH), 108.1 (CH).  
IR (ATR): 3115, 1656, 1552, 1324, 944, 748 cm-1.  
MS (EI) m/z (relative intensity) 297 (5) [M+], 205 (100), 178 (5), 150 (10), 142 (5), 123 (5). 
Experimental Section 
240 
HR-MS (EI) m/z calcd for C16H13N3OCl [M+H+] 298.0747, found 298.0742.  
 
5-Acetyl-N-phenyl-2-(1H-pyrazol-1-yl)benzamide  (130fa) 
 
The general procedure J was followed using 128f (93 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc 5:1:1) yielded 
130fa (60 mg, 39%) and 130fa' (72 mg, 34%) as off white solids. 130fa: M. p.: = 173−175 °C. 
1H-NMR (300 MHz, CDCl3): δ = 8.68 (br s, 1H), 8.34 (d, J = 1.9 Hz, 1H), 8.07 (dd, J = 8.3, 1.9 
Hz, 1H), 7.84–7.73 (m, 2H), 7.57–7.40 (m, 3H), 7.36–7.18 (m, 2H), 7.08 (d, J = 7.3 Hz, 1H), 
6.48 (dd, J = 1.9,1.8 Hz, 1H), 2.60 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 196.2 (Cq), 164.1 (Cq), 142.0 (CH), 140.4 (Cq), 137.6 (Cq), 
136.5 (Cq), 132.2 (Cq), 131.3 (CH), 130.9 (CH), 130.7 (CH), 128.9 (CH), 126.0 (CH), 124.7 
(CH), 120.1 (CH), 108.5 (CH), 26.7 (CH3).  
IR (ATR): 3289, 1677, 1651, 1594, 1243, 935, 750 cm-1.  
MS (EI) m/z (relative intensity) 305 (5) [M+], 213 (100), 170 (10), 143 (5), 115 (5).  




M. p.: = 89−91 °C. 
1H-NMR (300 MHz, CDCl3): δ = 11.29 (s, 1H), 7.95 (d, J = 2.0 Hz, 1H), 7.86 (dd, J = 8.5, 2.0 
Hz, 1H), 7.82 (dd, J = 1.8, 0.6 Hz, 1H), 7.71 (d, J = 2.6 Hz, 1H), 7.63–7.56 (m, 2H), 7.31 (t, J = 
8.0 Hz, 2H), 7.27 (d, J = 8.7 Hz, 1H), 7.14–6.99 (m, 4H), 6.81 (s, 2H), 6.55 (dd, J = 2.6, 1.7 Hz, 
1H), 2.55 (s, 3H).  
Experimental Section 
241 
13C-NMR (125 MHz, CDCl3): δ = 195.5 (Cq), 151.6 (Cq), 151.6 (Cq), 142.4 (CH), 138.6 (Cq), 
137.7 (Cq), 137.7 (Cq), 137.1 (Cq), 134.4 (Cq), 130.2 (CH), 129.7 (CH), 129.5 (CH), 129.0 (CH), 
129.0 (CH), 128.6 (CH), 128.4 (CH), 124.2 (CH), 120.2 (CH), 109.1 (CH), 26.5 (CH3).  
IR (ATR): 3067, 1714, 1521, 1226, 935, 752 cm-1.  
MS (EI) m/z (relative intensity) 425 (5) [M+], 213 (100), 170 (10), 143 (5), 119 (35).  
HR-MS (ESI) m/z calcd for C25H21N4O3 [M+H+] 425.1614 found 425.1608. 
 
Methyl 3-(phenylcarbamoyl)-4-(1H-pyrazol-1-yl)benzoate (130ga) 
 
The general procedure J was followed using 128g (101 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:1:1:1%) 
yielded 130ga (121 mg, 75%) as a colorless solid. M. p.: = 163−165 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.50 (d, J = 2.0 Hz, 1H), 8.32 (br s, 1H), 8.18 (dd, J = 8.3, 2.0 
Hz, 1H), 7.78 (d, J = 2.1 Hz, 2H), 7.53 (d, J = 8.3 Hz, 1H), 7.48–7.40 (m, 2H), 7.28 (t, J = 7.9 
Hz, 2H), 7.16–7.03 (m, 1H), 6.47 (dd, J = 2.0, 2.1 Hz, 1H), 3.95 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 165.4 (Cq), 164.0 (Cq), 142.0 (CH), 140.5 (Cq), 137.6 (Cq), 
132.3 (Cq), 132.3 (CH), 131.9 (CH), 131.4 (CH), 130.2 (Cq), 129.0 (CH), 126.0 (CH), 124.8 
(CH), 120.1 (CH), 108.4 (CH), 52.6 (CH3).  
IR (ATR): 3281, 1714, 1547, 1303, 1121, 742 cm-1.  
MS (EI) m/z (relative intensity) 321 (5) [M+], 290 (5), 229 (100), 197 (5), 170 (5).  






The general procedure J was followed using 128h (79 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 12:1:1:1%) 
yielded 130ha (112 mg, 81%) as a colorless solid. M. p.: = 109−111 °C.  
1H-NMR (500 MHz, CDCl3): δ = 7.85 (dd, J = 2.0, 0.6 Hz, 1H), 7.82 (br s, 1H), 7.80–7.76 (m, 
1H), 7.56 (dd, J = 2.4, 0.6 Hz, 1H), 7.48 (t, J = 7.6 Hz, 1H), 7.45–7.41 (m, 1H), 7.35–7.30 (m, 
2H), 7.25–7.21 (m, 2H), 7.09–6.98 (m, 1H), 6.46 (dd, J = 2.0, 2.2 Hz, 1H), 2.05 (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 164.3 (Cq), 141.6 (CH), 137.8 (Cq), 137.2 (Cq), 136.1 (Cq), 
135.1 (Cq), 133.1 (CH), 132.8 (CH), 129.9 (CH), 128.8 (CH), 128.2 (CH), 124.4 (CH), 119.9 
(CH), 107.6 (CH), 17.1 (CH3).  
IR (ATR): 3107, 1668, 1542, 1441, 1319, 752 cm-1.  
MS (EI) m/z (relative intensity) 277 (5) [M+], 185 (100), 156 (5), 142 (5), 130 (10), 103 (10). 




The general procedure J was followed using 128i (81 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:1%) 
yielded 130ia (112 mg, 80%) as a colorless solid. M. p.: = 175−177 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.64 (br s, 1H), 7.89–7.86 (m, 1H), 7.76 (d, J = 7.9 Hz, 1H), 
7.68 (td, J = 1.6, 0.7 Hz, 1H), 7.58–7.48 (m, 1H), 7.43–7.38 (m, 2H), 7.34 (ddd, J = 9.1, 8.3, 1.4 
Hz, 1H), 7.29–7.20 (m, 2H), 7.12–6.97 (m, 1H), 6.51 (dd, J = 2.5, 1.9 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 162.8 (Cq, JC-F = 3.2 Hz), 157.4 (Cq, JC-F = 253.5 Hz), 142.0 
(CH), 137.7 (Cq), 136.3 (Cq), 133.7 (CH, JC-F = 1.9 Hz), 130.9 (CH, JC-F = 8.2 Hz), 128.9 (CH), 
126.2 (CH, JC-F = 3.7 Hz), 125.7 (Cq, JC-F = 13.8 Hz), 124.6 (CH), 120.0 (CH), 118.7 (CH, JC-F 
= 20.6 Hz), 107.9 (CH).  
19F-NMR (376 MHz, CDCl3): δ = -121.9 (dd, J = 9.3, 5.1 Hz).  
IR (ATR): 3243, 1651, 1543, 1308, 977, 752 cm-1.  
Experimental Section 
243 
MS (EI) m/z (relative intensity) 281 (5) [M+], 189 (100), 162 (5), 148 (5), 134 (10), 107 (10). 




The general procedure J was followed using 128j (111 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 12:1:1:1%) 
yielded 130ja (116 mg, 68%) as a colorless solid. M. p.: = 123−124 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.44 (br s, 1H), 7.89–7.83 (m, 2H), 7.77 (dd, J = 8.1, 1.4 
Hz, 1H), 7.63 (dd, J = 2.4, 0.6 Hz, 1H), 7.43 (t, J = 7.9 Hz, 1H), 7.37–7.32 (m, 2H), 7.20 (dd, 
J = 8.5, 7.4 Hz, 2H), 7.12–6.98 (m, 1H), 6.52–6.47 (m, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 163.0 (Cq), 141.8 (CH), 137.6 (Cq), 137.1 (Cq), 136.2 (Cq), 
135.4 (CH), 133.3 (CH), 131.0 (CH), 129.6 (CH), 128.7 (CH), 124.5 (CH), 123.2 (Cq), 120.0 
(CH), 107.7 (CH).  
IR (ATR): 3244, 1656, 1540, 1440, 1318, 749 cm-1.  
MS (EI) m/z (relative intensity) 341 (5) [M+], 249 (100), 222 (5), 194 (5), 170 (10), 142 (10).  
HR-MS (EI) m/z calcd for C16H14N3O79Br [M+H+] 342.0242, found 342.0237.  
 
2-(1H-Indazol-1-yl)-5-methyl-N-phenylbenzamide  (130ka) 
 
The general procedure J was followed using 128k (104 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 12:1:1:1%) 
yielded 130ka (87 mg, 53%) as a colorless solid. M. p.: = 128–130 °C.  
Experimental Section 
244 
1H-NMR (500 MHz, CDCl3): δ = 8.42 (br s, 1H), 8.27 (d, J = 1.0 Hz, 1H), 7.91–7.85 (m, 1H), 
7.75 (d, J = 8.2 Hz, 1H), 7.42 (ddd, J = 8.2, 2.1, 0.9 Hz, 1H), 7.36 (ddd, J = 8.6, 6.9, 1.1 Hz, 1H), 
7.33 (d, J = 8.0 Hz, 1H), 7.28 (dd, J = 8.5, 1.0 Hz, 1H), 7.26–7.23 (m, 2H), 7.18 (m, 3H), 
7.07–6.94 (m, 1H), 2.49 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 164.4 (Cq), 141.4 (Cq), 139.7 (Cq), 137.7 (Cq), 135.7 (CH), 
133.9 (Cq), 133.3 (Cq), 132.3 (CH), 131.9 (CH), 128.7 (CH), 128.0 (CH), 127.8 (CH), 124.3 
(Cq), 124.3 (CH), 121.9 (CH), 121.2 (CH), 120.0 (CH), 110.2 (CH), 21.2 (CH3).  
IR (ATR): 3059, 1648, 1547, 1330, 831, 747 cm-1. 
MS (EI) m/z (relative intensity) 327 (5) [M+], 235 (100), 220 (10), 208 (10), 192 (10), 180 (10). 




The general procedure J was followed using 128l (79 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 12:1:1:1%) 
yielded 130la (91 mg, 66%) as a colorless solid. M. p.: = 130−132 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.52 (br s, 1H), 7.76 (d, J = 1.9 Hz, 1H), 7.74–7.69 (m, 1H), 
7.65 (d, J = 2.4 Hz, 1H), 7.43–7.38 (m, 2H), 7.35–7.29 (m, 1H), 7.28–7.20 (m, 3H), 7.09–7.01 
(m, 1H), 6.42 (s, 1H), 2.43 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 164.5 (Cq), 141.2 (CH), 139.5 (Cq), 137.9 (Cq), 134.8 (Cq), 
132.7 (Cq), 132.1 (CH), 131.9 (CH), 131.1 (CH), 128.8 (CH), 126.8 (CH), 124.4 (CH), 120.0 
(CH), 107.6 (CH), 21.0 (CH3).  
IR (ATR): 3241, 1661, 1543, 1323, 1025, 748 cm-1.  
MS (EI) m/z (relative intensity) 277 (5) [M+], 185 (100), 258 (5), 142 (5), 130 (10), 103 (10). 






The general procedure J was followed using 128m (106 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol), Cp*CoI2(CO) (112, 24 mg, 10 mol %), AgNTf2 (39.0 mg, 20 mol %) and AgOPiv (20.8 
mg, 20 mol %). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 
8:1:1:1%) yielded 130ma (78 mg, 42%) as a colorless solid. M. p.: = 142−144 °C.  
1H-NMR (300 MHz, DMSO-d6): δ = 10.39 (s, 1H), 8.26 (d, J = 2.5 Hz, 1H), 8.05 (s, 1H), 7.86 
(d, J = 1.1 Hz, 2H), 7.70 (d, J = 1.8 Hz, 1H), 7.62–7.53 (m, 2H), 7.31 (t, J = 7.9 Hz, 2H), 
7.16–7.04 (m, 1H), 6.51 (dd, J = 2.5, 1.8 Hz, 1H). 
13C-NMR (125 MHz, DMSO-d6): δ = 164.5 (Cq), 141.4 (CH), 138.7 (Cq), 137.6 (Cq), 135.0 
(Cq), 130.7 (Cq, JC-F = 32.6 Hz), 130.4 (CH), 130.2 (CH), 128.6 (CH), 123.3 (Cq, JC-F = 273.1 
Hz), 123.7 (CH), 120.2 (CH, JC-F = 3.9 Hz), 119.6 (CH), 107.8 (CH).  
IR (ATR): 3041, 1649, 1449, 1314, 1126, 758 cm-1.  
MS (EI) m/z (relative intensity) 331 (5) [M+], 312 (5), 239 (100), 212 (5), 198 (5), 184 (5). 




The general procedure J was followed using 128n (75 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:1%) 
yielded 130na (123 mg, 91%) as a colorless solid. M. p.: = 129−131 °C.  
1H-NMR (500 MHz, CDCl3): δ = 10.31 (br s, 1H), 7.88 (dd, J = 2.0, 0.6 Hz, 1H), 7.80 (dd, J = 
2.5, 0.7 Hz, 1H), 7.61–7.57 (m, 2H), 7.56 (d, J = 5.8 Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 7.29 (d, 




13C-NMR (125 MHz, CDCl3): δ = 159.5 (Cq), 142.0 (CH), 139.6 (Cq), 138.3 (Cq), 133.8 (CH), 
131.0 (Cq), 130.1 (CH), 128.9 (CH), 124.2 (CH), 121.2 (CH), 119.8 (CH), 108.6 (CH).  
IR (ATR): 3225, 1660, 1534, 1312, 1057, 751 cm-1.  
MS (EI) m/z (relative intensity) 269 (15) [M+], 177 (100), 150 (5), 122 (10), 105 (5).  




The general procedure J was followed using 128o (106 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol), Cp*CoI2(CO) (112, 24 mg, 10 mol %), AgNTf2 (39.0 mg, 20 mol %) and AgOPiv (20.8 
mg, 20 mol %). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 
8:1:1:1%) yielded 130oa (66 mg, 42%) as a yellow oil.  
1H-NMR (500 MHz, CDCl3): δ = 8.40 (ddd, J = 8.0, 1.3, 0.9 Hz, 1H), 8.08 (br s, 1H), 8.01 (dd, 
J = 1.9, 0.6 Hz, 1H), 7.78 (dd, J = 2.5, 0.6 Hz, 1H), 7.46–7.42 (m, 2H), 7.40 (ddd, J = 8.3, 6.7, 
1.3 Hz, 1H), 7.37–7.31 (m, 2H), 7.28–7.24 (m, 2H), 6.63 (dd, J = 2.5, 1.9 Hz, 1H), 3.50 (s, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 161.3 (Cq), 143.1 (CH), 138.5 (Cq), 134.4 (Cq), 134.3 (CH), 
133.3 (Cq), 128.8 (CH), 125.3 (Cq), 124.42 (CH), 123.6 (CH), 122.6 (CH), 122.5 (CH), 119.5 
(CH), 109.7 (CH), 108.5 (CH), 107.3 (Cq), 29.6 (CH3).  
IR (ATR): 1658, 1528, 1449, 1245, 1103, 747 cm-1. 
MS (EI) m/z (relative intensity) 316 (15) [M+], 224 (100), 209 (5), 196 (5), 169 (10).  
HR-MS (EI) m/z calcd for C19H16N4O [M+] 316.1324, found 316.1333. 
 




The general procedure J was followed using 128p (96 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol), Cp*CoI2(CO) (112, 24 mg, 10 mol %), AgSbF6 (34.4 mg, 20 mol %) and AgOPiv (20.8 
mg, 20 mol %). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 
8:1:1:1%) yielded 130pa (78 mg, 50%) as a colorless solid. M. p.: = 140−142 °C.  
1H-NMR (300 MHz, CDCl3): δ = 12.3 (br s, 1H), 8.26 (dd, J = 2.8, 0.6 Hz, 1H), 7.93 (d, J = 1.7 
Hz, 1H), 7.83 (s, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.34 (dd, J = 8.4, 7.5 Hz, 2H), 7.10 (dd, J = 7.5, 
7.5 Hz, 1H), 6.60 (dd, J = 2.8, 1.7 Hz, 1H), 3.91 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 158.1 (Cq), 157.3 (Cq), 144.2 (Cq), 142.2 (CH), 138.5 (Cq), 
138.3 (Cq), 130.2 (CH), 129.0 (CH), 124.2 (CH), 122.7 (CH), 120.0 (CH), 110.0 (Cq), 108.9 
(CH), 52.3 (CH3).  
IR (ATR): 3027, 1739, 1557, 1317, 1147, 748 cm-1.  
MS (EI) m/z (relative intensity) 311 (25) [M+], 280 (5), 243 (5), 219 (100), 187 (5), 151 (15). 
HR-MS (EI) m/z calcd for C16H13N3O4 [M+] 311.0906, found 311.0903.  
 
3-Methyl-2-(1H-pyrazol-1-yl)-N-(p-tolyl)benzamide  (130hb) 
 
The general procedure J was followed using 128h (79 mg, 0.5 mmol) and 129b (133 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 12:1:1:1%) 
yielded 130hb (74 mg, 51%) as a colorless solid. M. p.: = 149−151 °C.  
1H-NMR (500 MHz, CDCl3): δ = 7.84 (dd, J = 2.0, 0.6 Hz, 1H), 7.79 (dd, J = 7.6, 1.6 Hz, 1H), 
7.73 (br s, 1H), 7.55 (dd, J = 2.4, 0.6 Hz, 1H), 7.47 (dd, J = 7.6, 7.6 Hz, 1H), 7.42 (ddd, J = 7.6, 
1.7, 0.8 Hz, 1H), 7.21 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 8.4 Hz, 2H), 6.45 (dd, J = 2.2, 1.6 Hz, 1H), 
2.26 (s, 3H), 2.05 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 164.2 (Cq), 141.5 (CH), 137.1 (Cq), 136.1 (Cq), 135.2 (Cq), 
135.2 (Cq), 134.0 (Cq), 133.0 (CH), 132.7 (CH), 129.8 (CH), 129.3 (CH), 128.1 (CH), 120.0 
(CH), 107.5 (CH), 20.8 (CH3), 17.1 (CH3).  
Experimental Section 
248 
IR (ATR): 3244, 1672, 1523, 1317, 1050, 751 cm-1.  
MS (EI) m/z (relative intensity) 291 (5) [M+], 185 (100), 158 (5), 142 (5), 130 (10), 103 (5). 




The general procedure J was followed using 128h (79 mg, 0.5 mmol) and 129c (149 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:1:1:1%) 
yielded 130hc (78 mg, 51%) as colorless solids. M. p.: = 98−100 °C.  
1H-NMR (500 MHz, CDCl3): δ = 7.83 (dd, J = 2.0, 0.6 Hz, 1H), 7.76 (dd, J = 7.6, 1.1 Hz, 1H), 
7.71 (br s, 1H), 7.55 (dd, J = 2.4, 0.6 Hz, 1H), 7.47 (dd, J = 7.6, 7.6 Hz, 1H), 7.43–7.39 (m, 1H), 
7.22 (d, J = 9.0 Hz, 2H), 6.76 (d, J = 9.0 Hz, 2H), 6.46 (t, J = 2.1 Hz, 1H), 3.74 (s, 3H), 2.04 (s, 
3H).  
13C-NMR (125 MHz, CDCl3): δ = 164.1 (Cq), 156.4 (Cq), 141.4 (CH), 137.1 (Cq), 136.1 (Cq), 
135.2 (Cq), 132.9 (CH), 132.8 (CH), 130.9 (Cq), 129.8 (CH), 128.1 (CH), 121.7 (CH), 113.9 
(CH), 107.5 (CH), 55.4 (CH3), 17.1 (CH3).  
IR (ATR): 3103, 1659, 1511, 1243, 1035, 759 cm-1.  
MS (EI) m/z (relative intensity) 307 (5) [M+], 185 (100), 156 (5), 142 (5), 130 (5), 103 (5). 
HR-MS (EI) m/z calcd for C18H17N3O2 [M+] 307.1321, found 307.1327.  
 




The general procedure J was followed using 128h (79 mg, 0.5 mmol) and 129d (114 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:1:1:1%) 
yielded 130hd (143 mg, 97%) as a colorless solid. M. p.: = 144−146 °C.  
1H-NMR (400 MHz, CDCl3): δ = 7.94 (br s, 1H), 7.83 (dd, J = 2.0, 0.6 Hz, 1H), 7.78–7.71 (m, 
1H), 7.55 (dd, J = 2.4, 0.6 Hz, 1H), 7.46 (dd, J = 7.6, 7.6 Hz, 1H), 7.43–7.39 (m, 1H), 7.31–7.25 
(m, 2H), 7.01–6.77 (m, 2H), 6.46 (dd, J = 2.4, 1.9 Hz, 1H), 2.04 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 164.3 (Cq), 159.3 (Cq, JC-F = 243.7 Hz), 141.4 (CH), 137.1 
(Cq), 136.1 (Cq), 134.9 (Cq), 133.8 (Cq, JC-F = 2.9 Hz), 133.1 (CH), 132.8 (CH), 129.8 (CH), 
128.1 (CH), 121.7 (CH, JC-F = 7.9 Hz), 115.4 (CH, JC-F = 22.4 Hz), 107.5 (CH), 17.1 (CH3). 
19F-NMR (376 MHz, CDCl3): δ = -117.8 (td, J = 8.4, 4.5 Hz).  
IR (ATR): 3056, 1673, 1508, 1211, 1055, 754 cm-1.  
MS (EI) m/z (relative intensity) 295 (5) [M+], 185 (100), 156 (5), 142 (5), 130 (10), 103 (5). 
HR-MS (EI) m/z calcd for C17H14N3FO [M+] 295.1121, found 295.1123. 
 
N-(4-Chlorophenyl)-3-methyl-2-(1H-pyrazol-1-yl)benzamide  (130he) 
 
The general procedure J was followed using 128h (79 mg, 0.5 mmol) and 129e (153 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 
10:1:1:1%→10:2:1:0) yielded 130he (128 mg, 82%) as a colorless solid. M. p.: = 153−155 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.97 (br s, 1H), 7.83 (dd, J = 1.8, 0.6 Hz, 1H), 7.75 (ddd, J = 
7.6, 1.8, 0.6 Hz, 1H), 7.55 (dd, J = 2.4, 0.6 Hz, 1H), 7.47 (dd, J = 7.6, 7.6 Hz, 1H), 7.44–7.41 (m, 
1H), 7.28 (d, J = 8.9 Hz, 2H), 7.17 (d, J = 8.9 Hz, 2H), 6.46 (dd, J = 2.4, 1.9 Hz, 1H), 2.04 (s, 
3H).  
13C-NMR (100 MHz, CDCl3): δ = 164.3 (Cq), 141.5 (CH), 137.2 (Cq), 136.4 (Cq), 136.1 (Cq), 
134.8 (Cq), 133.3 (CH), 132.9 (CH), 129.9 (CH), 129.2 (Cq), 128.8 (CH), 128.1 (CH), 121.1 
(CH), 107.6 (CH), 17.1 (CH3). 
Experimental Section 
250 
IR (ATR): 3236, 1678, 1491, 1397, 1312, 753 cm-1.  
MS (EI) m/z (relative intensity) 311 (5) [M+], 185 (100), 156 (5), 142 (5), 130 (10), 103 (5). 
HR-MS (EI) m/z calcd for C17H14N3OCl [M+] 311.0825, found 311.0826.  
 
3-Methyl-2-(1H-pyrazol-1-yl)-N-(m-tolyl)benzamide  (130hf) 
 
The general procedure J was followed using 128h (79 mg, 0.5 mmol) and 129f (133 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:1%) 
yielded 130hf (74 mg, 51%) as a colorless solid. M. p.: = 119−121 °C.  
1H-NMR (400 MHz, CDCl3): δ = 7.84 (dd, J = 2.0, 0.6 Hz, 1H), 7.79 (br s, 1H), 7.76 (ddd, J = 
7.7, 1.8, 0.7 Hz, 1H), 7.55 (dd, J = 2.4, 0.6 Hz, 1H), 7.47 (dd, J = 7.6, 7.6 Hz, 1H), 7.42 (ddd, J 
= 7.6, 1.8, 0.7 Hz, 1H), 7.25 (dd, J = 1.3, 0.7 Hz, 1H), 7.16–7.08 (m, 1H), 7.05 (m, 1H), 
6.91–6.75 (m, 1H), 6.46 (dd, J = 2.4, 1.9 Hz, 1H), 2.28 (s, 3H), 2.05 (s, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 164.3 (Cq), 141.5 (CH), 138.7 (Cq), 137.7 (Cq), 137.2 (Cq), 
136.1 (Cq), 135.2 (Cq), 133.0 (CH), 132.7 (CH), 129.8 (CH), 128.5 (CH), 128.1 (CH), 125.1 
(CH), 120.5 (CH), 117.0 (CH), 107.5 (CH), 21.4 (CH3), 17.1 (CH3).  
IR (ATR): 3111, 1656, 1551, 1323, 944, 748 cm-1.  
MS (EI) m/z (relative intensity) 291 (5) [M+], 185 (100), 156 (5), 142 (5), 130 (10), 103 (5). 






The general procedure J (or K) was followed using 128a (72 mg, 0.5 mmol) and 129b (133 mg, 
1.0 mmol) (or 131b, 161 mg, 1.0 mmol). Purification by column chromatography 
(n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:1%) yielded 130ab (83 mg, 60%; or 72 mg, 52%) as a 
colorless solid. M. p.: = 167−169 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.22 (br s, 1H), 7.98–7.87 (m, 1H), 7.80–7.76 (m, 1H), 7.69 
(dd, J = 2.5, 0.6 Hz, 1H), 7.62–7.48 (m, 2H), 7.46–7.38 (m, 1H), 7.29 (d, J = 8.4 Hz, 2H), 7.06 
(d, J = 8.3 Hz, 2H), 6.44 (d, J = 2.5, 2.2 Hz, 1H), 2.28 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 164.1 (Cq), 141.3 (CH), 137.2 (Cq), 135.2 (Cq), 134.1 (Cq), 
133.0 (Cq), 131.9 (CH), 131.2 (CH), 130.6 (CH), 129.3 (CH), 129.1 (CH), 126.8 (CH), 120.0 
(CH), 107.7 (CH), 20.9 (CH3).  
IR (ATR): 3245, 1650, 1541, 1325, 1040, 753 cm-1.  
MS (EI) m/z (relative intensity) 277 (5) [M+], 171 (100), 144 (5), 130 (5), 116 (15), 89 (10). 




The general procedure K was followed using 128a (72 mg, 0.5 mmol) and 131c (177 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:1:1:1%) 
yielded 130ac (88 mg, 60%) as a colorless solid. M. p.: = 130−132 °C. 
1H-NMR (500 MHz, CDCl3): δ = 8.22 (br s, 1H), 7.94–7.88 (m, 1H), 7.77 (dd, J = 1.9, 0.7 
Hz, 1H), 7.70 (dd, J = 2.4, 0.7 Hz, 1H), 7.60–7.46 (m, 2H), 7.43–7.38 (m, 1H), 7.30 (d, J = 
9.0 Hz, 2H), 6.80 (d, J = 9.0 Hz, 2H), 6.45 (dd, J = 2.4, 1.9 Hz, 1H), 3.75 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 164.2 (Cq), 156.5 (Cq), 141.3 (CH), 137.2 (Cq), 133.1 (Cq), 
132.0 (CH), 131.2 (CH), 130.9 (Cq), 130.6 (CH), 129.1 (CH), 126.8 (CH), 121.8 (CH), 114.0 
(CH), 107.7 (CH), 55.4 (CH3).  
IR (ATR): 3049, 1665, 1510, 1243, 1031, 764 cm-1.  
Experimental Section 
252 
MS (EI) m/z (relative intensity) 293 (10) [M+], 171 (100), 144 (5), 116 (15).  
HR-MS (EI) m/z calcd for C17H15N3O2 [M+] 293.1164, found 293.1167.  
 
N-([1,1'-Biphenyl]-4-yl)-2-(1H-pyrazol-1-yl)benzamide  (130ag) 
 
The general procedure K was followed using 128a (72 mg, 0.5 mmol) and 131g (223 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:1:1:1%) 
yielded 130ag (97 mg, 57%) as a colorless solid. M. p.: = 168−169 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.63 (br s, 1H), 7.91 (dd, J = 7.2, 2.1 Hz, 1H), 7.80 (d, J = 1.9 
Hz, 1H), 7.71 (d, J = 2.4 Hz, 1H), 7.61–7.45 (m, 8H), 7.44–7.35 (m, 3H), 7.33–7.25 (m, 1H), 
6.46 (t, J = 2.1 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 164.4 (Cq), 141.4 (CH), 140.5 (Cq), 137.3 (Cq), 137.2 (Cq), 
137.2 (Cq), 132.9 (Cq), 132.0 (CH), 131.4 (CH), 130.7 (CH), 129.1 (CH), 128.7 (CH), 127.5 
(CH), 127.0 (CH), 126.8 (CH), 126.8 (CH), 120.3 (CH), 107.8 (CH).  
IR (ATR): 3243, 1656, 1518, 1303, 840, 734 cm-1.  
MS (EI) m/z (relative intensity) 339 (5) [M+], 171 (100), 144 (5), 130 (5), 116 (10).  




The general procedure K was followed using 128a (72 mg, 0.5 mmol) and 131h (225 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:1:1:1%) 
yielded 130ah (107 mg, 63%) as a colorless solid. M. p.: = 148−150 °C.  
Experimental Section 
253 
1H-NMR (500 MHz, CDCl3): δ = 8.64 (br s, 1H), 7.90 (dd, J = 7.5, 1.9 Hz, 1H), 7.77 (d, J = 1.9 
Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.61–7.47 (m, 2H), 7.40–7.28 (m, 5H), 6.45 (t, J = 2.2 Hz, 
1H).  
13C-NMR (125 MHz, CDCl3): δ = 164.3 (Cq), 141.4 (CH), 137.2 (Cq), 137.0 (Cq), 132.8 (Cq), 
132.1 (CH), 131.8 (CH), 131.5 (CH), 130.8 (CH), 129.2 (CH), 126.9 (CH), 121.5 (CH), 117.0 
(Cq), 107.9 (CH).  
IR (ATR): 3249, 1662, 1518, 1318, 1073, 750 cm-1.  
MS (EI) m/z (relative intensity) 341 (5) [M+], 171 (100), 144 (5), 116 (10), 89 (5).  
HR-MS (EI) m/z calcd for C16H12N3O79Br [M+] 341.0164, found 341.0164. 
 
2-(1H-Pyrazol-1-yl)-N-{4-(trifluoromethyl)phenyl}benzamide  (130ai) 
 
The general procedure K was followed using 128a (72 mg, 0.5 mmol) and 131i (215 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:1:1:1%) 
yielded 130ai (110 mg, 66%) as a colorless solid. M. p.: = 168−170 °C.  
1H-NMR (300 MHz, CDCl3): δ = 9.03 (br s, 1H), 7.88 (dd, J = 6.9, 2.5 Hz, 1H), 7.79 (d, J = 1.9 
Hz, 1H), 7.69 (d, J = 2.5 Hz, 1H), 7.62–7.41 (m, 6H), 7.35 (dd, J = 7.0, 2.2 Hz, 1H), 6.47 (dd, J 
= 2.2, 1.9 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 164.7 (Cq), 141.4 (CH), 141.0 (Cq), 137.2 (Cq), 132.6 (Cq), 
132.1 (CH), 131.7 (CH), 130.9 (CH), 129.2 (CH), 126.9 (CH), 126.1 (CH, JC-F = 7.5 Hz), 126.1 
(Cq, JC-F = 32.9 Hz) 124.0 (Cq, JC-F = 271.5 Hz), 119.5 (CH), 108.0 (CH).  
19F-NMR (CDCl3, 282 MHz): δ = -62.2 (s).  
IR (ATR): 3255, 1668, 1538, 1318, 1109, 749 cm-1.  
MS (EI) m/z (relative intensity) 331 (5) [M+], 171 (100), 144 (5), 130 (5), 116 (15), 89 (10). 




2-(1H-Pyrazol-1-yl)-N-(m-tolyl)benzamide  (130af) 
 
The general procedure K was followed using 128a (72 mg, 0.5 mmol) and 131f (161 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 8:1:1:1%) 
yielded 130af (87 mg, 63%) as a colorless solid. M. p.: = 127−129 °C.  
1H-NMR (500 MHz, CDCl3): δ = 8.29 (br s, 1H), 7.94–7.86 (m, 1H), 7.77 (d, J = 1.9 Hz, 1H), 
7.70 (d, J = 2.4 Hz, 1H), 7.53 (m, 2H), 7.41 (dd, J = 7.5, 1.7 Hz, 1H), 7.31 (s, 1H), 7.16–7.12 
(m, 2H), 6.88 (ddd, J = 4.5, 3.0, 1.1 Hz, 1H), 6.44 (t, J = 2.2 Hz, 1H), 2.29 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 164.4 (Cq), 141.4 (CH), 138.8 (Cq), 137.7 (Cq), 137.2 (Cq), 
133.1 (Cq), 131.9 (CH), 131.3 (CH), 130.6 (CH), 129.1 (CH), 128.6 (CH), 126.8 (CH), 125.3 
(CH), 120.7 (CH), 117.1 (CH), 107.8 (CH), 21.5 (CH3). 
IR (ATR): 3240, 1663, 1548, 1311, 1042, 742 cm-1.  
MS (EI) m/z (relative intensity) 277 (5) [M+], 171 (100), 144 (5), 116 (15).  
HR-MS (ESI) m/z calcd for C17H16N3O [M+H+] 278.1293, found 278.1286.  
 
N-(2-Fluorophenyl)-2-(1H-pyrazol-1-yl)benzamide  (130aj) 
 
The general procedure K was followed using 128a (72 mg, 0.5 mmol) and 131j (165 mg, 1.0 
mmol). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:1%) 
yielded 130aj (110 mg, 78%) as a colorless solid. M. p.: = 135−137 °C. 
1H-NMR (300 MHz, CDCl3): δ = 8.42 (br s, 1H), 8.36 – 8.26 (m, 1H), 7.90 (dd, J = 7.5, 1.7 Hz, 
1H), 7.74 (d, J = 1.9 Hz, 1H), 7.71 (d, J = 2.4 Hz, 1H), 7.62–7.48 (m, 2H), 7.43 (dd, J = 7.3, 1.9 
Hz, 1H), 7.09 (ddd, J = 8.2, 5.6, 3.1 Hz, 1H), 7.05 – 6.97 (m, 2H), 6.46–6.36 (m, 1H). 
Experimental Section 
255 
13C-NMR (125 MHz, CDCl3): δ = 164.8 (Cq), 152.6 (Cq, JC-F = 245.3 Hz), 141.6 (CH), 137.5 
(Cq), 132.3 (Cq), 131.5 (CH), 131.2 (CH), 130.6 (CH), 128.9 (CH), 126.4 (CH), 126.3 (Cq, JC-F 
= 10.5 Hz), 124.7 (CH, JC-F = 7.5 Hz), 124.4 (CH, JC-F = 3.7 Hz), 122.0 (CH), 114.9 (CH, JC-F = 
19.1 Hz), 107.8 (CH).  
19F-NMR (282 MHz, CDCl3): δ = -129.0 (ddd, J = 8.2, 2.8 Hz).  
IR (ATR): 3254, 1657, 1450, 1317, 1039, 749 cm-1.  
MS (EI) m/z (relative intensity) 281 (5) [M+], 171 (100), 144 (5), 130 (5), 116 (10).  
HR-MS (EI) m/z calcd for C16H12N3OF [M+] 281.0964, found 281.0976. 
 
(Z)-N,2-Diphenyl-3-(1H-pyrazol-1-yl)acrylamide  (133aa) 
 
The general procedure J was followed using 132a (85 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol), Cp*CoI2(CO) (112, 24 mg, 10 mol %), AgNTf2 (39.8 mg, 20 mol %) and AgOPiv (20.8 
mg, 20 mol %). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 
10:1:1:1%) yielded 133aa (80 mg, 55%) as a colorless solid. M. p.: = 180−181 °C.  
1H-NMR (500 MHz, CDCl3): δ = 7.87 (s, 1H), 7.87 (d, J = 2.6 Hz, 1H), 7.60 (d, J = 1.8 Hz, 1H), 
7.54 (dd, J = 8.6, 1.2 Hz, 2H), 7.52–7.48 (m, 2H), 7.43–7.28 (m, 6H), 7.18–7.07 (m, 1H), 6.33 
(dd, J = 2.6, 1.8 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 165.4 (Cq), 141.8 (CH), 137.5 (Cq), 134.9 (Cq), 130.0 (CH), 
129.1 (CH), 129.0 (CH), 128.6 (CH), 126.6 (CH), 126.5 (Cq), 126.2 (CH), 124.9 (CH), 120.2 
(CH), 108.1 (CH).  
IR (ATR): 3250, 1646, 1540, 1439, 953, 750 cm-1.  
MS (EI) m/z (relative intensity) 289 (5) [M+], 221 (5), 197 (100), 169 (40), 115 (10).  
HR-MS (ESI) m/z calcd for C18H15N3O [M+] 289.1215, found 289.1216. 
 




The general procedure J was followed using 132a (85 mg, 0.5 mmol) and 129d (137 mg, 1.0 
mmol), Cp*CoI2(CO) (112, mg, 10 mol %), AgNTf2 (39.8 mg, 20 mol %) and AgOPiv (20.8 
mg, 20 mol %). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 
8:1:1:1%→5:1:0:0) yielded 133ad (81 mg, 53%) as a colorless solid. M. p.: = 184−185 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.99 (br s, 1H), 7.81 (d, J = 2.6 Hz, 1H), 7.60 (d, J = 1.8 Hz, 
1H), 7.55–7.43 (m, 4H), 7.40–7.34 (m, 3H), 7.33 (s, 1H), 7.01 (t, J = 8.7 Hz, 2H), 6.34 (t, J = 
2.2 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 165.4 (Cq), 159.7 (Cq, JC-F = 244.3 Hz), 141.8 (CH), 134.9 
(Cq), 133.5 (Cq, JC-F = 2.9 Hz), 130.2 (CH), 129.0 (CH), 128.6 (CH), 126.6 (CH), 126.5 (Cq), 
126.1 (CH), 122.1 (CH, JC-F = 8.0 Hz), 115.7 (CH, JC-F = 22.6 Hz), 108.0 (CH).  
19F-NMR (282 MHz, CDCl3): δ = -117.2 (tt, J = 8.2, 4.8 Hz).  
IR (ATR): 3240, 1636, 1505, 1391, 1211, 747 cm-1.  
MS (EI) m/z (relative intensity) 307 (5) [M+], 239 (5), 197 (100), 169 (45), 142 (5), 115 (10). 
HR-MS (EI) m/z calcd for C18H14FN3O [M+] 307.1121, found 307.1125. 
 
(Z)-N,3-Diphenyl-3-(1H-pyrazol-1-yl)acrylamide  (133ba) 
 
The general procedure J was followed using 132b (85 mg, 0.5 mmol) and 129a (119 mg, 1.0 
mmol), Cp*CoI2(CO) (112, 24 mg, 10 mol %), AgNTf2 (39.8 mg, 20 mol %) and AgOPiv (20.8 
mg, 20 mol %). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 
8:1:1:1%) yielded 133ba (78 mg, 54%) as a colorless solid. M. p.: = 159−161 °C.  
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1H-NMR (300 MHz, CDCl3): δ = 9.69 (br s, 1H), 7.85 (d, J = 2.0 Hz, 1H), 7.51–7.45 (m, 3H), 
7.43–7.31 (m, 3H), 7.30–7.18 (m, 4H), 7.12–7.01 (t, J = 2.2 Hz, 1H), 6.45 (t, J = 2.2 Hz, 1H), 
6.37 (s, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 162.0 (Cq), 142.8 (Cq), 141.2 (CH), 138.0 (Cq), 136.4 (Cq), 
133.0 (CH), 130.4 (CH), 128.8 (CH), 128.8 (CH), 127.6 (CH), 124.2 (CH), 119.8 (CH), 119.2 
(CH), 107.7 (CH).  
IR (ATR): 3054, 1658, 1539, 1440, 1085, 755 cm-1.  
MS (EI) m/z (relative intensity) 289 (5) [M+], 197 (65), 169 (5), 129 (100), 102 (10), 77 (15). 
HR-MS (EI) m/z calcd for C18H15N3O [M+] 289.1215, found 289.1214. 
 
(Z)-N-(4-Fluorophenyl)-3-phenyl-3-(1H-pyrazol-1-yl)acrylamide  (133bd) 
 
The general procedure J was followed using 132b (85 mg, 0.5 mmol) and 129d (137 mg, 1.0 
mmol), Cp*CoI2(CO) (112, 24 mg, 10 mol %), AgNTf2 (39.8 mg, 20 mol %) and AgOPiv (20.8 
mg, 20 mol %). Purification by column chromatography (n-hexane/CH2Cl2/EtOAc/Et3N 
8:1:1:1%→5:1:0:0) yielded 133bd (97 mg, 63%) as a colorless solid. M. p.: = 150−152 °C. 
1H-NMR (500 MHz, CDCl3): δ = 9.92 (br s, 1H), 7.94–7.82 (m, 1H), 7.53 (dd, J = 2.5, 0.6 Hz, 
1H), 7.52–7.48 (m, 2H), 7.48–7.45 (m, 1H), 7.44–7.38 (m, 2H), 7.30–7.25 (m, 2H), 7.01 (dd, J 
= 9.1, 8.3 Hz, 2H), 6.52 (dd, J = 2.5, 1.9 Hz, 1H), 6.40 (s, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 162.0 (Cq), 159.2 (Cq, JC-F = 243.4 Hz), 143.0 (Cq), 141.1 
(CH), 136.3 (Cq), 134.1 (Cq, JC-F = 2.9 Hz), 133.0 (CH), 130.5 (CH), 128.8 (CH), 127.6 (CH), 
121.5 (CH, JC-F = 7.8 Hz), 118.8 (CH), 115.4 (CH, JC-F = 22.5 Hz), 107.7 (CH).  
19F-NMR (282 MHz, CDCl3): δ = -118.0 (tt, J = 8.3, 4.8 Hz).  
IR (ATR): 3006, 1659, 1508, 1210, 921, 761 cm-1.  
MS (EI) m/z (relative intensity) 307 (5) [M+], 197 (80), 169 (5), 129 (100), 102 (10).  




H/D Exchange Experiments: 
Cobalt-Catalyzed H/D Exchange in Substrate 128a with [D4]-MeOH as the Cosolvent 
without Isocyanate 129: 
 
A suspension of 1-phenyl-1H-pyrazole (128a) (72 mg, 0.50 mmol), Cp*CoI2(CO) (112, 12 
mg, 5.0 mol %), AgSbF6 (17.2 mg, 10.0 mol %) and AgOPiv (10.4 mg, 10.0 mol %) in a 
solvent mixture of DCE and CD3OD (0.9/0.1 mL) was stirred at 70 °C for 16 h under an 
atmosphere of Ar. At ambient temperature, the reaction mixture was evaporated in vacuo and 
the residue was purified by column chromatography on silica gel (n-hexane/EtOAc) to yield 
[Dn]-128a (59 mg, 82%) as a slightly yellow oil. The D-incorporation in [Dn]-128a was 
estimated by 1H-NMR spectroscopy. 
 
Scheme S-2. Cobalt-Catalyzed H/D Exchange in Substrate [D5]-128a with Isocyanate 
129a: 
 
A suspension of [D5]-128a (74 mg, 0.5 mmol), 129a (119 mg, 1.0 mmol), N-phenylbenzamide 
(99 mg, 0.5 mmol), Cp*CoI2(CO) (112, 12 mg, 5.0 mmol %), AgSbF6 (17.2 mg, 10 mol %) 
and AgOPiv (10.4 mg, 10 mmol %) in DCE (2.0 mL) was stirred at 70 °C for 2 h under an 
atmosphere of Ar. At ambient temperature, the solvent was evaporated in vacuo and the 
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residue was purified by column chromatography on silica gel (n-hexane/CH2Cl2/EtOAc/Et3N 
10:1:1:1%) to recover starting material [Dn]-128a (36 mg, 49%) as a slight yellow oil and 
yield product [Dn]-130aa (58 mg, 44%) as a colorless solid. The D-incorporation in [Dn]-128a 
and [Dn]-130aa was estimated by 1H-NMR spectroscopy. 
 
KIE Determination Experiments: 
KIE Determination Experiments with 128a and [D5]-128a as Substrates :  
 
1). Two independent reactions with 128a or deuterated substrate [D5]-128a under the standard 
conditions were performed: Two reaction mixtures each containing phenyl isocyanate (129a) 
(338 mg, 2.0 mmol), substrates 128a (144 mg, 1.00 mmol) or [D5]-128a (149 mg, 1.00 mmol), 
Cp*CoI2(CO) (112, 24 mg, 5.0 mol %), AgSbF6 (34.4 mg, 10.0 mol %) and AgOPiv (20.8 mg, 
10.0 mol %) in DCE (4.0 mL) were stirred at 70 °C under an atmosphere of Ar. The 
consumption of substrates 128a or [D5]-128a and the appearance of the products 130a or 
[Dn]-130a were monitored by GC analysis after 0.5 h, 1.0 h, 1.25 h, 1.5 h, 1.75 h, 2.0 h, 2.25 
h, 2.5 h, 2.75 h, 3.0 h, respectively. These experiments indicated that the C–H bond activation 




t/(h) 0.5 1.0 1.25 1.5 1.75 2.0 2.25 2.5 2.75 3.0 
130aa 0.06 0.16 0.22 0.28 0.35 0.39 0.47 0.56 0.56 0.61 
128a 0.94 0.84 0.78 0.72 0.65 0.61 0.53 0.44 0.44 0.49 
 
t/(h) 0.5 1.0 1.25 1.5 1.75 2.0 2.25 2.5 2.75 3.0 
[Dn]-130aa 0.01 0.04 0.06 0.11 0.16 0.20 0.27 0.32 0.32 0.39 









Intramolecular Competition Experiment: Kinetic Isotope Effect (KIE):  




















initial rate of 128a 


























2). 1-(Phenyl-2-d)-1H-pyrazole ([D1]-128a) (73.0 mg, 0.50 mmol), phenyl isocyanate (129a) 
(60.0 mg, 0.50 mmol),  Cp*CoI2(CO) (112, 12.0 mg, 5.0 mol %), AgSbF6 (17.2 mg, 10.0 
mol %) and AgOPiv (10.4 mg, 10.0 mol %) in DCE (2.0 mL) was stirred at 70 °C for 90 min 
under an atmosphere of Ar. At ambient temperature, the reaction mixture was evaporated in 
vacuo, and the residue was purified by column chromatography on silica gel 
(n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:0.01) to yield [Dn]-130aa (63.0 mg, 48%) as a 
colorless solid. The degree of deuterium incorporation in [Dn]-130aa was estimated by 
1H-NMR spectroscopy. 
 
1-(Phenyl-2-d)-1H-pyrazole  ([D1]-128a) 
 
1H-NMR (500 MHz, CDCl3): δ = 7.91 (dd, J = 2.5, 0.6 Hz, 1H), 7.71 (dd, J = 1.8, 0.7 Hz, 1H), 
7.70–7.67 (m, 1H), 7.51–7.36 (m, 2H), 7.27 (td, J = 7.5, 1.1 Hz, 1H), 6.45 (dd, J = 2.5, 1.8 Hz, 
1H).  
13C-NMR (125 MHz, CDCl3): δ = 141.0 (CH), 140.2 (Cq), 129.4 (CH), 129.4 (CH), 126.7 (CH), 
126.4 (CH, J = 1.6 Hz), 119.2 (CH), 119.2 (CH), 107.6 (CH).  
IR (ATR): 3066, 1593, 1391, 1045, 936, 742 cm-1.  
MS (EI) m/z (relative intensity) 145 (100) [M+], 118 (30), 91 (25), 78 (45).  





Intermolecular Competition Experiment between Substrates VI-1b and VI-1d:  
 
A suspension of phenyl isocyanate (129a) (60 mg, 0.5 mmol), 1-p-tolyl-1H-pyrazole (128b) 
(158 mg, 1.00 mmol), 1-(4-fluorophenyl)-1H-pyrazole (128d) (162 mg, 1.00 mmol), 
Cp*CoI2(CO) (112, 12 mg, 5.0 mol %), AgSbF6 (17.2 mg, 10.0 mol %) and AgOPiv (10.8 mg, 
10.0 mol %) in DCE (2.0 mL) was stirred at 70 °C for 16 h under an atmosphere of Ar. At 
ambient temperature, the reaction mixture was evaporated in vacuo and the residue was 
purified by column chromatography on silica gel (n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:0.01) 
to yield 130ba (25 mg, 18%) as a colorless solid.  
 
Intermolecular Competition Experiment between Substrates 129b and 129d:  
 
A suspension of 1-phenyl-1H-pyrazole (128a) (72 mg, 0.5 mmol), 
1-isocyanato-4-methylbenzene (129b) (133 mg, 1.00 mmol), 1-fluoro-4-isocyanatobenzene 
(129d) (137 mg, 1.00 mmol), Cp*CoI2(CO) (112, 12 mg, 5.0 mol %), AgSbF6 (17.2 mg, 10.0 
mol %) and AgOPiv (10.8 mg, 10.0 mol %) in DCE (2.0 mL) was stirred at 70 °C for 16 h 
under an atmosphere of Ar. At ambient temperature, the reaction mixture was evaporated in 
vacuo and the residue was purified by column chromatography on silica gel 
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(n-hexane/CH2Cl2/EtOAc/Et3N 10:1:1:1%) to yield 130ab (17 mg, 12%) and 130ad (77 mg, 




M. p.: = 130−132 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.58 (br s, 1H), 7.96–7.84 (m, 1H), 7.77 (d, J = 1.9 Hz, 1H), 
7.69 (d, J = 2.4 Hz, 1H), 7.62–7.46 (m, 2H), 7.43–7.30 (m, 3H), 6.94 (dd, J = 9.1, 8.3 Hz, 2H), 
6.46 (t, J = 2.2 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 164.4 (Cq), 159.4 (Cq, JC-F = 243.9 Hz), 141.3 (CH), 137.2 
(Cq), 133.9 (Cq, JC-F = 2.9 Hz), 132.8 (Cq), 132.0 (CH), 131.4 (CH), 130.7 (CH), 129.2 (CH), 
126.8 (CH), 121.8 (CH, JC-F = 7.9 Hz), 115.5 (CH, JC-F = 22.4 Hz), 107.8 (CH).  
19F-NMR (282 MHz, CDCl3): δ = -117.8 (tt, J = 8.2, 4.8 Hz).  
IR (ATR): 3258, 1652, 1507, 1209, 832, 754 cm-1.  
MS (EI) m/z (relative intensity) 281 (5) [M+], 171 (100), 144 (5), 130 (10), 116 (15).  
HR-MS (EI) m/z calcd for C16H12N3OF [M+] 281.0964, found 281.0961. 
 
4-Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one  (160) 
 
A suspension of N-phenyl-2-(1H-pyrazol-1-yl)benzamide (130aa) (53 mg, 0.2 mmol) and 
K2S2O8 (81 mg, 0.3 mmol) in H2O (5.0 mL) was stirred at 105 °C for 1.0 h. After completion of 
the reaction, at ambient temperature the reaction mixture was extracted with MTBE (3 × 10 mL) 
at ambient temperature. The combined organic layers were dried over Na2SO4 and filtered. The 
solvent was concentrated in vacuo and purification by column chromatography 
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(n-Hexane/EtOAc 4:1) yielded 160 (45 mg, 85%) as a colorless solid. M. p.: = 160−162 °C. 
1H-NMR (500 MHz, CDCl3): δ = 8.36–8.32 (m, 1H), 8.23–8.18 (m, 1H), 7.81 (ddd, J = 8.3, 7.3, 
1.5 Hz, 1H), 7.64 (d, J = 2.0 Hz, 1H), 7.59–7.54 (m, 2H), 7.52–7.47 (m, 1H), 7.47–7.40 (m, 3H), 
5.47 (d, J = 2.0 Hz, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 158.6 (Cq), 141.7 (CH), 141.5 (Cq), 137.7 (Cq), 136.8 (Cq), 
135.0 (CH), 130.0 (CH), 129.4 (CH), 129.3 (CH), 127.8 (CH), 125.5 (CH), 116.3 (CH), 114.7 
(Cq), 90.9 (CH).  
IR (ATR): 1668, 1553, 1482, 1127, 757, 684 cm-1.  
MS (EI) m/z (relative intensity) 261 (100) [M+], 234 (10), 205 (5), 128 (10), 103 (10), 77 (25). 
HR-MS (EI) m/z calcd for C16H11N3O [M+] 261.0902, found 261.0903. 
 
3-(4-Methoxybenzyl)-N-phenyl-2-(1H-pyrazol-1-yl)benzamide  (161) 
 
According to the established protocol, a suspension of 
N-phenyl-2-(1H-pyrazol-1-yl)benzamide (130aa) (66 mg, 0.25 mmol), 
1-(chloromethyl)-4-methoxybenzene (163, 78 mg, 0.5 mmol), [RuCl2(p-cymene)]2 (7.8 mg, 
5.0 mol %), 1-AdCO2H (13.5 mg, 30 mol %) and K2CO3 (69 mg, 0.5 mmol) in PhMe (1.0 mL) 
was stirred at 100 °C for 20 h.167 At ambient temperature, the reaction mixture was extracted 
with MTBE (3 × 10 mL). The combined organic layers were dried over Na2SO4 and filtered. 
The solvent was concentrated in vacuo and purification by column chromatography 
(n-Hexane/EtOAc 5:1) yielded 161 (45 mg, 47%) as a colorless solid. M. p.: = 133−135 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.85 (d, J = 1.9 Hz, 1H), 7.80 (dd, J = 7.7, 1.6 Hz, 1H), 7.73 
(br s, 1H), 7.51 (t, J = 7.7 Hz, 1H), 7.42–7.35 (m, 2H), 7.35–7.29 (m, 2H), 7.25 (m, 1H), 7.22 (d, 
J = 8.3 Hz, 1H), 7.11–6.97 (m, 1H), 6.88 (d, J = 8.6 Hz, 2H), 6.75 (d, J = 8.6 Hz, 2H), 6.38 (t, J 
= 2.2 Hz, 1H), 3.75 (s, 3H), 3.64 (s, 2H).  
                                                                 
167 L. Ackermann, P. Novák, R. Vicente, N. Hofmann, Angew. Chem. Int. Ed. 2009, 48, 6045–6048. 
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13C-NMR (125 MHz, CDCl3): δ = 164.3 (Cq), 158.2 (Cq), 141.6 (CH), 140.6 (Cq), 137.7 (Cq), 
135.8 (Cq), 135.5 (Cq), 133.4 (CH), 133.0 (CH), 131.3 (Cq), 130.1 (CH), 129.7 (CH), 128.8 
(CH), 128.5 (CH), 124.4 (CH), 119.9 (CH), 113.9 (CH), 107.5 (CH), 55.2 (CH3), 35.8 (CH2). 
IR (ATR): 3274, 1650, 1508, 1245, 1025, 750 cm-1.  
MS (EI) m/z (relative intensity) 383 (15) [M+], 290 (80), 262 (100), 247 (25), 234 (5), 219 (15). 
HR-MS (EI) m/z calcd for C24H21N3O2 [M+] 383.1634, found 383.1629. 
 
Ethyl 3'-(Phenylcarbamoyl)-2'-(1H-pyrazol-1-yl)-[1,1'-biphenyl]-4-carboxylate (162) 
 
According to the established protocol, a suspension of 
N-phenyl-2-(1H-pyrazol-1-yl)benzamide (130aa) (63 mg, 0.24 mmol), which was prepared 
according the general procedure J, ethyl 4-chlorobenzoate (88k) (37 mg, 0.2 mmol), 
[Ru(MesCO2)2(p-cymene)] (5.6 mg, 5.0 mol %) and K2CO3 (55 mg, 0.4 mmol) in PhMe (1.0 
mL) was stirred at 120 °C for 20 h under an atmosphere of Ar.168 At ambient temperature, the 
reaction mixture was extracted with MTBE (3 × 10 mL). The combined organic layers were 
dried over Na2SO4 and filtered. The solvent was concentrated in vacuo and purification by 
column chromatography (n-hexane/EtOAc 5:1) and HPLC yielded product 162 (62 mg, 75%) 
as a colorless solid. M. p.: = 147−149 °C.  
1H-NMR (300 MHz, CDCl3): δ = 8.55 (br s, 1H), 8.04 (dd, J = 7.6, 1.8 Hz, 1H), 7.95 (d, J = 
8.7 Hz, 2H), 7.76–7.71 (m, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.63 (dd, J = 7.7, 1.8 Hz, 1H), 
7.49–7.38 (m, 2H), 7.34–7.25 (m, 3H), 7.20 (d, J = 8.7 Hz, 2H), 7.14–7.03 (m, 1H), 6.25 (dd, 
J = 2.4, 1.9 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 166.2 (Cq), 164.0 (Cq), 142.1 (Cq), 141.0 (CH), 140.0 (Cq), 
137.9 (Cq), 135.8 (Cq), 134.9 (Cq), 133.7 (CH), 132.8 (CH), 130.6 (CH), 130.1 (CH), 129.8 
(Cq), 129.4 (CH), 128.9 (CH), 128.3 (CH), 124.5 (CH), 120.0 (CH), 107.8 (CH), 61.1 (CH2), 
                                                                 
168 L. Ackermann, R. Vicente, H. K. Potukuchi , V. Pi rovano, Org. Lett. 2010, 12, 5032–5035. 
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14.3 (CH3).  
IR (ATR): 3279, 1708, 1551, 1278, 1106, 756 cm-1, 
MS (ESI) m/z (relative intensity) 412 (10) [M+H+], 434 [M+Na+], 450 [M+K+], 845 
[2M+Na+].  
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